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	ABSTRACT	
	
	
The	 mechanisms	 that	 govern	 the	 lineage	 commitment	 of	 haematopoietic	 stem	 and	
progenitor	cells	(HSPCs)	have	been	a	topic	of	debate	since	the	1960s.	Two	models	of	lineage	
commitment	have	been	described;	 a	 permissive	model,	 in	which	haematopoietic	 growth	
factors	(HGFs)	stimulate	proliferation	and	survival	of	distinct	HSPC	subpopulations	to	permit	
stochastic	 lineage-specification,	 and	 a	 deterministic	 model	 which	 proposes	 that	 HGFs	
instruct	HSPCs	to	differentiate	towards	a	specific	cell	lineage.	To	provide	further	insight	into	
whether	 HGFs	 provide	 instructive	 cues	 or	 act	 in	 a	 selective	 manner,	 this	 study	 has	
investigated	 the	 expression	 of	 fms-like	 tyrosine	 kinase	 3	 (Flt3),	 and	 the	 receptors	 for	
erythropoietin	(EpoR)	and	macrophage-colony	stimulating	factor	(M-CSFR)	by	single	HSPCs	
within	the	bone	marrow.	Using	single-cell	qRT-PCR	and	flow	cytometry,	a	large	number	of	
novel	HSPC	subpopulations	have	been	identified	based	on	receptor	expression.	Importantly,	
multiplex	analysis	of	protein	and	mRNA	expression	revealed	that	the	above	receptors	are	
rarely	co-expressed	during	the	early	stages	of	haematopoiesis.	Furthermore,	Flt3	expression	
was	 identified	 within	 the	 haematopoietic	 stem	 cell	 compartment	 and	 in	 vitro	 analysis	
demonstrated	that	Flt3	ligand	primarily	acts	on	a	subpopulation	of	downstream	progenitors.	
These	findings	suggest	that	Flt3,	EpoR	and	M-CSFR	differentially	regulate	distinct	early	HSPC	
subpopulations.
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CHAPTER	1:			 INTRODUCTION	
	
The	 formation	 of	 blood	 and	 immune	 cells	 in	 adult	 mammals	 is	 a	 complex	 and	 tightly	
regulated	 system	 controlled	 by	 the	 self-renewal	 and	 differentiation	 of	 rare	 quiescent	
haematopoietic	stem	cells	(HSCs)	that	reside	within	the	bone	marrow	(BM).	HSCs	are	at	the	
apex	of	the	haematopoietic	hierarchy,	and	have	the	ability	to	self-renew	and	differentiate	to	
maintain	 the	 haematopoietic	 system.	 As	 HSCs	 mature,	 they	 give	 rise	 to	 multipotent	
progenitors	(MPPs),	which	are	more	proliferative	than	HSCs	and	lack	long-term	self-renewal	
capacity.	MPPs	 then	 differentiate	 to	 give	 rise	 to	 functional	 cell	 types	 via	 progenitor	 cell	
intermediates.	These	terminally	differentiated	cells	are	typically	divided	into	the	lymphoid	
and	 myeloid	 families	 and	 will	 be	 discussed	 briefly	 below.	 For	 a	 detailed	 description	 of	
immune	cell	function,	see	[1].	
	
The	lymphoid	family	contains	cells	of	both	the	innate	and	adaptive	immune	systems,	and	is	
comprised	 of	 T-lymphocytes,	 B-lymphocytes	 and	 natural	 killer	 (NK)	 lymphocytes	 [1].	 T-
lymphocytes,	which	mature	in	the	thymus,	are	mainly	involved	in	cell-mediated	immunity,	
and	 can	be	divided	 into	 a	 number	 of	 subfamilies	 that	 are	 responsible	 for	 immunological	
memory,	 cell-mediated	 cytotoxicity	 and	 regulating	 the	 immune	 response.	 B-lymphocytes	
mature	 in	the	BM	and	are	classically	 involved	 in	regulating	 immune	function	via	humoral	
immunity.	NK	 lymphocytes,	which	classically	 form	the	 innate	component	of	the	 lymphoid	
family,	are	cytotoxic	cells	that	rapidly	respond	to	tumor	cells	and	viral	infection,	and	are	key	
players	in	transplant	rejection.		
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The	myeloid	 family	 includes	monocytes/macrophages,	 granulocytes,	megakaryocytes	 and	
erythrocytes	[1].	Monocytes,	which	are	precursors	to	macrophages,	circulate	in	the	blood	
and	play	an	important	role	in	both	homeostasis	and	inflammation.	Following	inflammation,	
monocytes	 migrate	 to	 target	 tissues	 and	 differentiate	 into	 macrophages	 which	 act	 as	
phagocytes	and	professional	antigen	presenting	cells	(AgPCs)	[1].	Under	normal	physiological	
conditions,	tissue-resident	macrophages	perform	general	and	tissue-specific	functions,	such	
as	 removal	 of	 cellular	 debris	 and	 immune	 surveillance	 [2].	 Granulocytes	 make	 up	 the	
polymorphonuclear	family	of	cells	and	can	be	divided	into	neutrophils,	eosinophils,	basophils	
and	mast	cells.	Neutrophils	are	the	most	abundant	immune	cells	within	the	blood	and	are	
key	players	in	the	early	innate	immune	response	to	infection.	In	response	to	inflammation,	
neutrophils	act	as	phagocytes,	AgPCs	and	undergo	degranulation,	releasing	molecules	with	
antimicrobial	properties	 into	 the	 surrounding	extracellular	matrix	 [1].	Eosinophils	are	 the	
main	component	of	the	immune	system	that	defend	against	multicellular	parasites,	such	as	
helminths,	and	also	contribute	towards	allergic	responses	[1].	Similarly,	basophils	and	mast	
cells	are	integral	in	the	development	of	allergy,	and	protect	against	parasitic	infections	[1].	
While	mast	cells	are	classically	thought	to	arise	from	basophils,	this	has	been	contested	[3].		
	
Megakaryocytes	 are	 large	 BM-resident	 cells	 that	 undergo	 fragmentation	 of	 their	 plasma	
membrane	 and	 cytoplasm	 to	 generate	 thrombocytes	 (platelets),	 which	 contribute	 to	
haemostasis:	a	process	that	prevents	bleeding	following	vessel	injury	[4].	Erythrocytes,	are	
responsible	 for	 oxygen	 homeostasis,	 and	 mature	 cells	 are	 enucleated	 in	 adults	 [5].	 	 As	
megakaryocytes	and	erythrocytes	are	not	classically	considered	to	be	involved	in	immune	
responses	[6,	7],	the	myeloid	family	is	commonly	divided	into	granulo-myelomonocytic	(GM)	
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and	megakaryocyte-erythroid	 (MegE)	 subfamilies,	which	 segregate	 the	 immune	and	non-
immune	cells	respectively.	
	
The	final	cellular	component	of	the	immune	system	is	the	dendritic	cell	(DC),	which	does	not	
align	with	conventional	myeloid	and	lymphoid	dichotomy	(Further	discussed	in	Section	1.2).	
DCs	are	AgPCs	that	are	important	in	linking	the	innate	and	adaptive	immune	responses,	and	
can	be	derived	from	both	myeloid	and	lymphoid	progenitor	cells.	Myeloid-	and	lymphoid-
derived	DCs	have	been	shown	to	be	phenotypically	and	transcriptomically	homogeneous	[8],	
and	it	has	been	suggested	that	DCs	should	be	considered	as	a	separate	lineage	given	their	
ancestry	[9].		
	
This	introduction	aims	to	give	a	comprehensive	review	of	the	haematopoietic	system	with	
emphasis	on	how	haematopoietic	stem	and	progenitor	cells	(HSPCs)	make	decisions	during	
differentiation	to	give	rise	to	the	mature	cell-fates	highlighted	above.	First,	characterisation	
of	the	adult	HSC	and	the	haematopoietic	hierarchy	will	be	addressed.	Then	the	mechanisms	
underlying	decision	making	in	haematopoiesis	will	be	explored	with	particular	focus	on	two	
models	of	haematopoietic	lineage	commitment.	
	
1.1			The	 nature	 of	 early	 haematopoietic	 stem	 and	
progenitor	cells	in	the	adult	
	
Advancements	 in	 cell	 isolation	 techniques	 have	 facilitated	 the	 purification	 of	 highly	
homogeneous	murine	HSPC	populations	based	on	the	expression	of	a	range	of	cell	surface	
markers.	 These	 techniques	 have	 permitted	 the	 functional	 classification	 of	 rare	
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subpopulations	of	HSCs	and	MPPs	within	the	mouse	BM.	In	the	adult	mouse,	HSCs	and	their	
early	progeny	express	the	surface	markers	c-Kit	and	Sca1	[10,	11].	These	markers	are	lost	as	
they	 begin	 to	 differentiate	 and	 acquire	 lineage	 associated	 cell	 surface	 markers	 (Lin),	
including;	 B220,	 which	 is	 present	 on	 B-lymphocytes	 [12];	 CD3,	 a	 marker	 for	 mature	 T-
lymphocytes	[13];	CD11b	and	Gr-1,	mature	DC	and	myeloid	cell	markers	[14,	15];	and	TER-
119,	 which	 is	 expressed	 by	 erythroid	 cells	 [16].	 As	 such,	 virtually	 all	 of	 the	multilineage	
potential	of	the	BM	resides	within	the	Lin−	Sca1+	c-Kit+	(LSK)	compartment.		
	
Traditionally,	 early	 HSPCs	 are	 functionally	 classified	 based	 on	 their	 ability	 to	 provide	
multilineage	reconstitution	for	a	defined	period	of	time	when	transplanted	into	an	irradiated	
host.	These	functionalities	are	assessed	by	performing	competitive	repopulating	unit	assays	
whereby	varying	numbers	of	genetically	distinct	 test	cells	 (such	as	HSCs)	and	helper	cells	
(usually	whole	BM	cell	suspensions)	are	transplanted	into	irradiated	mice.	The	contribution	
of	the	donor	test	cells	to	haematopoietic	cells	in	the	peripheral	blood	is	then	measured	over	
time.	Usually,	donor	contribution	of	>1%	to	each	lineage	is	required	to	confirm	multilineage	
reconstitution	 [17].	 Long-term	 repopulating	 HSCs	 (LT-HSCs)	 are	 defined	 as	 cells	 that	 are	
capable	of	multilineage	reconstitution	in	primary	irradiated	recipients	for	at	least	six	months,	
and	 can	 subsequently	 repopulate	 a	 secondary	 irradiated	 recipient	 [18].	 Short-term	
repopulating	 HSCs	 (ST-HSCs)	 are	 considered	 to	 possess	 multilineage	 potential,	 and	
reconstitute	the	haematopoietic	system	in	an	irradiated	host	for	8-12	weeks	[19,	20].	Finally,	
MPPs	 have	 very	 little	 self-renewal	 ability,	 and	 are	 only	 capable	 of	 transient	multilineage	
engraftment	when	transferred	 into	primary	 irradiated	hosts	[21,	22].	 Interestingly,	recent	
studies	have	shown	that	not	all	long-term	repopulating	cells	in	the	mouse	and	human	are	
capable	 of	 multilineage	 reconstitution	 [23,	 24],	 and	 some	 are	 biased	 towards	 particular	
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lineages	[9,	25-32].	These	findings	suggest	that	the	current	functional	criteria	used	to	define	
early	HSPCs	is	outdated	(discussed	in	Section	1.3.3).	
	
	 	
	
Figure	 1.1.	 Progression	 of	 the	models	 used	 to	 identify	HSPCs	 in	 the	 adult	mouse	 bone	
marrow.	 Cell	 surface	 antigens	 are	used	 to	distinguish	 LT-HSCs,	 ST-HSCs,	 and	MPPs.	 Early	
reports	 from	the	Weissman	group	made	use	of	 the	LSK	 	and	Thy1.1	 to	 identify	HSCs	and	
MPPs,	and	the	group	later	used		Flt3	expression	to	distinguish	between	LT-HSCs	and	ST-HSCs	
in	2001	[20,	33].	In	2005,	the	Jacobsen	further	refined	the	Weissman	model	by	showing	that	
Flt3	is	absent	from	ST-HSCs,	and	that	CD34	can	be	used	to	distinguish	between	LT-HSCs	and	
ST-HSCs	[21].	That	same	year,	the	Morrison	group	proposed	a	staining	strategy	to	identify	
early	 HSPCs	 using	 the	 signalling	 lymphocytic	 activation	molecule	 family	markers;	 CD150,	
CD48,	and	CD244	[22].	In	2013,	the	Morison	group	added	CD299	to	their	staining	strategy	to	
distinguish	myeloid-biased	HSC-1	and	lymphoid-biased	HSC-2	subpopulations,	which	share	
characteristics	 with	 LT-HSCs	 and	 ST-HSCs,	 respectively.	 They	 also	 identified	 three	 MPP	
subpopulations	[34].	HSPCs,	haematopoietic	stem	and	progenitor	cells;	LT-HSC,	 long-term	
haematopoietic	stem	cell;	ST-HSC,	short-term	haematopoietic	stem	cell;	MPP,	multipotent	
progenitor;	 LSK,	 lineage	 associated	 surface	markers−,	 Sca1+,	 c-Kit+;	 Flt3,	 fms-like	 tyrosine	
kinase	3.	
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The	LSK	compartment	was	originally	subdivided	based	on	the	expression	of	Thy1.1	and	fms-
like	 tyrosine	 kinase	3	 (Flt3),	 as	described	by	 the	Weissman	group	 (Figure	1.1;	Weissman	
model)	[20,	33,	35,	36].	At	the	time,	the	group	proposed	that	these	markers	could	be	used	
to	distinguish	between	Thy1.1loFlt3−	LT-HSCs,	Thy1.1loFlt3+	ST-HSCs,	and	Thy1.1−Flt3+	MPPs.	
In	2005,	Jacobsen’s	group	showed	that	Flt3	was,	in	fact,	absent	on	ST-HSCs	[21].	This	finding	
led	the	Jacobsen	group	to	propose	the	use	of	Flt3	and	CD34,	a	marker	previously	shown	to	
be	 absent	 from	 the	 surface	 of	 LT-HSCs	 [37,	 38],	 in	 combination	 with	 the	 LSK	
immunophenotype	 to	 identify	 LT-HSCs	 (LSK	 CD34−	 Flt3−),	 ST-HSCs	 (LSK	 CD34+	 Flt3−),	 and	
MPPs	(LSK	CD34+	Flt3+)	(Figure	1.1;	Jacobsen	model)	[21].	
	
The	Morrison	group	has	used	the	signalling	lymphocytic	activation	molecule	(SLAM)	family	
markers	(CD150,	CD48,	CD229	and	CD244)	to	resolve	HSC	and	MPP	subpopulations	(Figure	
1.1;	Morrison	model)	 [22,	34].	 In	2005,	Kiel	et	al.	defined	HSCs	and	MPPs	based	on	their	
expression	of	CD150,	CD48	and	CD244	[22].	They	reported	that	CD48	expression	in	the	BM	
marks	lineage	restricted	progenitors,	and	that	HSCs	and	MPPs	are	CD150+	CD48−	CD244−	and	
CD150−	CD48−	CD244+,	respectively.	In	this	study,	they	also	investigated	the	expression	of	
these	markers	by	cells	within	the	LSK	compartment	to	show	that	47%	of	CD150+	CD48−	LSK	
cells	provide	long-term	reconstitution	in	transplantation	assays,	while	only	20%	of	Thy1lo	LSK	
cells	were	capable	of	the	same	[22].	The	addition	of	CD229	to	this	panel	led	Oguro	and	co-
workers	 to	 characterise	 the	 HSC-1	 and	 HSC-2	 populations	 [34].	 The	 CD229−	 HSC-1	 are	
myeloid-biased	 (MyHSCs)	and	 rarely	divide,	while	 the	CD229+	HSC-2	are	 lymphoid-biased	
(LyHSCs)	 and	 are	 more	 proliferative,	 and	 share	 similarities	 with	 LT-HSCs	 and	 ST-HSCs,	
respectively	[34].	The	Morrison	group	has	proposed	that	the	loss	of	CD150	expression	marks	
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the	loss	of	self-renewal	ability,	while	others	have	reported	that	this	marker	can	be	used	to	
identify	CD150high/med	MyHSCs	(discussed	in	Section	1.3.3)	[25-27].	
	
While	 HSC	 isolation	 strategies	 have	 primarily	 relied	 on	 the	 use	 of	 cell	 surface	 markers,	
Wiessman’s	 group	 has	 recently	 identified	 the	 transcription	 factor	 (TF)	 Hoxb5	 as	 a	 highly	
specific	marker	of	 LT-HSCs	 [39].	Chen	et	al.	used	a	Hoxb5:tri-mCherry	 reporter	 system	to	
show	that	high	 levels	of	Hoxb5	strongly	correlated	with	 long-term	repopulating	potential	
[39].	 Notably,	 the	 authors	 demonstrated	 that	 63.9% ± 3%	 of	 LSK	 CD48−	 CD150+	 CD229−	
CD244−	HSCs	and	82.5% ± 0.4%	LSK	CD34−/lo	CD150+	CD41−	HSCs	were	Hoxb5−,	indicating	that	
HSC	isolation	strategies	that	only	utilise	cell	surface	markers	have	limited	specificity	for	true	
LT-HSCs.	
	
Human	 HSCs	 (hHSCs)	 are	 not	 as	 well	 characterised	 as	 their	 mouse	 counterparts,	 and	 a	
number	of	immunophenotypes	have	been	described	for	their	isolation.	hHSCs	are	commonly	
identified	in	vitro	using	long-term	culture-initiating	cell	(LTC-IC)	assays,	which	use	BM	stromal	
co-culture	 systems	 to	provide	quantitative	assessment	of	haematopoietic	 cell	 production	
over	 time	 [40].	 Another,	 more	 recent,	 method	 for	 characterising	 hHSCs	 is	 the	 use	 of	
xenograft	assays.	These	assays	 involve	the	xenotransplantation	of	human	haematopoietic	
cells	 into	 nonobese	 diabetic–severe	 combined	 immunodeficient	 mice,	 which	 support	
engraftment	of	human	HSPCs	[41,	42].	In	contrast	to	mouse	HSCs,	hHSCs	are	traditionally	
considered	to	be	CD34+	CD38−,	and	express	low	levels	of	c-Kit	[43-51].		
	
Controversy	 exists	 regarding	whether	 CD34	 is	 a	 reliable	marker	 for	 hHSCs.	 A	 number	 of	
research	groups	have	identified	long-term	repopulating	cells	as	Lin−	CD34+	CD38−,	suggesting	
that	hHSCs	are	present	within	this	compartment	of	the	adult	BM	and	umbilical	cord	blood	
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[47-51].	On	the	other	hand,	other	workers	have	demonstrated	that	Lin−	CD34−	cells	possess	
hHSC	characteristics,	and	that	Lin−	CD34−	cells	are	able	to	provide	multilineage	engraftment	
in	primary	and	secondary	recipients	[52-54].	Furthermore,	there	is	evidence	to	suggest	that	
CD34	 expression	 on	 human	 HSPCs	 is	 reversible,	 as	 CD34+	 cells	 capable	 of	 long-term	
multilineage	engraftment	can	give	 rise	 to	CD34−	cells	and	vice	versa	 [53,	55-57].	 In	2011,	
Notta	 and	 co-workers	 identified	 CD49f	 as	 a	 highly	 specific	 marker	 for	 hHSCs,	 and	
demonstrated	 that	 single	 CD49f+	 adult	 BM	 cells	 were	 capable	 of	 long-term	multilineage	
engraftment	 [58].	 Other	 markers	 that	 have	 been	 proposed	 to	 enrich	 for	 hHSCs	 include	
AC133,	HLA-DR,	Thy1	and	CD45R	[58-65].	
	
1.2			Models	 of	 haematopoiesis:	 The	 progeny	 of	
haematopoietic	stem	cells	
	
Classically,	the	development	of	HSCs	has	been	modelled	in	regards	to	a	dichotomy	of	the	
lymphoid	 and	myeloid	 lineages	 (Figure	 1.2A).	 The	model	 proposes	 that	 as	HSCs	mature,	
there	 is	a	point	 in	 their	development	whereby	 they	 irreversibly	 commit	 towards	either	a	
lymphoid	 or	myeloid	 fate.	 In	 this	model,	 there	 are	 only	 single	 ‘routes’	 of	 differentiation	
towards	 cells	 of	 a	 particular	 fate,	 suggesting	 a	 rigid	 haematopoietic	 architecture.	 The	
myeloid-lymphoid	dichotomy	model	was	proposed	by	 the	Weissman	group	 following	 the	
isolation	of	two	progenitors	in	the	adult	mouse	BM.	In	1997,	Kondo	et	al.	described	a	Lin−	
Sca1lo	 c-Kitlo	 Thy1−	 IL-7R+	 BM	 cell	 which	 could	 rapidly	 generate	 T-lymphocytes	 and	 B-
lymphocytes	when	transplanted	into	an	irradiated	host	[66].	As	the	authors	did	not	detect	
significant	myeloid	potential	during	 these	experiments,	 the	cell	was	 termed	the	common	
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lymphoid	 progenitor	 (CLP)	 [66].	 Shortly	 after	 this,	 Akashi	 and	 co-workers	 identified	 a	
common	myeloid	progenitor	(CMP)	as	Lin−	Sca1−	c-Kit+	(LS−K)	IL-7R−	CD16/32lo	CD34hi	[67].	
This	cell	gives	rises	to	all	myeloid	cells	in	vivo	through	megakaryocyte-erythroid	progenitor	
(MEP)	and	granulocyte-macrophage	progenitor	(GMP)	intermediates	[67].	
	
	
	
Figure	1.2.	Models	of	haematopoiesis.	(A)	Following	the	identification	of	CLPs	[66]	and	CMPs	
[67],	 the	 Weissman	 group	 proposed	 a	 myeloid-lymphoid	 dichotomy	 model	 of	
haematopoiesis	whereby	HSCs	irreversibly	commit	towards	either	the	lymphoid	or	myeloid	
lineage	during	the	early	stages	of	maturation.	(B)	The	Katsura	group	has	used	fetal	thymic	
cultures	 to	 describe	 a	myeloid-based	model	 of	 haematopoiesis	 in	which	GM	potential	 is	
maintained	as	a	default	during	HSPC	differentiation	towards	erythroid,	B-lymphocyte	and	T-
lymphocyte	cell	fates	[68-72].	(C)	depicts	a	model	proposed	by	the	Jacobsen	group	following	
the	 characterisation	 of	 the	 LMPP	 [73].	 HSC,	 haematopoietic	 stem	 cell;	 CMP,	 common	
myeloid	 progenitor;	 CLP,	 common	 lymphoid	 progenitor;	 GMP,	 granulocyte-macrophage	
progenitor;	MEP,	megakaryocyte-erythroid	progenitor;	LMPP,	lymphoid-primed	multipotent	
progenitor;	CMLP,	 common	myelo-lymphoid	progenitor;	CMEP,	 common	myelo-erythroid	
progenitor;	GM/B,	granulocyte-macrophage/B-lymphocyte	progenitor;	GM/T,	granulocyte-
macrophage/T-lymphocyte	progenitor;	G/M,	granulocyte/monocyte.	
A
B C
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Although	the	myeloid-lymphoid	dichotomy	model	of	haematopoiesis	became	a	very	popular	
model	following	the	studies	published	by	the	Weissman	group	[66,	67],	a	number	of	other	
groups	have	reported	findings	that	disagree	with	a	myeloid-lymphoid	dichotomy.	In	1997,	
Kawamoto	et	al.	isolated	single	Sca1+	progenitor	cells	from	mouse	fetal	livers	and	used	an	in	
vitro	fetal	thymic	organ	culture	system	to	monitor	their	differentiation	potential	[68].	After	
10	days	in	culture,	the	colonies	generated	by	single	Sca1+	progenitors	were	analysed	for	the	
presence	of	T-lymphocytes,	B-lymphocytes	and	GM	cells.	Some	of	these	cells	gave	rise	to	
colonies	containing	all	three	lineages,	while	others	contained	only	one	or	two	lineages.	Of	
the	colonies	containing	two	lineages,	T-lymphocytes	and	GM	cells	or	B-lymphocytes	and	GM	
cells	were	 commonly	 observed	 together.	 However,	 the	 authors	 never	 observed	 colonies	
containing	 T-lymphocytes	 and	 B-lymphocytes	 without	 GM	 cells.	 Using	 a	 similar	 in	 vitro	
approach,	 the	 group	 later	 identified	 two	 distinct	 progenitor	 cells;	 i)	 a	 cell	 with	 GM	 and	
lymphoid	potential	(common	myelolymphoid	progenitor	[CMLP])	and,	ii)	a	cell	with	GM	and	
erythroid	potential	(common	myeloerythroid	progenitor	[CMEP])	[71].	This	led	the	Katsura	
group	to	propose	a	myeloid-based	model	of	haematopoiesis	(Figure	1.2B)	[69,	70].	In	this	
model,	 GM	 potential	 is	 retained	 as	 HSPCs	 differentiate	 towards	 the	 T-lymphocyte,	 B-
lymphocyte	and	erythroid	lineages.	GM	potential	is	only	lost	during	the	final	stages	of	the	T-
lymphocyte,	 B-lymphocyte	 and	 erythroid	 maturation.	 The	 myeloid-based	 model	 is	
controversial,	especially	considering	that	it	is	based	solely	on	findings	from	in	vitro	culture	
experiments.	The	identification	of	restricted	lymphoid	progenitors	in	vivo,	such	as	the	CLP	
and	T-lymphocyte/NK	lymphocyte	progenitor,	argues	against	such	a	model	[66,	74].		
	
Other,	more	recent	studies	have	also	challenged	the	myeloid-lymphoid	dichotomy.	In	2005,	
Adolfsson	et	al.	described	the	lymphoid-primed	multipotent	progenitor	(LMPP),	a	Flt3hi	LSK	
	 11	
progenitor	cell	which	preferentially	generates	lymphoid	cells	but	also	possesses	significant	
GM	 potential	 [73].	 The	 authors	 noted	 that	 these	 cells	 generated	 few	 erythrocytes	 and	
megakaryocytes	 both	 in	 vitro	 and	 in	 vivo,	 and	 proposed	 a	 new	model	 in	which	 the	 first	
commitment	 decision	made	 during	 haematopoiesis	 results	 in	 either	 loss	 of	 lymphoid	 or	
MegE	potential	(Figure	1.2C).	Subsequently,	the	Rolink	group	described	another	progenitor	
cell	with	similar	potential	to	the	LMPP	[75,	76].	This	cell,	termed	the	early	progenitor	with	
lymphoid	 and	 myeloid	 potential,	 has	 the	 ability	 to	 differentiate	 into	 lymphocytes	 and	
macrophage/monocytes	in	vitro,	and	gives	rise	to	B-lymphocytes	and	T-lymphocytes	in	vivo	
[75,	76].	 	 Furthermore,	Chi	and	co-workers	have	shown	that	CD150−	CMPs	 (preGMs)	can	
generate	T-lymphocytes,	but	not	B-lymphocytes,	in	vivo	[77].	
	
The	myeloid-lymphoid	dichotomy,	myeloid-based	and	Jacobsen	models	of	haematopoiesis	
all	 rely	 on	 strict	 branching	 patterns	 during	 HSC	 differentiation,	 and	 depict	 lineage	
commitment	as	a	rigid	process.	A	more	recent	model	described	by	Ceredig	et	al.	forgoes	a	
lineage	branching	architecture	and	proposes	that	HSCs	can	progressively	differentiate	via	
intermediate	progenitors	towards	a	continuum	of	mature	cell	fates	(Figure	1.3).	This	model,	
termed	 the	 pairwise	 relationship	 model,	 proposes	 that	 as	 HSCs	 differentiate	 towards	 a	
specific	cell	fate,	fates	that	are	the	least	related	to	this	dominant	cell	type	become	latent	
first,	while	more	closely	related	fates	persist	as	possible,	but	less	preferred,	potentials.	The	
arcs	within	each	 layer	of	 the	model	depict	 the	 lineage	potential	 of	 a	particular	HSPC.	As	
HSPCs	mature,	they	progress	from	the	centre	towards	the	outer	mature	cell	fates	and	they	
become	more	restricted	in	regard	to	their	lineage	potential	(represented	by	the	shortening	
of	the	arcs).	HSPCs	can	only	lose	lineage	potentials	as	they	progress	along	a	maturation	path,	
they	cannot	gain	lineage	potential.	Therefore,	the	only	maturation	paths	permitted	by	the	
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representative	 illustration	 (Figure	 1.3)	 are	 ones	 where	 each	 subsequent	 arc	 is	 fully	
encompassed	by	the	previous	arc.	For	example,	the	LMPP	can	give	rise	to	an	EPLM	because	
this	step	results	in	the	loss	of	granulocyte	potential.	However,	an	EPLM	cannot	then	progress	
a	neutrophil-monocyte	progenitor	stage	as	this	would	require	the	restoration	of	neutrophil	
potential.	
	
	
Figure	1.3.	The	pairwise	relationship	model	of	haematopoiesis.	The	pairwise	relationship	
model	describes	HSC	maturity	towards	a	continuum	of	mature	cell	fates,	forgoing	traditional	
lineage-branching.	 The	 inner	 arcs	 depict	 the	 maturation	 potential	 of	 haematopoietic	
progenitors.	Both	CMPs	and	CLPs	can	give	rise	to	DCs	[8],	as	depicted	by	the	arrowheads.	
Modified	 from	 [78]	 ©	 Macmillan	 Magazines	 Ltd.	 HSC,	 haematopoietic	 stem	 cell;	 DC,	
dendritic	cell;	CMP,	common	myeloid	progenitor;	CLP,	common	lymphoid	progenitor;	LMPP,	
lymphoid-primed	 multipotent	 progenitor;	 EPLM,	 early	 progenitor	 with	 lymphoid	 and	
myeloid	potential.	
	
The	arrangement	of	mature	cell	fates	is	supported	by	mapping	of	TF	expression;	cell	fates	
that	 are	 placed	 adjacent	 to	 each	 other	 have	 been	 shown	 to	 share	 similar	 TF	 expression	
patterns	 [78,	79].	Additionally,	 this	arrangement	of	 cell	 lineages	 is	also	 supported	by	 the	
possibility	 of	 bipotent	 progenitor	 cells	 and	 infers	 the	 existence	 of	 only	 certain	 bipotent	
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progenitors.	For	example,	monocyte-DC	progenitors	and	MEPs	exist,	while	a	megakaryocyte-
T-lymphocyte	bipotent	progenitor	has	not	yet	been	described.	However,	it	should	be	noted	
that	this	model	is	not	consistent	with	some	progenitors	that	have	been	previously	identified.	
In	particular,	ETP	progenitors	do	not	differentiate	into	B-lymphocytes	but	possess	GM,	DC,	
NK	lymphocyte	and	T-lymphocyte	potential	[80-82].	Additionally,	T-lymphocyte,	but	not	B-
lymphocyte,	potential	has	been	detected	in	the	preGM	compartment	of	the	mouse	BM	[77].	
Lastly,	 a	 monocyte-B-lymphocyte	 bipotent	 progenitor	 has	 been	 described,	 but	 the	 DC	
potential	of	 this	 cell	has	not	yet	been	 investigated	 [83,	84].	As	 the	authors	 state,	 certain	
environments	and	factors	may	alter	the	availability	and	loss	of	potential	cell	fates,	explaining	
such	progenitors.	
	
Although	the	pairwise	relationship	model	outlines	a	less	restrictive	and	more	flexible	model	
of	haematopoiesis,	it	does	not	describe	a	detailed	haematopoietic	hierarchy.	As	such,	Figure	
1.4	shows	the	mapping	of	a	number	of	previously	described	progenitor	cells	to	the	pairwise	
relationship	model.	The	CLP	and	EPLM	have	been	combined	in	Figure	1.4	given	their	similar	
maturation	 potentials	 [66,	 75,	 76].	 As	 described	 for	 Figure	 1.3,	 each	 arc	 represents	 the	
lineage	potential	of	a	given	cell.	Again,	cells	can	only	mature	along	a	path	that	does	not	result	
in	a	gain	of	 lineage	potential.	 The	CMP	cannot	give	 rise	 to	a	CLP	or	EPLM,	as	 this	would	
require	the	resoration	of	lymphoid	potential.	However,	it	can	give	rise	to	GMPs	and	MEPs.	
The	 figure	 depicts	 multiple	 paths	 of	 differentiation	 to	 end	 cell	 types	 and	 forgoes	 the	
restrictive	 nature	 of	 past	models.	 For	 example,	 neutrophils	 can	 be	 generated	 from	both	
CMPs	and	LMPPs	(Figure	1.5)	[67,	73].	Similarly,	Ishikawa	et	al.	have	shown	that	CLP-	and	
CMP-derived	 DCs	 are	 indistinguishable	 from	 each	 other,	 indicating	 two	 routes	 of	 DC	
differentiation	[8].	
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Figure	1.4.	HSPC	hierarchy	applied	to	the	pairwise	relationship	model.	The	maturation	potential	of	HSPCs	is	depicted	by	the	inner	arcs.	HSPC,	
haematopoietic	stem	and	progenitor	cell;	HSC,	haematopoietic	stem	cell;	MPP,	multipotent	progenitor;	LMPP,	lymphoid-primed	multipotent	
progenitor	[73];	CMP,	common	myeloid	progenitor	[67];	CLP,	common	lymphoid	progenitor	[66];	EPLM,	early	progenitor	with	 lymphoid	and	
myeloid	 potential	 [75];	MEP,	megakaryocyte-erythroid	 progenitor	 [67];	GMP,	 granulocyte-macrophage	 progenitor	 [67];	 DC/Pro-B,	 dendritic	
cell/B-lymphocyte	progenitor	[85];	Mon/B/DC?,	monocyte/B-lymphocyte	progenitor	(dendritic	cell	potential	has	not	been	assessed)	[83,	84,	86];	
EoGM,	 eosinophil-neutrophil-monocyte	 progenitor;	 Eo/B-CFU,	 eosinophil/basophil	 progenitor	 [87];	 NK/T,	 natural	 killer	 lymphocyte/T-
lymphocyte	progenitor	[74];	Mon/DC,	monocyte/dendritic	cell	progenitor	[88].	
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Figure	1.5.	Alternative	developmental	 routes	of	HSCs	 towards	neutrophils.	 The	 red	 solid	
arrows	depict	routes	that	have	been	confirmed	by	previous	studies,	while	the	blue	dashed	
arrow	depicts	putative	routes.	HSC,	haematopoietic	stem	cell;	MPP,	multipotent	progenitor;	
LMPP,	 lymphoid-primed	multipotent	progenitor;	CMP,	common	myeloid	progenitor;	GMP,	
granulocyte-macrophage	progenitor;	EoGM,	eosinophil-neutrophil-monocyte	progenitor.	
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1.3			Decision-making	during	haematopoiesis	
	
1.3.1			A	stochastic	model	of	haematopoiesis	
	
Whether	the	behavior	of	cells	can	be	described	as	a	stochastic	process	has	been	a	matter	of	
debate	since	 the	1960s.	 In	 the	case	of	haematopoiesis,	various	aspects	of	 the	behavior	of	
haematopoietic	 cells	 appear	 to	be	 governed	 in	 a	 random	manner.	 These	 include	 the	 self-
renewal	of	HSCs,	differentiation	and	lineage	commitment	of	HSPCs,	and	death	of	these	cells	
by	apoptosis.	In	the	case	of	lineage	commitment,	the	adult	organism	is	generated	from	an	
embryo	in	seemingly	flawless	and	predictable	manner.	At	first	sight,	it	might	seem	odd	that	
random	cellular	events	can	underlie	this	process.	However,	the	throw	of	a	dice	enough	times	
gives	rise	to	the	same	and	predictable	number	of	1s,	2s,	3s	etc.	Such	behaviour,	together	with	
environmental	influences,	can	give	rise	to	a	proper	and	predictable	outcome	during	normal	
development.	This	premise	underlies	a	stochastic	model	of	haematopoiesis.	
	
	
1.3.1.1			Stochastic	self-renewal	and	differentiation	of	HSPCs	
	
The	notion	that	stochastic	events	might	occur	during	haematopoiesis	was	first	proposed	by	
Till	and	colleagues	in	1964	[89].	These	workers	examined	the	extent	to	which	HSPCs	undergo	
self-renewal	as	compared	to	differentiation	or	death.	Individual	HSPCs	are	capable	of	forming	
discrete	colonies	in	the	spleen	of	a	mouse	when	transplanted	into	an	irradiated	host	[90].	The	
group	 performed	 serial	 transplantation	 experiments	 and	 examined	 the	 number	 of	 CFUs	
within	spleen	colonies	[89].	Ten	days	post-transplantation,	Till	et	al.	prepared	cell	suspensions	
from	 individual	 spleen	 colonies	 from	 the	 recipient	 mice,	 performed	 a	 second	 set	 of	
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transplantation	 experiments,	 and	 counted	 the	 number	 of	 spleen	 colonies	 in	 secondary	
recipients	after	10-14	days.	As	to	the	spleen	colonies	observed	in	the	secondary	recipients,	
the	 number	 present	 in	 each	 mouse	 was	 not	 uniform.	 The	 data	 obtained	 followed	 a	 γ-
distribution,	and	Till	et	al.	concluded	that	the	distribution	of	spleen	colony	forming	units	(CFU-
S)	 within	 each	 of	 the	 spleen	 colonies	 was	 variable	 [89].	 	 The	 group	 proposed	 that	 the	
frequency	of	CFU-S	within	an	individual	spleen	colony	was	due	to	a	‘birth	and	death’	process.	
Using	 a	 Monto	 Carlo	 method	 [91],	 a	 mathematical	 equation,	 the	 authors	 concluded	 the	
process	 in	 which	 CFU-S	 undergo	 self-renewal	 (birth)	 and	 differentiation	 (or	 death)	 was	
stochastic.	In	1973,	the	Till	group	provided	further	evidence	to	support	the	notion	that	the	
self-renewal	and	differentiation	of	CFU-S	is	a	stochastic	process.	Using	the	same	approach	as	
before	 [89],	 	 they	 examined	 the	 differentiation	 of	 CFU-S	 towards	 the	 erythroid	 and	
granulocyte	 lineages	 [92].	 The	authors	 concluded	 that	 the	 fate	of	CFU-S	 is	determined	by	
random	probabilities	of	the	cell	undergoing	either	self-renewal,	granulocytic	differentiation	
or	erythroid	differentiation.	They	also	reported	that	a	granulocytic	fate	is	favoured	over	an	
erythroid	fate	by	a	factor	of	10.	
	
In	1982,	Humphries	et	al.	performed	experiments	whereby	the	non-adherent	cells	generated	
from	 a	 primary	 BM-derived	 cell	 line	 were	 seeded	 into	methylcellulose	 cultures	 [93].	 The	
number	of	CFUs	in	each	of	the	secondary	colonies	were	found	to	be	heterogeneous	in	their	
capacity	 to	 generate	 tertiary	 colonies.	 The	 results	 could	 not	 be	 explained	 by	 Poisson	
distribution,	and	Humphries	et	al.	concluded	the	self-renewal	versus	differentiation	of	CFUs	
during	colony-formation	is	governed	by	a	stochastic	process.	Similar	results	were	obtained	
when	the	experiments	were	repeated	using	fresh	whole	BM.	The	following	year,	the	Ogawa	
group	 examined	 the	 extent	 to	which	 spleen	 colonies	 are	 capable	 of	 forming	 granulocyte-
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erythroid-megakaryocyte-macrophage	colonies	(CFUs-GEMM)	or	colonies	of	blast	cells	(CFU-
blast)	 in	vitro	[94].	The	group	reported	that	the	number	of	CFU-blast	and	CFU-GEMM	cells	
generated	from	each	spleen	colony	was	variable,	and	that	the	data	fit	a	γ-distribution	model.	
In	vitro	 analysis	of	 the	generation	of	T-lymphocyte	and	erythroid	CFUs	have	 led	 to	similar	
findings,	adding	support	to	the	viewpoint	that	self-renewal	versus	differentiation	of	HSPCs	
occurs	in	a	stochastic	manner	[95,	96].		
	
Later	 work	 by	 Abkowitz	 et	 al.	 examined	 the	 extent	 to	 which	 clones	 of	 individual	 HSCs	
contribute	to	haematopoiesis	[97].	Safari	cats	were	used,	which	possess	two	distinct	X-linked	
G6PD	 alleles	 (encoding	 glucose-6-phosphate	 dehydrogenase),	 d-G6PD	 and	 G-G6PD.	
Inactivation	of	the	X	chromosome	during	embryogenesis	is	a	random	process,	and	therefore,	
the	somatic	cells	of	the	Safari	cat	express	either	d-G6PD	or	G-G6PD.	Autologous	BM	cells	were	
transplanted	into	irradiated	Safari	cats	and	the	G6PD	phenotypes	of	peripheral	erythroid	blast	
forming	units	(BFU-Es)	and	granulocyte-macrophage	CFUs	(CFU-GMs)	were	monitored	over	a	
period	of	6	years.	This	work	revealed	that	the	contribution	of	d-G6PD	and	G-G6PD	HSCs	to	
peripheral	progenitors	was	highly	variable	for	up	to	4.5	years	after	transplantation.	After	this	
time,	 the	 contribution	 of	 HSCs	 to	 peripheral	 cells	 stabalised.	 To	 determine	 whether	 this	
pattern	of	HSC	behaviour	was	due	to	chance,	the	authors	performed	computer	simulations	
of	the	experiments	in	which	the	fate	of	HSCs	was	designated	at	random.	The	findings	from	
the	computer	simulations	accurately	mirrored	the	findings	obtained	from	the	in	vivo	analysis.	
Hence,	 the	 results	 suggest	 that	 the	manner	 in	which	 an	 individual	 HSC	 does	 or	 does	 not	
contribute	 to	 steady-state	 haematopoiesis	 at	 any	 given	 time	 is	 governed	 by	 a	 stochastic	
process.	Although,	 it	 should	be	noted	that	 the	simulated	model	did	not	predict	 the	stable	
clonal	contribution	of	HSCs	that	ultimately	occurred	in	the	in	vivo	experiments	[97].	
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In	2000,	Abkowitz	and	colleagues	carried	out	an	analysis	similar	to	the	above	in	mice	[98].	
These	workers	transplanted	a	limited	number	of	glucose	phosphate	isomerase	1	a	(GPI-1a)	
BM	cells	alongside	competitor	GPI-1b	BM	cells	into	irradiated	mice.	The	number	of	peripheral	
granulocytes	generated	from	these	cells	was	assessed	for	30	weeks.	When	individual	mice	
were	compared,	the	ratios	of	GPI-1a/GPI-1b	contribution	to	peripheral	cells	were	found	to	be	
variable	 and	 to	 change	 over	 time.	 As	 before,	 the	 group	 accurately	 reproduced	 the	
experimental	 data	 using	 a	 stochastic	 computational	 model,	 adding	 support	 to	 their	
experiments	performed	in	Safari	cats.	The	Loeffer	group	has	also	examined	the	contribution	
of	DBA/2	and	C57BL/6	fetal	liver	cells	to	peripheral	leukocytes	for	up	to	20	months	following	
competitive	transplantation	into	primary	and	secondary	hosts	[99].	Again,	a	computational	
simulation	was	used	to	examine	the	data	obtained	and	the	authors	reported	that	the	kinetics	
of	the	contribution	of	DBA/2	and	C57BL/6	cells	to	peripheral	leukocytes	in	both	primary	and	
secondary	recipients	fitted	a	stochastic	model.	
	
Evidence	to	support	a	stochastic	model	of	haematopoiesis	has	also	been	obtained	from	the	
analysis	of	restricted	haematopoietic	progenitor	cells	(HPCs).	Recently,	Hyrien	et	al.	employed	
sub-lethal	irradiation	to	generate	a	murine	model	of	stress	erythropoiesis	and	investigated	
the	kinetics	of	murine	erythroid	colony	forming	unit	(CFU-E)	and	BFU-E	recovery	[100].	BM	
CFU-E	and	BFU-E	were	quantified	during	 the	 recovery	phase	using	 in	vitro	colony	 forming	
assays,	and	the	findings	were	compared	to	a	stochastic	computer	simulation	whereby	single	
cells	from	each	cell	type	either	underwent	self-renewal,	differentiation	or	death	at	random.	
The	 authors	 concluded	 that	 emergency	 erythropoiesis	 can	 be	 explained	 by	 a	 stochastic	
process	 and	 that	 the	probability	of	BFU-E	and	CFU-E	 replicating	during	 stress	 is	 increased	
when	compared	to	steady	state	haematopoiesis.	
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1.3.1.2			Stochastic	 lineage	 commitment	 of	 haematopoietic	 stem	 and	
progenitor	cells	
	
In	 1973,	 the	 Till	 group	 reported	 that	 the	 probability	 of	 CFU-S	 undergoing	 commitment	
towards	the	granulocyte	lineage	was	greater	than	the	probability	of	these	cells	undergoing	
commitment	to	the	erythroid	pathway,	and	concluded	that	differentiation	of	CFU-S	towards	
both	granulocyte	and	erythroid	fates	occurs	in	a	random	manner	[92].	Ten	years	later,	Ogawa	
et	al.	extended	this	theory,	and	proposed	that	commitment	of	HPCs	to	all	lineages	is	governed	
by	 a	 stochastic	 process	 [101].	 To	 test	 this	 theory,	 Ogawa’s	 group	 undertook	 in	 vitro	
experiments	to	analyse	the	commitment	of	HSPCs	towards	a	specific	lineage	[102,	103].	In	
their	 first	study,	Suda	et	al.	 isolated	single	cells	 from	primary	blast	cell	colonies	 (prepared	
from	 suspensions	 of	 mouse	 spleen	 cells)	 and	 performed	 methylcellulose	 colony	 forming	
assays	to	determine	their	patterns	of	lineage	commitment	[102].	The	authors	noted	that	the	
blast	 colony-derived	 cells	 generated	 colonies	 that	 contained	 variable	 combinations	 of	 cell	
lineages,	and	reported	that	the	types	of	cells	generated	by	each	colony	displayed	no	pattern.	
	
To	further	characterise	the	lineage	specification	of	single	blast	colony-derived	cells,	Suda	et	
al.	performed	a	second	study	whereby	the	lineage	commitment	of	two	cells	that	were	the	
progeny	of	a	single	parent	cell	was	compared	[103].	Single	cells	were	isolated	from	primary	
blast	colonies,	and	cultured	in	methylcellulose	medium	for	18-24	hours	until	one	round	of	cell	
proliferation	 had	 occurred.	 The	 two	 daughter	 cells	 were	 then	 harvested,	 separated	 and	
cultured	under	the	same	conditions.	Colony	forming	assays	were	performed	using	each	of	the	
daughter	cells,	and	the	lineage	composition	of	secondary	and	tertiary	colonies	was	examined.	
Five	hundred	pairs	of	daughter	cells	were	cultured,	and	387	pairs	generated	colonies.	Of	these	
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pairs,	319	pairs	produced	colonies	that	contained	the	same	number	and	types	of	cell	lineages,	
while	for	68	pairs	the	daughter	cells	generated	colonies	that	were	dissimilar.	These	68	pairs	
differed	as	to	their	lineage	combinations,	and	displayed	varying	potency,	from	unipotency	to	
multipotency.	As	not	all	of	the	paired	daughter	cells	displayed	homologous	lineage	potential,	
Suda	and	co-workers	proposed	that	both	the	lineage	commitment	and	lineage	potential	of	
HPC	progeny	are	not	ordered,	and	are	therefore,	governed	by	a	stochastic	process	[103].	
	
The	Ogawa	group	has	performed	similar	studies	using	human	HPCs	and	have	arrived	at	the	
same	conclusion.	 In	1984,	Leary	and	co-workers	prepared	blast	colonies	 from	either	 fresh	
human	cord	blood	or	BM,	and	used	 individual	 cells	 from	 these	blast	 colonies	 to	generate	
secondary	colonies	 [104].	The	 investigators	 then	compared	 the	number	and	 types	of	 cells	
present	in	each	secondary	colony.	The	authors	reported	that	the	types	of	cells	found	in	the	
secondary	colonies	were	variable.	For	example,	one	cell	derived	from	a	blast	colony	formed	
a	secondary	colony	containing	approximately	1,000	eosinophils	and	basophils,	while	another	
cell	 from	 the	 same	 blast	 colony	 generated	 a	 secondary	 colony	 which	 contained	 180	
neutrophils	and	macrophages.	A	year	later,	Leary	and	co-workers	used	a	similar	approach	to	
generate	 paired	 daughter	 cells	 from	My-10+	 cord	 blood-derived	 blast	 colonies	 [105].	 The	
group	 successfully	 generated	 colonies	 from	75	pairs	 of	 daughter	 cells.	When	 the	 colonies	
were	characterised,	forty	of	these	pairs	were	shown	to	generate	homologous	colonies,	while	
the	 other	 35	 pairs	 generated	 non-homologous	 colonies.	 Though	 the	 homologous	 paired	
colonies	displayed	similar	lineage	compositions,	the	colony	size	and	number	of	cells	from	each	
lineage	 was	 variable.	 Thus,	 the	 Ogawa	 group	 reported	 that	 human	 haematopoiesis,	 like	
murine	haematopoiesis,	is	a	stochastic	process.	
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1.3.1.3			Mechanisms	underlying	stochastic	lineage	commitment	
	
In	a	stochastic	model	of	haematopoiesis,	lineage	specification	is	regulated	by	fluctuations	in	
cell-intrinsic	 factors	 that	 occur	 through	 stochastic	 gene	 expression	 and	 competitive	
interactions	between	TFs,	which	eventually	result	 in	the	manifestations	of	specific	 lineage-
associated	transcriptional	programs.	These	 lineage-associated	programs	are	then	enforced	
through	 positive	 feedback	 mechanisms,	 leading	 to	 commitment	 of	 the	 cell	 towards	 a	
particular	 cell	 fate.	 This	 model	 is	 underscored	 by	 studies	 which	 show	 that	 multipotent	
haematopoietic	cells	express	a	number	of	genes	that	are	associated	with	several	different	
lineages.	This	permissive	multilineage	gene	expression	activity	has	been	seen	as	a	state	of	
transcriptional	priming	that	precedes	lineage	commitment.	Due	to	the	limitations	of	isolating	
and	maintaining	HSPCs	from	the	mouse	BM,	early	studies	investigating	the	gene	expression	
of	 multipotent	 haematopoietic	 cells	 made	 use	 of	 haematopoietic	 cell	 lines.	 In	 particular,	
factor-dependent	 cell	 Paterson	 (FDCP)-mix	 cell	 lines	have	been	 indispensable	due	 to	 their	
extensive	self-renewal	capacity	when	cultured	in	the	presence	of	IL-3	[106].	
	
In	 1992,	 Herberlein	 and	 colleagues	 performed	 gene	 expression	 analysis	 of	 a	 number	 of	
different	embryonic	stem	cell	(ESC)	and	HPC	lines,	including	the	FDCP-mix	cell	line	[107].	Using	
reverse	 transcriptase	 polymerase	 chain	 reaction	 (RT-PCR)	 and	 northern	 blot	 analysis,	 the	
authors	showed	that	the	genes	encoding	the	erythropoietin	(Epo)	receptor	(EpoR)	and	the	
erythroid-associated	 TF,	 GATA-1,	 are	 expressed	 in	 erythroid	 committed	 progenitors,	
multipotent	HPCs	and	ESCs.	The	authors	then	performed	DNase	hypersensitivity	analysis	of	
FDCP-mix	 and	 commitment	 progenitor	 cells,	 demonstrating	 that	 the	 accessibility	 of	 the	
chromatin	within	the	EPOR	locus	changes	as	multipotent	cells	commit	to	different	lineages.	
The	chromatin	within	 the	EPOR	 locus	 is	 in	an	open	conformation	 in	multipotent	 cells	 and	
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either	 becomes	 more	 accessible	 as	 these	 cells	 differentiate	 towards	 erythroid	 fates,	 or	
becomes	less	accessible	as	they	differentiate	towards	non-erythroid	fates.	In	the	same	year,	
Jimenez	et	al.	demonstrated	that	the	β-globin	(HBB)	locus	is	DNase	I	hypersensitive	in	FDCP-
mix	 cells,	 but	 not	 in	 granulocytes	 and	 monocytes	 derived	 from	 granulocyte-macrophage	
colony	 stimulating	 factor	 (GM-CSF)/granulocyte	 colony	 stimulating	 factor	 (G-CSF)	 treated	
FDCP-mix	 cells	 [108].	 Thus,	 Jimenez	 and	 colleagues	 reported	 that	 erythroid	 genes	 are	
expressed	in	multipotent	haematopoietic	cells	prior	to	lineage	commitment	[108].	
	
The	Greaves	group	has	observed	the	expression	of	lymphoid-associated	genes	in	FDCP-mix	
cells.	 Using	 RT-PCR	 analysis,	 Ford	 et	 al.	 detected	 expression	 of	 TCRG	 (T-cell	 receptor	 γ)	
transcripts	in	these	cells	[109].	DNase	I	hypersensitivity	analysis	also	revealed	that	FDCP-mix	
cell	chromatin	within	the	 loci	encoding	the	CD3δ	(CD3D)	and	 immunoglobulin	heavy	chain	
(IGH)	proteins	is	in	an	active	conformation	[110].	Differentiation	of	FDCP-mix	cells	towards	
non-T-lymphocyte	lineages	suppresses	TCRG	expression	and	results	in	a	decrease	in	DNase	I	
hypersensitivity	 within	 the	 CD3D	 and	 IGH	 regions	 [109,	 110].	 The	 expression	 of	 other	
lymphoid-associated	genes,	such	as	GZMB,	has	also	been	confirmed	 in	FDCP-mix	cells	and	
human	CD34+	HPCs	[111,	112].	Finally,	both	Ford	et	al.	[113]	and	Zhu	et	al.	[114]	have	shown	
that	 FDCP-mix	 cells	 express	 low	 levels	 of	 the	 gene	encoding	 the	myeloperoxidase	protein	
(MPO),	which	is	associated	with	the	GM	lineage.	
	
The	 studies	 highlighted	 above	 provided	 early	 evidence	 to	 support	 the	 viewpoint	 that	
multilineage	 gene	 expression	 in	 haematopoietic	 cells	 precedes	 lineage	 commitment.	
However,	 these	 studies	 examined	 gene	 expression	 by	 performing	 analysis	 on	 whole	
populations	of	 cells,	 and	do	not	 exclude	 the	possibility	 that	 a	 number	of	 transcriptionally	
distinct	 subpopulations	 exist	 within	 multipotent	 haematopoietic	 cell	 populations.	 To	
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investigate	 this	 premise,	 the	 Enver	 group	 has	 performed	 multiplex	 RT-PCR	 analysis	 of	
individual	 HPCs	 to	 determine	 if	 multiple	 lineage-associated	 transcriptional	 programs	 are	
expressed	simultaneously	in	single	multipotent	cells	[115].	
	
Hu	et	al.	studied	the	expression	of	HPRT,	KIT,	EPOR,	GCSFR,	GATA1,	HBB,	and	MPO	by	single	
FDCP-mix	cells,	and	77	individual	cells	were	successfully	analysed	using	this	assay	[115].	Sixty-
seven	percent	and	61%	of	single	cells	expressed	HBB	and	MPO,	respectively,	and	37%	of	these	
cells	 co-expressed	 these	 genes,	 displaying	 an	 erythroid-macrophage	 expression	 profile.	
Similarly,	 30%	 of	 cells	 co-expressed	HBB	 and	GCSFR,	 and	 were	 considered	 to	 express	 an	
erythroid-granulocyte	 profile.	 Using	 a	 second	 multiplex	 RT-PCR	 assay,	 the	 group	 then	
investigated	the	co-expression	of	HPRT,	and	the	haematopoietic	growth	factor	(HGF)	receptor	
genes,	KIT,	EPOR,	GCSFR,	IL3R,	GMCSFR,	and	MCSFR.	The	findings	demonstrated	that	FDCP-
mix	cells	are	highly	heterogeneous	 in	 regards	 to	 the	expression	of	HGF	receptors,	and	co-
expression	 of	 these	 genes	 was	 noted	 in	 a	 number	 of	 cells.	 For	 example,	 36%	 of	 the	 87	
individual	cells	assayed	were	positive	for	Csf3r,	Kit	and	Csf2r	mRNA,	while	6%	of	single	cells	
co-expressed	 Csf2r	 and	 Epor	 transcripts.	 The	 expression	 of	 multiple	 lineage-associated	
transcripts	was	then	confirmed	in	purified	mouse	Lin−	CD34+	BM	cells,	demonstrating	that	the	
observed	multilineage	expression	was	not	an	artifact	of	the	FDCP-mix	cell	line.	As	such,	Enver	
and	 colleagues	 were	 the	 first	 to	 provide	 evidence	 for	 the	 expression	 of	 several	 distinct	
lineage-associated	 transcripts	 by	 single	 HPCs,	 confirming	 the	 existence	 of	 multilineage	
transcriptional	programed	states	in	multipotent	cells	[115].		
	
In	2002,	Miyamoto	et	al.	provided	further	evidence	to	support	a	model	of	multilineage	gene	
expression	 in	HSPCs	 [116].	Using	 single	cell	RT-PCR,	 the	authors	 first	demonstrated	 that	a	
subpopulation	 of	 HSCs	 (LSK	 CD34−	 Thy1.1lo)	 and	 CMPs	 (LS−K	 CD16/32loCD34+)	 co-express	
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MegE-	and	GM-associated	genes.	Within	the	CMP	population,	39%	of	single	cells	analysed	co-
expressed	HBB,	EPOR,	MPO	and	GCSFR,	and	a	further	9%	expressed	a	combination	of	three	
of	these	genes.	In	comparison,	16%	of	single	HSCs	expressed	three	of	the	four	MegE-	and	GM-
associated	genes,	indicating	a	lower	level	of	promiscuous	gene	expression	in	this	population.	
Lymphoid-associated	gene	expression	was	then	determined	in	HSCs	and	CLPs	(Lin−	Sca1lo	c-
Kitlo	IL-7R+)	using	a	second	multiplex	RT-PCR	primer	set.	Interestingly,	only	9%	of	single	HSCs	
expressed	T-lymphocyte-associated	genes,	while	expression	of	genes	associated	with	the	B-
lymphocyte	 lineage	were	not	detected.	On	the	other	hand,	21%	of	single	CLPs	displayed	a	
promiscuous	lymphoid	profile,	expressing	genes	associated	with	both	the	B-lymphocyte	and	
T-lymphocyte	 lineages.	 Finally,	 the	 authors	 demonstrated	 that	 HPCs	 express	 lineage-
associated	 genes	 at	 much	 lower	 levels	 (approximately	 10-fold	 lower)	 than	 mature	 cells.	
Miyamoto	and	colleagues	concluded	that	promiscuous	multilineage	gene	expression	occurs	
in	both	multipotent	and	oligopotent	HPCs,	and	that	expression	of	MegE-	and	GM-assoicated	
mRNAs	predominates	over	the	expression	of	lymphoid	transcripts	in	HSCs.		
	
While	neither	Hu	et	al.	[115]	nor	Miyamoto	et	al.	[116]	investigated	if	multilineage	expression	
patterns	 in	 single	 cells	 resulted	 in	 translation	of	 functional	proteins,	 Enver	and	colleagues	
have	proposed	that	the	increase	in	expression	and	accessibility	of	particular	gene	loci	during	
differentiation	 demonstrates	 a	 transition	 between	 transcriptional	 priming	 and	 protein	
expression	 [115].	 In	 this	 transcriptionally	 primed	 state,	 multilineage	 gene	 expression	 is	
governed	by	stochastic	fluctuations	in	cell-intrinsic	factors,	such	as	lineage-determining	TFs.	
Stochastic	fluctuations	in	cell-intrinsic	factors	have	been	studied	in	many	organisms	and	are	
thought	 to	 propagate	 ‘gene	 expression	 noise’	 through	 TF	 networks	 to	 provide	 cell-to-cell	
individuality	(reviewed	in	[117]).	
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In	2008,	Chang	et	al.	proposed	that	stochastic	fluctuations	in	gene	expression	in	HPCs	reflect	
transitions	 through	 metastable	 states	 which	 confer	 priming	 of	 cells	 towards	 particular	
lineages	[118].	The	authors	isolated	cells	from	a	mouse	Erythroid-Myeloid-Lymphoid	(EML)	
cell	 line	according	to	the	levels	of	Sca1	expressed	on	their	surface,	dividing	the	population	
into	Sca1lo,	Sca1med	and	Sca1hi	fractions.	When	maintained	 in	vitro	for	over	9	days,	all	Sca1	
fractions	were	capable	of	generating	a	cell	population	that	displayed	a	similar	Sca1	surface	
expression	profile	as	the	parent	population.	To	determine	if	this	behaviour	could	be	explained	
by	a	stochastic	model,	Chang	and	colleagues	performed	computer	simulations	 [118].	They	
reported	that	the	experimental	data	could	only	be	described	by	a	stochastic	process	in	which	
cells	are	attracted	towards	particular	pseudo-subpopulations.	Thus,	the	authors	proposed	the	
existence	of	transitional	stable	cellular	states	that	are	briefly	maintained	by	the	equilibrium	
of	intrinsic	factors.	
	
Chang	et	al.	then	examined	the	lineage	potential	of	the	Sca1lo,	Sca1med	and	Sca1hi	EML	cells	
to	 investigate	 whether	 fluctuations	 in	 Sca1	 expression	 marked	 distinct	 functional	
subpopulations	[118].	When	cultured	in	the	presence	of	Epo	immediately	after	isolation,	the	
Sca1lo	 fraction	 generated	 erythroid	 cells	 more	 efficiently	 than	 the	 other	 populations.	
Conversely,	the	Sca1hi	cells	were	the	most	efficient	at	generating	myeloid	cells	(Mac+/Gr-1+)	
when	stimulated	with	GM-CSF	immediately	after	sorting.	If	the	Sca1lo,	Sca1med	and	Sca1hi	EML	
cells	were	stimulated	with	Epo	7,	14	and	21	days	after	 isolation,	the	variation	 in	erythroid	
potential	was	seen	to	gradually	disappear	over	time.	This	loss	of	distinct	erythroid	potentials	
reflected	the	change	in	Sca1	expression	profiles.	The	authors	then	investigated	whether	the	
disparities	 in	 lineage	potential	 immediately	 following	 isolation	was	due	 to	variation	 in	 the	
expression	of	lineage-determining	TFs.	Analysis	of	protein	and	transcript	expression	revealed	
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that	GATA-1	expression	was	highest	in	erythroid-primed	Sca1lo	EML	cells,	while	expression	of	
PU.1,	 a	 GM-lymphoid-associated	 TF,	 was	 highest	 in	 Sca1lo	 cells.	 The	 differences	 in	 gene	
expression	between	cells	were	steadily	lost	over	a	period	of	two	weeks.	Lastly,	Chang	et	al.	
performed	microarray	mRNA	expression	analysis	to	show	that	the	fluctuations	in	GATA-1	and	
PU.1	seen	in	EML	subpopulations	reflected	variations	in	global	gene	expression	[118].	
	
These	findings	indicate	that	differentiation	of	a	cell	towards	a	particular	lineage	is	governed	
by	 the	 transition	 of	 cells	 through	 metastable	 states	 that	 display	 differing	 affinities	 for	
particular	cell	fates.	As	highlighted	by	Chang	et	al.,	these	transitions	appear	to	occur	due	to	
fluctuations	 in	 cell-intrinsic	 factors,	 such	 as	 lineage-determining	 TFs,	 which	 generate	
transcriptome	wide	noise	and	mediate	lineage	specification	[118].		Studies	of	prokaryotic	and	
eukaryotic	cells	have	shown	that	stochastic	fluctuations	in	gene	expression	are	affected	by	
many	 factors,	 including	 cell	 size	 and	 location	 of	 gene	 loci	 [119-122].	 However,	 studies	
investigating	regulation	of	gene	expression	during	haematopoietic	lineage	specification	have	
largely	 focused	on	 interactions	between	 lineage-associated	TFs.	 In	particular,	 the	mutually	
antagonistic	interactions	between	GATA-1	and	PU.1	have	been	extensively	characterised.		
	
In	 1999,	 Rekhtman	 and	 co-workers	 provided	 the	 initial	 evidence	 for	 a	 direct	 interaction	
between	PU.1	and	GATA-1	using	a	erythroleukaemia	cell	line	[123].	Using	a	combination	of	
glutathione	S-transferase	pull	down	and	immunoprecipitation	assays,	PU.1	and	GATA-1	were	
shown	to	directly	interact	through	their	respective	DNA	binding	domains.	The	binding	of	PU.1	
to	GATA-1	was	then	shown	to	result	in	a	dose-dependent	inhibition	of	GATA-1	transcriptional	
activity,	suggesting	that	the	aberrant	expression	of	PU.1	by	erythroleukaemia	cells	prevents	
erythroid	specification	and	maintains	the	cells	in	an	undifferentiated	state.	Further	analysis	
provided	evidence	for	such	an	interaction	in	normal	haematopoiesis,	as	ectopic	expression	of	
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PU.1	was	shown	to	reduce	normal	erythropoiesis	in	Xenopus	embryos.	Increasing	the	levels	
of	GATA-1	expression	in	these	cells	restored	erythropoiesis	to	normal	levels.	
	
Since	the	study	by	Rekhtman	and	colleagues	[123],	a	number	of	others	have	reported	similar	
findings	[124-126],	and	have	shown	that	GATA-1	is	capable	of	inhibiting	PU.1	activity	[127,	
128],	indicating	that	a	cross-inhibitory	relationship	exists	between	the	two	TFs.	For	example,	
the	Graf	group	has	shown	that	ectopic	expression	of	GATA-1	in	chicken	myoblasts	decreases	
expression	of	a	myeloid	associated	marker,	major	histocompatibility	complex	(MHC)	class		II	
γ	chain,	and	increases	expression	of	EOS47,	a	marker	for	eosinophils	[127].	By	using	a	PU.1	
responsive	luciferase	reporter	construct,	the	authors	reported	that	GATA-1	was	capable	of	
inhibiting	 PU.1	 transcriptional	 activity.	 The	 Graf	 group	 demonstrated	 that	 the	 interaction	
between	PU.1	and	GATA-1	is	mediated	via	their	respective	DNA	binding	motifs	[127],	adding	
support	to	the	findings	of	Rekhtman	et	al.	[123].	
	
Given	 the	 interactions	 between	 PU.1	 and	 GATA-1,	 the	 two	 TFs	 are	 thought	 to	 form	 a	
competitive	transcriptional	network,	or	developmental	switch,	that	primarily	regulates	the	
choice	 between	 the	GM-lymphoid	 and	MegE	 lineages.	 Once	 this	 developmental	 switch	 is	
triggered,	the	selected	lineage-associated	transcriptional	program	is	thought	to	be	reinforced	
through	 autoregulatory	 feedback	 mechanisms	 in	 which	 TFs	 positively	 self-regulate	
themselves.	These	autoregulatory	 loops	have	been	identified	for	PU.1	[129],	GATA-1	[130]	
and	a	number	of	other	lineage-associated	TFs	[131,	132].	
	
Other	lineage-determining	TF	factors	have	been	shown	to	directly	interact	with	each	other,	
providing	evidence	to	support	the	existence	of	other	developmental	switches	that	regulate	
lineage	 commitment.	 For	 example,	 the	 ratio	 of	 MafB	 to	 PU.1	 expression	 mediates	 the	
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differentiation	of	myeloid	progenitor	cells	towards	either	a	macrophage	or	DC	fate	 in	vitro	
[133],	 and	 CCAAT	 enhancer-binding	 protein	 α	 (C/EBPα),	 a	 granulocyte-associated	 TF,	 has	
been	shown	to	antagonise	PU.1	to	promote	a	granulocyte	rather	than	a	DC/macrophage	fate	
[134,	135].	Similarly,	co-operative	and	inhibitory	interactions	between	GATA-2	and	PU.1	have	
been	shown	to	be	important	in	the	differentiation	of	mast	cells	[136].	The	Akashi	group	has	
also	shown	that	the	order	in	which	TFs	are	expressed	is	important	for	lineage	commitment	
[137].	 Iwasaki	et	 al.	 transduced	mouse	 CLPs	with	 a	 gene	 construct	 that	 enforced	 C/EBPα	
expression	 and	 reported	 that	 these	 cells	 almost	 exclusively	 formed	 GM	 cells	 in	
methylcellulose	colony	forming	assays	[137].	When	CLPs	were	transduced	to	express	C/EBPα,	
and	then	GATA-2	24	hours	later,	they	only	gave	rise	to	eosinophil	colonies.	Strikingly,	if	CLPs	
were	 forced	 to	 express	 GATA-2	 first,	 followed	 by	 C/EBPα,	 they	 generated	 mostly	
basophils/mast	cells.	Thus,	the	authors	concluded	that	a	hierarchy	exists	in	which	step-wise	
expression	of	specific	TFs	drives	particular	fates.	While	the	list	of	TF	networks	highlighted	here	
is	not	exhaustive,	it	provides	an	overview	of	the	complex	interplay	that	occurs	between	TFs	
in	 haematopoietic	 cells.	 The	 existence	 of	 such	 TF	 developmental	 switches	 has	 increased	
support	for	a	stochastic	model	of	haematopoiesis.		
	
Most	of	 the	 studies	 investigating	 the	existence	of	 TF-driven	developmental	 switches	have	
relied	 on	 the	 use	 of	 cell	 lines,	 ectopic	 expression	 systems	 and	 the	 analysis	 of	 whole	
populations.	However,	in	2016,	Hoppe	et	al.	examined	the	co-expression	of	GATA-1	and	PU.1	
by	 individual	endogenous	HSPCs	from	mouse	BM	[138].	The	authors	developed	a	knock-in	
reporter	mouse	model	that	expresses	functional	GATA-1:mCherry	and	PU.1:eYFP	(enhanced	
yellow	 fluorescent	 protein),	 and	 examined	 the	 HSC,	 CMP	 and	 GMP	 compartments	 to	
determine	 if	 GATA-1	 and	 PU.1	 are	 co-expressed	 in	 a	 single	 cell	 at	 any	 time	 during	
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haematopoiesis.	Within	 the	CMP	population	 there	were	 two	discrete	 subpopulations	 that	
could	be	identified	based	on	GATA-1-mCherry	and	PU.1-eYFP	expression;	the	first	exclusively	
expressed	 high	 levels	 of	 PU.1-eYFP,	 while	 the	 second	 expressed	 high	 levels	 of	 GATA-1-
mCherry	with	low	to	no	expression	of	PU.1-eYFP.	When	these	cells	were	characterised	using	
colony	forming	assays,	the	results	showed	that	the	PU.1hi	GATA-1−	population	was	restricted	
to	the	GM	population,	while	the	PU.1−/lo	GATA-1hi	population	was	composed	of	distinct	GM-	
and	MegE-restricted	progenitors.	A	small	number	of	PU.1+	GATA-1+	GMPs	were	also	detected,	
but	these	were	shown	to	lack	MegE	potential.	When	analysing	the	LSK	CD150+	CD48−	CD34−	
HSC	 compartment,	 the	 authors	 only	 detected	 low	 levels	 of	 PU.1-eYFP	 expression.	 In	
contradiction	 with	 a	 stochastic	 model	 of	 haematopoiesis,	 these	 findings	 indicate	 that	 no	
multipotent	 HSPC	 population	 is	 maintained	 in	 a	 PU.1+	 GATA-1+	 state	 prior	 to	 lineage	
commitment.	
	
To	determine	if	HSCs	transitioned	through	a	PU.1+	GATA-1+	phenotype	during	differentiation,	
Hoppe	and	coworkers	cultured	GATA-1:mCherry/PU.1:eYFP	HSCs	in	conditions	that	promoted	
GM	and	MegE	differentiation,	and	tracked	the	fate	of	single	cells	by	expression	of	GATA-1,	
and	CD16/32	which	are	markers	of	GM	maturation	[138].	At	the	time	of	isolation,	these	cells	
were	PU.1lo.	During	differentiation	of	HSCs	towards	a	GM	fate,	eYFP	intensity	increased	over	
time	until	onset	of	CD16/32	expression,	while	GATA-1	expression	was	not	detected	at	any	
time.	On	the	other	hand,	all	HSCs	that	acquired	mCherry	expression	during	tracking	eventually	
committed	 to	a	GATA-1+	PU.1−	MegE	 fate.	Further	analysis	of	 these	cells	 showed	that	 the	
decrease	in	PU.1-eYFP	was	independent	of	GATA-1-mCherry	expression,	and	in	some	cases	
PU.1-eYFP	 expression	 had	 already	 disappeared	 before	 the	 onset	 of	 GATA-1-mCherry	
expression.	As	such,	the	authors	concluded	that	GATA-1	is	not	expressed	at	any	point	during	
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the	GM	differentiation	of	HSCs,	and	that	the	commitment	of	HSCs	towards	a	MegE	fate	does	
not	rely	on	interactions	between	GATA-1	and	PU.1	[138].	
	
Overall,	the	findings	of	Hoppe	et	al.	are	inconsistent	with	a	developmental	PU.1-GATA1	switch	
[138].	 While	 these	 findings	 do	 not	 entirely	 rule	 out	 the	 possibility	 of	 PU.1	 and	 GATA-1	
competitive	 interplay	 occurring,	 they	 strongly	 argue	 against	 a	 stochastic	 model	 of	
commitment	whereby	differentiation	is	initiated	by	a	PU.1/GATA-1	network.	As	this	study	is	
the	first	to	investigate	the	role	of	these	TFs	in	differentiation	at	the	single	cell	level,	further	
work	 will	 be	 required	 to	 confirm	 the	 findings,	 and	 determine	 how	 PU.1	 and	 GATA-1	
expression	are	regulated	in	the	absence	of	developmental	switches.	On	a	technical	note,	it	is	
possible	that	PU.1	and	GATA-1	are	co-expressed	at	levels	below	the	limits	of	detection	for	the	
techniques	 used	 in	 this	 study,	 and	 that	 only	 low	 levels	 of	 expression	 are	 required	 for	
competitive	interactions.	
	
Ultimately,	a	stochastic	model	of	haematopoiesis	concerns	the	apparent	random	behavior	of	
HSPCs.	Early	studies	of	HSPCs	support	this	model	by	demonstrating	that	the	fate	of	a	cell	can	
be	predicted	using	stochastic	computational	simulations.	According	to	these	findings,	cell	fate	
is	 determined	 by	 random	 probabilities	 of	 a	 cell	 undergoing	 self-renewal,	 differentiation,	
lineage	commitment	or	death.	This	would	imply	that	haematopoiesis	is	determined	by	factors	
that	alter	these	probabilities.	It	has	been	suggested	that	stochastic	fluctuations	in	cell-intrinsic	
factors	are	sufficient	to	regulate	such	probabilities.	However,	this	theory	has	been	contested	
[138],	and	the	exact	mechanisms	that	lead	to	established	transcriptional	programs	are	largely	
unknown.	As	such,	the	current	stochastic	model	of	haematopoiesis	cannot	fully	explain	how	
cell	fate	is	determined.	As	an	alternative,	a	model	of	haematopoiesis	has	been	described	in	
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which	the	decisions	of	HSPCs	are	regulated	by	cell-extrinsic	factors,	such	as	HGFs.	This	model,	
known	as	the	deterministic	model	of	haematopoiesis,	will	be	discussed	in	Section	1.3.2.4.	
	
1.3.2			Haematopoietic	growth	factors	
	
HGFs	 shape	haematopoiesis	by	 regulating	 the	 survival,	 proliferation	and	differentiation	of	
haematopoietic	cells.	These	 factors	may	be	expressed	on	 the	cell	 surface	 in	a	membrane-
bound	form	to	provide	growth	signals	through	direct	cell	contact,	or	they	may	be	secreted	by	
the	producing	cell	to	act	in	an	autocrine,	paracrine	or	endocrine	fashion	[139-141].	There	is	a	
wide	range	of	HGFs	with	differing	activities,	including	some	that	are	associated	with	particular	
cell	 lineages,	 and	 others	 that	 act	 on	 multiple	 different	 cell	 types.	 Early	 studies	 of	 HGFs	
characterised	them	according	to	their	ability	to	promote	cell	survival	and	proliferation,	and	
provided	little	evidence	to	suggest	they	played	a	role	in	cell	fate.	This	led	some	to	propose	
that	HGF	act	permissively,	and	that	lineage-associated	factors	provide	committed	progenitor	
cell	 populations	 with	 a	 proliferative	 advantage.	 However,	 as	 techniques	 allowing	 the	
manipulation	of	haematopoietic	cells	in	vitro	advanced,	evidence	supporting	a	role	for	HGFs	
in	the	regulation	of	HSPC	fate	materialised.	These	studies	support	a	deterministic	model	of	
haematopoiesis,	in	which	individual	HGFs	are	capable	of	instructing	the	self-renewal	of	HSCs,	
and	the	differentiation	and	lineage	commitment	of	HSPCs	towards	particular	lineage	fates.	
This	section	will	first	introduce	a	number	of	HGFs	that	are	relevant	to	HSPC	function,	and	then	
discuss	how	the	perceptions	of	HGF	functionality	has	changed	over	time.	Finally,	the	current	
evidence	supporting	a	deterministic	model	of	haematopoiesis	will	be	considered.	
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1.3.2.1			The	 discovery	 and	 early	 history	 of	 haematopoietic	 growth	
factors	
	
The	first	HGF	to	be	described	was	Epo.	In	1906,	Carnot	and	Deflandre	demonstrated	that	the	
production	of	erythrocytes	was	increased	in	rabbits	that	received	a	transfusion	of	serum	from	
hypoxic	animals	[142].	The	authors	proposed	the	existence	of	a	humoral	factor,	which	they	
named	 haemopoietine,	 which	 was	 produced	 to	 stimulate	 erythropoiesis	 during	 hypoxia.	
However,	this	factor,	now	known	as	Epo,	was	not	purified	until	1977	[143],	and	cloning	of	the	
gene	encoding	Epo	was	achieved	in	the	mid-1980’s	[144-146].	EpoR	was	later	cloned	in	1991	
[147,	148],	and	is	the	only	known	receptor	for	Epo.	Epo	is	primarily	produced	by	peritubular	
fibroblasts	 in	the	cortex	of	the	kidneys,	 though	perisinusoidal	cells	and	hepatocytes	 in	the	
liver	have	also	been	shown	to	secrete	Epo	[149].	Early	in	vitro	studies	showed	that	Epo	was	
integral	 for	 the	 proliferation	 [150]	 and,	 subsequently,	 the	 survival	 [151]	 of	 erythroid	
progenitors	(EPs).	As	a	result,	Epo	quickly	became	a	routine	therapeutic	for	the	treatment	of	
anaemia	in	patients	with	renal	disease	[152].	
	
The	next	HGFs	to	be	identified	were	the	colony	stimulating	factors	(CSFs).	These	molecules	
were	first	described	as	factors	that	are	required	for	the	formation	of	haematopoietic	colonies	
in	 vitro.	 In	 1965,	 Pluznik	 and	 Sachs	 reported	 that	 cell	 suspensions	 prepared	 from	mouse	
spleens	were	only	 capable	of	 forming	granulocyte	colonies	 in	 soft	agar	medium	when	co-
cultured	with	 a	 feeder	 layer	 derived	 from	mouse	 embryo	 cells	 [153].	 The	 following	 year,	
Bradley	 and	 Metcalf	 demonstrated	 that	 the	 generation	 of	 mouse	 BM-derived	 myeloid	
colonies	required	the	presence	of	kidney-derived	feeder	cells	[154].	These	findings	 led	the	
authors	of	both	studies	to	propose	that	the	feeder	cells	were	capable	of	producing	factors	
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that	 stimulate	 haematopoietic	 cells	 to	 produce	 colonies.	 Further	 characterisation	 of	 such	
molecules	eventually	led	the	identification	of	4	CSFs.	
	
In	1975,	Stanley	et	al.	purified	the	first	CSF	from	human	urine	[155].	This	CSF	was	capable	of	
stimulating	the	formation	of	mouse	macrophage	colonies	in	vitro,	hence	why	it	is	now	known	
as	macrophage-CSF	(M-CSF).	Mouse	M-CSF	was	later	purified	in	1977	from	medium	that	was	
conditioned	from	intestinal	endocrine	cells	[156].	The	same	year,	GM-CSF,	a	CSF	capable	of	
stimulating	the	formation	of	GM	colonies	in	vitro,	was	purified	from	murine	lung-conditioned	
medium	[157].	Recombinant	murine	GM-CSF	was	successfully	synthesised	in	1984	[158].	A	
third	 CSF,	multi-CSF,	 also	 known	 as	 interleukin-3	 (IL-3),	was	 purified	 from	 leukaemic	 cell-
conditioned	medium	by	Ihle	and	colleagues	in	1982	[159].	Early	studies	of	IL-3	showed	that	is	
required	for	the	maintenance	of	a	number	of	murine	BM-derived	cell	lines	[160],	and	that	it	
promotes	 BM-derived	 CFU	 to	 form	 a	 number	 of	 different	 colony	 types	 in	 vitro,	 including	
macrophage,	granulocytic	and	megakaryocytic	colonies	[161,	162].	The	final	CSF,	G-CSF,	was	
identified	by	Metcalf	and	coworkers	in	1983.	The	group	purified	G-CSF	from	medium	that	was	
conditioned	 by	 murine	 lung	 cells	 [163],	 and	 demonstrated	 that	 it	 was	 highly	 efficient	 at	
stimulating	the	generation	of	granulocytic	colonies	in	vitro	[164].	Studies	have	also	revealed	
that	G-CSF	stimulates	the	mobilisation	of	HSPCs	from	the	BM	into	the	blood,	and	so	it	is	now	
commonly	used	in	the	isolation	of	human	haematopoietic	cells	for	clinical	therapies	[165].	A	
number	of	different	sources	have	been	identified	for	the	production	of	CSFs,	and	some	tissues	
produce	 more	 than	 one	 CSF.	 These	 include	 skeletal	 and	 cardiac	 muscle,	 lung	 and	
haematopoietic	cells	[166,	167].	CSFs	act	on	target	cells	by	binding	their	cognate	receptors,	
M-CSFR	[168],	GM-CSFR	[169],	IL-3R	[170]	and	G-CSFR	[171].
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Figure	1.6.	A	timeline	for	the	discovery	and	early	characterisation	of	haematopoietic	growth	factors.	Citations	are	shown	in	square	brackets.	
Epo,	 erythropoietin;	CSF,	 colony	 stimulating	 factor;	M,	macrophage;	G,	 granulocyte;	GM,	 granulocyte-macrophage;	Mpl,	myeloproliferative		
leukaemia;	IL-1,	interleukin-1;	IL-3,	interleukin-3;	IL-7,	interleukin-7;	Flt3,	fms-like	tyrosine	kinase	3;	BM,	bone	marrow;	CM,	conditioned	medium;	
HSPC,	haematopoietic	stem	and	progenitor	cell.
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IL-3	is	a	member	of	the	interleukin	superfamily	of	HGFs.	This	large	family	of	factors	contains	
many	members.	However,	given	the	purpose	of	this	section,	only	two	other	interleukins	will	
be	discussed,	 interleukin-1	 (IL-1)	and	 interleukin-7	 (IL-7).	 IL-1	was	 the	 first	member	of	 the	
interleukin	 family	 to	 be	 described,	 and	 was	 purified	 from	 human	 monocyte-conditioned	
medium	in	1980	[172].	IL-1	exists	in	two	forms,	IL-1α	and	IL-1β	[173],	and	is	extremely	diverse	
in	 regards	 to	 its	 function.	 These	molecules	 primarily	 act	 as	 pro-inflammatory	 agents,	 but	
recent	evidence	has	shown	that	IL-1	also	acts	on	HSPCs	[174,	175].	IL-1	is	expressed	mostly	
by	mature	haematopoietic	cells,	such	as	myelomonocytic	cells	[176,	177]	and	lymphocytes	
[178],	but	it	is	also	expressed	by	epithelial	cells	[179,	180]	and	fibroblasts	[181].	There	are	two	
IL-1	receptors,	IL-1	receptor	type	I	mediates	IL-1	signalling,	while	IL-1	receptor	type	II	exists	as	
a	cell	surface	receptor	and	a	soluble	receptor	to	inhibit	the	action	of	IL-1	[182,	183].		
	
IL-7	was	first	identified	by	Namen	et	al.	in	1988	[184].	The	authors	cloned	the	IL7	gene	from	
BM	stromal	cells,	and	then	demonstrated	its	ability	to	promote	proliferation	of	B-lymphocyte	
progenitors.	IL-7	was	also	shown	to	be	important	for	T-lymphocyte	progenitors,	as	addition	
of	IL-7	to	thymic	organ	cultures	greatly	increased	the	generation	of	thymocytes	[185].	IL-7	is	
primarily	 expressed	 by	 stroma	 cells	 in	 the	 thymus,	 spleen	 and	 BM	 [186-188],	 but	 is	 also	
expressed	by	intestinal	epithelium	[189]	and	keratinocytes	[190].	IL-7	signals	through	a	single	
receptor,	IL-7R	[191].	
	
In	1990,	Zsebo	et	al.	identified	a	HGF	that	is	capable	of	maintaining	primitive	haematopoietic	
cells	in	vitro	[192].	They	treated	mice	with	5-fluorouracil,	an	agent	that	induces	apoptosis	in	
highly	proliferative	cells,	and	harvested	BM	cells	2	days	later.	The	BM	samples,	which	were	
enriched	for	early	HSPCs,	were	shown	to	require	rat	liver	cell-conditioned	medium	to	form	
colonies	when	cultured	in	soft	agar.	Zsebo	and	coworkers	identified	and	isolated	a	molecule	
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from	the	conditioned	medium	and	reported	that	it	acts	synergistically	with	other	factors,	such	
as	IL-1,	to	promote	expansion	of	HSPCs.	They	concluded	that	this	molecule,	commonly	known	
as	stem	cell	factor	(SCF),	acted	on	pre-CFUs	to	activate	and	sensitise	them	to	other	HGFs.	SCF	
was	 cloned	 later	 that	 year	 [139],	 and	 its	 receptor	 was	 identified	 as	 c-Kit	 [193],	 which	 is	
primarily	expressed	by	early	HSPCs	[194].	
	
Shortly	 after	 the	 isolation	of	 SCF,	 another	 stem	and	progenitor	 cell	 factor-ligand	pair	was	
identified.	In	1991,	Matthews	et	al.	cloned	a	receptor	that	is	predominantly	expressed	by	fetal	
liver	HSPCs	in	mice	[195].	The	authors	identified	the	receptor	as	a	member	of	the	tyrosine	
kinase	receptor	family,	and	named	it	fetal	liver	kinase-2,	though	it	is	more	commonly	known	
as	Flt3.	The	ligand	for	Flt3	(Flt3L)	was	later	cloned	from	a	murine	T-lymphocyte	line	in	1993,	
and	was	shown	to	stimulate	the	proliferation	of	early	murine	HSPCs	enriched	from	the	fetal	
liver,	and	human	CD34+	BM	cells	[196].	Since,	Flt3L	has	been	shown	to	be	important	for	the	
development	and	function	of	DCs	[197].	
	
In	 1989,	 Wendling	 and	 co-workers	 reported	 that	 murine	 BM	 HSPCs	 infected	 with	
myeloproliferative	 leukemia	 (Mpl)	 virus	 were	 capable	 of	 forming	 colonies	 in	 semisolid	
medium	in	the	absence	of	supplementary	HGFs,	such	as	Epo	or	IL-3	[198,	199].	When	cloning	
the	virus,	the	group	identified	a	gene	encoding	a	protein	that	shared	sequence	and	structural	
similarities	with	numerous	HGF	receptors	[200].	This	led	to	the	identification	and	cloning	of	a	
human	homolog	[201],	named	the	Mpl	receptor,	which	was	shown	to	be	primarily	expressed	
by	 megakaryocytes	 [202].	 This	 led	 to	 the	 eventual	 purification	 and	 cloning	 of	 its	 ligand,	
thrombopoietin	(Tpo),	in	1994	[203-205].	While	Tpo	was	quickly	identified	as	an	important	
regulator	of	thrombopoiesis/megakaryocytopoiesis	[206],	it	regulates	HSC	quiescence	[207],	
and	 has	 been	 shown	 to	 protect	 a	 number	 of	 tissues	 against	 ischaemia	 [208,	 209].	 Tpo	 is	
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predominately	expressed	by	hepatocytes	in	the	liver,	but	it	is	also	synthesised	in	the	spleen,	
kidney,	BM	and	brain	[210,	211].	See	Figure	1.6	for	a	timeline	of	the	discovery,	purification	
and	cloning	of	the	HGFs	discussed	above.	
	
1.3.2.2			The	mitogenic	and	pro-survival	properties	of	haematopoietic	
growth	factors	
	
Initial	characterisation	of	HGFs	demonstrated	that	they	were	essential	for	the	formation	of	
haematopoietic	colonies	in	vitro.	At	the	time,	it	was	unclear	whether	HGFs	acted	to	stimulate	
cell	cycling,	cell	survival,	or	both.	Early	studies	 investigating	the	function	of	HGFs	provided	
evidence	 that	 they	 were	 capable	 of	 recruiting	 cells	 into	 active	 cell	 cycling.	 This	 was	 first	
demonstrated	in	the	1980s	using	conditioned	medium	containing	CSFs.	Using	lung-,	spleen-	
and	 leukaemic	 cell-conditioned	 medium	 as	 a	 source	 of	 CSFs,	 Pluznik	 and	 co-workers	
investigated	 the	 effects	 of	 CSFs	 on	 the	 cell	 cycle	 kinetics	 of	 a	 GM-CSF-dependent	 mast	
cell/basophil	 line,	PT-18	 [212].	 Following	culture	 in	 the	presence	of	CSF,	propidium	 iodide	
staining	revealed	that	CSF	stimulation	increased	the	proportion	of	PT-18	cells	in	the	G2	+	M	
and	S	phases	of	the	cell	cycle.	In	addition,	the	incorporation	of	[3H]-thymidine	into	PT-18	cells	
was	increased	following	culture	with	CSFs.	
	
In	1987,	London	et	al.	investigated	the	effects	of	a	number	of	HGFs,	including	IL-3	and	GM-
CSF,	on	the	cell	cycle	status	of	an	IL-3-dependent	myeloid	progenitor	cell	line,	FDCP-1,	and	an	
IL-3	dependent	lymphoid	progenitor	cell	line,	FL5.12	[213].	By	monitoring	the	DNA	and	RNA	
content	of	haematopoietic	cells	using	acridine	orange,	the	authors	demonstrated	that	IL-3,	
but	not	GM-CSF,	is	capable	of	recruiting	FDCP-1	and	FL5.12	cells	from	a	quiescent	state	into	
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active	cycling.	However,	once	cells	were	drawn	into	active	cycling	by	IL-3,	GM-CSF	was	capable	
of	 maintaining	 proliferation.	 Although	 this	 demonstrates	 that	 both	 HGFs	 are	 capable	 of	
stimulating	cell	proliferation,	the	authors	concluded	that	GM-CSFR	is	likely	to	be	absent	from	
quiescent	 HSPCs	 and	 that	 its	 expression	 is	 stimulated	 by	 IL-3	 signalling.	 Shortly	 after	 this	
study,	Spivak	and	co-workers	used	an	erythroleukaemic	cell	line,	HCD-17,	to	demonstrate	the	
mitogenic	 activity	 of	 Epo	 [214].	 When	 stimulated	 with	 Epo,	 the	 incorporation	 of	 [3H]-
thymidine	and	[3H]-uridine	into	HCS-17	cells	increased	significantly	when	compared	to	cells	
cultured	without	Epo,	indicating	an	increase	in	DNA	and	RNA	synthesis,	respectively.	Further	
investigation	demonstrated	that	Epo	recruited	the	factor-deprived	HCS-17	into	the	S-phase.	
These	reports	were	shortly	followed	by	a	number	of	studies	showing	that	other	HGFs,	such	as	
M-CSF	[215],	IL-7	[216]	and	SCF	[217],	possess	mitogenic	activity,	and	that	certain	factors	act	
synergistically	to	promote	cell	proliferation	[218,	219].	
	
Similar	studies	of	HGF	activity	have	demonstrated	that	these	factors	also	promote	survival	by	
suppressing	 apoptosis.	 This	 was	 first	 demonstrated	 by	Williams	 et	 al.	 in	 1990	 [220].	 The	
authors	 investigated	 the	 effects	 of	withdrawing	CSFs	 from	a	 number	 of	 factor-dependent	
FDCP-1	and	FDCP-mix	cell	lines.	Withdrawal	of	IL-3,	GM-CSF	and	G-CSF	from	factor-dependent	
cells	 resulted	 in	 DNA	 fragmentation.	 As	 apoptosis	 is	 dependent	 on	 protein	 synthesis,	 the	
authors	treated	factor-deprived	cells	with	cycloheximide,	a	protein	synthesis	 inhibitor,	and	
noted	that	it	significantly	reduced	the	rate	of	cell	death.	In	the	same	year,	two	independent	
studies	 reported	 that	 Epo	 [151]	 and	 IL-3	 [221]	 are	 capable	 of	 suppressing	 apoptosis	 in	
erythroleukaemia	and	multipotent	progenitor	cell	lines,	respectively.	Using	a	similar	approach	
as	Williams	et	al.,	Epo	and	IL-3	were	shown	to	prevent	DNA	fragmentation	in	target	cells	and	
	 40	
increase	cell	viability.	The	same	has	been	shown	for	a	number	of	other	factors,	indicating	that	
suppression	of	cell	death	programs	is	a	common	property	of	HGFs	[222-224].	
	
As	HGFs	display	mitogenic	and	pro-survival	properties,	it	was	of	interest	to	determine	if	these	
responses	 were	 distinct,	 or	 the	 result	 of	 a	 single	 signalling	 pathway.	 This	 required	
characterisation	of	HGF	receptors,	and	studies	of	G-CSFR	[225],	M-CSFR	[226]	and	IL-3R	[227]	
eventually	revealed	that	these	responses	were	independent	of	each	other.	In	the	case	of	G-
CSFR,	Ward	and	 colleagues	have	 reported	 that	 the	proliferative	and	 survival	 responses	of	
human	G-CSF	(hG-CSF)	signalling	are	mediated	by	different	regions	of	the	G-CSFR	cytoplasmic	
domain	 and	 activate	 two	 distinct	 signalling	 pathways	 [225].	 G-CSFR	 contains	 4	 tyrosine	
residues	within	its	cytoplasmic	domain	that	are	phosphorylated	upon	binding	of	G-CSF.	The	
authors	 transduced	a	myeloid	progenitor	cell	 line,	32D,	with	wild-type	 (WT)	G-CSFR	and	a	
series	of	G-CSFR	mutants	lacking	specific	cytoplasmic	tyrosine	residues.	Cells	transduced	with	
G-CSFR	mutants	lacking	all	four	tyrosine	residues	were	capable	of	surviving	in	the	presence	
of	G-CSFR	 for	 10	days	but	did	not	divide.	 This	 response	was	primarily	mediated	by	 signal	
transducer	 and	 activator	 of	 transcription	 (STAT)	 3	 activation.	 The	 cytoplasmic	 tyrosine	
residues	of	G-CSFR	were	required	for	proliferation	of	32D	cells,	particularly	the	residues	at	
positions	704	and	764.	These	residues	were	shown	to	bind	and	activate	the	accessory	proteins	
SHP-2,	Grb2,	and	Shc.	
	
Given	these	findings,	it	quickly	became	well	accepted	that	HGFs	are	required	to	stimulate	the	
proliferation	 and	 survival	 of	 haematopoietic	 cells.	 However,	 the	 role	 of	HGFs	 in	HSC	 self-
renewal	 and	 HSPC	 differentiation/lineage-specification	 was	 less	 clear	 at	 this	 time.	 In	 an	
attempt	to	explain	how	HGFs	influenced	cell	fate,	two	models	of	HGF	activity	were	proposed,	
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a	permissive	model	(Section	1.3.2.3,	Figure	1.7)	and	a	deterministic	model	(Section	1.3.2.4,	
Figure	1.8).		
	
	
1.3.2.3			A	 permissive	 role	 for	 haematopoietic	 growth	 factors	 in	 the	
maintenance	of	haematopoietic	cells	
	
Studies	investigating	the	biological	activity	of	HGFs	indicated	that	a	number	of	these	factors,	
such	 as	 Epo,	M-CSF,	 G-CSF	 and	 IL-7,	 are	 associated	with	 the	 survival	 and	 proliferation	 of	
particular	lineages.	For	example,	Metcalf	and	Johnson	assessed	the	ability	of	Epo	to	stimulate	
mouse	fetal	 liver	cells	to	form	colonies	in	soft	agar.	When	these	cells	were	cultured	in	the	
presence	 of	 spleen	 conditioned	medium,	 they	 generated	multilineage	 colonies.	 However,	
when	cultured	with	Epo	alone,	they	did	not	form	any	colonies	[228].	Epo	was	only	able	to	
stimulate	these	cells	 to	generate	erythroid	colonies	after	 they	had	been	pre-cultured	with	
spleen	 conditioned	 medium.	 In	 the	 same	 year,	 Udupa	 et	 al.	 examined	 its	 effects	 on	
stimulating	 CFU-S,	 CFU-E	 and	 BFU-E	 proliferation	 in	 mice	 following	 administration	 of	
chemotherapeutic	agents	[229].	After	treatment	with	alkylating	agents,	there	was	a	dramatic	
decrease	 in	 the	number	of	BM	CFU-S,	CFU-E	and	CFU-B,	and	 the	authors	monitored	 their	
regeneration	 over	 a	 period	 of	 14	 days.	 Daily	 injections	 of	 Epo	 following	 treatment	 with	
alkylating	agents	resulted	in	a	significant	increase	in	the	number	of	BM	CFU-E	and	BFU-E	when	
compared	to	control	animals.	However,	the	number	of	CFU-S	following	Epo	treatment	was	
unchanged.	As	such,	the	authors	of	both	studies	concluded	that	pluripotent	cells	only	become	
sensitive	to	Epo	once	they	have	become	committed	towards	the	erythroid	lineage.	
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Early	 studies	 of	 G-CSF	 suggest	 that	 it	 primarily	 acts	 on	 committed	 progenitors.	 In	 1983,	
Metcalf	 and	 Nicola	 performed	 colony	 forming	 assays	 with	 mouse	 BM	 and	 fetal	 liver	 to	
examine	if	G-CSF	could	promote	colony	formation	in	vitro	[164].	When	BM	and	fetal	liver	cells	
were	 treated	 with	 serum-containing	 medium	 supplemented	 with	 G-CSF,	 they	 exclusively	
formed	colonies	containing	GM	cells.	When	monitoring	BM	and	fetal	liver	cultures	that	were	
treated	with	G-CSF	alone,	the	authors	noted	that	cells	survived	for	a	short	period	of	time	but	
did	not	proliferate,	suggesting	that	G-CSF	has	limited	pro-survival	activity	on	multipotent	cells.	
A	later	study	by	the	Ogawa	group	also	indicates	that	G-CSF	alone	is	ineffective	at	stimulating	
multipotent	cells	to	form	colonies	[230].	When	1,000	BM	cells	were	cultured	in	serum-free	
methylcellulose	 medium	 supplemented	 with	 G-CSF,	 only	 7	 granulocytic	 colonies	 were	
observed.	 However,	 when	 IL-3	 was	 added,	 20	 granulocytic	 colonies,	 1	 GM	 colony	 and	 2	
eosinophil	colonies	were	generated.	When	the	BM	cells	were	cultured	in	serum-containing	
medium	 supplemented	 with	 G-CSF,	 over	 80	 colonies	 containing	 granulocytes	 and/or	
macrophages	formed.	Thus,	Sonoda	et	al.	proposed	that	multipotent	BM	cells	require	factors	
such	as	IL-3	to	survive	and	produce	GM-committed	progenitors,	which	are	sensitive	to	G-CSF.		
	
At	this	time,	other	HGFs	were	considered	to	be	lineage-non-specific	HGFs	that	acted	on	early	
HSPCs.	This	included	factors	such	as	IL-3,	SCF	and	GM-CSF.	GM-CSF	was	initially	thought	to	be	
lineage-specific	 based	 on	 its	 ability	 to	 promote	 the	 formation	 of	 GM	 colonies,	 but	 some	
studies	 showed	 that	 it	was	 also	 capable	 of	 acting	 on	multipotent	 and	 erythroid	 cells.	 For	
instance,	when	 fetal	 liver	 cells	 are	 cultured	 in	GM-CSF	 for	2	days	and	 then	 transferred	 to	
mouse	 spleen	 cell-conditioned	 medium,	 they	 are	 capable	 of	 forming	 multilineage	 and	
erythroid	 colonies	 [231].	 Similarly,	 the	 addition	 of	 GM-CSF	 to	 serum-free	methylcellulose	
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cultures	 containing	 human	 Lin−	 BM	 cells	 allows	 the	 formation	 of	 erythroid,	 GM	 and	
multipotent	colonies	[232].	
	
The	 categorisation	 of	 HGFs	 based	 on	 their	 lineage-specific	 and	 non-specific	 activities	 led	
advocates	 of	 a	 stochastic	 model	 of	 haematopoiesis	 to	 propose	 that	 such	 factors	 do	 not	
influence	the	self-renewal	of	HSCs,	differentiation	of	HSPCs	or	the	 lineage	commitment	of	
these	cells	[233-235].	Instead,	HSPC	fate	is	governed	by	a	cell-intrinsic	stochastic	process	that	
is	facilitated	by	factor-induced	proliferation	and	survival.	In	this	model,	HGFs	are	thought	to	
act	permissively.	In	the	case	of	committed	progenitors,	expression	of	receptors	for	lineage-
specific	HGFs	allows	 for	 the	 selective	expansion	of	 cell	populations.	 For	example,	 in	 cases	
where	 lineage-specific	 HGFs	 promote	 the	 development	 of	 particular	 lineages	 from	
multipotent	 cells,	 it	 is	 thought	 that	 these	 factors	 provide	 a	 proliferative	 advantage	 to	 a	
subpopulation	of	committed	cells,	rather	than	providing	instructive	cues	to	multipotent	cells	
(Figure	1.7).	
	
In	1985,	the	Ogawa	group	published	the	first	study	supporting	a	permissive	role	of	HGFs.	Suda	
et	al.	generated	blast	cell	colonies	using	spleen	cells	from	5-fluorouracil	treated	mice	and	then	
isolated	254	 individual	cells	 from	the	colonies.	 Individual	cells	were	cultured	 in	serum-rich	
medium	containing	IL-3,	and	after	the	first	cell	division	occurred,	the	progeny	were	separated	
within	the	culture	dish	allowing	the	formation	of	two	distinct	colonies	[235].	One-hundred	
and	five	paired	daughter	cells	were	successfully	separated,	and	97	of	these	formed	colonies.	
Sixty-six	 pairs	 formed	 colonies	 with	 the	 same	 lineage-composition.	 However,	 when	
comparing	these	colonies,	the	total	cellularity	and	composition	of	each	cell	type	within	the	
colony	differed	wildly	between	paired	daughter	cells.	The	 remaining	paired	daughter	cells	
formed	colonies	with	differing	 lineage-composition.	Given	 the	variation	between	colonies,	
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the	authors	concluded	that	IL-3	does	not	play	a	role	in	regulating	the	differentiation	and/or	
fate	of	multipotent	cells.		
	
In	1993,	Fairbairn	et	al.		provided	more	evidence	to	support	the	viewpoint	that	cell-extrinsic	
factors	are	not	required	for	differentiation	and/or	cell	fate	determination	[236].	The	authors	
transduced	IL-3-dependent	FDCP-Mix	cells	with	the	human	BCL2	gene,	a	gene	encoding	an	
anti-apoptotic	factor,	and	reported	that	they	were	capable	of	factor-independent	survival	for	
2-3	weeks	in	vitro.	In	comparison,	almost	all	control	FDCP-Mix	cells	transduced	with	an	empty	
vector	died	after	2	days	of	culture	in	the	absence	of	HGFs.	The	BCL2-tranduced	FDCP-Mix	cells	
did	 not	 proliferate	 in	 cultures	 lacking	 HGFs.	 However,	 cytospin	 preparations	 of	 BCL2-
transduced	 FDCP-Mix	 cells	 revealed	 that	 they	matured	 into	 granulocytes,	monocytes	 and	
erythroid	cells	over	an	8-day	period.	Northern	blotting	analysis	of	the	BCL2-transduced	FDCP-
Mix	cells	showed	that	they	did	not	express	the	genes	encoding	GM-CSF	(CSF2),	G-CSF	(CSF3)	
and	 IL-3	 (IL3),	 and	 conditioned	 medium	 from	 these	 cells	 was	 not	 sufficient	 to	 promote	
differentiation	of	untransduced	FDCP-Mix	cells.	This	ruled	out	the	possibility	of	differentiation	
being	 caused	 by	 autocrine	 signalling,	 and	 indicated	 that	 the	 suppression	 of	 apoptosis	 is	
sufficient	for	survival	and	differentiation	of	multipotent	cells	in	the	absence	of	HGFs.	These	
findings	led	Fairbairn	et	al.	to	conclude	that	while	the	data	do	not	exclude	the	possibility	of	
HGFs	stimulating	differentiation,	they	do	suggest	that	these	factors	are	not	required	for	this	
process.	
	
Studies	of	mice	lacking	the	expression	of	particular	HGFs	and	their	receptors	further	support	
a	permissive	action	of	these	factors.	Introduction	of	null	mutations	into	the	gene	encoding	
CSF2	results	in	mice	that	display	normal	haematopoiesis	and	they	have	comparable	numbers	
of	mature	myeloid	and	lymphoid	cells	to	WT	controls	[237,	238].		Only	minor	haematological	
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differences	were	observed	during	 initial	 characterisation	of	CSF2−/−,	 as	 they	 showed	more	
variability	in	the	weight	of	their	spleens	and	granulocyte	counts	when	compared	to	control	
animals.	However,	the	lung	physiology	of	CSF2−/−	mice	is	significantly	different	from	WT	mice.	
CSF2−/−	 have	 increased	 numbers	 of	 infiltrating	 lymphocytes	 and	 large	 intra-alveolar	
macrophages,	 and	 are	more	 prone	 to	 bacterial	 and	 fungal	 infections	 than	WT	mice.	 This	
suggests	that	GM-CSF	signalling	is	required	for	the	function	of	mature	GM	cells	in	the	lung	but	
not	for	their	development.	
	
	
Figure	1.7.	Permissive	actions	of	HGFs.	In	a	permissive	model	of	haematopoiesis,	HGFs	are	
envisaged	to	provide	survival	and	proliferative	cues	that	permit	HSPC	differentiation/lineage	
commitment	and	the	self-renewal	of	HSCs.	Lineage	non-specific	factors,	such	as	IL-3	and	SCF,	
stimulate	the	proliferation	and	survival	of	multipotent	haematopoietic	cells,	resulting	in	the	
generation	of	committed	progenitors	through	a	stochastic	process.	Lineage	specific	factors,	
such	as	M-CSF	and	Epo,	then	act	selectively	to	provide	a	survival/proliferative	advantage	to	
lineage	 committed	 progenitors.	 HSC,	 haematopoietic	 stem	 cell;	 IL-3,	 interleukin-3;	 IL-7,	
interleukin-7;	 SCF,	 stem	 cell	 factor;	M-CSF,	 macrophage-colony	 stimulating	 factor;	 G-CSF,	
granulocyte-colony	 stimulating	 factor;	 Epo,	 erythropoietin;	 Tpo,	 thrombopoietin;	 HGF,	
haematopoietic	growth	factor.	
	
Targeted	disruption	of	EPO	and	EPOR	is	embryonically	lethal,	at	approximately	embryonic	day	
13	(E13),	due	to	a	lack	of	mature	definitive	erythrocytes	[239,	240].	However,	definitive	pro-
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erythroblasts	and	yolk-sac	derived	erythrocytes	are	present	in	the	fetal	liver.	As	shown	using	
colony	forming	assays,	E13	EPO−/−	fetal	livers	contain	higher	numbers	of	BFU-E	and	CFU-E	than	
fetal	livers	from	WT	animals	[239].	When	transduced	with	EPOR,	E13	EPOR−/−	fetal	liver	cells	
form	similar	numbers	BFU-E	and	CFU-E	 in	 the	presence	of	Epo	 [239,	240].	Wu	et	al.	have	
demonstrated	an	increased	number	of	cells	with	pyknotic	nuclei	in	EPO−/−	and	EPOR−/−	fetal	
livers	compared	to	WT	fetal	livers,	suggesting	an	increased	rate	of	apoptosis.	These	findings	
indicate	that	Epo	is	required	for	the	survival	of	definitive	EPs,	but	not	for	the	commitment	of	
upstream	progenitors	towards	the	erythroid	lineage.	
	
Knock-out	of	IL-7R	in	mice	led	to	the	suggestion	that	IL-7	is	not	required	for	the	differentiation	
of	cells	towards	a	lymphoid	fate.	IL7R−/−	mice	generate	a	limited	number	of	mature	T-	and	B-
lymphocytes.	However,	the	number	of	pre-pro-B-lymphocytes	in	these	mice	is	comparable	to	
controls,	 indicating	 that	 the	 generation	 of	 lymphoid	 progenitors	 is	 unaffected	 [241].	
Furthermore,	work	from	Akashi	and	co-workers	 indicates	that	selective	over-expression	of	
Bcl-2	in	IL7R−/−	lymphoid	cells	is	sufficient	to	rescue	lymphopoiesis	in	these	mice	[242].	The	
introduction	of	the	Eμ-BCL2	gene	(BCL2	under	the	control	of	the	IGH	Eμ	enhancer)	into	the	
IL7R−/−	mouse	strain	restored	T-lymphopoiesis	to	normal	levels.	Additionally,	T-lymphocytes	
from	these	mice	functionally	respond	to	activating	stimuli	 in	vitro.	Together,	these	studies	
suggest	that	IL-7R	does	not	influence	lineage	choice	and	only	serves	to	stimulate	the	survival	
of	committed	lymphocyte	progenitors.	
	
Mice	 lacking	 M-CSFR	 have	 decreased	 numbers	 of	 macrophages	 and	 osteoclasts	 when	
compared	to	littermate	controls	[243,	244].	However,	CSF1R−/−	mice	have	similar	numbers	of	
BM	 macrophage	 progenitors	 to	 WT	 mice	 and	 heterozygous	 CSF1R+/−	 controls,	 when	
compared	using	colony	forming	assays	[245].	Lagasse	and	Weissman	have	demonstrated	that	
	 47	
ectopic	 expression	 of	 human	 Bcl2	 in	 CSF1R−/−	 myeloid	 cells	 partially	 restores	
monocyte/macrophage	 counts	 in	 vivo	 [246].	 Using	 a	 BCL-MRP8	 transgene,	 the	 authors	
selectively	 suppressed	 the	 apoptosis	 of	 myeloid	 cells	 in	 CSF1R−/−	mice	 and	 reported	 an	
increase	in	peripheral	blood	monocytes	compared	to	CSF1R−/−	control	mice.	The	findings	from	
both	studies	indicate	that,	like	IL-7R,	M-CSF	is	not	required	for	lineage	commitment	decisions	
but	does	facilitate	the	survival	of	committed	progenitors	in	vivo.	
	
Although	 these	 knock-out	 studies	 support	 a	 permissive	 role	 of	 HGFs,	 they	 should	 be	
interpreted	 with	 caution.	 Firstly,	 they	 do	 not	 exclude	 the	 possibility	 of	
compensatory/redundant	mechanisms	 between	 the	 actions	 of	 HGFs.	 For	 instance,	 G-CSF,	
GM-CSF	and	M-CSF	all	stimulate	the	growth	of	GM	cells.	Secondly,	 in	the	case	of	receptor	
knock-out	 studies,	 it	 is	 possible	 that	 certain	 HGFs	 act	 through	 currently	 unidentified	
receptors.	Although,	given	that	these	factors	have	been	the	center	of	intense	scrutiny	over	
the	past	40	years,	this	is	unlikely.	
	
Some	 studies	 that	 have	 investigated	 the	 ectopic	 expression	 of	 HGF	 receptors	 in	 lineage-
restricted	cells	suggest	that	these	do	not	influence	lineage	specification.	In	1994,	Pharr	and	
colleagues	 transduced	 blast	 cell	 colonies	 with	 a	 constitutively	 active	 viral	 form	 of	 EpoR,	
EPOR(R129C),	or	human	M-CSFR	(hM-CSFR)	and	examined	their	ability	 to	 form	colonies	 in	
vitro	 [247].	 In	 the	presence	of	 SCF,	 IL-3	 and	Epo,	 EPOR(R129C)-transduced	 cells	 produced	
comparable	numbers	of	erythroid	and	GM	colonies	when	compared	to	control	cells,	though	
the	colonies	were	larger.	Similarly,	when	cultured	with	IL-3	and	M-CSF,	hM-CSFR-transduced	
cells	 and	 control	 cells	 generated	 comparable	 numbers	 of	 GM	 colonies,	 with	 similar	
macrophage	 compositions.	 Although,	 M-CSFR	 transduced-cells	 displayed	 increased	
secondary	 plating	 efficiency	 when	 compared	 to	 control	 cultures.	 As	 such,	 the	 authors	
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concluded	 that	 neither	 EpoR	 nor	 M-CSFR	 is	 capable	 of	 influencing	 lineage-choice	 in	
multipotent	cells,	though	they	do	provide	a	proliferative/survival	advantage.	
	
McArthur	et	al.	have	performed	a	similar	study	using	mouse	M-CSFR	[248].	They	transduced	
mouse	 fetal	 liver	 cells	 and	 BM	 cells	 from	 5-fluorouracil	 treated	 mice	 with	 M-CSFR	 and	
assessed	their	colony	forming	potential.	M-CSF	was	capable	of	maintaining	EPs,	and	increased	
the	number	of	megakaryocyte	and	GM	colonies	formed	when	compared	to	cells	transduced	
with	 an	 empty	 vector.	 These	 findings	 suggest	 that	 M-CSF	 signalling	 provides	 permissive	
proliferative	cues,	and	does	not	instruct	lineage	specification.	
	
Some	 studies	 using	 chimeric	 fusion	 HGF	 receptors	 have	 also	 provided	 evidence	 of	 a	
permissive	model	of	HGF	activity.	Stoffel	et	al.	generated	a	chimeric	Mpl	receptor	by	replacing	
its	cytoplasmic	domain	with	the	cytoplasmic	domain	of	G-CSFR	[249].	This	receptor,	which	
binds	Tpo	and	 stimulates	G-CSFR-mediated	 intracellular	 signalling,	was	 introduced	 into	an	
MPL−/−	mouse	strain	to	prevent	Mpl	signalling	in	vivo.	Characterisation	of	these	mice	revealed	
similar	platelet	and	granulocyte	counts,	and	comparable	numbers	of	BM	megakaryocyte	and	
GM	progenitors	 to	WT	 controls.	 Using	 a	 similar	 approach,	 Semerad	et	 al.	 have	 created	 a	
transgenic	mouse	model	that	expresses	a	chimeric	receptor	that	binds	G-CSF	and	transmits	
EpoR	signalling	[250].	These	mice	have	normal	granulopoiesis	and	erythropoiesis.	However,	
G-CSF-mediated	mobilisation	 of	 haematopoietic	 cells	 from	 the	 BM	 is	 deficient.	 Given	 the	
findings,	both	studies	suggest	that	Tpo,	G-CSF	and	Epo	signalling	do	not	influence	the	lineage	
choice	of	HSPCs.	
	
Finally,	Mayani	 and	 co-workers	 have	 provided	 evidence	 for	 a	 permissive	 role	 of	 HGFs	 in	
human	haematopoiesis	by	analysing	the	fate	of	paired	multipotent	daughter	cells	cultured	in	
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the	 presence	 of	 different	 HGFs.	 [251].	 Individual	 CD34+	 CD45RAlo	 CD71lo	 haematopoietic	
progenitors	were	sorted	 from	human	umbilical	 cord	blood,	and	 it	was	 shown	that	34%	of	
these	cells	are	capable	of	forming	multilineage	colonies	in	vitro	[252].	CD34+	CD45RAlo	CD71lo	
cells	were	cultured	until	their	first	cell	division	(2-5	days),	and	then	separated	into	serum-free	
medium	containing	either	an	erythroid	growth	factor	combination	(EGFC:	SCF,	interleukin-6	
[IL-6],	IL-3	and	Epo)	or	a	myeloid	growth	factor	combination	(MGFC:	SCF,	IL-6,	M-CSF,	G-CSF	
and	an	 IL-3/GM-CSF	fusion	protein).	Two-hundred	and	six	pairs	were	split	and	96	of	these	
pairs	formed	colonies	following	separation.		
	
When	daughter	cells	were	placed	in	separate	erythroid	growth	factor	cultures	(EGFC/EGFC),	
58%	 of	 paired	 daughter	 cells	 gave	 rise	 to	 similar	 colonies	 (29%	 GM,	 14%	 erythroid,	 15%	
mixed).	In	31%	of	EGFC/EGFC	cases,	the	daughter	cells	generated	colonies	of	different	types.	
This	included	cases	where	cells	formed	small	cell	clusters	that	could	not	be	identified	due	to	
limited	 cell	 numbers.	 In	 the	 remaining	 cases,	 both	 cells	 generated	 small	 unidentifiable	
clusters.	In	cases	where	daughter	cells	were	placed	in	separate	myeloid	growth	factor	cultures	
(MGFC/MGFC),	67%	of	colonies	formed	the	same	colony	type	(47%	GM,	3%	mixed,	17%	small	
unidentifiable	 cell	 clusters).	 In	 3%	of	MGFC/MGFC	 cases,	 one	daughter	 cell	 gave	 rise	 to	 a	
mixed	colony	while	the	other	gave	rise	to	a	GM	colony.	In	30%	of	MGFC/MGFC	cases,	one	
daughter	cell	gave	rise	to	a	GM	colony	while	the	other	formed	a	small	unidentified	cluster.	
No	 erythroid	 colonies	were	 detected	 in	MGFC/MGFC	 cultures.	When	 daughter	 cells	were	
placed	in	differing	HGF	mixtures	(EGFC/MGFC),	both	paired	daughter	cells	gave	rise	to	similar	
colonies	in	49%	of	cases	(26%	GM,	18%	mixed	colonies,	5%	of	unidentifiable	clusters).	In	the	
remaining	EGFC/MGFC	cases,	daughter	cells	gave	rise	to	different	colonies.	For	8%	of	cases,	
one	cell	gave	rise	a	GM	colony,	while	the	other	gave	rise	to	an	erythroid	colony.	
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Mayani	et	al.	proposed	that	in	cases	when;	i)	daughter	cells	formed	the	same	colony	types,	
both	daughter	cells	were	already	committed	to	a	fate	when	they	were	placed	in	culture;	ii)	
daughter	cells	formed	distinct	colonies,	this	was	primarily	due	to	an	asymmetrical	cell	division	
which	gave	rise	to	a	committed	daughter	cell	and	a	multipotent	daughter	cell;	iii)	cells	formed	
unidentified	 clusters,	 either	 this	 occurred	 as	 a	 result	 of	 manipulation	 or	 these	 colonies	
contained	cells	 that	could	not	 thrive	 in	particular	HGF	mixtures	 [251].	For	example,	 in	 the	
myeloid	 cytokine	mixture,	 the	 small	unidentified	 clusters	may	have	 represented	erythroid	
cells	that	could	not	proliferate	in	the	absence	of	Epo.	The	authors	also	stated	that	there	was	
no	evidence	for	lineage	instructive	by	HGFs	from	the	data,	and	that	these	factors	likely	act	
permissively	to	facilitate	a	stochastic	model	of	haematopoiesis.	
	
A	recent	study	by	Ward	et	al.	suggests	that	Epo	is	not	required	for	the	commitment	of	CMPs	
towards	the	erythroid	lineage	[253].	The	group	isolated	CMPs	from	human	peripheral	blood	
and	monitored	their	proliferation	and	maturation	into	MEPs	in	cultures	with	or	without	Epo.	
Both	the	proliferation	and	maturation	rates	of	CMPs	were	unchanged	when	stimulated	with	
Epo.	In	both	culture	conditions	(±	Epo),	20%	of	CMPS	differentiated	into	MEPs	over	24	hours.	
However,	after	9	days,	Epo	cultures	contained	over	20-fold	more	MEPs	when	compared	to	
control	 cultures.	 Examination	 of	 MEP	 proliferation	 revealed	 that	 there	 was	 a	 significant	
increase	 in	 the	 expansion	 of	 MEPs	 in	 the	 presence	 of	 Epo.	 These	 results	 agreed	 with	 a	
stochastic	mathematical	model,	so	the	authors	concluded	that	Epo	does	not	influence	lineage	
specification	of	CMPs.	
	
As	evident	from	the	studies	highlighted	above,	a	wide	range	of	studies	support	a	model	of	
haematopoiesis	 whereby	 cell	 fate	 is	 governed	 by	 cell-intrinsic	 stochastic	 processes,	 and	
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proliferation	 and	 survival	 are	 mediated	 by	 cell-extrinsic	 factors.	 However,	 other	 studies	
carried	 out	 at	 the	 same	 time	 disagree	 with	 such	 a	 model,	 and	 provide	 evidence	 for	 an	
instructive	role	of	HGFs.	This	model	will	be	discussed	below.	
	
1.3.2.4			The	role	of	haematopoietic	growth	 factors	 in	 instructing	cell	
fate:	A	deterministic	model	of	haematopoiesis	
	
At	odds	with	a	stochastic	model	of	haematopoiesis,	a	deterministic	model	of	HGFs	proposes	
that	the	cell	fate	of	HSPCs	is	regulated	by	cell-extrinsic	factors	(Figure	1.8).	Such	a	model	was	
first	postulated	by	Trentin	and	colleagues	 in	the	late	1960s.	When	transplanting	 irradiated	
mice	with	whole	BM,	Curry	and	Trentin	noted	a	pattern	in	the	distribution	of	different	colony	
types	within	the	spleen.	Over	a	number	of	experiments,	approximately	60%	of	colonies	were	
erythroid,	 20%	 were	 granulocytic,	 15%	 were	 megakaryocytic	 and	 2%	 were	 eosinophilic,	
suggesting	that	the	spleen	microenvironment	regulated	the	lineage	commitment	of	CFU-S.	In	
a	subsequent	study,	Wolf	and	Trentin	demonstrated	that	BM	stroma	selectively	promoted	
the	 formation	 of	 granulocytic	 colonies,	 while	 erythroid	 colonies	 primarily	 formed	 in	 the	
spleen	[254].	The	authors	transplanted	BM	stroma	containing	a	small	number	of	CFU-S	into	
the	spleens	of	irradiated	hosts,	and	reported	that	CFU-S	that	gave	rise	to	granulocytic	colonies	
remained	in	the	BM	stroma,	while	CFU-S	that	gave	rise	to	erythroid	colonies	migrated	from	
the	BM	stroma	to	the	surrounding	spleen	stroma	before	maturation.	As	such,	Trentin	et	al.	
proposed	 the	 existence	 of	 distinct	 stromal	 haematopoietic	 inductive	 microenvironments	
(HIMs)	that	regulate	the	fate	of	HSPCs,	although	it	was	unclear	how	at	the	time	[255].	
	
A	 decade	 after	 Trentin	 and	 colleagues	 proposed	 the	 HIM	 model	 [254-256],	 Metcalf	 and	
Burgess	provided	strong	evidence	to	suggest	that	HGFs	can	act	directly	on	HPCs	to	regulate	
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their	differentiation	and	lineage	commitment.	In	1980,	Metcalf	examined	the	colony	forming	
potential	of	paired	GM-CFU	daughter	cells	 in	cultures	with	varying	GM-CSF	concentrations	
[257].	Whole	BM	cells	were	cultured	in	the	presence	of	GM-CSF	until	the	first	cell	division,	
and	then	paired	daughter	cells	separated	into	different	cultures.	In	the	first	experiment,	one	
daughter	cell	was	transferred	to	a	culture	containing	a	high	concentration	of	GM-CSF	(2,500	
units),	while	the	other	was	transferred	to	a	culture	containing	a	low	concentration	of	GM-CSF	
(50	units).	Of	 the	 41	 cases	where	 at	 least	 one	 cell	 formed	a	 colony	 (>50	 cells),	 15	paired	
daughter	 cells	 displayed	 differing	 lineage	 potentials.	 The	 progeny	 cultured	 in	 medium	
containing	2,500	units	GM-CSF	were	more	 likely	 to	 form	colonies	containing	granulocytes,	
while	 progeny	 cultured	 in	 the	 presence	 of	 50	 units	 GM-CSF	 formed	 more	 macrophage-
containing	colonies.	In	the	remaining	cases,	paired	daughter	cells	formed	colonies	of	similar	
lineage	 composition	 and	 size.	 In	 a	 second	 experiment,	 both	 paired	 daughter	 cells	 were	
transferred	into	separate	cultures	containing	2,500	units	of	GM-CSF.	At	least	one	colony	(>50	
cells)	 was	 detected	 in	 48	 cases,	 and	 in	 45	 of	 these	 cases	 the	 daughter	 cells	 generated	
colonies/clusters	 of	 similar	 lineage	 composition	 and	 size.	 Statistical	 analysis	 of	 these	
experiments	showed	that	dissimilar	colony	 formation	 from	paired	daughter	cell	 formation	
was	 significantly	 more	 likely	 when	 two	 different	 concentrations	 of	 GM-CSF	 were	 used.	
Furthermore,	it	was	shown	that	the	formation	of	colonies	containing	macrophages	occurred	
more	often	when	BM	progenitors	were	cultured	in	 low	concentration	of	GM-CSF.	As	such,	
Metcalf	concluded	that	GM-CSF	regulates	lineage	commitment	of	GM	bipotent	progenitors	
in	a	dose-dependent	manner	[257].	
	
The	 following	 year,	 Metcalf	 and	 Burgess	 performed	 a	 similar	 study	 by	 separating	 paired	
daughter	cells	of	BM	progenitors	into	medium	containing	either	M-CSF	or	high	concentrations	
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of	GM-CSF	and	examined	their	colony	forming	potential	[258].	BM	cells	were	first	dispersed	
in	medium	containing	either	M-CSF	or	GM-CSF	and	individual	cells	were	monitored	until	the	
first	cell	division.	One	daughter	cell	was	then	transferred	to	a	culture	containing	M-CSF,	while	
the	 other	was	 cultured	 in	 GM-CSF.	When	 cells	 were	 pre-cultured	with	M-CSF	 before	 cell	
division,	88%	of	the	progeny	separated	into	M-CSF	formed	colonies	containing	macrophages,	
while	56%	of	progeny	separated	into	medium	containing	GM-CSF	formed	colonies	containing	
granulocytes.	 In	 a	 parallel	 experiment,	 cells	 were	 pre-cultured	 with	 GM-CSF	 before	 cell	
division.	Eighty-six	percent	of	daughter	cells	transferred	to	media	containing	GM-CSF	formed	
colonies	containing	granulocytes,	while	76%	of	daughter	cells	transferred	to	M-CSF	containing	
cultures	 formed	colonies	 containing	macrophages.	The	authors	noted	 that	 the	progeny	of	
cells	cultured	in	GM-CSF	prior	to	cell	division	were	statistically	more	likely	to	form	granulocyte	
colonies	 in	 cultures	 containing	 GM-CSF	 or	 M-CSF.	 On	 the	 contrary,	 the	 progeny	 of	 cells	
cultured	in	M-CSF	prior	to	cell	division	were	more	likely	to	differentiation	into	macrophages	
in	the	presence	of	GM-CSF	or	M-CSF.	
	
When	the	initial	stimulation	of	BM	cells	with	GM-CSF	or	M-CSF	was	increased	from	24	hours	
to	2-3	days	before	separating	the	progeny	into	cultures	containing	either	GM-CSF	or	M-CSF,	
it	was	even	more	evident	that	these	factors	influence	lineage	commitment.	Over	90%	of	the	
clones	 pre-cultured	 with	 M-CSF	 for	 2-3	 days	 generated	 macrophage	 colonies	 when	
transferred	to	cultures	containing	either	M-CSF	or	GM-CSF.	Similarly,	when	compared	to	cells	
pre-treated	with	GM-CSF	for	24	hours,	the	clones	initiated	with	GM-CSF	for	2-3	days	formed	
a	significantly	higher	number	of	granulocyte-containing	colonies	regardless	of	whether	they	
were	transferred	to	medium	containing	GM-CSF	or	M-CSF.	Given	these	findings,	Metcalf	and	
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Burgess	concluded	that	GM-CSF	and	M-CSF	are	capable	of	influencing	the	differentiation	of	
GM-CFU	towards	granulocyte	and	macrophage	fates,	respectively	[258].	
	
Since	the	studies	from	Metcalf	and	Burgess,	a	large	number	of	studies	have	been	published	
that	 argue	against	 the	permissive	action	of	HGFs,	 and	provide	evidence	against	 individual	
aspects	of	a	stochastic	model	of	haematopoiesis.	Firstly,	a	role	for	HGFs	in	the	maturation	of	
HSPCs	 is	 supported	 by	 studies	 that	 have	 investigated	 the	 effects	 of	 HGF	 stimulation	 on	
leukaemic	 cell	 lines.	 A	 number	 of	 independent	 studies	 have	 shown	 that	 both	human	 and	
mouse	 G-CSF	 suppresses	 proliferation	 and	 stimulates	 the	 terminal	 differentiation	 of	 the	
murine	 myelomonocytic	 leukaemic	 cells	 [259-261].	 In	 one	 particular	 study,	 Souza	 et	 al.	
showed	that	hG-CSF	can	also	induce	the	differentiation	of	primary	human	promyelocytic	and	
myeloblastic	leukaemic	cells,	as	observed	by	colony	forming	assays	[261].	Bedi	et	al.	have	also	
shown	that	IL-6	and	GM-CSF	are	capable	of	stimulating	the	differentiation	of	mouse	BCR-ABL-
transduced	 FDCP-1	 cells	 and	 human	 chronic	myeloid	 leukaemia	 cells	 in	 vitro,	 respectively	
[262].	
	
The	identification	of	HGF	receptor	cytoplasmic	domains	that	are	required	for	differentiation	
has	provided	further	evidence	to	support	the	viewpoint	that	HGFs	influence	HSPC	maturation.	
A	number	of	studies	have	demonstrated	that	the	C-terminal	region	of	G-CSFR	is	necessary	for	
the	transduction	of	differentiation	signals	[225,	226,	263,	264].	Specifically,	targeted	mutation	
of	 the	 four	 tyrosine	 residues	 in	 the	 cytoplasmic	 region	 of	 G-CSF	 have	 demonstrated	 that	
tyrosine	 residues	 at	 positions	 704,	 729	 and	 744	 are	 involved	 in	mediating	 differentiation	
signals	 [225,	 265].	 Furthermore,	 mutations	 in	 human	 CSF3R	 that	 result	 in	 proteins	 with	
truncated	 C-terminals	 have	 been	 identified	 in	 patients	 with	 congenital	 neutropenia,	
demonstrating	the	importance	of	this	region	in	differentiation	[266].	
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Figure	1.8.	 Instructive	actions	of	HGFs.	 In	a	deterministic	model	of	haematopoiesis,	HGFs	
influence	proliferation,	survival	and	cell-fate	decisions.	Some	HGFs,	such	as	IL-3	and	SCF,	act	
on	HSCs	to	regulate	their	self-renewal.	Other	lineage-associated	HGFs	instruct	HSPCs	towards	
a	specific	cell	lineage.	For	example,	M-CSF	has	been	reported	to	act	on	HSCs	to	upregulate	
PU.1	and	drive	them	towards	a	granulocyte/monocyte	fate	[267].	There	is	also	evidence	to	
suggest	 that	 G-CSF	 [268]	 and	 Epo	 [269]	 stimulate	 HPCs	 to	 differentiate	 towards	 the	
granulocyte	and	erythroid	lineages,	respectively.	These	HGFs	are	shown	as	examples,	though	
there	 are	 a	 number	of	 other	HGFs	 that	 have	been	 reported	 to	 instruct	 lineage	 fate.	HSC,	
haematopoietic	 stem	 cell;	 IL-3,	 interleukin-3;	 SCF,	 stem	 cell	 factor;	 M-CSF,	 macrophage-
colony	stimulating	factor;	G-CSF,	granulocyte-colony	stimulating	factor;	Epo,	erythropoietin;	
HPC,	haematopoietic	progenitor	cell;	HGF,	haematopoietic	growth	factor.	
	
	
Targeted	mutation	of	the	CSF1R	gene,	which	encodes	M-CSFR,	has	also	been	used	to	identify	
residues	within	M-CSFR	that	are	required	for	progenitor	cell	differentiation.	Like	G-CSFR,	M-
CSFR	has	 4	 tyrosine	 residues	 in	 the	 cytoplasmic	 region	 that	 are	 phosphorylated	 following	
ligand	binding.	Rohrschneider	et	al.	transduced	a	series	of	M-CSFR	mutants	into	FDCP-1	cells	
and	 demonstrated	 that	 the	 tyrosine	 residue	 at	 position	 807	 is	 essential	 to	 mediate	
differentiation	of	these	cells	in	the	presence	of	M-CSF	[270].	The	other	three	tyrosine	residues	
at	positions	697,	706,	and	721	promote	maturation,	but	are	are	not	required.	Regions	within	
both	 the	 α	 and	 β	 subunits	 of	 human	 GM-CSFR	 (hGM-CSFR)	 have	 also	 been	 shown	 to	 be	
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important	 in	 inducing	 differentiation.	 Transduction	 of	 the	myelomonocytic	 leukaemia	 cell	
lines	 M1	 and	 WEHI-3B	 with	 hGM-CSFR	 containing	 a	 WT	 β	 subunit	 promotes	 their	
differentiation	when	cultured	with	GM-CSF	[271].	However,	when	these	cells	are	transduced	
with	 hGM-CSFR	 containing	 a	 truncated	 β	 subunit	 lacking	 the	 amino	 acid	 residues	 from	
position	541	to	897,	GM-CSF	does	not	stimulate	differentiation.	Similarly,	mutant	GM-CSFR	α	
subunits	 that	 lack	 a	 proline	 residue	 at	 either	 position	 385	 or	 360	 are	 unable	 to	 transmit	
differentiation	signals	when	transduced	into	FCDP-1	cells	[272].	
	
Targeted	 disruption	 of	 the	Mpl	 cytoplasmic	 domain	 also	 suggests	 that	 Tpo	 can	 stimulate	
maturation.	 In	1996,	Alexander	et	al.	 transduced	two	myelomonocytic	 leukaemia	cell	 lines	
with	WT	Mpl,	 and	C-terminal	 truncated	Mpl	mutants	 [273].	 In	 colony	 forming	assays,	 the	
myelomonocytic	leukaemia	cells	formed	large	undifferentiated	blast	colonies	in	the	presence	
of	Tpo.	However,	when	the	myelomonocytic	leukaemia	cells	were	transduced	with	WT	Mpl	
and	cultured	in	the	presence	of	Tpo,	they	formed	myelomonocytic	colonies,	as	confirmed	by	
northern	 blotting	 analysis.	 In	 contrast,	 cells	 transduced	 with	 the	 mutant	 Mpl	 receptors	
displayed	 an	 impaired	 ability	 to	 form	 differentiated	 colonies	 when	 stimulated	 with	 Tpo.	
Targeted	disruption	of	 specific	 tyrosine	 residues	 in	 the	 cytoplasmic	domain	of	 the	Mpl	C-
terminal	 revealed	 that	 the	 tyrosine-599	 residue	 was	 required	 for	 leukaemia	 cell	
differentiation.	These	data	provide	evidence	to	suggest	that	Mpl	can	drive	the	differentiation	
but	not	the	lineage-specification	of	cells.	However,	as	leukaemic	cells	were	used	in	this	study,	
it	is	possible	that	aberrant	expression	of	other	factors	may	have	pre-determined	the	lineage	
commitment	of	the	cells.	Performing	a	similar	study	using	WT	haematopoietic	progenitors	
would	provide	more	information	regarding	the	potential	instructive	properties	of	Tpo.	
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In	 contrast	 to	 the	 above	 study,	 ectopic	 expression	 of	 other	 HGF	 receptors	 by	 lineage-
restricted	 progenitors	 substantiates	 a	 role	 for	 these	 factors	 in	 promoting	 lineage	
specification.	In	1990,	Borzillo	et	al.	transduced	a	number	of	early	pre-B	lymphocyte	lines	with	
WT	human	CSF1R	and	a	viral	oncogene,	v-fms,	which	encodes	a	constitutively	activated	form	
of	M-CSFR	[274].	When	these	cells	were	cultured	in	medium	supplemented	with	human	M-
CSF,	 they	 formed	 small	 colonies	 of	 macrophage-like	 cells,	 displayed	 phagocytic	 activity,	
upregulated	expression	of	Mac1α,	and	decreased	expression	of	 the	B-lymphocyte	antigen	
marker,	B220.	In	2000,	Kondo	et	al.	demonstrated	that	transduction	of	hGM-CSFR	into	mouse	
BM	CLPs	confers	GM	potential	in	these	cells	when	assessed	using	colony	forming	assays	[275].	
Similarly,	lineage	switching	has	also	been	observed	in	human	MEPs	transduced	with	human	
Flt3	in	vitro	[276].	When	cultured	in	the	presence	of	Flt3L,	Flt3-transduced	MEPs	are	capable	
of	upregulating	cell	surface	DC	markers	and	forming	GM	colonies	in	methycellulose	medium.	
	
Carroll	 and	 colleagues	 have	 demonstrated	 that	 transduction	 of	 mouse	 EpoR	 into	 pro-B-
lymphocytes	 from	 the	 Ba/F3	 cell	 line	 confers	 Epo-dependent	 erythroid	maturation	 [277].	
Interestingly,	when	the	authors	transduced	the	cells	with	chimeric	receptors	consisting	of	the	
extracellular	EpoR	domain	and	the	IL-3R	cytoplasmic	domain,	these	cells	also	differentiated	
into	erythroid	cells	in	the	presence	of	Epo.	However,	enforced	expression	of	truncated	EpoR	
mutants	lacking	the	cytoplasmic	domain	in	these	cells	showed	that	the	cytoplasmic	domain	
alone	 is	 not	 sufficient	 to	 stimulate	 erythroid	 differentiation.	 This	 study	 suggests	 that	 the	
extracellular	regions	of	HGF	receptors	are	important	in	transmitting	differentiation	signals.	If	
this	is	the	case,	then	it	may	explain	why	the	studies	of	Mpl/G-CSFR	[249]	and	EpoR/G-CSFR	
[250]	chimeric	fusion	receptors	described	in	Section	1.3.2.3	did	not	observe	any	changes	in	
the	haematopoiesis	of	transgenic	mouse	models.	
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HGFs	have	also	been	shown	to	regulate	the	self	renewal	of	both	human	and	mouse	HSCs.	This	
is	evident	by	the	need	for	HGFs	to	expand	and	maintain	long-term	HSC	cultures.	For	example,	
in	1997,	Zandstra	et	al.	examined	the	effects	of	varying	HGF	concentrations	on	the	expansion	
of	LTC-ICs	in	cultures	derived	from	human	CD34+	CD38−	BM	cells	[278].	CD34+	CD38−	BM	cells	
were	cultured	in	serum-free	medium	supplemented	with	different	concentrations	of	Flt3L,	IL-
3	and	SCF	 for	10	days.	 Self-renewal	of	 these	cells	was	assessed	by	 the	number	of	 LTC-ICs	
present	 in	 the	 culture	 after	 this	 period.	 LTC-ICs	 were	 quantified	 by	 transferrring	 cells	 to	
fibroblast	feeder	layers	and	monitoring	the	production	of	CFUs	over	a	period	of	6	weeks.	The	
differentiation	of	CD34+	CD38−	BM	cells	was	measured	by	the	number	of	CFUs	present	in	the	
cultures	following	a	10	day	period.	The	authors	demonstrated	that	cultures	containing	high	
concentrations	 of	 Flt3L	 produced	 an	 increased	 ratio	 of	 LTC-ICs:CFUs	 when	 compared	 to	
cultures	containing	low	concentrations	of	Flt3L.	Using	a	similar	approach,	Audit	et	al.	have	
shown	that	IL-6	promotes	the	self-renewal	of	hHSCs	in	vitro	[279].	
	
These	 studies	 strongly	 support	 a	 role	 for	 HGFs	 in	 the	 self-renewal	 of	 HSCs	 and	 the		
differentiaiton	of	HSPCs,	and	this	is	now	generally	accepted.	However,	their	role	in	lineage	
commitment	is	still	controversial.	Although	the	findings	highlighted	above	provide	evidence	
to	suggest	that	HGFs	can	influence	cell-fate	decisions,	a	large	number	conflicting	studies	exist	
(see	Section	1.3.2.3).	In	this	regard,	it	is	difficult	to	discern	which	model	of	haematopoiesis	is	
correct.	With	 the	 exception	 of	 studies	 examining	 the	 fate	 of	 paired	 daughter	 cells,	 most	
investigations	 have	 been	 limited	 by	 their	 ability	 to	 thoroughly	 examine	 and	 monitor	
differentiation	at	the	single	cell	 level.	Furthermore,	a	number	of	reports	have	manipulated	
haematopoietic	cells	to	ectopically	express	HGF	receptors.	As	a	result,	theses	studies	do	not	
provide	 an	 understanding	 of	 how	 HGFs	 influence	 the	 lineage	 commitment	 of	 individual	
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haematopoetic	cells	 in	vivo.	 Insight	 into	such	a	mechanism	was	not	provided	until	the	late	
2000s,	and	a	number	of	recent	studies	have	used	live	imaging	techniques	to	track	the	fate	of	
single	cells	following	stimulation	with	HGFs.	
	
In	 2009,	 Rieger	 et	 al.	 provided	 the	 first	 real-time	 analysis	 of	 HPC	 differentiation	 in	 the	
presence	 of	 cytokines	 at	 the	 single	 cell	 level	 [268].	 The	 authors	 purified	 GMPs	 from	 a	
LYSM:eGFP	transgenic	mouse	model,	in	which	the	enhanced	green	fluorescent	protein	(eGFP)	
is	expressed	under	the	control	of	the	LysozymeM	gene	locus,	and	monitored	them	in	culture	
using	 real-time	bioimaging	 techniques.	Mature	granulocytes	 and	monocytes/macrophages	
express	LysM,	but	GMPs	do	not.	Therefore,	the	onset	of	eGFP	expression	in	LYSM:eGFP	GMPs	
marks	their	maturation	towards	a	GM	fate.	First,	Rieger	and	co-workers	performed	colony	
forming	assays	using	freshly	isolated	LYSM:eGFP	GMPs	and	reported	that	23	±	6	%	of	cells	
formed	macrophage	colonies	while	53	±	7	%	of	cells	formed	granulocyte	colonies	[268].	When	
LYSM:eGFP	GMPs	were	pre-treated	with	either	G-CSF	or	M-CSF	before	the	colony	forming	
assay,	they	almost	exclusively	formed	granulocyte	or	macrophage	colonies,	respectively.		
	
To	determine	whether	this	result	occurred	due	to	the	instruction	of	bipotent	GMPs	or	the	
selective	 expansion	 of	 unilineage	 progenitors,	 the	 authors	 monitored	 the	 death	 and	
maturation	of	 individual	GMPs	 following	G-CSF	or	M-CSF	 treatment	 using	 live	 imaging.	 In	
cultures	containing	M-CSF,	88	±	2	%	of	individual	cells	matured	to	form	eGFP+	macrophage	
colonies,	 while	 in	 G-CSF	 cultures,	 87	 ±	 6	 %	 of	 individual	 cells	 formed	 eGFP+	 granulocyte	
colonies.	From	comparing	these	results	to	the	outcome	of	the	colony	forming	assays	prepared	
with	freshly	isolated	GMPs,	the	authors	concluded	that	G-CSF	and	M-CSF	instructed	at	least	
34%	and	65%	of	individual	cells	to	differentiate	towards	granulocyte	and	macrophage	fates,	
respectively.	The	number	of	cell	deaths	observed	when	GMPs	were	cultured	with	either	G-
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CSF	or	M-CSF	was	very	 low,	and	 therefore	 this	 result	 strongly	argues	against	a	permissive	
action	of	HGFs.	
	
Mossadegh-Keller	et	al.	have	used	PU.1:GFP	 (green	fluorescent	protein)	reporter	mice	and	
bioimaging	techniques	to	show	that	M-CSF	is	also	capable	of	instructing	LT-HSCs	towards	a	
GM	fate	[267].	First,	they	reported	that	M-CSF	induced	PU.1	expression	in	LSK	Flt3−	CD34+	
CD150+	HSCs.	When	PU.1:GFP	HSCs	were	cultured	in	medium	lacking	M-CSF,	PU.1	expression	
in	single	cells	was	not	detected	until	after	8	hours.	After	24	hours,	approximately	17%	of	HSCs	
were	GFP+.	In	cultures	containing	M-CSF,	PU.1	expression	was	detected	almost	immediately,	
and	approximately	35%	of	HSCs	were	GFP+	after	24	hours.	No	cell	division	was	detected	during	
the	24-hour	culture	period,	indicating	that	these	findings	were	not	due	to	the	expansion	of	a	
PU.1+	 HSC	 subpopulation.	 Following	 16	 hours	 of	 culture	 in	 the	 presence	 of	 M-CSF,	
transcriptome	 analysis	 revealed	 an	 increase	 in	 the	 expression	 of	GM-associated	 genes	 by	
HSCs.	 When	 PU.1+	 HSCs	 were	 transplanted	 into	 irradiated	 recipients,	 they	 generated	
significantly	more	GMPs	and	peripheral	myelomonocytic	cells	at	the	expense	of	MegE	and	
lymphoid	development	when	compared	to	PU.1−	HSCs.	Finally,	when	injecting	mice	with	M-
CSF,	the	authors	noted	that	there	was	no	change	in	the	number	of	MyHSCs	or	expression	of	
M-CSFR,	arguing	against	a	selective	process	[267].	Carras	et	al.	have	since	used	a	bipotent-
GM	cell	line	to	determine	the	mechanism	of	M-CSF	instruction	[280].	M-CSF	was	shown	to	
stimulate	extracellular	signal-regulated	kinase	(ERK)	signalling	[280],	which	is	important	for	
macrophage	 differentiation	 [281].	 Additionally,	 the	 authors	 reported	 that	 M-CSF	 causes	
activation	of	protein	kinase	Cδ	[280],	which	activates	PU.1	[282]		and	inhibits	the	expression	
of	FLI1,	an	important	TF	for	granulocytic	differentiation	[283].	These	results	strongly	suggest	
that	M-CSF	is	capable	of	stimulating	HSCs	to	undergo	monocyte/macrophage	specification.	
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In	 2011,	 Tsapogas	 et	 al.	 provided	 evidence	 to	 suggest	 that	 IL-7	 signalling	 promotes	
commitment	of	mouse	CLPs	toward	the	B-lymphocyte	lineage	[284].	The	authors	generated	
IL-7	knock-out	mice	and	noted	that	they	displayed	impaired	B-lymphopoiesis,	and	that	the	
number	of	CLPs	in	IL7−/−	mice	was	5-fold	less	than	the	number	of	CLPs	in	WT	mice.	Analyses	
revealed	 that	 this	 decrease	 is	 largely	 due	 to	 the	 reduced	 number	 of	 Ly6D+	 CLPs,	 a	
subpopulation	of	CLPs	that	is	restricted	to	the	B-lymphocyte	lineage	[285].	When	Ly6D+	CLPs	
from	 IL7−/−	mice	were	cultured	on	an	OP9	stromal	 layer	 in	 the	presence	of	 IL-7	and	other	
supplementary	 HGFs,	 they	 were	 capable	 of	 generating	 both	 NK	 lymphocytes	 and	 B-
lymphocytes.	 This	 was	 in	 contrast	 to	 Ly6D+	 CLPs	 from	 WT	 mice	 which	 only	 formed	 B-
lymphocytes,	 suggesting	 that	 there	was	a	developmental	block	 that	prevented	Ly6D+	CLPs	
from	undergoing	commitment	to	the	B-lineage	in	IL7−/−	mice.	
	
Gene	expression	analysis	revealed	that	the	expression	of	the	early	B-lymphocyte	TF,	EBF1,	
was	significantly	reduced	in	Ly6D+	CLPs	from	IL7−/−	mice	when	compared	to	Ly6D+	CLPs	from	
WT	 mice.	 Previous	 work	 has	 shown	 that	 the	 enforced	 expression	 of	 EBF1	 in	 IL7R−/−	 BM	
progenitors	restores	B-lymphopoiesis	[286],	and	EBF1	has	been	proposed	to	be	a	target	of	IL-
7	signalling	[287].	Thus,	Tsapogas	and	colleagues	investigated	whether	EBF1	deficient	mice	
displayed	a	 similar	phenotype	 to	 IL7−/−	mice	 [284].	 Indeed,	when	single	EBF1−/−	CLPs	were	
seeded	onto	OP9	feeder	layers,	in	the	presence	of	the	relevant	HGFs,	they	were	capable	of	
developing	 into	 NK	 lymphocytes,	 but	 not	 B-lymphocytes.	 Analysis	 of	 EBF1−/−	 mice	
demonstrated	 that	 they	 had	 normal	 levels	 of	 Ly6D−	 and	 Ly6D+	 CLPs,	 indicating	 that	 the	
decreased	number	of	Ly6D+	CLPs	 in	 IL7−/−	mice	 is	a	direct	 result	of	 impaired	 IL-7	signalling	
rather	than	EBF1	expression.	Thus,	the	authors	concluded	that	IL-7	likely	drives	expression	of	
EBF1	in	lymphoid	progenitors,	which	results	in	the	commitment	of	these	cells	towards	a	B-
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lymphocyte	fate.	Interestingly,	these	findings	are	in	direct	contrast	with	studies	of	IL7R−/−	mice	
that	show	no	change	in	the	number	of	B-lymphocyte	progenitors	[241,	242].	
	
Tsapogas	 et	 al.	 have	 also	 proposed	 that	 Flt3	 signalling	 influences	 HSPC	 fate	 [288].	 They	
developed	 a	 transgenic	mouse	model	 (FLT3L-Tg)	 which	 expresses	 the	 human	 FLT3L	 gene	
under	 the	 regulation	 of	 the	 ACTB	 promoter.	 This	 mouse	 constitutively	 expresses	 a	 high	
concentration	of	Flt3L,	resulting	in	anemia,	thrombocytopenia,	and	a	large	expansion	of	DCs	
in	both	the	BM	and	spleen.	Analysis	of	other	cell	populations	showed	that	BM	B-lymphocytes	
are	reduced,	while	GM	and	T-lymphocytes	are	increased	in	the	spleen.	The	BM	progenitor	
compartments	are	also	altered	in	FLT3L-Tg	when	compared	to	WT	mice.	All	of	the	analysed	
progenitor	cell	populations	were	shown	to	be	increased	in	FLT3L-Tg	mice,	apart	from	the	MEP	
population.	 There	 are	 two	 possible	 explanations	 for	 this;	 i)	 Flt3L	 selectively	 expands	 all	
haematopoietic	 progenitor	 populations	 except	 MEP,	 or;	 ii)	 Flt3L	 drives	 early	 HSPCs	 to	
differentiate	 towards	 non-MegE	 fates.	 To	 examine	 this,	 Tsapogas	 and	 colleagues	
administered	recombinant	Flt3L	to	WT	mice	and	noted	that	this	resulted	in	a	rapid	decrease	
in	the	percentage	of	MEPs	in	the	BM	after	injection.	From	to	the	kinetics	of	this	result,	the	
authors	concluded	that	low	concentrations	of	Flt3L	lead	to	commitment	of	multipotent	cells	
towards	the	MegE	fates,	while	at	high	concentrations	of	Flt3L	multipotent	cells	are	instructed	
towards	the	GM-lymphoid	lineages	[288].		
	
It	 should	be	noted	 that,	while	 the	 study	by	 Tsapogas	et	al.	 suggests	 Flt3L	 acts	 to	 instruct	
lineage	fate,	the	data	provided	does	not	exclude	the	possibility	of	selective	expansion	of	non-
MegE	 progenitors.	 A	 figure	 for	 the	 absolute	 number	 of	MEPs	was	 not	 provided	 from	 the	
studies	 in	which	mice	were	administered	with	Flt3L.	 Therefore,	 it	 is	difficult	 to	determine	
whether	the	percentage	of	MEPs	decreased	due	to	a	reduced	influx	of	upstream	progenitors	
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or	due	to	the	proliferation	of	other	BM	progenitors.	In	this	regard,	more	work	will	be	required	
to	investigate	whether	Flt3L	can	instruct	progenitors	upstream	of	MEPs.	
	
In	contrast	to	the	findings	of	Ward	et	al.	[253],	Grover	et	al.	have	reported	that	Epo	is	capable	
of	stimulating	erythroid	commitment	in	early	HSPCs	[269].	The	group	analysed	the	response	
of	haematopoietic	progenitors	to	high	systemic	Epo	levels	by	injecting	mice	with	a	viral	vector	
encoding	the	EPO	gene.	Analysis	of	the	BM	progenitor	compartments	in	these	mice	showed	
an	 expansion	 of	 committed	 erythroid	 and	 MegE	 progenitors,	 whereas	 megakaryocyte	
progenitor	(MkPs),	preGMP,	GMP	and	LMPP	populations	were	decreased.	When	examining	
the	 LSK	 Flt3−	 BM	 compartment,	 the	 authors	 reported	 an	 increase	 in	 the	 expression	 of	
erythroid	lineage-associated	genes,	such	as	KLF1	and	GATA1,	relative	to	LSK	Flt3−	cells	from	
control	mice	that	had	received	a	control	vector.	Analysis	of	single	LSK	Flt3−	cells	2	days	after	
injection	of	the	EPO	vector	revealed	a	50%	increase	in	the	number	of	cells	expressing	one	or	
more	 erythroid	 associated	 genes.	 Additionally,	 these	 cells	 significantly	 decreased	 their	
expression	of	GM-associated	genes	when	compared	to	LSK	Flt3−	from	control	mice.	Further	
work	indicated	that	these	changes	were	mediated	by	GATA-1-dependent	signalling,	as	HSPCs	
lacking	GATA1	did	not	respond	to	Epo.	Finally,	transplantation	of	LSK	Flt3−	CD150+	cells	from	
mice	that	had	received	the	EPO	vector,	or	control	vector,	into	irradiated	hosts	revealed	that	
Epo	skewed	the	differentiation	of	these	cells	towards	an	erythroid	fate	in	vitro.	As	such,	the	
authors	concluded	that	Epo	stimulates	erythroid	specification	of	early	HSPCs.	
	
Recently,	Pietras	et	al.	have	shown	that	IL-1	promotes	the	differentiation	of	HSCs	towards	the	
GM	lineage	[175].	When	stimulated	with	IL-1β,	LSK	Flt3−	CD48−	CD150+	HSCs	were	shown	to	
increase	 the	 expression	 of	 GM-associated	 genes,	 such	 as	 CSF2R,	 CSF3R	 and	 SPI1	 (which	
encodes	PU.1),	and	form	more	GM	colonies	in	methylcellulose	relative	to	unstimulated	cells.	
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By	monitoring	PU.1:GFP	HSCs	in	culture	until	the	first	cell	division	(>20	hours),	the	authors	
demonstrated	 that	 IL-1β	 stimulated	 87%	 of	 these	 cells	 to	 upregulate	 SPI1	 expression.	 In	
contrast,	only	32%	of	these	cells	upregulated	SPI1	expression	in	cultures	lacking	IL-1β.	When	
IL-1β	treated	HSCs	were	transplanted	into	irradiated	recipients,	they	generated	an	increased	
number	of	myeloid	cells	at	the	expense	of	lymphoid	cells	when	compared	to	unstimulated	
HSCs.	As	such,	the	results	indicate	that	IL-1β	can	activate	and	drive	GM	differentiation	of	at	
least	55%	of	LSK	Flt3−	CD48−	CD150+	HSCs.	
	
There	 is	 also	 evidence	 to	 suggest	 that	 other	 extrinsic	 factors,	 such	 as	 hormones	 and	
metabolites,	influence	the	lineage	specification	of	HSPCs.	In	2014,	Oburoglu	and	colleagues	
isolated	 CD34+	 CD38−	 hHSCs	 and	 investigated	 the	 effects	 of	 inhibiting	 glutaminolysis	 or	
glycolysis	on	Epo-mediated	erythroid	specification	in	vitro	[289].	First,	the	authors	performed	
small-hairpin	(sh)RNA-mediated	knock-down	of	the	glutamine	transporter	gene,	ASCT2,	and	
examined	 the	 differentiation	 of	 hHSCs	 towards	 the	 erythroid	 lineage	 by	 monitoring	 the	
expression	of	the	erythroid-associated	cell	surface	marker,	glycophorin	A.	Following	6	days	of	
culture,	only	10%	of	 shASCT2-transduced	hHSCs	had	acquired	expression	of	glycophorin	A	
when	 compared	 to	 40-80%	 of	 control	 cells.	 In	 contrast,	 approximately	 50%	 of	 shASCT2-
transduced	hHSCs	 differentiated	 into	 CD11b+	myeloid	 cells.	 Similar	 results	were	 observed	
when	hHSCs	were	treated	with	a	glutiminase	inhibitor.	When	the	authors	inhibited	glycolysis	
in	 hHSCs	 using	 a	 phosphoglucoisomerase	 inhibitor,	 an	 increased	 number	 of	 these	 cells	
differentiated	 into	 erythroid	 cells	 in	 the	 presence	 of	 Epo.	 Finally,	 these	 findings	were	 re-
created	 in	 anaemic	 mouse	 models	 by	 the	 administration	 of	 glutiminase	 and	
phosphoglucoisomerase	enzyme	inhibitors.		
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The	following	year,	Xia	and	colleagues	showed	that	insulin	skews	the	development	of	LMPPs	
towards	 a	 lymphoid	 fate	 [290].	 LMPPs	 that	 were	 pre-treated	 with	 insulin	 for	 18	 hours	
produced	significantly	more	lymphoid	cells,	at	the	expense	of	myeloid	cells	in	colony	forming	
and	in	vivo	transplantation	assays	when	compared	to	untreated	cells.	Using	gene	expression	
analysis,	 the	 authors	 demonstrated	 that	 insulin	 stimulated	 the	 expression	 of	 IKZF1,	 a	
lymphoid-associated	 TF,	 in	 all	 of	 the	 LMPPs	 assayed,	 indicating	 that	 the	 insulin-induced	
lymphoid	bias	of	LMPPs	is	not	a	result	of	selective	expansion	of	a	distinct	subpopulation.	As	
such,	these	two	studies	indicate	that	the	lineage	commitment	of	haematopoietic	cells	can	be	
affected	by	hormone	signalling	and	cell	metabolism.	
	
Most	of	the	recent	reports	investigating	the	role	of	HGFs	in	lineage	commitment	support	a	
deterministic	 model	 of	 haematopoiesis.	 Indeed,	 the	 study	 by	 Rieger	 et	 al.	 provides	
comprehensive	evidence	for	the	instructive	actions	of	M-CSF	and	G-CSF	on	GMPs	due	to	real-
time	tracking	of	cell	death	and	differentiation	events,	and	disputes	a	selective	role	for	these	
factors	in	the	GMP	population	[268].	However,	other	studies	do	not	provide	enough	evidence	
to	 refute	 a	 model	 in	 which	 HGFs	 act	 in	 a	 selective	 manner.	 For	 example,	 the	 studies	
investigating	 the	 effects	 of	 M-CSF	 [267],	 Epo	 [269]	 and	 IL-1β	 [175]	 on	 early	 HSPCs	 have	
demonstrated	that	these	factors	act	on	multipotent	cells,	but	it	cannot	be	excluded	that	HGFs	
are	selectively	expressed	within	 these	populations.	As	mentioned	previously,	 the	study	by	
Tsapogas	et	al.	does	not	provide	enough	information	to	confirm	that	Flt3L	acts	on	progenitors	
upstream	of	MEPs	to	skew	their	development	towards	a	GM-lymphoid	fate	[288].	As	such,	
the	role	of	HGFs	in	lineage	fate	is	still	controversial.	To	determine	whether	HGFs	truly	provide	
instructive	 cues,	 or	 act	 to	 selectively	 expand	distinct	 haematopoietic	 subpopulations,	 it	 is	
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important	to	investigate	the	expression	of	HGF	receptors	by	different	stem	and	progenitor	
cell	compartments	at	the	single	cell	level.	
	
1.3.3			Lineage-bias	in	the	haematopoietic	system	
	
A	number	of	lineage-biased	HSPC	populations	have	been	identified	in	the	mouse	BM.	These	
cells	are	considered	 to	be	biased	because	 they	disproportionately	 contribute	 to	particular	
lineages	when	compared	to	the	average	output	of	the	population.	In	2002,	Sieburg’s	group	
performed	 long-term	 reconstitution	 assays	 using	 the	 progeny	 derived	 from	 single	mouse	
HSCs	 in	 vitro	 [291].	 These	 experiments	 revealed	 three	 subpopulations	 of	 HSCs	 that	 were	
capable	of	generating	cells	with	distinct	repopulating	characteristics;	balanced	HSCs,	which	
repopulated	 irradiated	mice	with	normal	 ratios	of	myeloid	 and	 lymphoid	 cells	 (as	 seen	 in	
unmanipulated	mice);	MyHSCs;	and	LyHSCs.	Characterisation	of	these	populations	using	serial	
transplantation	assays	revealed	that	MyHSCs	had	more	self-renewal	potential	than	balanced	
HSCs	and	LyHSCs	[292].	
	
Muller-Sieburg	et	al.	demonstrated	that	the	lymphoid	progenitors	derived	from	these	HSCs	
express	different	levels	of	IL-7R.	Lymphoid	progenitors	derived	from	MyHSCs	expressed	IL7R	
at	 levels	 approximately	 2.2-fold	 lower	 than	 those	 derived	 from	 LyHSCs	 [292].	 When	 the	
progeny	of	MyHSCs	were	cultured	in	vitro,	they	failed	to	respond	to	IL-7	stimulation.	These	
cells	generated	the	same	number	of	lymphoid	cells	in	culture	regardless	of	whether	IL-7	was	
present.	 As	 such	 the	 authors	 concluded	 that	 the	 bias	 of	 these	MyHSCs	 and	 LyHSCs	 was	
dependent	on	varying	patterns	of	HGF	receptor	expression	[292].	Further	analysis	of	aging	
mice	 by	 Cho	et	 al.	 revealed	 that	 the	MyHSC	 pool	 increased	 at	 the	 expense	 of	 the	 LyHSC	
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population	 with	 age.	 These	 workers	 suggested	 that	 this	 process	 might	 explain	 the	 shift	
towards	myelopoiesis	in	older	mice	and	humans	[293].		
	
In	2010,	Challen	and	colleagues	purified	mouse	MyHSCs	and	LyHSCs	based	on	their	exclusion	
of	 Hoechst	 33342	 [25].	MyHSCs	 were	 identified	 as	 the	 lower	 side	 population	 (SP),	 while	
LyHSCs	represent	the	upper	SP,	allowing	for	isolation	and	further	characterisation	of	these	
populations.	 In	 vitro	 characterisation	 revealed	 that	 SPlow	 MyHSCs	 and	 SPlow	 LyHSCs	 are	
differentially	regulated	by	transforming	growth	factor	(TGF)	β1	[25].	TGF-β1	stimulates	the	
proliferation	of	SPlow	MyHSCs,	but	inhibits	the	expansion	of	SPlow	LyHSCs.	Other	markers	have	
since	been	identified	for	the	purification	of	MyHSCs	and	LyHSCs.	Gekas	et	al.	have	isolated	a	
population	of	MyHSCs	based	on	their	expression	of	CD41	[30].	Two	independent	studies	have	
also	 demonstrated	 that	 MyHSCs	 are	 enriched	 for	 in	 the	 CD150hi	 fraction	 of	 the	 LSK	
compartment	of	the	BM	[27,	294].	Shimazu	and	colleagues	have	identified	a	LyHSC	population	
that	 expresses	 CD86	 [31].	 Lastly,	 Oguro	 et	 al.	 have	 reported	 that	 CD229	 can	 be	 used	 to	
distinguish	between	MyHSCs	and	LyHSCs	[34].	Whether	these	populations	are	the	same	as	
the	cells	initially	isolated	by	Challen	et	al.	remains	to	be	seen	[25].	
	
Jacobsen’s	group	recently	identified	platelet-biased	mouse	LT-HSCs	that	are	maintained	by	
Tpo	[29].	These	cells	express	von	Willebrand	factor	(vWF),	a	glycoprotein	involved	in	platelet	
adhesion,	and	express	higher	levels	of	megakaryocyte-associated	genes	when	compared	to	
vWF–	 HSCs.	 Using	 single	 cell	 transplantation	 assays,	 the	 authors	 showed	 that	 vWF+	 HSCs	
generate	 significantly	 more	 platelets	 than	 the	 balanced	 vWF–	 HSCs.	 Additionally,	 these	
experiments	revealed	that	vWF+	HSCs	are	upstream	of	vWF−	HSCs,	leading	Sanjuan-Pla	et	al.	
to	propose	that	platelet-biased	vWF+	HSCs	are	at	the	apex	of	haematopoiesis	[29].	HSCs	that	
express	high	levels	of	c-Kit	have	also	been	shown	to	be	biased	towards	the	megakaryocyte	
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lineage	 [32].	 However,	 these	 c-Kithigh	 HSCs	 have	 reduced	 self-renewal	 capacity	 when	
compared	to	c-Kitlo	and	are	derived	from	c-Kitlo	cells,	suggesting	that	platelet-biased	c-Kithigh	
and	vWF+	HSCs	may	define	distinct	populations.		
	
‘Cellular	barcoding’	of	 single	cells	also	suggests	 the	existence	of	additional	B-lymphocyte-,	
granulocyte-	 and	DC-biased	HSCs	 in	mice	 [9,	 28].	 This	 technique	allows	 for	 the	 tagging	of	
individual	cells	with	a	unique	genetic	sequence	from	a	 library	of	randomly	generated	DNA	
sequences,	 and	 has	 been	 used	 to	 monitor	 the	 differentiation	 of	 HSPCs	 during	 BM	
transplantation	 assays.	 Donor	 cells	 are	 first	 transduced	 with	 lentiviruses	 containing	
sequences	 from	 a	 DNA	 library,	 resulting	 in	 the	 labelling	 of	 individual	 cells	 with	 a	 unique	
barcode.	 The	 donor	 cells	 are	 then	 transplanted	 into	 recipients,	 and	 high-throughput	
sequencing	of	haematopoietic	cells	is	used	to	determine	the	contribution	of	each	individual	
HSPC	 to	 the	haematopoietic	 system.	The	Weissman	 [28]	and	Schumacher	 [9]	groups	have	
used	 this	 technique	 to	 identify	 lymphoid-,	 myeloid-	 and	 DC-biased	 populations	 of	 HSCs.	
Notably,	lineage-bias	is	not	restricted	to	HSCs,	as	LMPPs	can	also	be	subdivided	into	lymphoid-
,	myeloid-	and	DC-biased	populations	[9].	
	
Lineage-restricted	 cells	 with	 long-term	 repopulating	 activity	 have	 also	 been	 identified.	
Yamamoto	et	al.	have	identified	three	long-term	repopulating	myeloid-restricted	progenitor	
(MyRP)	 subpopulations	 within	 the	 HSC	 compartment	 of	 the	 mouse	 BM	 [23].	 The	 group	
isolated	 CD150+	 CD41–,	 CD150+	 CD41+	 and	 CD150–	 CD41–	 cells	 from	 the	 LSK	 CD34–	
compartment	of	the	mouse	BM	and	performed	single	cell	serial	transplantation	assays.	When	
monitoring	the	output	of	these	cells	over	time,	the	authors	noted	that	each	fraction	contained	
some	individual	cells	that	were	restricted	to	particular	lineages.	These	cells	were	capable	of	
long-term	 reconstitution	 and	 displayed	 lineage	 potentials	 similar	 to	MkPs	 (MkRPs),	 CMPs	
	 69	
(CMRPs)	and	MEPs	(MERPs).	
	
CMRPs	accounted	for	approximately	24%,	49%	and	16%	of	the	CD150+	CD41–,	CD150+	CD41+	
and	CD150–	CD41–	cells	within	the	LSK	CD34–	compartment,	respectively.	Approximately	7%	
of	CD150+	CD41–	cells	and	5%	of	CD150+	CD41+	cells	displayed	MERP	activity,	and	these	cells	
were	not	detected	in	the	CD150–	CD41–	fraction.		Similarly,	24%	of	CD150+	CD41–	cells	and	
28%	of	CD150+	CD41+	cells	were	MkRPs,	while	MkRPs	was	not	detected	in	the	CD150–	CD41–	
fraction.	The	authors	then	performed	paired	daughter	cell	analysis	of	LT-HSCs,	and	reported	
that	LT-HSCs	directly	give	rise	to	CMRPs,	MERPs	and	MkRPs.	Finally,	Yamamoto	et	al.	used	a	
similar	approach	to	demonstrate	that	the	MPP	and	LMPP	populations	contained	a	variety	of	
lineage	 restricted	 progenitors	 [23].	 The	 authors	 concluded	 that	 currently	 defined	 HSPC	
populations	are	not	comprised	of	homogeneous	progenitors	with	similar	lineage-potentials.	
Rather,	 they	 contain	 a	 number	 of	 distinct	 subpopulations	 that	 together	 contribute	 to	 the	
lineage	potential	of	the	whole	population.	
	
A	 number	 of	 lineage-biased	 populations	 have	 been	 identified	 within	 the	 haematopoietic	
hierarchy,	and	some	of	these	have	been	shown	to	be	differentially	regulated	by	HGFs,	such	
as	IL-7,	Tpo	and	TGF-β1.	This	adds	further	complexity	when	trying	to	determine	a	model	of	
haematopoiesis.	If	these	lineage-biased	progenitors	differentially	express	HGF	receptors	and	
respond	to	particular	factors,	then	this	would	support	a	permissive	model	of	haematopoiesis.	
On	the	other	hand,	if	HGFs	are	responsible	for	driving	lineage-biases	in	multipotent	cells,	then	
this	 suggests	 that	 HGFs	 are	 instructive.	 As	 highlighted	 in	 Section	 1.3.2.4,	 analysis	 of	 HGF	
receptor	expression	within	different	compartments	will	help	to	provide	clarity	on	whether	
such	 factors	 selectively	 regulate	 the	 differentiation	 and/or	 lineage	 fate	 of	 HSPC	
subpopulations.	
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1.4			Aims	of	project	
	
There	are	a	 large	number	of	conflicting	studies	available	regarding	the	role	of	HGFs	 in	the	
lineage	specification	of	HSPCs.	Some	of	the	work	provides	clear	evidence	that	certain	HGFs	
can	 instruct	HSPC	 fate,	while	other	 studies	 indicate	 that	HGFs	act	permissively.	 The	exact	
mechanisms	 that	 govern	 lineage	 commitment	 in	 HSPCs	 remains	 unclear.	 It	 is	 also	 largely	
unknown	how	heterogeneous	HSPC	populations	are	in	regards	to	their	response	to	HGFs.	For	
example,	 lineage-biased	 populations	 have	 been	 shown	 to	 be	 differentially	 regulated	 by	
certain	HGFs,	and	it	has	been	shown	that	not	all	cells	within	the	HSC	compartment	respond	
to	M-CSF	[267],	Epo	[269]	and	IL-1β	[175].	This	suggests	that	the	receptors	for	these	factors	
are	selectively	expressed	by	certain	subpopulations	within	haematopoietic	compartments.	If	
such	 subpopulations	of	 cells	 exist	within	 the	early	HSPC	 compartments,	 then	HGFs	would	
selectively	stimulate	these	subpopulations	to	drive	their	differentiation.	This	would	suggest	
that	 certain	 HSPC	 populations	 are	 somewhat	 primed	 to	 repopulate	 particular	 lineages,	
favouring	a	selective	model	of	haematopoiesis	over	a	deterministic	model.	On	the	other	hand,	
some	previous	studies	have	reported	the	co-expression	of	particular	growth	factor	receptors	
by	early	HSPCs,	such	as	EPOR	and	CSF3R,	suggesting	that	Epo	and	G-CSF	act	to	instruct	lineage	
fate	in	these	cells	[116].	Additionally,	Rieger	et	al.	have	elegantly	demonstrated	the	instructive	
properties	 of	 G-CSF	 and	 M-CSF	 using	 GMP	 progenitors	 in	 vitro,	 strongly	 supporting	 a	
deterministic	model	of	haematopoiesis	[268].		
	
Previous	studies	have	attempted	to	define	HGFs	as	either	selective	or	instructive	molecules	
and,	 as	 highlighted	 in	 Section	 1.3,	 have	 considered	 these	 two	 properties	 to	 be	mutually	
exclusive.	However,	as	highlighted	 in	the	previous	paragraph,	 there	 is	evidence	to	suggest	
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that	aspects	of	both	a	selective	and	deterministic	model	play	a	role	 in	HSPC	development.	
Therefore,	defining	lineage	specification	as	either	a	selective	or	deterministic	process	based	
on	 the	 action	 of	 HGFs	 is	 possibly	 an	 oversimplification	 of	 an	 extremely	 complex	 process,	
especially	 considering	 the	 heterogeneity	 of	 HSPCs.	 To	 further	 explore	 this	 postulate,	 the	
analysis	of	HGF	receptor	expression	at	the	single	cell	level	is	required,	with	particular	focus	
on	 the	 selective	 expression	 and	 co-expression	 of	 such	 receptors	 within	 early	 HSPC	
populations.	Ultimately,	this	will	provide	insight	into	how	HGFs	regulate	HSPC	differentiation,	
and	help	to	determine	whether	HGFs	act	in	a	selective	or	instructive	manner.	Understanding	
such	a	process	will	be	helpful	in	the	manipulation	of	HSPCs	for	clinical	purposes,	such	as	the	
in	vitro	manufacturing	of	erythrocytes	for	blood	transfusions	[295].	
	
The	purpose	of	this	project	is	to	investigate	the	expression	of	HGFs	on	single	HSPCs.	Single	
cell	quantitative	RT-PCR	(qRT-PCR)	assays	were	first	designed	and	optimised,	and	then	used	
to	examine	the	expression	of	HGF	transcripts	by	cells	of	all	major	HSPC	compartments	of	the	
mouse	BM.	The	design	of	multiplex	qRT-PCR	assays	allowed	for	the	analysis	of	potential	co-
expression	of	HGF	receptor	genes	within	the	multipotent	haematopoietic	cell	compartments	
of	 the	 BM.	 Expression	 of	HGF	 receptor	 protein	within	 each	HSPC	 compartment	was	 then	
investigated	and	the	data	was	compared	with	the	findings	from	the	qRT-PCR	studies.	Finally,	
in	vitro	 culture	experiments	were	undertaken	to	examine	 the	 responsiveness	of	particular	
HSPC	 compartments	 to	 Flt3L.	 These	 included	 analyses	 of	 cell	 signalling	 pathways	 and	 cell	
differentiation/lineage	commitment.	The	findings	generated	from	this	work	have	identified	
novel	patterns	of	HGF	receptor	expression	throughout	the	haematopoietic	hierarchy,	and	add	
to	the	debate	regarding	the	role	of	HGFs	in	regulating	haematopoiesis.	 	
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CHAPTER	2:			 MATERIALS	AND	METHODS	
2.1			Mice	
	
C57/BL6	 mice	 (WT)	 were	 purchased	 from	 	
	All	mice	were	treated	
in	accordance	to	guidelines	set	out	by	The	Home	Office	(project	license	numbers	30/2850	and	
PPL70/8011),	and	were	culled	by	cervical	dislocation	between	7-14	weeks	of	age	for	this	study.	
	
2.2			Analysis	 of	 HemaExplorer	 and	 BloodSpot	
databases	
Raw	values	for	FLT3,	EPOR,	CSF1R	and	CSF3R	expression	by	HSPCs	were	exported	from	the	
HemaExplorer	 and	 BloodSpot	 databases	 [296,	 297].	 When	 searching	 for	 genes	 in	 the	
databases,	the	‘Mouse	normal	haematopoietic	system’	dataset	was	selected.	This	included	
LT-HSC,	ST-HSC,	LMPP,	CLP,	ETP,	pro-B-lymphocytes,	pre-B-lymphocytes,	preGM,	GMP,	MEP,	
MkP,	 preCFU-E,	 CFU-E	 and	 EP	 populations.	 Other	 populations	 were	 also	 included	 in	 the	
dataset	 but	 these	 were	 excluded,	 as	 they	 were	 not	 relevant	 to	 this	 study.	 Data	 was	
downloaded	in	Microsoft	Excel	format	from	the	website.	Where	the	data	included	more	than	
one	set	of	results,	all	results	were	averaged	and	the	mean	was	included	in	the	data	analysis.	
As	 the	data	 could	only	be	exported	 in	 log2	 format,	 the	data	was	 transformed	back	 to	 the	
original	expression	values	using	the	formula:		
2^[Log	transformed	expression	values]	=	[Original	expression	values]	
	
Mean	and	standard	error	for	expression	of	each	gene	by	each	HSPC	population	was	calculated	
individually	and	then	plotted	for	analysis.	
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2.3			Bone	marrow	cell	preparation	
	
BM	cells	were	isolated	from	both	mouse	hindlimbs	and	forelimbs	to	ensure	high	cell	numbers	
were	obtained	during	experiments.	 To	prepare	 the	hindlimb	 for	processing,	 scissors	were	
used	 to	 cut	 through	 the	 pelvis	 of	 the	 mouse,	 removing	 the	 femur,	 tibia	 and	 fibula.	 This	
ensured	that	 the	 femur	head	remained	 intact	during	preparations.	The	hindpaw	was	 then	
separated	at	the	ankle	and	the	skin	over	the	limb	was	removed.	To	separate	the	femur	from	
the	tibia,	the	knee	was	hyperextended	and	pulled	apart.	The	bones	were	then	cleaned	of	any	
excess	muscle	or	fat.	To	remove	the	forelimbs	from	the	mouse,	the	skin	around	the	limb	was	
cut	and	reflected.	The	limb	was	then	gently	pulled	away	from	the	axial	skeleton.	The	scapula,	
humerus	and	radius/ulna	were	then	each	separated	by	pulling	apart	the	joints.	As	before,	the	
bones	were	 cleaned	of	muscle	 and	 fat.	Of	 the	 forelimb,	only	 the	humerus	and	ulna	were	
retained	as	the	radius	and	scapula	did	not	contain	a	significant	amount	of	BM.		
	
Unless	 otherwise	 stated,	 cells	 were	 flushed	 from	 the	 BM	 cavity	 using	 a	 1mL	 syringe	 (BD	
biosciences,	 NJ,	 USA)	 and	 18-gauge	 needle	 (Terumo,	 Leuven,	 Belgium),	 and	 fluorescent	
activated	cell	sorting	(FACS)	buffer.	FACS	buffer	was	prepared	by	adding	2%	fetal	calf	serum	
(FCS)	and	2mM	EDTA	to	Dulbecco's	phosphate	buffered	saline	(DPBS)	without	Ca+/Mg+	(all	
Sigma-Aldrich,	Haverhill,	UK).	The	18-gauge	needle	was	inserted	into	both	sides	of	each	bone	
before	all	cells	from	the	BM	of	a	single	mouse	were	flushed	into	15mL	falcon	tubes	(Thermo	
Fisher	 Scientific,	 Loughborough,	 UK).	 Cell	 suspensions	were	mixed	 using	 a	 pipette	 before	
being	strained	using	70	μM	Cell	strainers	(Thermo	Fisher	Scientific)	and	then	centrifuged	at	
4˚C,	394	relative	centrifugal	force	(rcf,	g)	for	4	minutes.	The	pellet	was	resuspended	in	500μL	
of	ACK	Lysing	Buffer	(Gibco,	Thermo	Fisher	Scientific)	to	lyse	erythrocytes	and	incubated	on	
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ice	for	10	minutes.	Cells	were	then	diluted	to	5mL	using	FACS	buffer	and	spun	down	at	4˚C,	
394	 rcf	 for	 4	minutes.	 The	 pellet	 was	 resuspended	 in	 buffer	 or	 cell	 culture	medium	 and	
processed	as	required.	
	
2.4			Preparation	 of	 bone	marrow	 for	 flow	 cytometric	
analysis	
	
BM	cells	were	prepared	from	C57/BL6	mice	as	described	in	Section	2.3.	Once	the	erythrocytes	
were	 lysed,	 cells	 were	 resuspended	 in	 FACS	 buffer,	 divided	 into	 multiple	 samples	 and	
transferred	to	non-sterile	v-bottomed	96-well	plates	(Greiner	Bio-One,	Gloucestershire,	UK).	
The	 samples	 were	 then	 pelleted	 at	 4˚C,	 394	 rcf	 for	 4	 minutes	 and	 the	 supernatant	 was	
removed	by	rapidly	turning	the	plates	upside	down	over	the	sink.	Unless	CD16/32	expression	
was	 examined	 using	 fluorescently-labelled	 antibodies	 (as	 needed	 for	 myeloid	 progenitor	
analysis),	cells	were	incubated	with	anti-CD16/CD32	for	20	minutes	to	block	CD16	(FcγIII)	and	
CD32	 (FcγII)	 receptors,	 prior	 to	 staining.	After	 blocking,	 samples	were	 then	 stained	 in	 50-
100μL	FACS	buffer	containing	antibody	cocktails	or	a	single	antibody	for	compensation	for	at	
least	1	hour	on	ice.	Following	staining,	samples	were	washed	twice	using	FACS	buffer,	and	
subsequently	 resuspended	 in	 FACS	buffer.	 Cells	were	 finally	 filtered	using	 Partec	 CellTrics	
sterile	 filters	 (Sysmex-Partec,	 Münster,	 Germany)	 and	 transferred	 to	 polypropylene	 FACS	
tubes	 (Thermo	 Fisher	 Scientific).	 Samples	 were	 acquired	 using	 a	 CyAN	 FACS	 Analyser	
(Beckman	 Coulter,	 High	 Wycombe,	 UK)	 controlled	 by	 Summit	 v4.3	 software.	 Post-
experimental	analysis	was	carried	out	using	FlowJo	software,	version	10.1.	
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2.5			Preparation	 of	 bone	 marrow	 for	 fluorescent	
activated	cell	sorting	
	
BM	cells	were	prepared	from	C57/BL6	mice	as	described	in	Section	2.3,	and	the	protocol	for	
cell	sorting	was	similar	to	the	protocol	used	for	flow	cytometry	(Section	2.4).	However,	when	
BM	samples	were	prepared	for	FACS,	sterile	DPBS	(without	Ca+/Mg+)	containing	10%	FCS	was	
used.	After	erythrocyte	lysis,	cell	suspensions	were	resuspended	in	500μL	of	10%	FCS	DPBS	
and	 transferred	 to	 sterile	 1.5	 mL	 Eppendorfs	 (Eppendorf,	 Stevenage,	 UK)	 before	 being	
pelleted	at	4˚C,	394	rcf	for	4	minutes.	Unless	analysing	CD16/32	expression,	Fc	receptors	were	
blocked	as	per	Section	2.4.		As	most	of	the	cells	from	a	single	mouse	were	processed	when	
sorting	 single	HSCs,	 cell	pellets	were	 resuspended	 in	a	volume	of	200μL	of	10%	FCS	DPBS	
containing	antibody	cocktails.	Samples	were	then	incubated	with	the	antibody	cocktails	for	at	
least	1	hour	on	 ice.	Samples	were	then	washed	twice	 in	10%	FCS	DPBS,	and	subsequently	
resuspended	in	10%	FCS	DPBS.	Cells	were	finally	filtered	using	Partec	CellTrics	sterile	filters	
(Sysmex-Partec)	 and	 transferred	 to	 either	 sterile	 polypropylene	 FACS	 tubes	 or	 sterile	
polystyrene	FACS	tubes	(Thermo	Fisher	Scientific).	All	samples	were	sorted	twice	to	ensure	
high	purity;	the	first	sort	was	set	to	‘purify’	on	the	Summit	software	(Beckman	Coulter)	and	
cells	were	sorted	into	500μL	of	10%	FCS	DPBS.	The	initial	sort	was	set	to	‘purify’	with	a	drop	
envelope	of	1.	This	usually	resulted	in	a	good-to-high	purity	when	analysing	with	strict	gates,	
and	it	was	only	a	rare	occurrence	for	impurities	to	fall	far	outside	of	the	gating	strategy.	The	
second	sort	was	set	to	‘single-cell’	with	a	drop	envelope	of	0.5	to	ensure	high	purity	when	
sorting.	Cells	were	either	sorted	into	LightCycler	480	384-well	plates	(Roche)	containing	1μL	
of	H2O	in	each	well	for	qRT-PCR	analysis,	or	into	buffer/culture	medium	for	further	processing.	
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Figure	2.1.	Isolation	of	single	LT-HSCs.	(A)	LT-HSCs	were	sorted	from	whole	BM	into	500μL	of	phosphate	buffered	saline	supplemented	with	10%	
fetal	calf	serum.	(B)	Single	LT-HSCs	from	the	initial	sort	(A)	were	sorted	a	second	time	to	ensure	high	purity.	Values	depicted	in	(B)	indicate	the	
number	of	cells	within	the	gate	as	a	percentage	of	singlets.	Lin,	lineage	markers;	LT-HSC,	long-term	haematopoietic	stem	cell;	ST-HSC,	short-term	
haematopoietic	stem	cell;	BM,	bone	marrow.	
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Once	 sorting	 was	 complete,	 PCR	 plates	 were	 sealed	 with	 adhesive	 PCR	 film	 and	 were	
immediately	frozen	and	stored	at	-80˚C	until	required.	Sorting	was	carried	out	using	either	a	
MoFlo	High	Speed	Sorter	(Beckman	Coulter)	or	a	MoFlo	Astrios	(Beckman	Coulter)	controlled	
by	 Summit	 v4.3	 or	 Summit	 v6.2.3	 software,	 respectively.	 Post-experimental	 analysis	 was	
carried	out	using	FlowJo	software,	version	10.1,	to	ensure	quality	of	sorts.	A	representative	
isolation	of	single	LT-HSCs	is	shown	in	Figure	2.1.	Unfortunately,	given	the	small	numbers	of	
cells	sorted,	especially	when	sorting	HSCs,	 it	was	not	feasible	to	check	the	purity	after	the	
second	sort.	
	
	
2.6			Antibody	 titration	 for	 fluorescent	 activated	 cell	
sorting	and	flow	cytometric	analysis	
	
Antibodies	 were	 titrated	 by	 staining	 whole	 BM	 cells	 at	 different	 dilutions	 of	 the	 original	
antibody	concentration.	Unless	a	more	concentrated	dilution	was	specified	by	the	supplier,	
the	most	concentrated	dilution	that	each	antibody	was	tested	at	was	1/50.	Optimum	dilutions	
were	chosen	as	the	least	concentrated	dilution	that	did	not	yield	a	decrease	in	staining	when	
compared	to	the	most	concentrated	sample	(e.g.	1/50).	Where	there	was	an	immediate	loss	
in	staining	following	dilution	at	1/100,	1/50	was	chosen	as	the	optimum	concentration.	An	
example	of	an	antibody	titration	can	be	seen	in	Figure	2.2.	
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Figure	2.2.	Example	of	an	antibody	titration	used	for	flow	cytometry.	An	antibody	specific	
for	CD34	was	titrated	at	dilutions	of	1/50,	1/100	and	1/200	to	determine	the	optimum	dilution	
for	flow	cytometry.	The	optimum	dilution	was	chosen	as	1/50,	as	there	was	a	clear	decrease	
in	staining	when	diluting	the	antibody	further.	Values	indicate	the	percentage	of	cells	that	are	
within	the	given	gate.	
	
2.7			Preparation	of	bone	marrow	cell	lysates	for	testing	
and	optimisation	of	qRT-PCR	assays	
	
Cells	were	isolated	from	BM	as	described	in	Section	2.3.	Whole	BM	cells	were	transferred	to	
1.5	mL	Eppendorfs,	pelleted	at	4˚C,	394	rcf	for	10	minutes,	and	the	supernatant	was	aspirated.	
Cells	were	lysed	by	adding	20-50μL	of	H2O	to	the	pellet	before	the	samples	were	vortexed	
and	 incubated	 on	 ice	 for	 5	 minutes.	 The	 nucleotide	 concentration	 of	 cell	 lysates	 was	
determined	by	analysing	0.5μL	of	the	sample	on	a	Nanodrop	2000.	Samples	were	then	stored	
at	-80˚C	until	required.	
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2.8			qRT-PCR	 assay	 design	 and	 optimisation	 for	 gene	
expression	analysis	
	
For	a	brief	and	succinct	summary	of	the	qRT-PCR	assay	design	and	optimisation	workflow	
used	in	this	thesis,	see	Figure	2.3.	
	
Figure	2.3.	Workflow	of	multiplex	qRT-PCR	assay	design	and	optimisation	for	detection	of	
gene	expression	 in	single	cells.	BLAST,	Basic	Local	Alignment	Search	Tool;	gDNA,	genomic	
DNA.	
	
2.8.1			Identification	of	candidate	sequences	for	the	design	of	
qRT-PCR	assays	
	
Information	 regarding	 a	 gene	 of	 interest	 was	 obtained	 by	 searching	 Ensembl	 Genome	
Browser	 (http://www.ensembl.org/index.html)	 using	 the	 gene	 name.	Using	 this	 database,	
details	about	a	gene	was	gathered	including	the	DNA	sequence,	the	mRNA	sequence	of	any	
protein	coding	transcripts,	and	the	number	of	exons	present	within	the	gene.	To	analyse	the	
gene	and	transcript	sequences,	the	freely	available	Basic	Local	Alignment	Search	Tool	(BLAST,	
http://blast.ncbi.nlm.nih.gov/Blast.cgi)	was	used.	BLAST	 is	an	algorithm	that	allows	for	 the	
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comparison	 of	 input	 protein	 and	 nucleotide	 sequences	 to	 known	 protein	 and	 nucleotide	
sequences	within	a	biological	database/library	[298].		
	
To	ensure	accurate	analysis	of	gene	expression	at	the	single	cell	level,	qRT-PCR	assays	were	
designed	to	specifically	detect	mRNA	transcripts	but	not	genomic	DNA	(gDNA).	For	this	reason,	
qRT-PCR	 assays	 were	 only	 designed	 to	 be	 specific	 for	 regions	 spanning	 exon	 junctions.	
Additionally,	 as	 the	qRT-PCR	 assays	were	 intended	 to	 detect	 all	 protein	 coding	 transcripts	
within	a	cell,	all	protein	coding	transcripts	for	a	gene	of	interest	were	analysed	to	determine	
shared	exon	 junctions	 that	could	be	 interrogated	using	a	qRT-PCR	assay.	This	strategy	was	
used	for	the	design	of	generic	mRNA-specific	qRT-PCR	assays	that	detected	all	protein	coding	
transcripts.	Once	all	of	the	generic	exon	junctions	were	identified	within	a	gene,	they	were	
analysed	using	BLAST	to	ensure	that	no	pseudogenes	were	present	at	these	sequences.	The	
BLAST	 mouse	 genomic	 database	 was	 used	 to	 analyse	 the	 mRNA	 sequences	 flanking	 the	
candidate	 exon-exon	 junction	 (20	 nucleotides	 either	 side	 of	 each	 exon-exon	 junction)	 to	
determine	whether	similar	sequences	existed	within	the	mouse	genome.	For	completeness,	
these	sequences	were	also	analysed	using	the	BLAST	RefSeq	RNA	database,	which	determined	
if	the	sequences	spanning	the	exon-exon	junctions	shared	any	complementarity	to	any	other	
transcripts	in	the	mouse	transcriptome.		
	
For	design	of	qRT-PCR	primers	and	hydrolysis	probes,	RealTimeDesign	Software,	 an	online	
interactive	 program	 hosted	 by	 Biosearch	 Technologies	 (California,	 USA),	 was	 used.	 The	
RealTimeDesign	Software	calculates	the	best	primers	and	hydrolysis	probe	sequences	for	a	
chosen	DNA	 sequence	based	on	melting	 temperature,	 length	 and	 internal	 stability.	 It	 also	
allows	 manual	 input	 and	 modification	 of	 these	 sequences	 allowing	 users	 to	 tailor	 any	
suggested	assay	sequence	to	their	needs.		Hydrolysis	probe-based	qRT-PCR	assays	allow	for	
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greater	 specificity	 and	 are	 required	 for	 the	 combination	 of	 assays	 in	 duplex/multiplex	
reactions,	so	all	of	the	assays	that	were	designed	for	this	thesis	were	hydrolysis	probe-based.		
	
Using	 the	 RealTimeDesign	 Software,	 sequences	 (usually	 containing	 100	 nucleotides	 either	
side	 of	 a	 candidate	 exon	 junction)	 were	 input	 and	 the	 specific	 location	 of	 an	 exon-exon	
junction	was	marked	using	the	‘^’	key.	This	allowed	the	software	to	tailor	the	hydrolysis	probe	
and	primer	 sequences	 to	directly	 interrogate	 the	 specified	exon-exon	 junction.	Under	 the	
‘Express:	qPCR	-	BHQ	Probe’	menu,	the	application	was	either	set	to	‘qPCR	-	BHQ’	or	‘qPCR	-	
BHQ	Plus’,	the	mode	was	set	to	‘custom’,	and	the	software	was	used	in	‘Single	Plex’	mode.	
Assays	were	designed	to	amplify	100-200	nucleotide	sequences.	Where	needed,	some	assays	
were	 designed	 using	 BHQplus	 Probes	 (Biosearch	 Technologies),	which	 are	 designed	 using	
duplex	stabilizing	technology	that	permits	the	use	of	shorter	sequences.	Hydrolysis	probes	
were	covalently	attached	to	FAM,	Cal560,	Cal610	or	Quasar670	fluorophores.		
	
Once	 the	 sequences	 for	 a	 qRT-PCR	 assay	 (hydrolysis	 probe,	 forward	 primer	 and	 reverse	
primer)	were	designed,	they	were	analysed	using	the	BLAST	database.	Firstly,	the	RefSeq	RNA	
BLAST	database	was	used	to	analyse	the	primer	and	hydrolysis	probe	sequences	to	confirm	
that	they	were	specific	for	the	chosen	target	mRNA,	and	also	to	ensure	that	the	sequences	
did	 not	 share	 high	 complementarity	 with	 any	 other	 regions	 in	 the	mouse	 transcriptome.	
Lastly,	the	primer	and	hydrolysis	probe	sequences	were	analysed	using	the	genomic	BLAST	
database	to	ensure	that	they	did	not	share	complementarity	with	any	genomic	sequences	in	
the	mouse.	If	the	RealTime	Design	software	was	unable	to	design	a	hydrolysis	probe	RT-PCR	
assay	for	a	given	exon	junction,	or	the	probe	and	primer	sequences	designed	for	a	given	exon	
junction	 shared	 high	 sequence	 homology	with	 another	mouse	 genomic	 or	 transcriptomic	
sequence,	another	exon	junction	within	the	same	gene	was	identified	and	a	qRT-PCR	assay	
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was	designed	for	this	sequence	using	the	same	protocol.	Overall,	this	design	strategy	helped	
to	prevent	the	design	of	qRT-PCR	assays	that	detected	gDNA	and/or	non-specific	targets.		
	
Once	primer	and	probe	sequences	that	suited	the	parameters	described	above	were	selected,	
assays	were	ordered	from	Biosearch	Technologies	and	its	sister	company,	DNA	Technology	
(Risskov,	 Denmark).	 All	 oligonucleotides	 were	 shipped	 as	 lyophilised	 powders.	 The	
oligonucleotides	were	resuspended	in	H2O	as	instructed	by	the	manufacturer.	
	
2.8.2			Optimisation	of	qRT-PCR	primer	concentrations	
	
Once	qRT-PCR	assays	were	designed,	they	required	primer	and	hydrolysis	probe	optimisation	
to	ensure	accurate	and	sensitive	amplification	of	 transcripts	 in	 single	cells.	 Firstly,	 limiting	
concentrations	of	the	forward	and	reverse	primers	of	each	qRT-PCR	assay	were	determined.	
For	each	assay,	both	primer	sequences	were	tested	in	variable	combinations.	This	included	
final	 experimental	 concentrations	of	 300nM,	200nM,	100nM,	80nM,	60nM	and	40nM.	All	
possible	 combinations	of	 these	 forward	 and	 reverse	primer	 concentrations	were	 assayed,	
resulting	in	preparation	of	36	reactions	that	were	tested	using	3	technical	replicates.	Mean	
values	for	each	reaction	were	calculated	from	the	technical	replicates	and	used	for	analysis.	
When	preparing	the	reactions,	a	dilution	of	whole	BM	lysate	(approximately	200ng	of	RNA	
and	 DNA)	 and	 an	 excess	 concentration	 of	 hydrolysis	 probe	 (250nM)	 remained	 constant,	
ensuring	 that	 the	 only	 variables	 in	 the	 reactions	 were	 the	 primer	 concentrations	 and	
combinations.	A	master	mix	for	all	reactions	was	prepared	containing	Quantitect	Master	Mix	
and	RT	mix	(Qiagen,	Manchester,	UK),	H2O,	whole	BM	lysate	and	hydrolysis	probe	but	did	not	
contain	primers	as	these	were	added	at	a	later	stage.	Using	an	electronic	pipette,	4μL	of	the	
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master	mix	was	dispensed	into	108	individual	wells	(36	reactions	in	triplicate)	of	a	LightCycler	
480	384-well	plate	(Roche,	West	Sussex,	UK).	Solutions	of	both	forward	and	reverse	primers	
were	prepared	at	the	following	stock	concentrations:	1.8μM,	1.2μM,	600nM,	480nM,	360nM	
and	240nM.	Again,	using	an	electronic	pipette,	1μL	each	of	the	forward	and	reverse	primer	
stocks	were	dispensed	 into	the	LightCycler	480	384-well	plate	 to	bring	reactions	 to	a	 final	
volume	of	6μL.	An	example	of	the	master	mix	used	for	primer	optimisation	protocols	is	shown	
in	 Table	 1.	 Figure	 2.4	 represents	 the	 format	 used	 on	 a	 384-well	 PCR	 plate	 to	 ensure	 all	
combinations	of	primer	concentrations	were	tested	for	a	given	qRT-PCR	assays.	
	
	
Table	 1:	 Example	 of	 a	 master	 mix	 preparation	 for	 the	 optimisation	 of	 qRT-PCR	 primer	
concentrations.	
	
Assay	Constituent	
Volume		for	
x1	reaction	
Volume	for	
x125	reactions	
Quantitect	Master	Mix	 3	μL	 375	μL	
Quantitect	RT	Mix	 0.06	μL	 7.7	μL	
Hydrolysis	probe	(5μM	stock)	 0.3	μL	 37.5	μL	
Whole	BM	lysate	 0.2	μL	 25	μL	
H2O	 0.44	μL	 55	μL	
Total	 4	μL	 500	μL	
BM,	bone	marrow;	RT,	reverse	transcriptase.	
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Figure	2.4.	384-well	plate	format	used	to	determine	limiting	primer	concentrations	for	qRT-
PCR	 assays.	 This	 plate	 format	was	 used	 to	 test	 all	 possible	 combinations	 of	 forward	 and	
reverse	primer	concentrations	using	final	primer	concentrations	of	300nM,	200nM,	100nM,	
80nM,	60nM	and	40nM.	The	red	boxes	represent	technical	replicates	of	a	specified	primer	
concentration	combination	in	nM.	For	example,	sample	‘100/80’	labels	a	sample	containing	
100nM	of	the	forward	primer	and	80nM	of	the	reverse	primer.	
	
To	compare	primer	concentration	combinations,	reactions	with	300nM	of	forward	primer	and	
300nM	of	reverse	primer	were	used	as	a	‘reference’	reaction	(300nM/300nM	reaction),	as	
this	 reaction	was	 considered	 to	have	non-limiting	amounts	of	both	primers.	 To	 select	 the	
optimal	 limiting	 primer	 concentrations,	 two	 parameters	 in	 each	 reaction	 were	 analysed.	
Firstly,	the	threshold	cycle	(Ct)	for	each	reaction	was	calculated.	Any	reactions	that	had	a	Ct	
value	 that	was	 >0.5	 cycles	 greater	 than	 the	Ct	 value	of	 the	300nM/300nM	 reaction	were	
considered	to	have	compromised	efficiency,	so	they	were	excluded	from	selection.	Secondly,	
the	level	of	fluorescence	at	the	end	of	the	plateau	phase	of	the	reactions	was	calculated,	and	
this	 value	 was	 termed	 the	 ‘end	 fluorescence	 value’.	 Amongst	 the	 reactions	 that	 were	
considered	efficient	based	on	Ct	value,	the	reaction	with	the	lowest	end	fluorescence	value	
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was	identified.	The	primer	concentrations	within	this	reaction	were	selected	as	the	optimal	
limiting	primer	conditions.	See	Figure	2.5	for	a	representative	amplification	plot	showing	the	
reference	reaction	(300nM/300nM),	a	reaction	containing	the	optimum	primer	concentration	
combination	(60nM	of	forward	primer	and	300nM	of	reverse	primer;	60nM/300nM),	and	a	
reaction	that	has	lost	efficiency	due	to	low	primer	concentrations	(60nM	of	forward	primer	
and	60nM	of	reverse	primer;	60nM/60nM).	
	
	
	
Figure	2.5.	Selection	of	limiting	primer	concentrations	for	a	qRT-PCR	assay.	The	reference	
reaction,	containing	300nM	of	forward	primer	and	300nM	of	reverse	primer	(300nM/300nM	
reaction),	was	used	to	select	an	optimal	limiting	primer	concentration	combination.	Firstly,	
reactions	that	had	a	Ct	value	that	was	>0.5	cycles	greater	than	the	Ct	value	of	the	reference	
reaction	(300nM/300nM	reaction)	were	not	considered	efficient	(see	the	reaction	containing	
60nM	of	forward	primer	and	60nM	of	reverse	primer;	60nM/60nM).	Of	the	samples	that	had	
a	Ct	value	that	was	<0.5	cycles	greater	than	the	Ct	value	of	the	reference	reaction	(see	the	
reaction	containing	60nM	of	forward	primer	and	300nM	of	reverse	primer;	60nM/300nM),	
the	reaction	with	the	lowest	end	fluorescence	value	was	selected	to	be	the	optimum	primer	
concentration	combination.	The	horizontal	 line	was	used	to	calculate	the	Ct.	Ct,	 threshold	
cycle.	
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2.8.3			Optimisation	of	hydrolysis	probe	concentrations	
	
Optimum	 hydrolysis	 probe	 concentrations	 for	 qRT-PCR	 assays	 were	 determined	 using	 a	
similar	 protocol	 as	 described	 in	 Section	 2.8.2.	 The	 hydrolysis	 probes	 were	 analysed	 at	
concentrations	of	250nM,	225nM,	200nM,	175nM,	150nM,	125nM,	100nM,	75nM,	50nM	and	
25nM.	 Reactions	 were	 performed	 with	 3	 technical	 triplicates,	 and	 mean	 values	 for	 each	
reaction	 were	 calculated	 and	 used	 for	 analysis.	 When	 preparing	 the	 reactions,	 the	
concentration	of	whole	BM	lysate	(approximately	200ng	of	RNA	and	DNA)	remained	constant	
and	optimal	limiting	primer	concentrations	were	used,	ensuring	that	the	only	variable	in	the	
reactions	was	the	concentration	of	hydrolysis	probe.		
	
Table	2:	Example	of	a	master	mix	preparation	for	the	optimisation	of	qRT-PCR	hydrolysis	
probe	concentrations.	
	
Assay	Constituent	
Volume		for	
x1	reaction	
Volume	for	
x35	reactions	
Quantitect	Master	Mix	 3	μL	 105	μL	
Quantitect	RT	Mix	 0.06	μL	 2.1	μL	
Whole	BM	lysate	 0.2	μL	 7	μL	
Forward	primer	 1	μL	 35	μL	
Reverse	primer	 1	μL	 35	μL	
H2O	 0.44	μL	 15.4	μL	
Total	 5.7	μL	 199.5	μL	
BM,	bone	marrow;	RT,	reverse	transcriptase	
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A	master	mix	was	prepared	containing	qRT-PCR	buffer	and	enzyme	solution,	H2O,	whole	BM	
lysate	and	 limiting	primer	concentrations.	Using	an	electronic	pipette,	5.7μL	of	the	master	
mix	was	dispensed	into	30	individual	wells	(10	reactions	in	triplicate)	of	a	LightCycler	480	384-
well	plate.	Solutions	of	the	hydrolysis	probe	were	prepared	at	the	following	concentrations:	
5μM,	4.5μM,	4μM,	3.5μM,	3μM,	2.5μM,	2μM,	1.5μM,	1μM,	0.5μM.	Again,	using	an	electronic	
pipette,	 0.3μL	 of	 the	 relevant	 hydrolysis	 probe	 stock	 solution	 was	 dispensed	 into	 the	
LightCycler	480	384-well	plate	to	bring	reactions	to	a	final	volume	of	6μL.	A	typical	master	mix	
preparation	used	to	optimise	hydrolysis	probe	concentrations	is	shown	in	Table	2.		
	
	
Figure	 2.6.	 Optimisation	 of	 hydrolysis	 probe	 concentrations	 for	 a	 qRT-PCR	 assay.	 The	
reference	 reaction,	 containing	 250nM	 of	 hydrolysis	 probe,	 is	 used	 to	 select	 a	 primer	
concentration	combination	(250nM	reaction).	Firstly,	reactions	that	had	a	Ct	value	that	was	
>0.5	 cycles	 greater	 than	 the	 Ct	 value	 of	 the	 reference	 reaction	 (250nM	 reaction)	 were	
considered	 to	 have	 compromised	 efficiency,	 and	 were	 removed	 from	 analysis	 (see	 the	
reaction	containing	100nM	of	hydrolysis	probe).	Of	the	remaining	reactions,	the	reaction	with	
the	lowest	hydrolysis	probe	concentration	was	selected	to	be	the	optimal	hydrolysis	probe	
concentration	(see	the	reaction	containing	175nM	of	hydrolysis	probe).	Ct,	threshold	cycle.	
	
	
The	reaction	containing	250nM	of	hydrolysis	probe	was	included	as	a	reference	reaction	as	
this	was	considered	to	be	a	non-limiting	amount	of	probe.	The	Ct	value	of	each	reaction	was	
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analysed	and	compared	to	the	Ct	value	of	the	reaction	containing	250nM	of	hydrolysis	probe.	
Any	 reactions	 that	 had	 a	 Ct	 value	 that	 was	 >0.5	 cycles	 greater	 than	 the	 Ct	 value	 of	 the	
reference	reaction	were	considered	to	have	lost	efficiency	due	to	low	probe	concentrations,	
so	 they	 were	 excluded	 from	 selection.	 Amongst	 the	 remaining	 reactions,	 the	 lowest	
concentration	of	hydrolysis	probe	was	selected	as	the	optimum	concentration.	If	all	reactions	
produced	 a	 Ct	 value	 >0.5	 cycles	 greater	 than	 the	 reference	 Ct	 value	 then	 the	 optimum	
hydrolysis	probe	concentration	was	chosen	as	250nM.	Data	from	a	representative	hydrolysis	
probe	optimisation	experiment	is	shown	in	Figure	2.6.	
	
2.9			qRT-PCR	analysis	
	
	
2.9.1			Preparation	of	cells	previously	sorted	into	LightCycler	
480	384-well	plates	for	qRT-PCR	analysis	
	
Gene	expression	of	FACS	sorted	cells	was	analysed	using	a	one-step	QuantiTect	Multiplex	RT-
PCR	Kit	(Qiagen)	with	optimised	primer	and	hydrolysis	probe	concentrations	in	LC480	384-well	
plates.	 Reactions	 were	 prepared	 on	 ice,	 for	 a	 final	 reaction	 volume	 of	 6uL.	 No	 template	
controls	(NTCs)	and	reactions	without	reverse	transcriptase	(-RT)	were	prepared	and	loaded	
into	 the	 plate	 as	 controls	 for	 complementary	 DNA	 (cDNA)	 contamination	 and	 gDNA	
amplification,	respectively.	For	the	single-cell	samples,	a	master	mix	was	prepared	containing	
a	 qRT-PCR	 buffer	 and	 enzyme	 solution,	 H2O,	 and	 limiting	 concentrations	 of	 primers	 and	
hydrolysis	probe.	The	volume	of	water	 in	each	master	mix	was	adjusted	depending	on	the	
number	of	assays	included	in	each	reaction.	An	example	of	a	master	mix	used	to	detect	the	
expression	of	three	genes	in	a	single	cell	is	shown	in	Table	3.	When	preparing	reactions	using	
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a	 LightCycler	 480	384-well	 plate	 that	was	previously	 stored	at	 -80˚C,	 the	plate	was	briefly	
centrifuged	to	collect	any	sample	at	the	bottom	of	the	well	before	removing	the	adhesive	PCR	
film.	Using	an	electronic	pipette,	5	μL	of	the	master	mix	was	added	to	each	well,	which	already	
contained	1	μL	of	H2O	from	when	the	cell	was	initially	sorted.	This	resulted	in	a	final	reaction	
volume	of	6uL.	The	PCR	plate	was	then	sealed	using	adhesive	PCR	film	and	stored	on	ice	until	
it	was	analysed	on	a	LC480	II	instrument	(Roche).	
	
Table	3:	Example	of	a	master	mix	preparation	for	the	analysis	of	gene	expression	in	single	
cells.	
Assay	Constituent	 Volume		for	x1	reaction	
Volume	for	
x30	reactions	
Quantitect	Master	Mix	 3	μL	 90	μL	
Quantitect	RT	Mix	 0.06	μL	 1.8	μL	
Assay	1	-	Forward	Primer		 0.15	μL	 4.5	μL	
Assay	1	-	Reverse	Primer		 0.15	μL	 4.5	μL	
Assay	1	-	Hydrolysis	probe		 0.15	μL	 4.5	μL	
Assay	2	-	Forward	Primer		 0.15	μL	 4.5	μL	
Assay	2	-	Reverse	Primer		 0.15	μL	 4.5	μL	
Assay	2	-	Hydrolysis	probe		 0.15	μL	 4.5	μL	
Assay	3	-	Forward	Primer		 0.15	μL	 4.5	μL	
Assay	3	-	Reverse	Primer		 0.15	μL	 4.5	μL	
Assay	3	–	Hydrolysis	probe		 0.15	μL	 4.5	μL	
H2O	 0.59	μL	 17.7	μL	
Total	 5	μL	 150	μL	
RT,	reverse	transcriptase.	
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2.9.2			Amplification	program	used	on	the	Roche	LC480	II	PCR	
instrument	for	analysis	of	gene	expression	
	
LightCycler	480	384-well	plates	were	loaded	into	a	LC480	II	instrument	(Roche)	for	the	analysis	
of	gene	expression.	The	Quantitect	RT-PCR	kit	(Qiagen)	allows	for	single-step	amplification	of	
targets	and	the	manual	contains	detailed	protocols	for	the	use	of	this	kit.	The	program	used	
on	the	instrument	is	outlined	in	Table	4.	The	first	step	in	the	amplification	process	was	the	
conversion	of	mRNA	to	cDNA	by	RT.	This	step	was	carried	out	at	50˚C	for	20	minutes.	The	
second	step	in	the	Quantitect	protocol	requires	an	 initial	activation	step	of	the	HotStarTaq	
DNA	polymerase	at	95˚C	for	15	minutes.	The	remaining	steps	are	part	of	a	2-step	denaturation	
and	annealing/extension	cycle.	The	denaturation	step	was	carried	out	at	94˚C	for	45	seconds,	
followed	 by	 60˚C	 at	 45	 seconds	 for	 the	 annealing/extension	 stage.	 This	 2-step	 cycle	 was	
repeated	for	40-50	cycles.		
	
Table	4:	Amplification	program	used	for	the	one-step	gene	expression	analysis	using	the	
Qiagen	Quntitect	qRT-PCR	kit.	
Stage	 Length	 Temperature	 Description	 	
Reverse	Transcription	 20	minutes	 50˚C	 mRNA	>	cDNA	 	
Polymerase	Activation	 15	minutes	 95˚C	
Activation	of	
HotStarTaq	DNA	
polymerase	
	
2-step	cycling	 	 	 	 	
-	Denaturation	 45	seconds	 94˚C	 	
X	40-50	
cycles	-	Annealing/extension	 45	seconds	 60˚C	
	
cDNA,	complementary	DNA	
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Fluorescence	analysis	was	performed	using	LC480	SX1.5	software	(Roche),	and	the	threshold	
for	analysis	was	set	manually	at	0.03	arbitrary	units	(AU)	above	the	median	NTC	fluorescence	
value	at	cycle	43.	This	ensured	that	results	were	comparable	across	all	experiments	as	this	
controlled	for	background	fluorescence.	
	
2.10			Conjugation	of	purified	antibodies	 to	APC	using	
Lightning	Link	
	
Innova	Biosciences	(Babraham,	UK)	provide	Lightning	Link	kits	that	allow	the	conjugation	of	
fluorophores	to	purified	antibodies.	The	Lightning-Link	allophycocyanin	(APC)	kit	was	used	in	
an	attempt	to	conjugate	APC	to	a	purified	anti-CD114	antibody.	The	method	was	carried	out	
according	 to	 the	 manufacturer’s	 instructions.	 Firstly,	 100μL	 of	 the	 CD114	 antibody	 was	
aliquoted	 into	 an	 Eppendorf.	 Ten	 μL	 of	 the	 LL-Modifier	 reagent	 (1μL	 of	 LL-Modifier	
reagent:10μL	of	antibody)	was	added	to	the	antibody	and	the	solution	was	gently	mixed	with	
a	pipette.	The	antibody	and	LL-Modifier	reagent	was	added	to	a	commercial	vial	of	Lightning	
Link	mix	and	the	lyophilised	powder	was	gently	dissolved	into	the	solution	using	a	pipette.	
The	 solution	 was	 left	 in	 the	 dark	 at	 room	 temperature	 (20-25˚C)	 for	 3	 hours.	 Following	
incubation,	10μL	of	the	LL-Quencher	reagent	was	added	to	the	mixture.	The	solution	was	left	
to	stand	at	room	temperature	for	30	minutes	and	then	placed	at	4˚C	for	later	use.	
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2.11			Haematopoietic	 stem	 cell	 and	 multipotent	
progenitor	in	vitro	culture	
	
HSCs	and	MPPs	were	sorted	from	murine	BM	according	to	the	protocol	outlined	in	Section	
2.5.	 Unless	 otherwise	 stated,	 cells	 were	 double	 sorted	 into	 Eppendorfs	 containing	 500μL	
Iscove's	Modified	Dulbecco's	Media	 (IMDM,	Thermo	Fisher	Scientific)	 containing	10%	FCS,	
1,000 U/mL	penicillin	and	1,000 μg/mL	streptomycin	(Thermo	Fisher	Scientific),	50 ng/mL	Tpo	
and	20 ng/mL	SCF	 (Peprotech,	 London,	UK),	with	 and	without	100ng/mL	Flt3L	 (Biolegend,	
London,	UK).	Cells	were	then	transferred	to	either	sterile	48-well	or	96-well	culture	plates	
(Greiner	Bio-One)	and	incubated	at	37˚C	in	a	5%	CO2	incubator	for	a	defined	period	of	time.	
After	incubation,	cells	were	transferred	to	FACS	tubes	for	sorting.	To	reduce	loss	of	cells	after	
transferring	 the	cell	 suspension,	 the	wells	of	 the	culture	plates	were	washed	out	with	cell	
culture	medium	and	this	solution	was	added	to	the	cell	suspension.		
	
2.12			Phosphoflow:	 Analysis	 of	 phosphorylated	
proteins	using	flow	cytometry	
	
Cells	were	isolated	from	BM	and	stained	using	specified	antibodies	as	described	in	Section	
2.3.	However,	when	BM	cells	were	isolated	for	phosphoflow	analysis,	DPBS	(without	Ca+/Mg+)	
containing	 0.5%	 FCS	 was	 used	 to	 prepare	 the	 cells.	 Once	 the	 cells	 were	 stained	 with	
antibodies,	they	were	washed	three	times	using	serum-free	DPBS	before	resuspending	the	
cells	in	pre-warmed	serum-free	IMDM.	Each	cell	suspension	from	1	mouse	was	divided	into	2	
samples	and	cells	were	starved	in	sterile	48-well	culture	plates	at	37˚C	in	a	5%	CO2	incubator	
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for	 approximately	 3	 hours.	 After	 starvation,	 half	 of	 each	 sample	 was	 stimulated	 with	
150ng/mL	Flt3L	 for	7.5	minutes.	The	same	volume	of	serum-free	 IMDM	was	added	to	the	
other	half	of	each	sample	(unstimulated	control).	All	samples	were	promptly	fixed	in	a	1.6%	
paraformaldehyde	 (PFA)	 solution	 by	 diluting	 either	 4%	 PFA	 prepared	 in	 the	 lab,	 or	 16%	
commercial	electron	microscopy-grade	(EM-grade)	PFA,	for	15	minutes	at	room	temperature.	
Cells	were	pelleted	at	4˚C,	394	rcf	for	4	minutes	and	the	fixing	solution	was	removed	using	a	
pipette.	Ice-cold	acetone	or	methanol	was	added	to	permeabilise	the	cells	and	samples	were	
incubated	at	-20˚C	for	15	minutes.	Cells	were	pelleted	at	4˚C,	394	rcf	for	4	minutes	and	the	
acetone	or	methanol	was	removed	by	aspiration.	The	cells	were	subsequently	washed	in	2%	
FCS	DPBS.	Samples	were	stained	by	resuspending	cells	in	200μL	of	2%	FCS	DPBS	containing	
anti-phospho-ribosomal	protein	S6	(pS6)	and	incubated	on	ice	for	1	hour.	Cells	were	washed	
twice	 using	 2%	 FCS	DPBS	 before	 acquisition	 on	 a	 CyAN	 FACS	Analyser	 (Beckman	 Coulter)	
controlled	 by	 Summit	 v4.3	 software.	 Stimulated	 and	 unstimulated	 samples	 from	 a	 single	
mouse	were	compared	during	analysis,	which	was	carried	out	using	FlowJo	software,	version	
10.1.		
	
2.13			Methylcellulose	colony	forming	assays	
	
2.13.1			Plating	 of	 haematopoietic	 stem	 cells	 on	 MethoCult	
M3434	
	
For	 analysis	 of	 the	 survival	 and	 differentiation	 of	 HSCs,	 MethoCult	 M3434	 (StemCell	
Technologies,	 Cambridge,	 UK)	 was	 used.	 M3434	 contains	 50ng/mL	 recombinant	 mouse	
(rm)SCF,	 10ng/mL	 rmIL-3,	 10ng/mL	 rmIL-6,	 3	 units/mL	 recombinant	 human	 Epo	 and	 is	
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optimised	for	growth	of	murine	macrophage	progenitors	(CFU-M),	granulocyte	progenitors	
(CFU-G),	CFU-GM,	CFU-GEMM,	and	CFU-E/BFU-E.	During	colony	forming	assays,	M3434	was	
supplemented	with	Tpo	to	support	growth	of	megakaryocyte	progenitors	(CFU-Meg)	[299].	
M3434	MethoCult	medium	(StemCell	Technologies)	was	purchased	in	100mL	bottles.	As	soon	
as	the	medium	arrived,	the	bottle	was	rigorously	vortexed	to	ensure	complete	mixing	of	the	
contents.	The	medium	was	left	to	sit	at	room	temperature	until	the	bubbles	settled	at	the	top	
of	the	medium.	Once	mixed,	the	entire	bottle	was	divided	into	3.5mL	aliquots	using	sterile	
5mL	polypropylene	tubes.	Care	was	taken	to	ensure	there	was	minimal	transfer	of	bubbles.	
The	aliquots	were	then	stored	at	-20˚C	until	required.	
	
To	assess	HSC	survival	and	differentiation,	varying	numbers	of	HSCs	(LSK	CD150+	CD48−)	were	
sorted	 into	 IMDM	 medium	 containing	 10%	 FCS,	 1,000 U/mL	 penicillin	 and	 1,000 μg/mL	
streptomycin.	 Sorted	HSCs	were	added	 to	M3434	MethoCult	medium	 supplemented	with	
25ng/mL	TPO,	1,000 U/mL	penicillin	and	1,000 μg/mL	streptomycin.	Flt3L	or	equal	volumes	
of	IMDM	were	then	added	to	each	sample,	and	a	uniform	cell	suspension	was	made	by	gently	
vortexing	the	sample.	Cells	were	plated	using	a	1mL	syringe	into	a	35mm	petri	dish	and	were	
plated	as	duplicates.	Duplicate	plates	were	placed	in	100mm	petri	dishes	with	a	35mm	petri	
dish	 full	 of	 water	 before	 incubating	 the	 cultures	 at	 37˚C	 in	 a	 5%	 CO2	 incubator.	 Colony	
numbers	and	type	were	scored	on	day	11.		
	
2.13.2			Cytospin	preparations	
	
Colonies	 were	 identified	 by	 picking	 representative	 colonies	 with	 a	 10μL	 pipette	 tip,	
resuspending	 the	 cells	 in	 100μL	 of	 DPBS,	 and	 loading	 them	 into	 cytospin	 funnels	 (VWR	
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International,	 Lutterworth,	 UK)	 for	 centrifugation.	 Samples	were	 centrifuged	 at	 23g	 for	 8	
minutes	onto	microscope	slides	(Thermo	Fisher	Scientific)	and	then	air-dried.	Subsequently,	
cytospin	samples	were	stained	using	Diff-Quick	staining	solutions	(Polysciences,	Hirschberg	
an	der	Bergstrasse,	Germany).	 Samples	were	dipped	15	 times	 for	1	 second	 into	Solution1	
(Fixative),	Solution2	(Eosin	G)	and	then	Solution3	(Thiazine	dye),	before	being	washed	with	
distilled	water.	Square	cover	 slides	 (Agar	Scientific,	 Stansted,	UK)	were	mounted	onto	 the	
cytospins	 using	 neutral	 mounting	 medium.	 Images	 were	 taken	 using	 a	 Leica	 DM6000B	
microscope	(Leica	Microsystems,	Milton	Keynes,	UK).	
	
2.13.3			Identification	of	colonies	
	
When	colonies	were	counted	and	scored	in	the	M3434	medium,	colony	types	were	identified	
based	on	the	phenotype	of	the	cells	within	the	colony	and	by	using	the	MethoCult	technical	
manual	supplied	by	StemCell	Technologies.	Colonies	that	contain	CFU-M	appear	dispersed	
with	 large	oval	or	round	cells.	CFU-G	contain	cells	that	are	smaller	than	monocytes.	These	
cells	are	round	and	relatively	uniform	in	size.	When	both	of	these	cell	types	were	present	in	
a	highly	cellular	colony,	it	was	scored	as	CFU-GM.	CFU-GEMM	are	the	largest	colonies,	and	
are	distinguished	from	other	colonies	by	their	densely	populated	dark	brown	cores.	There	are	
no	distinct	borders	separating	peripheral	cells	 from	the	core	of	CFU-GEMM	colonies.	CFU-
Meg	were	observed	as	colonies	with	few	round,	very	large	cells.	Finally,	when	these	cells	were	
present	with	other,	smaller	cells	in	sparsely	populated	colonies,	the	colonies	were	scored	as	
megakaryocyte-mixed	 (CFU-MegMix).	 Only	 colonies	 containing	 more	 than	 50	 cells	 were	
scored.	
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To	confirm	that	the	colonies	were	scored	correctly,	cytospin	preparations	of	representative	
colonies	were	stained	with	a	Differential	Quik	Stain	Kit.	Monocytes	were	identified	as	cells	
with	abundant	dull	blue/grey	cytoplasms	and	usually	kidney	shaped	nuclei	[300].	Granulocyte	
progenitors	 were	 recognised	 as	 cells	 with	 pale	 blue	 cytoplasms,	 with	 high	 nuclear	 to	
cytoplasmic	ratio	(myeloblast)	and	dark	to	pale	pink	cytoplasms	(promyelocytes)	[300,	301].	
The	cytoplasm	of	promyelocytes	appears	 this	way	due	 to	 the	basophilic	nature	 (pale	blue	
staining)	 of	 the	 cytoplasm	 and	 magenta	 staining	 of	 cytoplasmic	 granules	 [300].	
Megakaryocytes	 and	 their	 progenitors	 were	 easily	 distinguished	 by	 their	 size.	
Promegakaryocytes	contain	granules	which	can	cause	pink/purple	staining	of	the	cytoplasm.	
As	 these	 cells	 differentiate	 into	 megakaryocytes,	 endomitosis	 occurs	 to	 produce	 highly	
polyploidy	cells	with	dark	blue	 (basophilic)	cytoplasms	 [300,	302,	303].	Erythroblasts	were	
identified	as	cells	with	high	nuclei	to	cytoplasm	ratio,	and	have	intensely	basophilic	purple,	
sometimes	gray,	cytoplasms	[301,	302].	
	
2.14			Graphing	of	data	and	statistical	analysis	
	
All	 data,	 apart	 from	 primer	 optimisation	 results,	 were	 graphed	 in	 and	 exported	 from	
GraphPad	Prism	version	6.	Matlab	R2015b	was	used	to	create	3	dimensional	surface	plots	to	
present	primer	optimisation	data.	Microsoft	PowerPoint	2011,	version	14,	was	used	to	group	
graphs	into	the	figures	presented	in	this	study.	The	statistical	tests	used	to	analyse	the	data	
presented	in	this	study	are	included	in	the	relevant	figure	legends.	Results	were	considered	
statistically	significant	for	p	values	<0.05.		
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2.15			Figure	illustration	
	
Adobe	Illustrator	CC	was	used	to	create	all	illustrated	figures	for	this	thesis.	 	
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CHAPTER	3:			 EXPRESSION	 OF	 RECEPTORS	 FOR	
GROWTH	FACTORS	DURING	HAEMATOPOIESIS	
	
3.1			Introduction	
	
Analysis	of	a	population	of	cells	is	not	very	informative	when	studying	stem	and	progenitor	
cells,	 given	 the	 possible	 heterogeneous	 nature	 of	 these	 populations.	 It	 results	 in	 the	
generation	of	misleading	data	that	represent	an	average	of	an	entire	population,	and	does	
not	account	for	a	change	in	or	the	presence	of	rare	sub-fractions	within	the	sample.	Recent	
advances	in	high	throughput	single	cell	analysis	techniques	have	been	crucial	in	furthering	our	
understanding	 of	HSPC	biology.	 For	 example,	 the	 LS−K	 compartment	 of	 the	murine	BM	 is	
commonly	divided	into	CMP,	GMP,	and	MEP	populations	using	the	CD16/32	and	CD34	surface	
markers	[67].	However,	Paul	et	al.	have	used	index	sorting	and	RNA-sequencing	to	identify	19	
subpopulations	 within	 the	 LS−K	 compartment,	 indicating	 that	 the	 above	 surface	 marker	
approach	does	not	accurately	capture	the	heterogeneity	of	myeloid	progenitors	[304].	Tsang	
et	 al.	 have	 also	 analysed	 RNA-sequencing	 data	 for	 single	 HSCs	 (LSK	 CD150+	 CD48−)	 and	
reported	 a	 large	 degree	 of	 transcriptional	 heterogeneity.	 The	 group	 found	 that	 genes	
associated	with	cell	cycle	activity,	protein	localisation	and	transcription	were	highly	variable	
at	 the	 single	 cell	 level	 [305].	 Wilson	 and	 colleagues	 have	 reported	 similar	 findings,	 and	
identified	4,533	genes	that	were	variably	expressed	between	92	LT-HSCs	(LSK	CD150+	CD48−	
CD34−	Flt3−)	using	RNA-sequencing	analysis	[306].	These	studies,	and	many	more	[294,	307,	
308],	highlight	the	heterogeneous	nature	of	HSPC	populations.	
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The	heterogeneity	observed	in	HSPC	populations	is	further	confounded	by	the	presence	of	
lineage-biased	subpopulations.	Cellular	barcoding	has	been	used	to	monitor	the	fate	of	single	
LMPPs	 and	 HSCs	 in	 vivo,	 revealing	 a	 number	 of	 lineage-biased	 populations	 within	 each	
compartment.	A	number	of	HSC	and	LMPP	subpopulations	can	be	classified	based	on	their	
granulocyte,	 B-lymphocyte,	 DC	 and	 monocyte	 output	 [9,	 28].	 Similarly,	 Benz	 et	 al.	 have	
observed	 MyHSCs	 and	 LyHSCs	 when	 transplanting	 single	 HSCs	 into	 irradiated	 mice	 and	
monitoring	 their	 long-term	 output	 [309].	 These	 lineage-biased	 HSCs	 can	 also	 be	 isolated	
based	on	the	expression	of	particular	surface	or	 intracellular	markers.	The	Jacobsen	group	
have	identified	vWF+	HSCs	that	possess	increased	platelet	potential	in	vivo	when	compared	
to	vWF−	HSCs	 [29],	while	MyHSCs	and	LyHSCs	 can	be	 isolated	based	on	 their	exclusion	of	
Hoechst	stain	and	expression	of	CD150,	CD86	and	CD41	[25-27,	30,	31,	310].		
	
While	recent	studies	have	focused	on	characterising	lineage-biased	populations	of	HSPCs,	it	
is	still	unclear	how	lineage-bias	first	arises.	As	described	in	Chapter	1,	there	is	strong	evidence	
to	 suggest	 that	HGFs	within	 the	BM	microenvironment	modulate	haematopoiesis	 through	
instructional	cues.	M-CSF	and	Epo	upregulate	lineage-associated	genes	in	early	HSPCs,	and	
stimulate	 them	 to	 differentiate	 towards	 a	 GM	 or	 erythroid	 fate,	 respectively	 [267,	 269].	
Similarly,	 Reiger	 et	 al.	 have	 shown	 that	 M-CSF	 and	 G-CSF	 are	 capable	 of	 instructing	 a	
macrophage	or	granulocytic	lineage	fate	in	single	GMPs	in	vitro,	respectively	[268].	There	is	
also	 evidence	 to	 suggest	 that	 Flt3L	may	 act	 on	multipotent	 progenitors	 to	 promote	 GM-
lymphoid	development	at	the	expense	of	MegE	fate	[288].	Given	their	role	in	driving	lineage	
decisions,	these	factors	may	regulate	HSPC	lineage-biases.	In	fact,	stimulation	of	multipotent	
cells	with	M-CSF	in	vitro	results	in	a	myeloid	developmental	program	that	persist	for	up	to	6	
weeks	 after	 the	 cells	 have	been	 transplanted	 into	WT	hosts,	 suggesting	 an	 induction	of	 a	
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temporary	 GM-bias	 [267].	 Determining	 the	 expression	 patterns	 of	 receptors	 for	 HGFs	 by	
developing	haematopoietic	cells	will	be	important	in	understanding	how	and	at	what	point	in	
the	haematopoietic	hierarchy	ligands	might	instruct	lineage	fate.	
	
There	is	evidence	to	suggest	that	HSPCs	are	heterogeneous	as	to	the	expression	of	receptors	
for	Flt3L,	Epo,	M-CSF	and	G-CSF.	Following	exposure	to	M-CSF	or	Epo,	some,	but	not	all,	HSCs	
upregulate	lineage-associated	genes	[267,	269].	Additionally,	Miyamoto	have	reported,	using	
single	cell	gene	expression	analysis,	that	CSF3R	and	EPOR	are	selectively	expressed	by	a	large	
proportion	of	HSCs	[116].	These	findings	suggest	the	presence	of	HSC	subpopulations	that	
differentially	respond	to	HGFs.	In	fact,	 in	more	mature	progenitors,	selective	expression	of	
particular	HGFs	 has	 been	 used	 to	 isolate	 functionally	 distinct	 subpopulations.	 The	 preGM	
compartment	can	be	divided	into	Flt3+	and	Flt3−	fractions	that	contain	T-lymphocyte/myeloid	
and	myeloid-restricted	progenitors,	respectively	[77].	Similarly,	co-expression	of	M-CSFR	and	
Flt3	on	the	surface	of	CMPs	marks	a	population	of	DC	progenitors	[304].	Given	these	findings,	
further	 investigation	 into	 the	 expression	 of	 HGF	 receptors	 within	 other	 compartments,	
including	the	HSC	compartment,	may	identify	distinct	lineage-biased	subpopulations.	
		
As	evidence	suggests	that	Flt3,	EpoR,	M-CSFR	and	G-CSFR	are	variably	expressed	by	HSC,	it	is	
important	 to	 determine	 whether	 co-expression	 of	 these	 receptors	 occurs	 at	 this	 stage.	
Miyamoto	et	al.	have	provided	insight	into	this,	as	they	have	shown	that	some	single	HSCs	
(LSK	CD34−	Thy1.1lo)	co-express	EPOR	and	CSF3R	[116].	However,	single	cell	analysis	has	not	
been	carried	out	to	determine	if	other	HGF	receptor	transcripts	are	co-expressed	by	HSCs.	
Furthermore,	it	is	unclear	if	Flt3,	EpoR,	M-CSFR	and	G-CSFR	proteins	are	co-expression	at	the	
surface	of	HSCs.	As	the	expression	of	these	receptors	has	not	been	investigated	in	the	LT-HSC,	
ST-HSC	and	MPP	compartments,	it	is	unclear	if	co-expression	patterns	change	as	HSCs	exit	a	
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quiescent	state	and	begin	to	differentiate.	Understanding	this	will	help	to	determine	if	HGFs	
act	 on	 discrete	 subpopulations	 of	 early	 HSPCs,	 and	 if	 these	 factors	 differentially	 regulate	
multipotent	cells	as	they	mature.		
	
3.1.1			Aims	of	chapter	
	
Current	 evidence	 suggests	 that	 HSPCs	 are	 heterogeneous	 in	 regard	 to	 expression	 of	 the	
receptors	 for	Flt3L,	Epo,	M-CSF	and	G-CSF.	While	HSCs	have	been	shown	to	express	these	
receptors,	it	is	largely	unclear	whether	co-expression	of	these	HGF	receptors	is	commonplace	
during	 the	 early	 stages	 of	 haematopoiesis,	 or	 if	 HSC	 and	MPP	 subpopulations	 exclusively	
express	particular	receptors.	This	is	an	important	distinction.	If	cells	within	the	HSC	and	MPP	
compartments	are	found	to	exclusively	express	particular	HGF	receptors,	this	would	suggest	
that	HGFs	act	permissively	by	activating	distinct	HSPC	subpopulations,	supporting	a	selective	
model	 of	 haematopoiesis.	 On	 the	 other	 hand,	 if	 single	 HSCs	 and	 MPPs	 co-express	 HGF	
receptors,	this	would	support	a	deterministic	model	of	haematopoiesis	whereby	single	cells	
have	the	ability	to	respond	to	multiple	environmental	cues.	As	described	in	section	1.4,	there	
is	 evidence	 to	 suggest	 that	 both	 selective	 expression	 and	 co-expression	 of	HGF	 receptors	
occurs	during	haematopoiesis.	If	this	is	the	case,	then	the	selective	and	deterministic	models	
of	haematopoiesis	are	not	exclusive.	Therefore,	HSPC	differentiation	may	be	 regulated	by	
features	of	both	models.	 Identifying	 the	expression	patterns	of	multiple	HGF	receptors	by	
HSPCs	will	help	to	investigate	whether	this	is	the	case,	and	further	our	understanding	of	the	
mechanisms	that	regulate	HSPC	differentiation.	
	
This	chapter	focused	on	mapping	the	expression	profiles	of	the	FLT3,	EPOR,	CSF1R	and	CSF3R	
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genes,	and	their	encoded	proteins,	during	murine	haematopoiesis.	As	described	above,	the	
purpose	of	this	was	to	determine	if	distinct	subpopulations	could	be	identified	within	HSPC	
populations	based	on	expression	of	these	HGF	receptors,	and	to	what	extent	these	receptors	
are	co-expressed	by	early	HSPCs.	Firstly,	 freely	accessible	HSPC	gene	expression	databases	
were	 interrogated	 to	 investigate	 the	expression	of	FLT3,	EPOR,	 CSF1R	 and	CSF3R	by	well-
defined	HSPC	populations,	and	to	determine	at	what	point	these	genes	are	expressed	during	
haematopoiesis.	Secondly,	FACS	staining	strategies	and	qRT-PCR	assays	were	designed	and	
optimised	for	the	analysis	of	HGF	receptor	expression	by	single	LT-HSCs,	ST-HSCs,	MPPs	and	
lineage-restricted	progenitors.	Lastly,	multiplex	analysis	was	employed	to	investigate	whether	
these	receptors	are	co-expressed	at	both	the	mRNA	and	protein	level	within	the	HSC	and	MPP	
compartments.		
	
3.2			Investigation	 of	 FLT3,	 EPOR,	 CSF1R	 and	 CSF3R	
expression	 during	 haematopoiesis	 using	 the	
HemaExplorer	and	BloodSpot	databases	
	
In	2013,	Bagger	et	al.	published	a	paper	describing	their	HemaExplorer	database,	terming	it	
“a	 curated	 database	 of	 processed	 mRNA	 Gene	 expression	 profiles	 that	 provides	 an	 easy	
display	 of	 gene	 expression	 in	 haematopoietic	 cells”	 [296].	 The	 database	 provides	 gene	
expression	data	of	mouse	and	human	haematopoietic	cells,	including	data	for	human	acute	
myeloid	leukaemia,	from	271	microarray-based	experiments.	More	recently,	Bagger	and	co-
workers	 described	 the	 BloodSpot	 database,	 which	 greatly	 expands	 on	 the	 HemaExplorer	
database	in	terms	of	the	number	of	HSPC	populations	that	can	be	analysed,	and	includes	new	
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functionalities,	 such	 as	 graphical	 tree	 plots	 that	 illustrate	 how	 genes	 are	 differentially	
expressed	during	haematopoiesis	[297].	As	the	expression	of	FLT3,	EPOR,	CSF1R	and	CSF3R	
by	mouse	HSPCs	was	of	 interest,	the	expression	data	for	these	particular	genes	within	the	
haematopoietic	 hierarchy	were	 extracted	 from	 the	 databases.	When	 the	 databases	were	
created,	the	batch	effects	caused	by	compilation	of	studies	were	estimated	and	samples	were	
normalised	accordingly.	As	such,	the	gene	expression	values	obtained	from	the	databases	are	
measured	in	normalised	AU.		
	
Data	for	expression	of	HGF	receptors	by	each	of	the	relevant	HSPC	populations	were	exported	
from	the	database	for	analysis,	as	shown	in	Figure	3.1.	The	cell	populations	included	the	LT-
HSC,	ST-HSC,	LMPP,	preGM,	GMP,	MEP,	MkP,	preCFU-E,	CFU-E,	EP,	CLP,	pro-B-lymphocyte,	
pre-B-lymphocyte	 and	 ETP	 populations.	 The	 available	 information	 regarding	 the	 surface	
marker	profile	used	 to	 isolate	each	HSPC	population	 included	 in	 the	databases	 is	 listed	 in	
Table	5	so	that	the	results	can	be	compared	to	the	single	cell	gene	expression	analysis	carried	
out	later	in	this	chapter	[296,	297].	Notably,	the	studies	included	in	the	HemaExplorer	and	
BloodSpot	databases	isolated	LT-HSCs	and	ST-HSCs	as	LSK	CD34−	Flt3−	and	LSK	CD34+	Flt3−,	
respectively,	 instead	 of	 their	 SLAM	 phenotypes.	 Unfortunately,	 the	 phenotypes	 used	 to	
isolate	the	MEP,	MkP,	CLP,	pro-B-lymphocyte,	pre-B-lymphocyte	and	ETP	populations	were	
not	available.		
	
When	exporting	the	data,	it	became	clear	that	the	databases	only	included	2	data	points	for	
some	 populations,	 so	 statistical	 analysis	 could	 not	 be	 performed	 for	 these	 samples.	
Additionally,	as	can	be	seen	in	Figure	3.1,	the	data	obtained	from	the	databases	show	that	
targets	 were	 amplified	 in	 all	 populations.	 The	 consistent,	 but	 low,	 levels	 of	 expression	
observed	in	certain	populations	suggest	that	the	microarray	experiments	detected	gDNA,	and	
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that	the	assays	were	not	RNA	specific.	Despite	this,	 there	were	clear	distinctions	between	
cells	that	expressed	high	levels	of	mRNA,	and	those	that	expressed	little	to	none.		
	
	
Figure	3.1.	Expression	of	growth	factor	receptors	by	HSPCs	according	to	the	HemaExplorer	
and	BloodSpot	databases.	Raw	values	of	FLT3,	EPOR,	CSF1R	and	CSF3R	expression	in	murine	
HSPCs	were	obtained	from	the	HemaExplorer	and	BloodSpot	databases.	Values	are	expressed	
in	arbitrary	units,	as	the	data	obtained	from	the	databases	are	normalised	using	calculated	
batch	 effect	 estimators	 so	 that	 results	 can	 be	 compared	 across	 the	 numerous	 studies	
compiled	within	the	databases.	Targets	were	amplified	in	all	populations,	suggesting	that	the	
assays	 used	 during	 analysis	 of	 gene	 expression	 detected	 gDNA.	 To	 estimate	 the	 gDNA	
amplification	threshold,	the	dotted	lines	are	included	in	each	bar	chart	to	depict	the	lowest	
mean	expression	value	from	the	analysed	populations.	Expression	is	plotted	on	a	log	scale.	
HSPCs,	haematopoietic	stem	and	progenitor	cells;	LT-HSC,	 long-term	haematopoietic	stem	
cell;	 ST-HSC,	 short-term	 haematopoietic	 stem	 cell;	 LMPP,	 lymphoid-primed	 multipotent	
progenitor;	preGM,	pre-granulocyte-macrophage	progenitor;	GMP,	granulocyte-macrophage	
progenitor;	 MEP,	 megakaryocyte-erythroid	 progenitor;	 EP,	 erythroid	 progenitor;	 MkP,	
megakaryocyte	 progenitor;	 CFU-E,	 erythroid	 colony	 forming	 unit;	 CLP,	 common	 lymphoid	
progenitor;	proB,	pro-B-lymphocyte;	preB,	pre-B-lymphocyte;	ETP,	early	thymic	progenitor;	
gDNA,	genomic	DNA;	EPOR,	erythropoietin	receptor;	FLT3,	fms-like	tyrosine	kinase	3;	CSF1R,	
macrophage-colony	stimulating	factor	receptor;	CSF3R,	granulocyte-colony	stimulating	factor	
receptor.	
*"
*" *"
*"
n.s.$
n.s.$
n.s.$
*"**"
*" *"
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FLT3	was	highly	expressed	by	lineage-restricted	progenitors	that	have	lymphoid,	granulocytic	
and/or	myelomonocytic	potential,	which	is	as	expected	[73,	311].	LMPPs,	preGMs	and	CLPs	
expressed	the	highest	levels	of	FLT3,	with	lower	levels	being	expressed	by	pro-B-lymphocyte	
and	 ETP	 cells.	 Interestingly,	 when	 compared	 to	 the	 remaining	 populations,	 ST-HSCs	 (LSK	
CD34+	Flt3−)	and,	to	a	lesser	extent,	LT-HSCs	(LSK	CD34−	Flt3−)	expressed	slightly	higher	levels	
of	FLT3.	The	expression	of	FLT3	by	LT-HSCs	was	significantly	lower	than	the	levels	expressed	
by	LMPPs	[p=0.0159],	but	significantly	higher	than	the	levels	expressed	by	the	MEP	population	
[p=0.0286].	 As	 the	 MEP	 population	 is	 not	 considered	 to	 express	 FLT3	 [312],	 the	 above	
indicates	that	FLT3	expression	is	present	within	the	LSK	Flt3−	HSC	compartment.	
	
	
EPOR	expression	was	much	more	restricted	when	compared	to	FLT3	expression,	as	only	late	
progenitors	with	erythroid	potential	expressed	this	gene	at	a	high	level	(CFU-E,	preCFU-E,	EP	
and	MEP).	 This	 is	 commensurate	with	 the	 known	 association	 of	EPOR	with	 the	 erythroid	
lineage.	LMPPs	are	known	to	lack	expression	of	erythroid	related	genes	[73],	and	the	levels	of	
EPOR	 detected	 in	 preGMs,	 GMPs,	 CLPs,	 pro-B-lymphocytes,	 pre-B-lymphocytes	 and	 ETPs	
were	similar	to	those	detected	in	LMPPs,	indicating	that	amplification	in	these	populations	
were	due	to	gDNA	amplification	[73].	 Indeed,	the	levels	of	EPOR	expressed	by	CFU-E	were	
significantly	more	than	the	levels	detected	in	the	LMPP	populations	[p=0.0357].	Significantly	
higher	 levels	of	EPOR	were	detected	 in	LT-HSCs	when	compared	to	LMPPs,	 indicating	that	
Epor	mRNA	is	expressed	by	LSK	Flt3−	HSCs	[p=0.0159].		
	
MEPs,	CFU-Es,	preCFU-Es	and	EPs	expressed	CSF1R	at	a	very	low	level.	Megakaryocyte	and	
EPs	are	known	to	express	few	myelomonocytic-associated	genes	and,	therefore,	amplification	
in	these	populations	is	likely	to	be	due	to	CSF1R	gDNA	[313,	314].	When	compared	to	the	MEP	
population,	there	was	no	significant	difference	in	the	levels	of	CSF1R	expressed	by	LT-HSCs	
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[p=0.3427],	MkPs	 [p=0.495]	 and	 Pro-B-lymphocytes	 [p=0.29],	 indicating	 that	 the	 levels	 of	
CSF1R	 expression	 in	 these	 populations	 were	 also	 due	 to	 gDNA	 amplification.	 This	 was	
interesting,	considering	that	HSCs	are	known	to	express	M-CSFR	protein	[267].	Conversely,	
high	levels	of	CSF1R	were	detected	in	the	preGM,	GMP,	ETP,	LMPP	and	CLP	populations.	CLPs	
[p=0.0182]	and	preGMs	[p=0.002]	also	expressed	significantly	higher	 levels	of	CSF1R	when	
compared	to	MEPs,	indicating	that	these	populations	expressed	Csf1r	transcripts.	
	
	
Table	 5:	 Surface	 marker	 expression	 profile	 of	 the	 HSPC	 populations	 included	 in	 the	
HemaExplorer	and	BloodSpot	databases	[296,	297].	
HSPC	Population	 Phenotype	
LT-HSC	 c-kit+	Lin−	Sca1+	CD34−	flt3−	
ST-HSC	 c-kit+	Lin−	Sca1+	CD34+	flt3−	
LMPP	 c-kit+	Lin−	Sca1+	CD34+	flt3+	
preGM	 c-kit+	Lin−	Sca1−	CD150−	FcgRlo	CD105lo	
GMP	 c-kit+	Lin−	Sca1−	CD150−	FcgRhi	
MEP	 Data	not	available	
MkP	 Data	not	available	
preCFU-E	 c-kit+	Lin−	Sca1−	CD150+	FcgRlo	CD105hi	
CFU-E	 c-kit+	Lin−	Sca1−	CD150−	FcgRlo	CD105	hi	TER-119−	
EP	 c-kit+	Lin−	Sca1−	CD150−	FcgRlo	CD105	hi	CD71+	TER-119+	
CLP	 Data	not	available	
Pro-B-lymphocyte	 Data	not	available	
Pre-B-lymphocyte	 Data	not	available	
ETP	 Data	not	available	
HSPC,	haematopoietic	stem	and	progenitor	cell;	LT-HSC,	long-term	haematopoietic	stem	cell;	
ST-HSC,	 short-term	 haematopoietic	 stem	 cell;	 LMPP,	 lymphoid	 primed	 multipotent	
progenitor;	preGM,	pre-granulocyte-macrophage	progenitor;	GMP,	granulocyte-macrophage	
progenitor;	 MEP,	 megakaryocyte-erythroid	 progenitor;	 EP,	 erythroid	 progenitor;	 MkP,	
megakaryocyte	 progenitor;	 CFU-E,	 erythroid	 colony	 forming	 unit;	 CLP,	 common	 lymphoid	
progenitor;	 ETP,	 early	 thymocyte	 progenitor;	 Flt3,	 fms-like	 tyrosine	 kinase;	 Lin,	 lineage	
markers.	
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Finally,	expression	of	CSF3R	was	largely	restricted	to	HSPC	populations	that	had	granulocytic	
potential,	 such	 as	 LMPPs,	 preGMs	 and	 GMPs.	 Interestingly,	 the	 highest	 level	 of	 CSF3R	
expression	was	found	to	be	in	the	ST-HSC	compartment.	However,	statistical	analysis	was	not	
performed	on	 this	population	as	 the	data	 included	 just	2	data	points.	Again,	 low	 levels	of	
CSF3R	expression	by	MEPs,	CFU-Es,	preCFU-Es	and	EPs	indicated	amplification	due	to	gDNA,	
implying	 that	 these	 populations	 did	 not	 express	 the	 CSF3R	 gene.	 LT-HSCs	 expressed	
significantly	lower	levels	of	CSF3R	than	LMPPs	[p=0.0317]	but	significantly	higher	levels	than	
MEPs	 [p=0.0286],	 suggesting	 that	 Csf3r	 mRNA	 was	 present	 in	 this	 population.	 The	 CLP	
population	also	expressed	higher	levels	of	CSF3R	than	MEPs	but	this	could	not	be	confirmed	
by	statistical	analysis	as	the	data	exported	from	the	database	only	included	2	data	points	for	
the	CLP	population.		
	
These	data	indicate	that	FLT3,	EPOR	and	CSF3R	are	expressed	by	HSCs,	and	that	expression	of	
these	 receptors	 by	 cells	 at	 later	 stages	 of	 development	 is	 largely	 restricted	 to	 progenitor	
populations	 that	possess	 the	associated	 lineage	potentials.	 For	 example,	EPOR	was	highly	
expressed	by	MEPs,	EPs	and	CFU-Es,	but	not	by	LMPPs,	CLPs	or	GMPs,	which	lack	erythroid	
potential.	This	analysis	provided	an	insight	into	where	FLT3,	EPOR,	CSF1R	and	CSF3R	genes	
are	expressed	during	haematopoiesis.	The	following	results	obtained	from	the	single	cell	gene	
expression	 analysis	 studies	 aim	 to	 confirm	 the	 validity	 of	 the	 data	 generated	 from	 the	
HemaExplorer	and	BloodSpot	databases.	
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3.3			Gating	 strategy	 for	 the	 isolation	 and	 analysis	 of	
haematopoietic	stem	and	progenitor	cells	
	
In	 order	 to	 analyse	 the	 patterns	 of	 HGF	 receptor	 expression	 during	 haematopoiesis,	 flow	
cytometry	antibody	panels	were	designed	for	the	identification	and	isolation	of	HSPCs.	The	
cell	 surface	 marker	 profiles	 were	 adapted	 from	 recent	 publications	 (Figure	 3.2).	 When	
performing	 flow	 cytometry	 or	 FACS,	 cells	were	 first	 gated	 based	 on	 their	 forward	 scatter	
(FSC)/side	scatter	(SSC)	profile	to	exclude	noise	and	debris.	Doublets	were	then	removed	by	
gating	for	cells	with	a	low	pulse	width	profile.	Auto-fluorescent	cells	were	also	removed	from	
analysis	using	a	fluorescent	channel	that	was	not	being	used,	as	these	cells	were	likely	to	be	
dead	or	dying.		
	
A	lineage	cocktail	was	created	by	combining	antibodies	for	CD3ε,	CD11b,	B220,	Gr-1,	TER-119	
to	allow	for	the	exclusion	mature	haematopoietic	cells,	such	as	lymphocytes,	monocytes	and	
erythroid	cells.	Thus,	all	HSPC	populations	were	first	gated	as	Lin−.	By	staining	for	Sca1	and	c-
Kit,	 the	 early	 HSPC	 populations	 could	 be	 identified.	 Within	 the	 LSK	 compartment,	 the	
Morrison	group	has	shown	that	CD150	and	CD48	allow	for	the	enrichment	of	HSCs,	MPPs	and	
progenitors	with	varying	lineage-potentials	[34].	Therefore,	this	gating	strategy	was	employed	
to	 identify	 HSCs	 and	MPPs	 as	 LSK	 CD150+	 CD48−	 and	 LSK	 CD150−	 CD48−	 respectively.	 To	
distinguish	 between	 LT-HSCs	 (LSK	 CD150+	 CD48−	 CD34−)	 and	 ST-HSCs	 (LSK	 CD150+	 CD48−	
CD34+)	cells,	CD34	was	added	to	the	panel	to	 identify	CD34−	and	CD34+	HSCs,	respectively	
[21].		
	
	
	
109	
	
Figure	3.2.	Isolation	of	HSPCs	from	mouse	BM.	Cells	 identified	as	HSCs,	subpopulations	of	
these	 cells	 and	 various	 progenitors	 are	 delineated	 by	 the	 black	 boxes.	 Shaded	 areas	 in	
histograms	depict	the	isotype	control	staining.	For	the	purpose	of	this	figure,	flow	cytometry	
plots	from	a	number	of	staining	strategies	and	experiments	have	been	combined	to	show	a	
comprehensive	gating	strategy	of	all	the	HSPC	populations	analysed	in	this	study.	After	gating	
for	singlet	cells,	a	channel	that	did	not	correspond	with	any	staining	was	used	to	exclude	AF	
cells,	as	these	were	likely	to	be	dead/dying	cells.	HSPCs,	haematopoietic	stem	and	progenitor	
cells;	Lin,	lineage	markers;	LS−K,	Lin−	Sca1−	c-Kit+;	LSK,	Lin−	Sca1+	c-Kit+;	Flt3,	fms-like	tyrosine	
kinase	 3;	 IL-7R,	 interleukin-7	 receptor;	 HSC,	 haematopoietic	 stem	 cell;	 MPP,	 multipotent	
progenitor;	 HPC,	 haematopoietic	 progenitor	 cell;	 LMPP,	 lymphoid-primed	 multipotent	
progenitor;	 CLP,	 common	 lymphoid	 progenitor;	 CMP,	 common	myeloid	 progenitor;	 GMP,	
granulocyte-macrophage	 progenitor;	MEP,	megakaryocyte-erythroid	 progenitor;	 AF,	 auto-
fluorescent;	BM,	bone	marrow.	
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CD150	and	CD48	staining	within	the	LSK	compartment	also	allowed	for	the	identification	of	
maturing	 progenitors,	 such	 as	 HPC-1	 (LSK	 CD48+	 CD150−),	 which	 possesses	 GM-lymphoid	
potential	and	minimal	MegE	potential,	and	HPC-2	(LSK	CD48+	CD150+),	a	population	that	can	
give	rise	to	MegE	cells	and	very	few	GM-lymphoid	cells	[34].	However,	as	some	HPC-1	are	
known	 to	 express	 high	 levels	 of	 Flt3,	 their	 staining	 profile	 overlaps	 with	 the	 LMPP	
compartment;	these	cells	have	been	described	as	LSK	Flt3hi	by	the	Jacobsen	group	[73].	To	
include	this	population,	the	staining	strategy	was	adapted	to	divide	the	LSK	CD48+	CD150−	
compartment	into	Flt3hi	and	Flt3−/lo	cells,	which	were	referred	to	as	LMPP	and	Flt3−/lo	HPC-1,	
respectively,	for	the	purpose	of	this	study.		
		
Table	6:	Proportion	and	phenotype	of	haematopoietic	stem	and	progenitor	cells	within	the	
mouse	BM	
	
Cell	population	 Phenotype	 %	of	whole	BM	
LT-HSC	 LSK	CD150+	CD48−	CD34−	 4.75	±	0.4	x10−3	
ST-HSC	 LSK	CD150+	CD48−	CD34+	 13.7	±	0.6	x10−3	
Total	HSC	 LSK	CD150+	CD48−		 1.85	±	0.06	x10−2	
MPP	 LSK	CD150−	CD48−	 6.1	±	0.58	x10−2	
Flt3−/lo	HPC-1	 LSK	CD150−	CD48+	Flt3−/lo	 8.25	±	0.8	x10−2	
LMPP	 LSK	CD150−	CD48+	Flt3hi	 0.1	±	0.02	
HPC-2	 LSK	CD150+	CD48+	 7.1	±	0.9	x10−3	
CLP	 Lin−	Sca1lo	c-Kitlo	IL-7Rα+	 7.1	±	1.7	x10−2	
CMP	 LS−K	IL-7Rα−	CD16/32lo	CD34hi	 0.41	±	0.007	
GMP	 LS−K	IL-7Rα−	CD16/32hi	CD34hi	 0.36	±	0.03	
MEP	 LS−K	IL-7Rα−	CD16/32lo	CD34lo	 0.45	±	0.006	
Percentages	are	given	as	mean	±	standard	error	of	the	values	obtained	for	n=6-9	mice.	BM	
cells	 were	 gated	 according	 to	 FSC/SSC	 and	 pulse	 width.	 BM,	 bone	 marrow;	 AF,	 auto-
fluorescence;	 LS−K,	 Lineage−	 Sca1−	 c-Kit+;	 LSK,	 Lineage−	 Sca1+	 c-Kit+;	 Flt3,	 fms-like	 tyrosine	
kinase	3;	IL-7Rα,	interleukin-7	receptor	α	subunit;	HSC,	haematopoietic	stem	cell;	LT,	 long-
term;	 ST,	 short-term;	MPP,	 multipotent	 progenitor;	 HPC,	 haematopoietic	 progenitor	 cell;	
LMPP,	 lymphoid-primed	multipotent	progenitor;	CLP,	common	 lymphoid	progenitor;	CMP,	
common	 myeloid	 progenitor;	 GMP,	 granulocyte-macrophage	 progenitor;	 MEP,	
megakaryocyte-erythroid	progenitor;	FSC,	forward	scatter;	SSC,	side	scatter.	
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The	lymphoid	restricted	CLP	population	was	identified	by	first	gating	for	IL-7Rα+	cells	within	
the	Lin−	population.	These	cells	were	then	gated	based	on	low	levels	of	Sca1	and	c-Kit	(Lin−	
Sca1lo	c-Kitlo	IL-7Rα+)	according	to	work	published	by	the	Weissman	group	[66].	Some	LMPPs	
express	IL-7Rα	[73],	so	the	Sca1	and	c-Kit	gating	strategy	for	CLP	isolation	was	modified	to	
ensure	it	did	not	overlap	with	the	strategy	used	to	isolate	LMPPs.	Finally,	according	to	Akashi	
et	al.,	BM	myeloid	progenitors	express	c-Kit,	but	lack	expression	of	Sca1	and	IL-7Rα	on	their	
surface	 [67].	As	 such,	myeloid	progenitors	were	 identified	by	gating	 for	 LS−K	 IL-7Rα−	cells.	
Within	this	compartment,	expression	of	CD16/32	and	CD34	was	used	to	identify	CMPs	(LS−K	
IL-7Rα−	 CD16/32lo	 CD34hi),	 GMPs	 (LS−K	 IL-7Rα−	 CD16/32hi	 CD34hi)	 and	MEPs	 (LS−K	 IL-7Rα−	
CD16/32lo	 CD34lo)	 [67].	 Table	 6	 lists	 the	 proportions	 and	 phenotypes	 of	 these	 HSPC	
populations	within	the	BM.	
	
3.4			Optimisation	of	qRT-PCR	assays	for	the	detection	
of	growth	factor	receptor	gene	expression	
	
3.4.1			ACTB	 as	 an	 endogenous	 control	 gene	 for	 qRT-PCR	
analysis	
	
Once	the	antibody	panels	were	defined	for	the	isolation	of	single	HSPCs,	qRT-PCR	assays	were	
designed	and	optimised	for	the	detection	of	HGF	receptor	gene	expression	in	single	cells.	Prior	
to	designing	any	assays,	a	reliable	endogenous	control	gene	was	selected.	ACTB	encodes	the	
cytoskeletal	protein	β-actin	and	is	a	commonly	used	control	gene.	[315-317].	To	determine	if	
this	gene	was	homogeneously	expressed	by	the	populations	that	were	going	to	be	analysed	
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during	this	study,	the	HemaExplorer	and	BloodSpot	databases	were	examined	to	compile	data	
for	the	HSPC	populations	of	interest.	These	included	the	LT-HSC,	ST-HSC,	LMPP,	preGM,	GMP,	
MEP	and	CLP	populations.		
	
	
	
	
	
Figure	3.3.	Investigation	of	ACTB	expression	by	HSPC	populations.	The	expression	of	ACTB	
by	HSPC	populations	was	analysed	using	the	HemaExlporer	and	BloodSpot	databases.	Values	
are	expressed	in	AU,	as	the	data	are	normalised	using	calculated	batch	effect	estimators	so	
that	results	can	be	compared	across	the	numerous	studies	compiled	within	the	databases.	
Data	is	plotted	on	a	log	scale.	HSPCs,	haematopoietic	stem	and	progenitor	cells;	LT-HSC,	long-
term	 haematopoietic	 stem	 cell;	 ST-HSC,	 short-term	 haematopoietic	 stem	 cell;	 LMPP,	
lymphoid-primed	multipotent	progenitor;	preGM,	pre-granulocyte-macrophage	progenitor;	
GMP,	granulocyte-macrophage	progenitor;	MEP,	megakaryocyte-erythroid	progenitor;	MkP,	
megakaryocyte	 progenitor;	 CFU-E,	 erythroid	 colony	 forming	 unit;	 CLP,	 common	 lymphoid	
progenitor;	ProB,	pro-B-lymphocyte;	Pre,	pre-B-lymphocyte	cell;	ETP,	early	thymic	progenitor;	
AU,	arbitrary	units;	ACTB,	β-actin.	
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All	of	the	cell	populations	expressed	the	ACTB	gene	at	a	high	level	(Figure	3.3).	There	were	
significant	 differences	 in	 the	 expression	 of	 ACTB	 between	 a	 number	 of	 populations.	 For	
example,	 the	 levels	 of	 ACTB	 expressed	 by	 ST-HSCs	 was	 significantly	 higher	 than	 LMPPs	
[p=0.0342],	 GMPs	 [p=0.0226]	 and	 MEPs	 [p=0.0146].	 This	 indicated	 that	 analysing	 HGF	
receptor	 gene	 expression	 relative	 to	 ACTB	 expression	 would	 not	 allow	 for	 accurate	
comparison	between	the	HSPC	populations.	However,	this	would	likely	be	the	case	with	other	
commonly	used	endogenously	control	genes.	As	the	expression	of	HGF	receptor	genes	was	
being	measured	in	single	cells,	the	Ct	values	obtained	directly	from	gene	expression	analysis	
could	be	compared	between	samples.	Thus,	the	endogenous	control	gene	was	only	required	
to	confirm	the	presence	of	a	single	cell	in	each	well	of	a	PCR	plate	during	analysis.	As	ACTB	
was	found	to	be	highly	expressed	by	all	populations	(when	compared	to	FLT3,	EPOR,	CSF1R	
and	CSF3R,	according	to	the	HemaExplorer	and	BloodSpot	databases	[Figure	3.1]),	this	gene	
was	chosen	as	an	endogenous	control.	
	
	
3.4.2			ACTB,	 FLT3,	 EPOR,	 CSF1R	 and	 CSF3R	 qRT-PCR	 assay	
design	
	
Following	endogenous	control	gene	selection,	qRT-PCR	assays	specific	 for	Actb,	Flt3,	Epor,	
Csf1r	 and	 Csf3r	 transcripts	 were	 designed.	 Each	 gene	 was	 examined	 using	 the	 Ensembl	
genome	 browser	 (FLT3,	 ENSMUSG00000042817;	 EPOR,	 ENSMUSG00000006235;	 CSF1R,	
ENSMUSG00000024621;	CSF3R,	ENSMUSG00000028859)	to	determine	the	sequences	of	all	
the	 possible	 protein	 coding	 splice	 variants,	 and	 from	 this,	 generic	 exon	 junctions	 were	
selected.	For	a	detailed	method	of	how	qRT-PCR	assays	were	designed,	see	Section	2.8.	To	
exclude	non-specific	priming	from	gDNA,	the	generic	exon	junction	sequences	were	analysed	
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using	BLAST	to	ensure	that	there	were	no	pseudogenes	containing	these	generic	exon-exon	
junction	sequences,	and	that	similar	sequences	were	not	present	in	non-relevant	genes	in	the	
mouse	 genome.	 BLAST	 analysis	 revealed	 that	 no	 pseudogenes	 containing	 the	 sequence	
spanning	the	junction	between	the	first	and	second	exon	in	the	murine	ACTB	gene	exist,	so	
this	 sequence	was	 selected	 as	 the	qRT-PCR	 assay	 target.	 Similarly,	 BLAST	 analysis	 did	 not	
reveal	any	sequence	homology	within	the	mouse	transcriptome	and	genome	for	the	selected	
target	sequences	of	the	FLT3,	EPOR,	CSF1R	and	CSF3R	genes.	For	both	the	EPOR	and	FLT3	
gene,	the	second	exon-exon	junction	was	chosen	for	qRT-PCR	assay	design,	while	the	14th	and	
3rd	exon-exon	junctions	of	the	CSF1R	and	CSF3R	genes	were	chosen,	respectively	(see	Table	
7	and	Figure	3.4).		
	
	
Table	7:	Intron	size	for	the	interrogated	exon-exon	junctions	in	the	ACTB,	FLT3,	EPOR,	CSF1R	
and	CSF3R	genes	
	
Assay	
Interrogated	exon-	
exon	junction	
Intron	size	
ACTB	 Exon	1	–	Exon	2	 959	nt	
FLT3	 Exon	2	–	Exon	3	 6,314	nt	
EPOR	 Exon	2	–	Exon	3	 337	nt	
CSF1R	 Exon	14	–	Exon	15	 2,028	nt	
CSF3R	 Exon	3	–	Exon	4	 2,362	nt	
ACTB,	β-actin;	FLT3,	fms-like	tyrosine	kinase	3;	
EPOR,	 erythropoietin	 receptor;	 CSF1R,	
macrophage-colony	 stimulating	 factor	
receptor;	 CSF3R,	 granulocyte-colony	
stimulating	factor	receptor	nt,	nucleotides.	
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Figure	 3.4.	 Sequence	 alignment	 of	ACTB,	 FLT3,	 EPOR,	 CSF1R	 and	CSF3R	 qRT-PCR	 assays	
within	regions	of	their	target	genes.	The	forward	primer,	reverse	primer	and	hydrolysis	probe	
sequences	are	shown	highlighted	in	blue,	green,	and	pink,	respectively.	The	red	box	highlights	
an	exon	junction.	The	numbers	to	the	right	of	the	gene	names	correspond	to	the	length	of	
the	interrogated	sequence	input	into	the	Biosearch	Technologies	RealTimeDesign	software	
and	do	not	relate	to	the	true	length	of	the	gene.	ACTB,	β-actin;	FLT3,	fms-like	tyrosine	kinase	
3;	 EPOR,	 erythropoietin	 receptor;	 CSF1R,	 macrophage-colony	 stimulating	 factor	 receptor;	
CSF3R,	granulocyte-colony	stimulating	factor	receptor.	
	
ACTB
FLT3
EPOR
CSF1R
CSF3R
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Table	8:	Primer	and	hydrolysis	probe	sequence	for	the	ACTB,	FLT3,	EPOR,	CSF1R	and	CSF3R	qRT-PCR	assays	
Assay/Target	 Forward	Primer	 Reverse	Primer	 Hydrolysis	Probe	
ACTB	 5’-CAGCTTCTTTGCAGCTCCTTC-3’	 5’-CGACCAGCGCAGCGATAT-3’	 5’-CACCAGTTCGCCATGGA-3’	
FLT3	 5’-ATCAGCGGGAAAGCCATCATC-3’	 5’-GGGCACACTGGAGGTCTTCT-3’	 5’-TCCTCGCACCATTCGGTA-3’	
EPOR	 5’-CATACCAGCTCGAGGGTGAGTCAC-3’	 5’-CTCCGGGATGGACTTCAACTAC-3’	 5’-CTGGTGCAGGCTACATGACT-3’	
CSF1R	 5’-ACCTGTCCTGGTCATCACT-3’	 5’-AACCTCTTGGGAGCCTGTACTCAC-3’	 5’-GCATAGCCTCGGCCTTCCTT-3’	
CSF3R	 5’-TGGACACATCGAGATTTCAC-3’	 5’-CTGCACCCTGACTGGAGTTAC-3’	 5’-GTGCAAGAGGCCAGGACAG-3’	
ACTB,	 β-actin;	 FLT3,	 fms-like	 tyrosine	 kinase	 3;	 EPOR,	 erythropoietin	 receptor;	 CSF1R,	 macrophage-colony	 stimulating	 factor	
receptor;	CSF3R,	granulocyte-colony	stimulating	factor	receptor.
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Hydrolysis	probe-based	qRT-PCR	assays	specific	for	the	detection	of	Actb,	Flt3,	Epor,	Csf1r	and	
Csf3r	 transcripts	were	designed	 to	 flank	each	corresponding	exon-exon	 junction	using	 the	
RealTimeDesign	Software	(described	in	Section	2.8).	Where	possible,	a	probe	was	designed	
to	 directly	 complement	 the	 exon-exon	 junction	 itself,	 especially	when	 short	 introns	were	
present	(Table	7)	between	the	chosen	exons	(see	annealing	location	of	hydrolysis	probe	for	
the	ACTB,	FLT3	and	EPOR	assays	 in	Figure	3.4).	Before	purchasing	the	assays,	primers	and	
hydrolysis	probes	were	analysed	for	complementarity	within	the	mouse	transcriptome	and	
genome	using	BLAST	to	ensure	specificity.	It	was	found	that	none	of	the	designed	primers	or	
probes	shared	complementarity	with	any	other	mouse	genomic	or	transcriptomic	sequences.	
Thus,	these	primers	and	hydrolysis	probes	for	the	detection	of	Actb,	Flt3,	Epor,	Csf1r	and	Csf3r	
transcripts	 were	 purchased	 from	 Biosearch	 Technologies	 (California,	 USA)	 and	 DNA	
Technology	(Aarhus,	Denmark).	Primer	and	hydrolysis	probe	sequences	for	the	ACTB,	FLT3,	
EPOR,	CSF1R	and	CSF3R	qRT-PCR	assays	are	listed	in	Table	8.		
3.4.3			Optimisation	 of	 ACTB,	 FLT3,	 EPOR,	 CSF1R	 and	 CSF3R	
qRT-PCR	assays	
	
Next,	 the	 specificity	 of	 the	 ACTB,	 FLT3,	 EPOR,	 CSF1R	 and	 CSF3R	 qRT-PCR	 assays	 was	
confirmed.	As	these	assays	were	designed	for	the	detection	of	mRNA,	they	were	tested	to	
ensure	 they	 did	 not	 amplify	 gDNA.	 To	 do	 this,	 qRT-PCR	 analysis	 of	whole	 BM	 lysate	was	
performed	 for	 each	 assay	 with	 (+)	 and	 without	 (-)	 the	 RT	 enzyme,	 using	 non-limiting	
concentrations	of	primers	and	probes	(900nM	of	primers	and	250nM	of	hydrolysis	probe).	As	
the	RNA	in	-RT	samples	is	not	converted	to	cDNA,	amplification	in	these	samples	would	only	
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occur	if	the	given	assay	spans	a	region	within	gDNA.	The	ACTB,	FLT3,	EPOR,	CSF1R	and	CSF3R	
qRT-PCR	assays	were	tested	using	approximately	200ng	of	RNA	and	DNA	obtained	from	whole	
BM	lysate,	and	amplification	was	carried	out	for	45-50	cycles.	All	assays	successfully	amplified	
targets	 in	 the	 +RT	but	 not	 the	 -RT	 reactions,	 indicating	 that	 they	were	 specific	 for	mRNA	
transcripts,	and	not	gDNA	(Figure	3.5).	This	was	essential	for	moving	forward	with	qRT-PCR	
optimisation,	and	confirmed	that	these	assays	could	be	used	for	analysis	of	gene	expression	
by	individual	cells	without	previous	DNase	digestion.		
	
For	accurate	analysis	of	single	cell	gene	expression,	each	of	the	FLT3,	EPOR,	CSF1R	and	CSF3R	
qRT-PCR	assays	needed	to	be	combined	with	the	endogenous	control	gene.	This	allowed	for	
the	discrimination	between	samples	that	did	not	express	the	target	HGF	receptor	gene	and	
empty	wells.	To	prevent	competition	occurring	between	assays	in	multiplex	reactions,	primer	
and	 probe	 concentrations	 needed	 to	 be	 optimised.	 The	 use	 of	 limiting	 concentrations	 of	
primers	ensured	 that	 assays	 reproducibly	 and	efficiently	 amplified	a	 target	 to	a	 level	 that	
could	be	detected,	but	did	not	impede	the	amplification	of	other	targets	through	excessive	
use	of	reaction	constituents.		
	
Optimum	 primer	 concentrations	 were	 determined	 for	 each	 qRT-PCR	 assay	 by	 comparing	
varying	 concentrations	 and	 combinations	 of	 forward	 and	 reverse	 primers	 using	 constant	
concentrations	of	template	(approximately	200ng	of	RNA	and	DNA	from	whole	BM	lysate)	
and	non-limiting	hydrolysis	probe	(250nM).	For	a	detailed	protocol	 for	the	optimisation	of	
qRT-PCR	assay	primer	concentrations	see	Section	2.8.	As	a	positive	control,	reactions	with	
unlimiting	primer	concentrations	containing	300nM	of	forward	primer	and	300nM	of	reverse	
primer	 were	 included	 (reference	 reaction;	 300nM/300nM	 reaction).	 Candidate	 primer	
combinations	were	first	selected	based	on	their	efficiency	(any	sample	with	a	Ct	value	of	>0.5	
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cycles	greater	than	the	Ct	value	of	the	reference	reaction	was	disregarded	due	to	a	loss	in	
efficiency)	(Figure	3.6).	Of	the	remaining	primer	combinations,	the	sample	with	the	lowest	
fluorescence	level	at	the	end	of	the	plateau	phase	of	the	amplification	curve	was	considered	
to	represent	the	optimal	limiting	primer	concentrations	(Figure	3.7).		
	
	
Figure	3.5.	Amplification	of	qRT-PCR	assay	targets	form	whole	BM	lysate	with	and	without	
reverse	transcriptase.	The	specificity	of	the	qRT-PCR	assays	was	tested	to	ensure	that	they	
did	not	detect	genomic	DNA.	Amplification	of	(A)	Actb,	(B)	Flt3,	(C)	Csf1r,	(D)	Epor	and	(E)	
Csf3r	 from	 whole	 BM	 samples	 with	 (red	 amplification	 curves)	 and	 without	 (green	
amplification	curves)	RT.	Fluorescence	is	plotted	on	a	log	scale.	BM,	bone	marrow;	RT,	reverse	
transcriptase.	ACTB,	β-actin;	FLT3,	fms-like	tyrosine	kinase	3;	EPOR,	erythropoietin	receptor;	
CSF1R,	 macrophage-colony	 stimulating	 factor	 receptor;	 CSF3R,	 granulocyte-colony	
stimulating	factor	receptor.	
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Figure	3.6.	Ct	values	obtained	during	primer	optimisation	of	qRT-PCR	assays.	
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Figure 3.6. Ct values obtained during primer
optimisation of qRT-PCR assays. Primers of the ACTB,
FLT3, EPOR, CSF1R and CSF3R qRT-PCR assays were
tested in varying concentrations and combinations to
determine limiting conditions. Grey transparent
panes are set to 0.5 cycles greater than the Ct of the
reference reaction (300nM forward primer, 300nM
reverse primer). All reactions with a Ct value above
this were considered to have maintained efficiency
when compared to the reference reaction (note z-axis
is in reverse). Each data point represents the mean of
3 technical replicates. Ct, threshold cycle; ACTB, β-
actin; FLT3, fms-like tyrosine kinase 3; EPOR,
erythropoietin receptor; CSF1R, macrophage-colony
stimulating factor receptor; CSF3R, granulocyte-
colony stimulating factor receptor.
ACTB FLT3 EPOR
CSF1R CSF3R
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Figure	3.7.	Peak	fluorescence	obtained	during	primer	optimisation	of	qRT-PCR	assays.
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Figure 3.7. Peak fluorescence obtained during
primer optimisation of qRT-PCR assay. Primers of
the ACTB, FLT3, EPOR, CSF1R and CSF3R qRT-PCR
assays were tested in varying concentrations and
combinations to determine limiting conditions.
Fluorescence values at the end of the plateau
phase were plotted for each primer combination.
Each data point represents the mean of 3 technical
replicates. AU, arbitrary units; ACTB, β-actin; FLT3,
fms-like tyrosine kinase 3; EPOR, erythropoietin
receptor; CSF1R, macrophage-colony stimulating
factor receptor; CSF3R, granulocyte-colony
stimulating factor receptor.
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This	method	was	 successful	 for	 the	ACTB,	 FLT3,	 EPOR	 and	 CSF3R	 assays.	 However,	when	
analysing	the	CSF1R	primer	optimisation	data,	all	of	the	primer	combinations	that	resulted	in	
a	Ct	value	of	<0.5	cycles	greater	 than	 the	 reference	 reaction	Ct	value	had	either	equal	or	
greater	 end	 fluorescence	 values.	 Even	minor	 decreases	 in	 peak	 fluorescence	 values	were	
accompanied	 by	 an	 increase	 in	 Ct	 values	 (Figure	 3.6	 and	 Figure	 3.7).	 Thus,	 the	 primer	
concentrations	 in	 the	 reference	 reaction	 (300nM/300nM)	were	 used	 for	 all	 future	CSF1R	
assays.	The	optimum	primer	concentrations	for	each	assay	are	listed	in	Table	8.	
	
Using	the	optimum	concentrations	of	primers	for	each	assay,	the	probe	concentrations	for	
the	 ACTB,	 FLT3,	 EPOR,	 CSF1R	 and	 CSF3R	 qRT-PCR	 assays	 were	 subsequently	 optimised.	
Reactions	were	set	up	using	varying	concentrations	of	hydrolysis	probe	to	amplify	a	constant	
concentration	of	 template	 (approximately	200ng	of	RNA	and	DNA	from	whole	BM	 lysate).	
Again,	 a	 detailed	 protocol	 is	 described	 in	 Section	 2.8.	 A	 reaction	 containing	 250nM	 of	
hydrolysis	 probe	 was	 included	 as	 a	 reference	 reaction	 as	 this	 was	 considered	 to	 contain	
excessive	amounts	of	probe.	As	with	the	primer	optimisation	protocol,	candidate	hydrolysis	
probe	concentrations	were	considered	to	have	lost	efficiency	if	they	yielded	a	Ct	value	of	>0.5	
cycles	greater	than	the	Ct	value	of	the	reference	reaction.	Of	the	reactions	that	had	retained	
efficiency,	 the	 lowest	 concentration	 of	 probe	 was	 selected	 as	 the	 optimal	 probe	
concentration	(Figure	3.8).	Probe	optimisation	was	successful	for	all	of	the	assays.	Therefore,	
the	ACTB,	FLT3,	EPOR,	CSF1R	and	CSF3R	qRT-PCR	assays	were	fully	optimised,	and	all	future	
reactions	 were	 carried	 out	 using	 the	 optimum	 conditions	 for	 each	 assay.	 The	 optimum	
hydrolysis	probe	concentration	for	each	assay	is	listed	in	Table	8.		
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Figure	 3.8.	Optimisation	 of	 hydrolysis	 probe	 concentration	 for	ACTB,	 FLT3,	EPOR,	 CSF1R	 and	CSF3R	 qRT-PCRs.	Varying	 concentrations	 of	
hydrolysis	probe	were	used	to	determine	the	optimum	concentration	for	the	detection	of	(A)	ACTB,	(B)	FLT3,	(C)	EPOR	(D)	CSF1R	and	(E)	CSF3R	
expression.	All	reactions	contained	limiting	primer	concentrations	and	a	constant	concentration	of	RNA/DNA	from	whole	BM	lysate.	Dotted	lines	
are	set	to	0.5	cycles	greater	than	the	reference	reaction	(reaction	containing	250nM	of	hydrolysis	probe).	All	reactions	below	this	 line	were	
considered	to	have	maintained	efficiency	when	compared	to	the	reference	reaction.	Data	represents	mean	±	standard	error	from	at	 least	3	
technical	replicates	at	each	point.	Ct,	 threshold	cycle;	ACTB,	β-actin;	FLT3,	 fms-like	tyrosine	kinase	3;	EPOR,	erythropoietin	receptor;	CSF1R,	
macrophage-colony	stimulating	factor	receptor;	CSF3R,	granulocyte-colony	stimulating	factor	receptor.	
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Figure	3.9.	Isolation	of	CD115+	leukocytes,	Ly6G+	granulocytes	and	EPs	from	mouse	BM	to	test	the	single	cell	sensitivity	of	the	CSF1R,	CSF3R	
and	EPOR	qRT-PCR	assays.	Populations	are	delineated	by	the	black	boxes.	Cells	were	first	gated	based	on	their	FSC/SSC	profile,	and	then	doublets	
were	excluded	by	gating	for	cells	with	a	low	pulse	width	value.	Values	shown	represent	the	percentage	of	singlet	events	within	the	given	gate.	
FSC,	forward	scatter;	SSC,	side	scatter;	Lin,	lineage	markers;	IL-3R,	interleukin-3	receptor;	EP,	erythroid	progenitor;	BM,	bone	marrow.	
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Once	 the	 qRT-PCR	 assays	 were	 optimised,	 they	 were	 tested	 to	 determine	 if	 they	 were	
sensitive	enough	to	detect	gene	expression	by	single	cells.	To	do	this,	single	cells	that	were	
known	to	express	the	gene	of	interest	were	sorted	and	analysed	using	the	optimised	assays.	
By	sorting	1,	2,	4,	8,	16,	32	and	64	cell(s)	into	single	wells	of	384-well	PCR	plates,	the	efficiency	
of	the	qRT-PCR	assays	could	also	be	determined	as,	on	average,	a	decrease	of	1	Ct	per	cell	
number	doubling	would	indicate	efficient	amplification	of	target	sequences	(see	dotted	lines	
in	Figure	3.10).	
	
	
Figure	 3.10.	 Detection	 of	 ACTB,	 FLT3,	 EPOR	 and	 CSF1R	 gene	 expression	 in	 single	 cells.	
Detection	of	gene	expression	in	varying	cell	numbers	using	(A)	ACTB,	(B)	FLT3,	(C)	EPOR	and	
(D)	CSF1R	qRT-PCR	assays	at	optimised	primer	and	probe	concentrations.	For	comparison,	the	
dotted	lines	represent	an	efficient	amplification	with	a	decrease	in	1	cycle	per	cell	number	
doubling.	 Common	 lymphoid	 progenitors,	 lymphoid-primed	 multipotent	 progenitors,	
erythroid	progenitors	and	CD115+	 leukocytes	were	sorted	 to	 test	 the	efficiency	of	 the	 (A)	
ACTB,	(B)	FLT3,	(C)	EPOR	and	(D)	CSF1R	qRT-PCR	assays,	respectively.	Data	represents	mean	
±	standard	error	 from	at	 least	3	samples.	Ct,	 threshold	cycle;	ACTB,	β-actin;	FLT3,	 fms-like	
tyrosine	 kinase	 3;	 EPOR,	 erythropoietin	 receptor;	 CSF1R,	 macrophage-colony	 stimulating	
factor	receptor;	CSF3R,	granulocyte-colony	stimulating	factor	receptor.	
B A 
D C 
ACTB FLT3 
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ACTB	is	expressed	by	all	cells,	so	CLPs	were	sorted	to	test	the	sensitivity	of	the	ACTB	qRT-PCR	
assay	due	to	their	simple	staining	profile.	LMPPs	were	identified	based	on	the	presence	of	
Flt3	on	their	surface,	so	variable	numbers	of	these	cells	were	sorted	to	determine	if	the	FLT3	
qRT-PCR	assay	could	detect	single	cell	gene	expression	[73].	CLPs	and	LMPPs	were	purified	
using	the	gating	strategy	depicted	in	Figure	3.2.	To	test	the	sensitivity	of	the	CSF1R	and	CSF3R	
qRT-PCR	assays,	single	BM	CD45+	CD115+	(M-CSFR+)	leukocytes	and	CD45+	Ly6G+	granulocytes	
were	sorted,	respectively	(Figure	3.9)	[318,	319].	Finally,	to	verify	the	sensitivity	of	the	EPOR	
qRT-PCR	assay,	LS−K	IL-3R−	IL-7Rα−	CD41−	CD71+	EPs	were	purified	(Figure	3.9)	[313].		
	
Table	9:	Optimum	primer	and	hydrolysis	probe	concentrations	of	qRT-PCR	assays	for	the	
detection	of	gene	expression	by	single	cells	
	
Assay	
Target	
Optimum	
Forward	Primer	
Conc.	(nM)	
Optimum	
Reverse	Primer	
Conc.	(nM)	
Optimum	
Hydrolysis	Probe	
Concentration	
Single-cell	gene	
expression	
detected	
ACTB	 60	 300	 125	 Yes	
FLT3	 80	 60	 225	 Yes	
EPOR	 80	 100	 150	 Yes	
CSF1R	 300	 300	 125	 Yes	
CSF3R	 300	 60	 175	 No	
ACTB,	 β-actin;	 FLT3,	 fms-like	 tyrosine	 kinase	 3;	 EPOR,	 erythropoietin	 receptor;	 CSF1R,	
macrophage-colony	stimulating	factor	receptor;	CSF3R,	granulocyte-colony	stimulating	factor	
receptor.	
	
Using	 the	 ACTB,	 FLT3,	 EPOR	 and	 CSF1R	 qRT-PCR	 assays,	 expression	 of	 the	 respective	
transcripts	 in	 single	 cells	were	 successfully	 detected.	On	 average,	 a	 decrease	 of	 1	 Ct	was	
observed	 for	each	cell	number	doubling,	 indicating	 that	 the	assays	were	amplifying	 target	
mRNA	in	an	efficient	manner	(Figure	3.10,	dotted	lines).	However,	when	the	expression	of	
CSF3R	was	analysed,	the	amplification	curves	began	to	diminish	as	the	cell	number	decreased.	
By	comparing	the	amplification	data	of	the	CSF3R	assay	to	that	of	the	CSF1R	assay,	it	was	clear	
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that	 the	CSF3R	assay	was	not	 sensitive	when	assaying	 single	cells	 (Figure	3.11).	Thus,	 this	
assay	was	not	used	to	analyse	CSF3R	expression	in	HSPCs	in	future	experiments.	The	ability	
of	 the	 ACTB,	 FLT3,	 EPOR,	 CSF1R	 and	 CSF3R	 qRT-PCR	 assays	 to	 detect	 single	 cell	 gene	
expression	is	listed	in	Table	8.	
	
	
	
Figure	3.11.	Amplification	of	Csf1r	and	Csf3r	from	single	cells.	The	(A)	CSF1R	qRT-PCR	assay	
detected	gene	expression	by	single	CD115+	leukocytes,	which	was	clearly	distinguished	from	
background	(no-template	controls;	green	curves).	On	the	other	hand,	the	(B)	CSF3R	qRT-PCR	
did	 not	 efficiently	 amplify	 Csf1r	 transcripts	 when	 analysing	 single	 Ly6G+	 neutrophils.	 The	
logarithmic	 phase	 of	 the	 Csf3r	 amplification	 curves	 begin	 to	 diminish	 as	 cell	 number	
decreases.	Each	red	curve	represents	amplification	of	the	given	gene	from	1,	8	or	64	cell(s).	
Green	amplification	curves	represent	background	fluorescence	seen	in	control	reactions	with	
no	template.	Fluorescence	is	plotted	on	a	log	scale.	CSF1R,	macrophage-colony	stimulating	
factor	receptor;	CSF3R,	granulocyte-colony	stimulating	factor	receptor.	
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Figure	3.12.	Validation	of	FLT3,	EPOR	and	CSF1R	qRT-PCR	assays	in	duplex	with	ACTB	using	
single	cells.	(A)	Amplification	of	Actb	and	Flt3	in	varying	numbers	of	LMPPs	using	singleplex	
and	duplex	reactions.	(B)	Amplification	of	the	Actb	and	Epor	genes	in	varying	numbers	of	EPs	
using	singleplex	and	duplex	reactions.	(C)	Amplification	of	Actb	and	Csf1r	in	varying	numbers	
of	CD115+	leukocytes	using	singleplex	and	duplex	reactions.	Each	data	point	represents	mean	
±	standard	error	from	at	least	3	samples.	SP,	singleplex;	DP,	duplex;	LMPP,	lymphoid-primed	
multipotent	 progenitor;	 EP,	 erythroid	 progenitor;	 Ct,	 threshold	 cycle;	ACTB,	 β-actin;	FLT3,	
fms-like	 tyrosine	 kinase	 3;	 EPOR,	 erythropoietin	 receptor;	 CSF1R,	 macrophage-colony	
stimulating	factor	receptor.	
	
As	 mentioned	 previously,	 in	 order	 to	 accurately	 determine	 the	 percentage	 of	 cells	 that	
express	a	HGF	receptor	within	a	cell	population,	the	FLT3,	EPOR	and	CSF1R	qRT-PCR	assays	
needed	to	be	combined	with	ACTB	which	was	used	to	confirm	the	presence	of	a	cell	within	
each	well	of	a	PCR	plate	during	analysis.	To	ensure	that	no	efficiency	was	lost	when	combining	
assays,	the	sensitivity	of	the	duplex	assays	was	tested	using	varying	numbers	of	single	cells	as	
before.	The	single-cell	sensitivity	of	the	ACTB	+	FLT3,	ACTB	+	EPOR	and	ACTB	+	CSF1R	duplex	
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qRT-PCR	reactions	was	tested	by	analysing	1,	2,	4,	8,	16,	32	and	64	LMPP(s),	EP(s)	and	CD115+	
leukocyte(s),	respectively.	Singleplex	reactions	of	each	assay	were	carried	out	in	parallel	to	
determine	if	there	was	any	loss	efficiency	when	assays	were	combined.	When	compared	to	
the	 singleplex	 reactions,	 it	 was	 clear	 that	 the	 FLT3,	 EPOR	 and	 CSF1R	 qRT-PCR	 assays	
maintained	efficiency	and	Ct	values	when	performed	in	duplex	with	ACTB	(Figure	3.12).	
	
Of	particular	interest	was	the	possible	co-expression	of	HGF	receptor	genes	during	the	early	
stages	of	haematopoiesis.	Hence,	some	qRT-PCR	assays	were	combined	in	triplex	reactions	
and	 efficiencies	were	 tested	 as	 before.	One	 reaction	 combined	 the	ACTB,	FLT3	and	EPOR	
assays	(ACTB	+	FLT3	+	EPOR	triplex	qRT-PCR	assay),	and	a	second	combined	the	ACTB	+	EPOR	
+	 CSF1R	 assays	 (ACTB	 +	EPOR	+	CSF1R	 triplex	 qRT-PCR	 assay).	 As	 there	 are	 not	 any	well-
defined	cells	that	constitutively	express	both	FLT3	and	EPOR,	the	ACTB	+	FLT3	+	EPOR	triplex	
qRT-PCR	assay	was	tested	by	sorting	both	LMPPs	and	EPs	into	the	same	wells	of	a	PCR	plate.	
Similarly,	there	are	no	well-defined	cells	that	constitutively	express	EPOR	and	CSF1R,	so	the	
ACTB	 +	 EPOR	 +	CSF1R	 triplex	 qRT-PCR	 assay	was	 tested	 by	 sorting	 both	 EPs	 and	 CD115+	
leukocytes	into	the	same	wells	of	a	PCR	plate.		
	
Unfortunately,	while	 the	Ct	values	 for	 the	ACTB	+	FLT3	+	EPOR	and	ACTB	+	EPOR	+	CSF1R	
triplex	 reactions	were	 comparable	 to	 singleplex	 reactions	 (Figure	 3.13),	 the	 amplification	
curves	of	the	assays	in	triplex	showed	a	loss	in	efficiency	of	at	least	one	of	the	assays	(Figure	
3.14	and	Figure	3.15).	As	this	may	cause	issues	when	assaying	cells	with	a	very	low	level	of	
gene	expression,	all	HSPCs	were	 first	assayed	 for	HGF	gene	expression	of	FLT3,	EPOR	 and	
CSF1R	 by	 performing	 qRT-PCR	 duplex	 assays	 in	 combination	 with	 the	 ACTB	 assay.	 Any	
potential	signs	of	gene	co-expression	in	early	HSPCs	were	investigated	at	a	later	stage.	
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Figure	3.13.	Validation	of	triplex	qRT-PCR	assays	using	single	cells.	(A)	Detection	of	ACTB,	
FLT3	and	EPOR	expression	in	varying	numbers	of	LMPPs	and	EPs	using	singleplex	and	triplex	
reactions.	Cell	number	values	for	FLT3	and	EPOR	assays	are	representative	of	the	number	of	
LMPPs	or	EPs	that	are	present	in	the	sample,	respectively.	Cell	number	values	for	the	ACTB	
assay	are	representative	of	the	combined	number	of	LMPPs	and	EPs	that	are	present	in	the	
sample.	 (B)	Detection	of	ACTB,	CSF1R	and	EPOR	expression	 in	varying	numbers	of	CD115+	
leukocytes	and	EPs	using	singleplex	and	triplex	reactions.	Cell	number	values	for	CSF1R	and	
EPOR	assays	are	representative	of	the	number	of	CD115+	leukocytes	or	EPs	that	are	present	
in	the	sample,	respectively.	Cell	number	values	for	the	ACTB	assay	are	representative	of	the	
combined	number	of	CD115+	leukocytes	and	EPs	that	are	present	in	the	sample.	Each	data	
point	 represents	mean	±	 standard	error	 from	at	 least	 3	 samples.	 LMPP,	 lymphoid	primed	
multipotent	 progenitor;	 EP,	 erythroid	 progenitor;	 SP,	 singleplex;	 TP,	 triplex;	 Ct,	 threshold	
cycle;	ACTB,	β-actin;	FLT3,	fms-like	tyrosine	kinase	3;	EPOR,	erythropoietin	receptor;	CSF1R,	
macrophage-colony	stimulating	factor	receptor.	
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Figure	 3.14.	 Amplification	 of	 Actb,	 Flt3	 and	 Epor	 in	 single	 cells	 using	 triplex	 qRT-PCR	
reactions.	Comparison	of	amplification	of	Actb,	Flt3	and	Epor	in	varying	numbers	of	cells	using	
singleplex	reactions	to	triplex	reactions.	The	amplification	of	Flt3	was	not	efficient	in	triplex	
reactions,	as	revealed	by	the	diminishing	amplification	curves.	Lymphoid-primed	multipotent	
progenitors	and	erythroid	progenitors	were	sorted	to	test	the	efficiency	of	the	ACTB,	FLT3	
and	EPOR	qRT-PCR	assays.		Fluorescence	is	plotted	on	a	log	scale.	ACTB,	β-actin;	FLT3,	fms-
like	tyrosine	kinase	3;	EPOR,	erythropoietin	receptor.	
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Figure	 3.15.	 Amplification	 of	 Actb,	 Epor	 and	 Csf1r	 in	 single	 cells	 using	 triplex	 qRT-PCR	
reactions.	Comparison	of	amplification	of	Actb,	Epor	and	Csf1r	 in	varying	numbers	of	cells	
using	 singleplex	 reactions	 to	 triplex	 reactions.	 The	 EPOR	 and	 CSF1R	 qRT-PCR	 assays	 lost	
efficiency	 when	 in	 triplex	 reactions,	 as	 depicted	 by	 the	 diminishing	 amplification	 curves.	
CD115+	leukocytes	and	erythroid	progenitors	were	used	to	test	the	efficiency	of	the	ACTB,	
EPOR	and	CSF1R	qRT-PCR	assays.	Fluorescence	is	plotted	on	a	log	scale.	ACTB,	β-actin;	EPOR,	
erythropoietin	receptor;	CSF1R,	macrophage-colony	stimulating	factor	receptor.	
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3.5			Expression	 of	 growth	 factor	 receptor	 transcripts	
during	haematopoiesis	
	
3.5.1			Expression	 of	 Flt3,	 Epor	 and	 Csf1r	 transcripts	 by	
haematopoietic	stem	and	progenitor	cells	
	
Having	successfully	designed	and	optimised	the	qRT-PCR	assays,	it	was	possible	to	investigate	
the	 expression	 of	 FLT3,	 EPOR	 and	 CSF1R	 genes	 within	 HSPC	 populations.	 For	 single	 cell	
analysis,	cells	from	3-6	mice	were	analysed	and	approximately	20-40	cells	were	obtained	from	
each	mouse.	As	such,	all	data	from	this	section	are	represented	in	two	ways;	i)	percentages	
as	 mean	 ±	 standard	 error	 of	 the	 values	 obtained	 from	 3-6	mice,	 and;	 ii)	 percentages	 as	
calculated	from	the	total	number	of	cells	that	were	assayed.	Any	wells	that	did	not	produce	
amplification	of	Actb	were	excluded	from	the	analysis	as	they	were	considered	to	be	empty.	
The	number	of	single	cells	sorted	into	wells	of	a	PCR	plate	according	to	the	sorting	software,	
and	the	number	of	these	wells	that	produced	successful	amplification	of	Actb,	is	listed	in	Table	
10.	For	all	populations	and	assays,	sorting	efficiency	never	dropped	below	90%.	Throughout	
the	analysis	of	HGF	receptor	gene	expression,	single	cells	expressing	these	receptors	could	
clearly	be	distinguished	from	those	that	did	not,	as	can	be	seen	in	Figure	3.16.	In	total,	more	
than	3,000	single	cells	were	assayed	for	gene	expression	analysis.		
	
Firstly,	 to	 investigate	 the	 expression	 of	 HGF	 receptors	 in	 the	 early,	 multipotent	 HSPC	
compartments,	the	number	of	cells	expressing	FLT3,	EPOR	and	CSF1R	genes	by	within	the	LT-
HSC,	ST-HSC	and	MPP	compartments	was	investigated	(Figure	3.17A).	Analysis	revealed	FLT3	
expression	within	a	small	subpopulation	of	LT-HSCs	(n=6	mice)	and	ST-HSCs	(n=6	mice).	Of	the	
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LT-HSCs	 that	 were	 analysed,	 11.6%	 ±	 2.19	 (28/248	 cells;	 11.3%	 of	 total)	 expressed	 Flt3	
transcripts,	and	21%	±	3.4	of	cells	in	the	ST-HSC	compartment	(56/252	cells;	22.2%	of	total)	
also	expressed	this	gene.	There	was	a	significant	increase	in	the	number	of	FLT3	expressing	
cells	 in	 the	 ST-HSC	 population	when	 compared	 to	 the	 LT-HSC	 population	 [p=0.0476].	 The	
number	of	cells	within	the	MPP	(n=6	mice)	compartment	expressing	FLT3	(64%	±	2.2	of	cells;	
190/297	 cells	 [64%	of	 total])	was	 greatly	 increased	when	 compared	 to	 ST-HSC	 [p=0.0022]	
(Figure	3.17A).	
	
	
	
Figure	3.16.	Analysis	of	FLT3	expression	by	single	LT-HSCs.	A	representative	amplification	
curve	showing	positive	(red)	and	negative	(green)	detection	of	FLT3	expression	by	LT-HSCs.	
Flt3+	and	Flt3−	cells	are	clearly	distinguished	from	each	other.	FLT3,	fms-like	tyrosine	kinase	
3;	LT-HSC,	long-term	haematopoietic	stem	cell.	
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A	small	number	of	cells	expressing	EPOR	within	the	LT-HSC	(n=6	mice)	and	ST-HSC	(n=6	mice)	
compartments	were	detected,	and	 these	values	 reflect	previous	 findings	 [115,	320].	EPOR	
was	expressed	by	12.8%	±	1.46	 (31/245	 cells;	 12.7%	of	 total)	 of	 LT-HSCs	and	19.3%	±	4.6	
(42/237	cells;	17.7%	of	total)	of	ST-HSCs,	and	these	values	were	not	significantly	different	[p=	
0.2188].	 Of	 the	MPPs	 (n=6	mice)	 analysed,	 only	 8.2%	 ±	 4.6	 (25/300	 cells;	 8.3%	 of	 total)	
expressed	EPOR.	While	 this	was	 lower	 than	 the	number	 of	 ST-HSCs	 expressing	EPOR,	 the	
difference	was	not	significant	[p=0.0628]	(Figure	3.17B).		
	
CSF1R	 expression	 was	 rarely	 detected	 within	 these	 populations.	 Csf1r	 transcripts	 were	
detected	in	0.9%	±	0.9	(1/122	cells;	0.8%	of	total)	of	LT-HSCs	(n=3	mice),	2.14%	±	1.3	(2/118	
cells;	1.7%	of	total)	of	ST-HSCs	(n=3	mice),	and	4.8%	±	3.8	(7/145	cells;	4.8%	of	total)	of	MPPs	
(n=3)	(Figure	3.17C).	Given	the	few	HSCs	that	expressed	CSF1R,	it	is	possible	that	these	Csf1r+	
cells	were	due	 to	 impurities	during	 sorting.	However,	 as	M-CSF	 is	 known	 to	 instruct	HSCs	
towards	myeloid	fates	by	stimulating	its	receptor,	CSF1R	expression	would	be	expected	in	this	
compartment	[267].	The	qRT-PCR	assay	used	here	may	not	have	been	sensitive	enough	to	
detect	CSF1R	 expression	 in	 single	HSCs.	Mossadegh-Keller	et	al.	have	also	 failed	 to	detect	
CSF1R	expression	in	single	LT-HSCs	(LSK	CD150+	CD48−	CD34−)	[267].	In	this	regard,	the	CSF1R	
gene	may	not	need	to	be	continuously	transcribed	to	maintain	expression	of	M-CSFR	on	the	
surface	of	HSCs,	and	so	CSF1R	expression	may	only	occur	very	rarely.	
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Table	10:	Percentage	of	wells	assayed	that	produced	successful	amplification	of	Actb	for	each	HSPC	population	
	 FLT3	qRT-PCR	assay	 EPOR	qRT-PCR	assay	 CSF1R	qRT-PCR	assay	
	 Total	number	of	
wells	assayed	
Actb+	 %	Actb+	 Total	number	of	
wells	assayed	
Actb+	 %	Actb+	 Total	number	of	
wells	assayed	
Actb+	 %	Actb+	
LT-HSC	 248	 248	 100	 258	 245	 94.96	 122	 122	 100	
ST-HSC	 269	 252	 93.68	 266	 237	 89.10	 122	 118	 96.72	
MPP	 305	 297	 97.38	 306	 300	 98.04	 151	 145	 96.03	
HPC1	 101	 101	 100	 104	 100	 96.15	 101	 101	 97.12	
HPC2	 58	 56	 96.55	 59	 58	 98.31	 57	 56	 98.25	
LMPP	 99	 97	 97.98	 99	 99	 100	 99	 97	 97.98	
CLP	 95	 94	 98.95	 97	 94	 96.91	 91	 90	 98.90	
CMP	 86	 81	 94.19	 87	 79	 90.80	 88	 81	 92.05	
GMP	 102	 98	 96.08	 102	 96	 94.12	 104	 99	 95.19	
MEP	 102	 92	 90.20	 102	 98	 96.08	 102	 96	 94.12	
LT-HSC,	long-term	haematopoietic	stem	cell;	ST-HSC	short-term	haematopoietic	stem	cell;	MPP,	multipotent	progenitor;	HSPC,	haematopoietic	
stem	 and	 progenitor	 cell	 LMPP,	 lymphoid-primed	 multipotent	 progenitor;	 CLP,	 common	 lymphoid	 progenitor;	 CMP,	 common	 myeloid	
progenitor;	GMP,	granulocyte-macrophage	progenitor;	MEP,	megakaryocyte-erythroid	progenitor;	ACTB,	β-actin;	FLT3,	fms-like	tyrosine	kinase	
3;	EPOR,	erythropoietin	receptor;	CSF1R,	macrophage-colony	stimulating	factor	receptor.
	
	
137	
Next,	 the	 expression	 of	 FLT3,	 EPOR	 and	 CSF1R	 by	 more	 mature	 BM	 progenitors	 was	
investigated,	 and	 the	 analysis	 revealed	 a	 clear	 association	 between	 the	 presence	 of	 HGF	
receptor	 transcripts	 and	 the	 lineage	potential	 of	 the	populations.	A	 large	number	of	 cells	
within	 the	 LMPP	 (n=3	 mice)	 (92.8%	 ±	 2.04;	 90/97	 cells	 [92.8%	 of	 total])	 compartment	
expressed	FLT3,	and	this	was	significantly	more	than	the	number	of	Flt3+	cells	present	in	the	
MPP	compartment	[p=0.0119].	This	was	to	be	expected	given	the	high	levels	of	Flt3	receptor	
within	this	compartment	[73].	Of	the	94	CLPs	(n=3	mice)	analysed,	a	66.2%	±	3.8	(62/94	cells;	
66%	 of	 total)	 expressed	 FLT3.	 Again,	 given	 that	 CLPs	 are	 regulated	 by	 Flt3L	 this	 was	 not	
surprising	[321].	When	Flt3−/lo	HPC-1	(n=3	mice)	were	analysed,	57.2%	±	14.1	(57/101	cells;	
56.4%	of	total)	of	cells	expressed	FLT3.	The	number	of	cells	that	expressed	FLT3	significantly	
decreased	 as	 MPPs	 committed	 to	 the	 myeloid	 lineage	 and	 differentiated	 into	 CMPs	
[p=0.0119].	Of	the	CMPs	(n=3	mice)	and	GMPs	(n=3	mice)	assayed,	24.9%	±	5.4	(21/81	cells;	
25.9%	of	total),	and	21.4%	±	2.8	(21/98	cells;	21.4%	of	total)	expressed	detectable	levels	of	
FLT3,	respectively.	The	number	of	GMPs	that	expressed	FLT3	was	similar	to	reported	findings,	
as	Böiers	et	al.	previously	showed	that	FLT3	expression	was	detectable	in	22%	±	9	GMPs	[322].	
Furthermore,	 9.9%	±	 5.95	 of	HPC-2	 (n=3	mice)	 (8/56	 cells;	 14.3%	of	 total)	were	 found	 to	
express	FLT3.	Finally,	FLT3	expression	was	only	detected	in	1	of	98	MEPs	(n=3	mice)	(1%	±	1;	
1/98	cells	[1%	of	total]).	Mouse	MegE	progenitors	have	been	reported	to	lack	Flt3	expression	
[323],	and	mouse	MEPs	have	been	shown	to	lack	Flt3	transcriptional	activity	[312].	Given	that	
purity	rarely	reaches	100%	when	sorting,	the	Flt3+	cell	purified	with	the	single	MEPs	was	likely	
due	to	contamination	(Figure	3.17A).	When	compared,	the	LT-HSC	compartment	contained	
significantly	more	Flt3+	cells	than	the	MEP	compartment	[p=0.0238],	indicating	that	the	FLT3	
expression	 observed	 in	 the	 LT-HSC	 population	 was	 not	 an	 artefact	 of	 analysis	 or	 due	 to	
impurities.	
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Figure	3.17.	Expression	of	Flt3,	Epor	and	Csf1r	transcripts	by	HSPCs.	The	percentage	of	cells	
within	each	HSPC	population	that	express	(A)	Flt3,	(B)	Epor	and	(C)	Csf1r	mRNA	when	analysed	
at	the	single	cell	level	are	shown.	Each	individual	point	represents	a	single	mouse.	Assays	were	
carried	out	in	duplex	with	a	qRT-PCR	assay	specific	for	Actb	transcripts,	and	reactions	that	did	
not	give	rise	to	detectable	amplification	of	Actb	were	removed	from	analysis	as	this	indicated	
an	 empty	 well.	 Data	 are	 the	mean	 of	 the	 values	 obtained	 for	 single	 cells	 from	 3-6	mice	
(approximately	20-40	cells/mouse).	p	values	obtained	by	two-tailed	non-parametric	student’s	
t-test	where;	*,	p	<	0.05;	**,	p	<	0.01.	LT-HSC,	long-term	haematopoietic	stem	cell;	ST-HSC	
short-term	haematopoietic	 stem	cell;	MPP,	multipotent	progenitor;	HSPC,	haematopoietic	
stem	 and	 progenitor	 cell;	 HPC,	 haematopoietic	 progenitor	 cell;	 LMPP,	 lymphoid-primed	
multipotent	 progenitor;	 CLP,	 common	 lymphoid	 progenitor;	 CMP,	 common	 myeloid	
progenitor;	 GMP,	 granulocyte-macrophage	 progenitor;	 MEP,	 megakaryocyte-erythroid	
progenitor;	Actb,	β-actin;	Epor,	erythropoietin	receptor;	Flt3,	fms-like	tyrosine	kinase	3;	Csf1r,	
macrophage-colony	stimulating	factor	receptor;	n.s.,	not	significant.	
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EPOR	expression	was	more	restricted	in	regard	to	different	HSPC	populations	when	compared	
to	the	expression	of	FLT3.	Almost	all	of	the	MEPs	(n=3	mice)	that	were	analysed	expressed	
EPOR	(97.9%	±	2.1;	96/98	cells	[98%	of	total]).	This	was	similar	to	the	findings	of	Miyamoto	et	
al.,	as	these	authors	reported	that	>90%	of	single	MEPs	express	EPOR	[116].	EPOR	was	also	
expressed	by	43%	±	2.8	of	CMP	(n=3)	(34/79	cells	[43%	of	total]),	and	this	was	significantly	
more	than	the	number	of	Epor+	MPPs	[p=0.0238].	Again,	the	number	of	CMPs	that	were	found	
to	express	EPOR	was	 similar	 to	 the	number	 reported	by	Miyamoto	and	 co-workers	 [116].	
Notably,	the	proportion	of	cells	expressing	EPOR	within	the	HPC-2	(n=3)	compartment	was	
quite	variable	between	mice,	as	49.6%	±	18.4	of	HPC-2	(20/58	cells	[34.5%	of	total])	expressed	
detectable	levels	of	the	gene	(Figure	3.17B).	Epor	mRNA	was	only	detected	in	1	of	100	Flt3−/lo	
HPC-1	(n=3)	(0.98%	±	1;	1/100	cells	[1%	of	total])	and	1	of	96	GMP	(n=3)	(1%	±	1;	1/96	cells	
[1%	of	 total])	 (Figure	3.17B).	While	 the	expression	of	EPOR	by	Flt3−/lo	HPC-1	has	not	been	
previously	investigated,	these	LSK	CD150−	CD48+	cells	possess	little	erythroid	potential	[34].	
Similarly,	single	GMPs	have	been	shown	to	lack	EPOR	expression	[116].	These	data	suggest	
that	the	single	Flt3−/lo	HPC-1	and	GMP	that	expressed	EPOR	were	due	to	contamination	during	
sorting.	Finally,	EPOR	expression	was	not	detected	in	any	LMPPs	(0/99	cells)	or	CLPs	(0/94).	
This	was	to	be	expected,	as	LMPPs	have	been	shown	to	lack	EPOR	expression	[73],	and	CLPs	
lack	erythroid	potential	and	do	not	respond	to	Epo	in	vitro	[66].		
	
Csf1r	transcripts	were	most	commonly	detected	 in	GMPs	(n=3),	as	92%	±	3.2	 (91/99	cells;	
91.9%	of	total)	of	these	cells	expressed	the	gene	(Figure	3.17C).	Approximately	one	third	of	
LMPPs	(n=3	mice)	(32.6%	±	12.7;	32/97	cells	[33%	of	total]),	and	28.3%	±	8.4	of	CMPs	(n=3)	
(24/81	cells;	29.6%	of	total)	also	expressed	CSF1R.	When	compared	to	the	MPP	population,	
the	 number	 of	 cells	 expressing	 Csf1r+	 cells	 in	 the	 LMPP	 [p=0.1]	 and	 CMP	 [p=0.1]	
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compartments	were	not	significantly	different.	Csf1r	transcripts	were	also	detected	in	14.8%	
±	11.7	of	CLPs	(n=3	mice)	(13/90	cells;	14.4%	of	total).	A	small	percentage	of	cells	within	the	
Flt3−/lo	HPC-1	(n=3	mice)	compartment	(9.9%	±	0.9;	10/101	cells	[9.9%	of	total])	expressed	
CSF1R,	and	this	proportion	fell	even	lower	when	analysing	HPC-2	(n=3	mice)	(3.8%	±	3.8;	4/56	
cells	 [7.14%	of	 total]).	CSF1R	 expression	was	not	detected	 in	 any	of	 the	MEPs	 (n=3	mice)	
analysed	 (0/96	 cells)	 (Figure	 3.17C),	 which	 is	 as	 expected	 considering	 the	 low	 level	 of	
myelomonocytic-associated	genes	expressed	by	this	population	[314].		
	
Levels	of	HGF	gene	expression	were	variable	across	and	within	HSPC	populations	at	the	single	
cell	level	(Figure	3.18).	When	FLT3	expression	was	compared	across	the	HSPC	compartments	
there	were	slight	differences	in	the	mean	expression	levels	of	this	gene	(Figure	3.18A).	Flt3+	
LMPPs	(Mean	Ct:	34.32)	expressed	the	highest	mean	levels	of	FLT3	when	compared	to	the	
other	populations,	and	this	level	was	significantly	increased	when	compared	to	the	Flt3+	MPPs	
population	(Mean	Ct:	34.76)	[p=0.0066].	As	LMPPs	are	identified	due	to	their	high	levels	of	
Flt3	at	the	surface,	this	was	not	surprising.	Interestingly,	despite	the	large	difference	between	
the	 number	 of	 cells	 expressing	 FLT3	 in	 the	 LMPP	 (92.8%	 ±	 2.04)	 and	 CMP	 (21.4%	 ±	 2.8)	
populations,	the	mean	levels	of	FLT3	expressed	by	these	cells	were	not	statistically	different	
[p=0.1071]	(Figure	3.18A).	However,	there	was	a	decrease	in	mean	expression	of	FLT3	in	the	
more	mature	Flt3+	GMP	(Mean	Ct:	35.4)	population	when	compared	to	Flt3+	CMPs	(Mean	Ct:	
34.74)	[p=0.0299].	Furthermore,	the	Flt3+	HPC-2	population	expressed	the	lowest	mean	level	
of	FLT3,	and	the	mean	 level	was	significantly	decreased	when	compared	to	 the	Flt3+	MPP	
population	 (Mean	 Ct:	 36.24)	 [p=0.0039].	 As	 the	 HPC-2	 population	 largely	 contains	 MegE	
primed	progenitors	 [34],	 this	was	expected	 (Figure	3.18A).	 Lastly,	 the	mean	expression	of	
FLT3	 in	 the	Flt3+	MPP	 (Mean	Ct:	34.76)	compartment	was	not	significantly	different	when	
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compared	to	the	Flt3+	ST-HSCs	(Mean	Ct:	35.5)	[p=0.0547].	There	was	further	variability	when	
comparing	FLT3	expression	within	HSPC	populations.	The	expression	of	FLT3	by	single	cells	in	
the	Flt3+	MPP,	Flt3+	LMPP,	Flt3+	CLP	and	Flt3+	HPC-1	populations	differed	by	as	much	as	6	
doublings,	or	64-fold	(Ct	32-38)	(Figure	3.18A).	Within	other	populations	(Flt3+	LT-HSC,	Flt3+	
ST-HSC,	Flt3+	HPC-2,	Flt3+	CMP	and	Flt3+	GMP),	expression	of	FLT3	by	individual	cells	differed	
by	up	to	4	doublings,	or	16-fold.		
	
Mean	levels	of	EPOR	expression	were	comparable	between	the	Epor+	LT-HSCs	(Mean	Ct:	34.3)	
and	 Epor+	 ST-HSCs	 [p=0.3161].	 Additionally,	 while	 Epor+	MPPs	 (Mean	 Ct:	 33.1)	 expressed	
higher	mean	 levels	 of	EPOR	 that	Epor+	 ST-HSCs	 (Mean	Ct:	 34.38),	 this	was	 not	 significant	
[p=0.2564]	(Figure	3.18B).	There	was	also	no	significant	change	 in	the	mean	expression	of	
EPOR	when	comparing	the	Epor+	MPP	and	CMP	(Mean	Ct:	34.07)	[p=0.3689].	However,	there	
was	a	very	significant	 increase	 in	mean	Epor	mRNA	levels	when	comparing	the	Epor+	MEP	
population	 (Mean	Ct:	31.4)	 to	 the	Epor+	CMP	population	 [p<0.0001].	 Interestingly,	a	 large	
variation	of	EPOR	gene	expression	was	observed	amongst	single	MPPs.	Some	cells	expressed	
EPOR	at	 levels	differing	by	up	to	10.82	doublings,	or	1,807-fold	(Figure	3.18B).	MPPs	have	
been	divided	into	subpopulations	based	on	their	expression	of	VCAM	and	Flt3,	and	this	has	
revealed	 the	 varying	 levels	 of	 erythroid	 potential	 possessed	 by	 cells	 within	 the	 MPP	
population	 [324].	Additionally,	analysis	of	PU.1	and	GATA-1	expression	 in	MPPs	using	GFP	
transgenic	mice	allows	for	the	purification	of	PU.1+	and	GATA-1+	LSK	CD34+	that	are	lymphoid-	
and	MegE-primed,	 respectively	 [325].	 Thus,	 it	 is	 possible	 that	 the	 large	 variation	 in	EPOR	
expression	 reflects	 the	 heterogeneous	 nature	 of	 the	 erythroid	 potential	 of	 the	 MPP	
compartment.	Finally,	the	expression	of	EPOR	within	the	Epor+	LT-HSC,	ST-HSC,	HPC-2,	CMP	
and	MEP	populations	was	less	variable	when	compared	to	the	Epor+	MPP	population,	and	the	
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levels	at	which	these	single	cells	expressed	EPOR	differed	by	up	to	6	doublings	(64-fold).		
	
	
Figure	3.18.	Levels	of	FLT3,	EPOR	and	CSF1R	expression	within	HSPC	populations.	Expression	
of	(A)	Flt3,	(B)	Epor	and	(C)	Csf1r	mRNAs	as	detected	within	single	cells.	The	expression	levels	
of	 target	mRNAs	are	depicted	as	 the	 threshold	 cycle	 (Ct)	 value	 and	each	 individual	 cell	 is	
represented	by	a	single	data	point.	Assays	were	carried	out	in	duplex	with	a	qRT-PCR	assay	
specific	for	Actb	transcripts,	and	reactions	that	did	not	give	rise	to	detectable	amplification	of	
Actb	were	removed	from	analysis	as	this	indicated	an	empty	well.	Single	cells	that	gave	rise	
to	a	detectable	amplification	of	Actb,	but	not	target	mRNAs,	are	plotted	below	the	dotted	
lines.	Mean	values	were	calculated	from	all	cells	that	had	successful	amplification	of	the	target	
mRNA.	p	values	obtained	by	two-tailed	non-parametric	student’s	t-test	where;	*,	p	<	0.05;	**,	
p	<	0.01;	***,	p	<	0.001;	****,	p	<	0.0001.	LT-HSC,	long-term	haematopoietic	stem	cell;	ST-
HSC	 short-term	 haematopoietic	 stem	 cell;	 MPP,	 multipotent	 progenitor;	 HSPC,	
haematopoietic	 stem	 and	 progenitor	 cell;	 HPC,	 haematopoietic	 progenitor	 cell;	 LMPP,	
lymphoid-primed	multipotent	progenitor;	CLP,	common	lymphoid	progenitor;	CMP,	common	
myeloid	 progenitor;	 GMP,	 granulocyte-macrophage	 progenitor;	 MEP,	 megakaryocyte-
erythroid	 progenitor;	 Actb,	 β-actin;	 Epor,	 erythropoietin	 receptor;	 Flt3,	 fms-like	 tyrosine	
kinase	3;	Csf1r,	macrophage-colony	stimulating	factor	receptor;	n.s.,	not	significant.	
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Mean	expression	levels	of	CSF1R	gradually	increased	as	progenitors	committed	to	a	GM	fate	
(Figure	3.18C).	The	mean	level	at	which	single	Csf1r+	MPPs	(Mean	Ct:	35.88)	expressed	CSF1R	
was	 lower	 than	 the	 level	 expressed	 by	 Csf1r+	 LMPPs	 (Mean	 Ct:	 35.17),	 but	 this	 was	 not	
significant	 [p=0.0804].	However,	when	compared	 to	 the	Csf1r+	CMP	population	 (Mean	Ct:	
33.91),	 Csf1r+	 MPPs	 expressed	 significantly	 lower	 mean	 levels	 of	 CSF1R	 [p=0.0055].	
Furthermore,	the	mean	levels	of	CSF1R	expressed	by	Csf1r+	GMPs	(Mean	Ct:	31.9)	was	very	
significant	 when	 compared	 to	 the	 levels	 expressed	 by	 the	 Csf1r+	 CMP	 compartment	
[p<0.0001].	 The	 Csf1r+	 Flt3−/lo	 HPC-1	 (Mean	 Ct:	 36.1)	 and	 Csf1r+	 CLP	 (Mean	 Ct:	 35.92)	
populations	expressed	the	lowest	mean	levels	of	CSF1R.	Considering	that	the	CLP	and	HPC-1	
populations	are	 largely	 lymphoid-primed	progenitors,	 this	was	not	surprising.	Single	Csf1r+	
MPPs	and	Flt3−/lo	HPC-1	expressed	levels	of	CSF1R	that	differed	by	up	to	3	doublings,	or	8-
fold.	 As	 cells	 differentiated	 towards	 CMPs	 and	 GMPs,	 expression	 of	CSF1R	 became	more	
variable.	Single	cells	within	the	Csf1r+	CMP	and	Csf1r+	GMP	compartments	expressed	CSF1R	
at	levels	differing	by	up	to	5.3	or	4.4	doublings	(39.4-	or	21-fold),	respectively	(Figure	3.18C).		
	
3.5.2			Analysis	 of	 FLT3	 and	 EPOR	 co-expression	 within	 the	
haematopoietic	 stem	 cell	 and	 multipotent	 progenitor	
compartments	
	
Single	cells	within	the	LT-HSC,	ST-HSC	and	MPP	compartments	expressed	detectable	levels	of	
FLT3	and	EPOR	(Section	3.5.1).	If	Flt3L	and	Epo	instruct	cells	within	LT-HSC,	ST-HSC	and	MPP	
HSPC	populations,	it	is	important	to	investigate	whether	co-expression	of	the	FLT3	and	EPOR	
genes	occurs	at	 this	 level.	This	would	help	 to	determine	whether	 these	 factors	act	on	 the	
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same	populations	of	cells,	or	if	there	are	distinct	populations	that	are	primed	to	respond	to	
either	Flt3L	or	Epo.	To	investigate	the	possible	co-expression	of	these	genes	by	single	LT-HSCs,	
ST-HSCs	and	MPPs,	a	triplex	qRT-PCR	assay	was	designed	to	detect	EPOR	and	FLT3	expression.	
Unfortunately,	 as	 described	 in	 Section	 3.4.3,	 the	 efficiency	 of	 the	 FLT3	 qRT-PCR	 assay	
decreased	when	 it	was	 combined	 in	 a	multiplex	 reaction	with	 the	ACTB	and	EPOR	 assays	
(Figure	3.14).	 Thus,	a	new	EPOR	qRT-PCR	assay,	 termed	EPOR-2,	was	designed.	This	 time,	
when	designing	the	assay,	an	attempt	was	made	to	try	and	minimalise	the	complementarity	
between	the	EPOR-2	qRT-PCR	assay	and	the	FLT3	and	ACTB	qRT-PCR	assays	by	comparing	
primer,	probe	and	target	sequences.	The	alignment	of	the	EPOR-2	primers	and	probe	can	be	
seen	 in	 Figure	3.19.	Details	of	 the	EPOR-2	qRT-PCR	assay,	 including	primer	and	hydrolysis	
probe	sequences,	are	shown	in	Table	11.	
	
	
Figure	3.19.	Sequence	alignment	of	EPOR-2	qRT-PCR	assay	within	a	region	of	the	EPOR	gene.	
The	 forward	 primer,	 reverse	 primer	 and	 probe	 sequences	 are	 shown	 highlighted	 in	 blue,	
green	and	pink,	respectively.	The	red	box	highlights	an	exon	junction.	EPOR,	erythropoietin	
receptor.	
	
As	 before,	 the	 EPOR-2	 qRT-PCR	 assay	 was	 tested	 and	 optimised	 to	 ensure	 efficient	
amplification	of	gene	targets.	Analysis	showed	that	it	was	specific	for	Epor	mRNA,	and	did	not	
detect	gDNA	(Figure	3.20A).	The	assay	conditions	were	optimised	as	before,	and	the	optimum	
forward	 primer,	 reverse	 primer	 and	 hydrolysis	 probe	 concentrations	 were	 found	 to	 be	
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100nM,	200nM	and	50nM,	respectively	(Figure	3.20B-D).	When	tested	using	single	EPs,	the	
assay	efficiently	detected	single-cell	EPOR	expression	(Figure	3.20E).	
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Figure	3.20.	Optimisation	of	EPOR-2	qRT-PCR	assay	for	detection	of	single	cell	gene	expression.	(A)	The	EPOR-2	assay	was	tested	with	(+)	and	
without	(-)	RT	to	ensure	that	the	assay	amplified	mRNA	(red	curves)	but	not	gDNA	(green	curves).	(B,	C)	Limiting	primer	concentrations	were	
determined	by	testing	multiple	primer	concentration	combinations.	(B)	Any	sample	with	a	Ct	value	of	>0.5	cycles	greater	than	the	Ct	value	of	
the	reference	reaction	(300nM	forward	primer/300nM	reverse	primer)	was	disregarded	due	to	a	loss	of	efficiency	(below	the	transparent	grey	
pane).	(C)	Of	the	remaining	samples,	the	primer	combination	with	the	lowest	peak	fluorescence	value	was	selected	as	the	limiting	reaction.	(D)	
Multiple	probe	concentrations	were	tested,	and	of	the	reactions	with	a	Ct	value	that	was	not	>0.5	cycles	greater	than	the	Ct	value	of	the	reference	
reaction	(250nM	hydrolysis	probe),	the	lowest	probe	concentration	was	selected	as	the	optimum	(below	the	dotted	line).	(E)	When	tested	using	
single	cells,	the	assay	clearly	amplified	expression	of	EPOR	by	single	EPs,	and	there	was	an	average	increase	in	1	cycle	per	cell	number	doubling	
(dotted	 line	 represents	 1	 Ct	 per	 cell	 number	 doubling,	 for	 reference).	 Optimum	 forward	 primer,	 reverse	 primer	 and	 hydrolysis	 probe	
concentrations	were	found	to	be	100nM,	200nM	and	50nM,	respectively.	gDNA,	genomic	DNA;	RT,	reverse	transcriptase;	Ct,	threshold	cycle;	
AU,	arbitrary	units;	EP,	erythroid	progenitor;	EPOR,	erythropoietin	receptor.		
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Figure	3.21.	Amplification	of	target	transcripts	using	the	ACTB,	FLT3	and	EPOR-2	qRT-PCR	
assays	in	singleplex	and	triplex.	Comparison	of	amplification	of	Actb,	Flt3	and	Epor	in	single	
cells	 using	 singleplex	 reactions	 and	 triplex	 reactions.	 The	 amplification	 curves	 of	 all	 three	
assays	were	comparable	when	comparing	singleplex	to	triplex	reactions.	Lymphoid-primed	
multipotent	progenitors	and	erythroid	progenitors	were	sorted	to	test	the	efficiency	of	the	
ACTB,	FLT3	and	EPOR	qRT-PCR	assays.	Fluorescence	is	plotted	on	a	log	scale.	ACTB,	β-actin;	
FLT3,	fms-like	tyrosine	kinase	3;	EPOR,	erythropoietin	receptor.	
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Table	11:	Details	of	the	EPOR-2	qRT-PCR	assay.	
	
EPOR-2	qRT-PCR	assay	
Forward	Primer	 5’-GCAGGAGGGACACAAAGGGT-3’	
Reverse	Primer	 5’-GGGCTCAGACCAGGCACT-3’	
Hydrolysis	Probe	 5’-CTCGAACAGCGAAGGTGTAGCGC-3’	
Interrogated	exon-exon	junction	 Exon	4	–	exon	5	
Intron	size	 604	nt	
EPOR,	erythropoietin	receptor;	nt,	nucleotides.	
	
	
To	ensure	that	the	new	EPOR	qRT-PCR	assay	did	not	interact	or	compete	with	the	ACTB	or	
FLT3	 assays,	 the	 three	 assays	 were	 tested	 in	 triplex	 using	 single	 cells.	 As	 before,	 varying	
numbers	of	LMPPs	and	EPs	were	sorted	 into	wells	of	a	PCR	plate,	and	the	qRT-PCR	assays	
were	tested	 individually	and	 in	 triplex	 (Figure	3.21	and	Figure	3.22).	When	comparing	the	
levels	of	 amplification	of	Flt3	 and	Epor	 transcripts	 in	 the	 triplex	 reaction	 to	 the	 individual	
assays,	there	was	no	clear	difference.	The	amplification	curves	of	the	assays	in	triplex	were	
also	comparable	to	those	seen	when	singleplex	assays	were	used	(Figure	3.21).	However,	the	
level	of	ACTB	expression	in	the	triplex	reaction	dropped	by	roughly	3	cycles	when	compared	
to	the	singleplex	ACTB	assay	(Figure	3.22).	As	ACTB	was	included	as	an	endogenous	positive	
control	to	test	the	presence	of	cells	in	the	wells	of	a	PCR	plate,	but	not	used	to	quantify	gene	
expression,	this	was	not	considered	to	be	an	issue.		
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Figure	3.22.	Single-cell	sensitivity	of	ACTB,	FLT3	and	EPOR-2	qRT-PCR	assays	in	triplex.	The	
ACTB,	FLT3	and	EPOR-2	qRT-PCR	assays	were	used	in	triplex	to	amplify	target	genes	in	varying	
numbers	of	LMPPs	and	EPs.	The	 individual	assays	were	 included	for	comparison	to	ensure	
efficiency	was	not	compromised	when	the	assays	were	combined	in	the	same	reaction.	Cell	
number	values	for	FLT3	and	EPOR	assays	are	representative	of	the	number	of	LMPPs	or	EPs	
that	 are	 present	 in	 the	 sample,	 respectively.	 Cell	 number	 values	 for	 the	ACTB	 assay	 are	
representative	 of	 the	 number	 of	 LMPPs	 and	 EPs	 that	 are	 present	 in	 the	 sample.	 Data	
represents	 mean	 ±	 standard	 mean	 from	 at	 least	 3	 samples.	 LMPP,	 lymphoid-primed	
multipotent	progenitor;	EP,	erythroid	progenitor;	 SP,	 singleplex;	TP,	 triplex:	ACTB,	β-actin;	
FLT3,	fms-like	tyrosine	kinase	3;	EPOR,	erythropoietin	receptor.	
	
	
To	 investigate	 the	 possible	 co-expression	 of	 FLT3	 and	 EPOR	 within	 the	 primitive	
compartments	of	the	BM,	136	single	LT-HSCs,	139	single	ST-HSCs	and	148	single	MPPs	were	
purified	and	assayed	using	the	ACTB	+	FLT3	+	EPOR	triplex	qRT-PCR	assay.	When	analysing	the	
results,	there	was	a	clear	distinction	between	cells	that	expressed	the	target	gene,	and	those	
that	did	not	(Figure	3.23).	None	of	the	LT-HSCs	or	MPPs	that	were	analysed	were	found	to	co-
express	both	FLT3	and	EPOR	(Figure	3.24A).	However,	co-expression	of	both	FLT3	and	EPOR	
was	detected	in	2	of	the	139	ST-HSC	samples	during	analysis	(1.45%	of	total)	(Figure	3.24).	
The	data	 in	Figure	3.24A	was	combined	with	the	previous	FLT3	and	EPOR	expression	data	
generated	in	Section	3.5.1.	
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Figure	3.23.	Amplification	of	Actb,	Flt3	and	Epor	transcripts	in	single	ST-HSCs	using	a	triplex	
qRT-PCR	assay.	The	amplification	curves	are	representative	of	amplification	of	Actb,	Flt3	and	
Epor	mRNA	in	single	ST-HSCs	using	a	triplex	qRT-PCR	assay	to	investigate	FLT3	and	EPOR	co-
expression.	Red	amplification	curves	depict	single	cells	that	expressed	detectable	levels	of	the	
given	gene,	while	the	green	amplification	curves	depict	‘no	template	controls’	and	single	cells	
that	did	not	express	detectable	levels	of	the	given	gene.	As	can	be	seen	in	the	figure,	cells	
expressing	these	genes	were	easily	identified.	Fluorescence	is	plotted	on	a	log	scale.	ACTB,	β-
actin;	 FLT3,	 fms-like	 tyrosine	 kinase	 3;	EPOR,	 erythropoietin	 receptor;	 ST-HSC,	 short-term	
haematopoietic	stem	cell.	
	
	
	
Figure	3.24.	Co-expression	analysis	of	Flt3	and	Epor	transcripts	by	haematopoietic	stem	and	
progenitor	cells.	(A)	The	percentages	of	LT-HSC,	ST-HSC	and	MPP	that	co-expressed	mRNAs	
for	FLT3	and	EPOR	are	compared	to	the	total	number	of	cells	that	expressed	either	mRNA.	(B)	
shows	 the	absolute	number	of	ST-HSCs	 that	did	not	express	FLT3	or	EPOR	 (clear	column),	
expressed	either	FLT3	or	EPOR	exclusively	(shaded	column),	or	co-expressed	both	FLT3	and	
EPOR	 (black	column).	Reactions	were	carried	out	 in	triplex	with	an	assay	specific	 for	ACTB	
expression.	Data	in	(A)	are	the	mean	±	standard	error	of	the	values	obtained	for	single	cells	
from	3-6	mice.	p	values	 in	 (B)	obtained	by	McNemar’s	 test	where;	**,	p	<	0.01;	****,	p	<	
0.0001.	 LT-HSC,	 long-term	 haematopoietic	 stem	 cell;	 ST-HSC,	 short-term	 haematopoietic	
stem	cell;	MPP,	multipotent	progenitor;	ACTB,	β-actin;	FLT3,	fms-like	tyrosine	kinase	3;	EPOR,	
erythropoietin	receptor.	
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One	of	the	ST-HSCs	that	co-expressed	FLT3	and	EPOR	expressed	these	genes	at	 levels	that	
were	comparable	to	the	levels	expressed	by	cells	that	exclusively	expressed	either	receptor,	
while	the	other	cell	expressed	relatively	 low	 levels	of	FLT3	and	EPOR	 (Figure	3.25).	Of	 the	
remaining	 ST-HSCs,	 86	 cells	 did	 not	 express	 either	 FLT3	 or	 EPOR	 and	 51	 cells	 exclusively	
expressed	either	FLT3	or	EPOR.	The	ST-HSC	population	mostly	contained	cells	that	were	Flt3−	
Epor−,	and	there	was	significantly	more	Flt3−	Epor−	ST-HSCs	when	compared	to	the	number	of	
ST-HSCs	that	expressed	only	one	of	the	receptors	[p=0.0037],	or	the	number	of	ST-HSCs	that	
co-expressed	FLT3	and	EPOR	[p<0.0001]	(Figure	3.24B).	Furthermore,	there	were	significantly	
more	cells	that	expressed	either	FLT3	or	EPOR	when	compared	to	the	number	of	ST-HSCs	that	
co-expressed	both	genes	[p<0.0001]	(Figure	3.24B).		
	
Given	the	low	percentage	of	co-expression	detected	in	the	ST-HSC	compartment,	it	is	possible	
that	 these	 positive	 events	were	 due	 to	 the	 presence	 of	more	 than	 one	 cell	 in	 the	wells.	
However,	the	parameters	of	the	sorting	experiments	were	modified	to	minimalise	the	chance	
of	sorting	doublets.	Firstly,	the	drop	envelope	was	set	to	0.5	during	sorting.	Secondly,	as	the	
ST-HSCs	were	 initially	 sorted	 into	 an	 Eppendorf	 before	 being	 sorted	 into	 PCR	 plates,	 the	
secondary	 single	 cell	 isolation	 sort	 rate	was	 very	 slow	 (from	observation).	 Finally,	 as	 cells	
expressing	FLT3	or	EPOR	represent	such	a	small	number	of	ST-HSCs	(approximately	21%	and	
19%,	 respectively),	 if	 these	 genes	were	 expressed	 exclusively,	 the	 likelihood	 of	 a	 doublet	
event	being	due	 to	a	Flt3+	ST-HSC	and	a	Epor+	ST-HSC	 is	 small	 (3.99	 in	100).	Ultimately,	 it	
impossible	 to	 determine	whether	 the	 amplification	 of	Flt3	 and	Epor	 in	 a	well	was	 due	 to	
impurities	 during	 sorting	 or	 the	 presence	 of	 a	 ST-HSC	 that	 co-expressed	 these	 genes.	
However,	a	total	of	413	early	HSPCs	were	assayed	and	there	were	only	2	instance	of	Flt3	and	
Epor	amplification	in	the	same	well,	indicating	that	even	if	FLT3	and	EPOR	co-expression	does	
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occur	during	early	haematopoiesis,	it	occurs	extremely	rarely.	Thus,	these	results	suggest	that	
FLT3	and	EPOR	are	largely	expressed	by	distinct	but	separate	populations	within	the	LT-HSCs,	
ST-HSC	and	MPP	compartments.	
	
	
	
	
Figure	3.25.	Levels	of	FLT3	and	EPOR	co-expression	by	ST-HSCs.	Co-expression	of	FLT3	and	
EPOR	was	analysed	in	139	individual	ST-HSCs.	FLT3	expression	was	detected	in	38	cells,	EPOR	
expression	was	detected	in	16	cells,	and	87	of	these	cells	did	not	express	detectable	levels	of	
either	 gene.	 Co-expression	of	 both	 genes	was	 detected	 in	 2	 of	 139	 cells.	 Each	data	 point	
represents	a	single	cell.	Assays	were	carried	out	in	triplex	with	a	qRT-PCR	assay	specific	for	
Actb	transcripts,	and	reactions	that	did	not	give	rise	to	detectable	amplification	of	Actb	were	
removed	from	analysis	as	this	indicated	an	empty	well.	Actb+	samples	that	did	not	give	rise	to	
amplification	of	the	given	gene	target	are	plotted	arbitrarily	below	40	cycles,	marked	by	the	
dotted	lines,	and	were	not	considered	to	express	the	gene.	Data	were	generated	from	single	
cells	 that	were	purified	 from	n=3	mice.	Gene	expression	 is	 depicted	 in	 Ct	 values.	 ST-HSC,	
short-term	haematopoietic	 stem	cell;	Ct,	 threshold	cycle;	ND,	not	detected;	FLT3,	 fms-like	
tyrosine	kinase	3;	EPOR,	erythropoietin	receptor.	
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3.6			Expression	 of	 growth	 factor	 receptor	 protein	
during	haematopoiesis	
	
3.6.1			Flt3	 and	M-CSFR	protein	 expression	on	 the	 surface	of	
single	haematopoietic	stem	and	progenitor	cells	
	
Single	cell	gene	expression	analysis	revealed	heterogenic	expression	patterns	of	FLT3,	EPOR	
and	CSF1R	within	HSPC	populations.	However,	gene	expression	does	not	accurately	represent	
the	levels	of	functional	receptor	expressed	by	a	cell	[326].	In	fact,	the	correlation	between	
mRNA	levels	and	protein	in	some	systems	can	be	as	low	as	40%	[327].	As	such,	the	expression	
of	a	HGF	receptor	gene	does	not	provide	an	accurate	indication	of	how	many	cells	within	a	
given	population	are	responsive	to	its	 ligand.	To	address	this,	flow	cytometric	analysis	was	
used	to	investigate	the	expression	of	HGF	receptors	on	the	surface	of	HSPCs.	
	
Flow	 cytometry	 antibodies	 specific	 for	 Flt3	 (CD135)	 and	 M-CSFR	 (CD115)	 were	 readily	
available,	as	they	had	been	used	to	isolate	cells	for	qRT-PCR	assay	optimisation	and	analysis	
of	HGF	receptor	gene	expression.	However,	sourcing	a	commercial	antibody	specific	for	EpoR	
that	 was	 suitable	 for	 flow	 cytometry	 proved	 unsuccessful.	 Additionally,	 no	 fluorescently	
conjugated	anti-G-CSFR	(CD114)	antibodies	could	be	obtained,	so	a	purified	rat	anti-mouse	
antibody	was	obtained.	As	most	of	the	antibodies	that	were	used	in	this	study	were	derived	
from	rat,	it	was	not	desirable	to	use	an	anti-rat	secondary	antibody	for	the	detection	of	G-
CSFR.	To	avoid	using	a	secondary	rat	antibody,	the	anti-G-CSFR	antibody	was	conjugated	to	
APC	using	a	Lightning-Link	APC	kit.	The	specificity	of	the	antibody	was	tested.	
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As	specified	in	Section	3.4.2,	Ly6G	is	a	surface	marker	for	the	identification	of	granulocytes,	
and	G-CSFR	is	highly	expressed	by	this	population	of	cells	[328].	By	staining	whole	BM	cells	
for	 G-CSFR	 and	 Ly6G	 the	 staining	 profile	 of	 the	 anti-G-CSFR	 antibody	 could	 be	 compared	
against	BM	Ly6G+	neutrophils	(Figure	3.26).	By	gating	Ly6G+	and	Ly6G−	cells	and	comparing	
the	staining	of	G-CSFR	within	these	compartments,	it	was	clear	that	the	anti-G-CSFR	antibody	
was	not	specific	for	the	desired	target.	There	was	no	clear	Ly6G+	G-CSFR+	population	present	
in	 the	 sample,	 suggesting	 that	 the	 anti-G-CSFR	 antibody	 did	 not	 mark	 neutrophils,	 and	
therefore	did	not	specifically	bind	to	G-CSFR.	Thus,	the	flow	cytometric	analysis	was	limited	
to	the	investigation	of	Flt3	and	M-CSFR	on	the	surface	of	HSPCs.	All	of	the	histograms	and	
values	for	Flt3	and	M-CSFR	staining	in	all	HSPC	populations	are	depicted	in	Figure	3.27.	The	
LMPP	population	was	identified	based	on	high	levels	of	Flt3	expression.	Thus,	the	histogram	
depicting	Flt3	expression	for	LMPPs	does	not	show	a	Flt3	isotype	control,	as	no	Flt3hi	LMPPs	
could	be	gated	in	the	isotype	control	sample.	
	
	
Figure	 3.26.	 Specificity	 of	 anti-G-CSFR	 antibody	 after	 APC	 conjugation.	 A	 commercially	
available	 purified	 anti-G-CSFR	 (CD114)	 antibody	 was	 purchased	 and	 conjugated	 with	 the	
fluorophore,	APC.	Whole	BM	was	stained	with	the	conjugated	anti-G-CSFR	antibody	and	an	
anti-Ly6G	 antibody	 to	 identify	 granulocytes.	 As	 Ly6G	 stains	 granulocytes,	 it	 was	 used	 to	
determine	 the	 specificity	 of	 the	 anti-G-CSFR	 antibody.	 The	 G-CSFR	 staining	 was	 analysed	
alongside	Ly6G	staining	(left	plot),	and	also	within	Ly6G+	and	Ly6G−	populations	to	determine	
the	distribution	of	G-CSFR	staining	(right	plot).	G-CSFR,	granulocyte-colony	stimulating	factor	
receptor;	BM,	bone	marrow;	APC,	allophycocyanin.	
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Figure	3.27.	Flt3	and	M-CSFR	expression	profiles	of	haematopoietic	stem	and	progenitor	
cells.	Representative	histograms	showing	the	presence	of	Flt3	and	M-CSFR	on	the	surface	of	
haematopoietic	stem	and	progenitor	cell	populations	(solid	black	line)	compared	to	an	isotype	
control	 (shaded	 histogram).	 Percentages	 of	 cells	within	 the	 given	 population	 that	 stained	
positive	for	the	HGF	receptors	are	depicted	in	the	upper	right	corner	of	each	histogram.	Data	
are	 the	mean	 ±	 standard	 error	 of	 values	 obtained	 from	 n	 =	 3-6	mice.	 LT-HSC,	 long-term	
haematopoietic	 stem	cell;	 ST-HSC	 short-term	haematopoietic	 stem	cell;	MPP,	multipotent	
progenitor;	 HPC,	 haematopoietic	 progenitor	 cell;	 LMPP,	 lymphoid-primed	 multipotent	
progenitor;	 CLP,	 common	 lymphoid	 progenitor;	 CMP,	 common	myeloid	 progenitor;	 GMP,	
granulocyte-macrophage	 progenitor;	 MEP,	 megakaryocyte-erythroid	 progenitor;	 LSK,	
Lineage−	Sca1+	c-Kit+;	Flt3,	fms-like	tyrosine	kinase	3;	M-CSFR,	macrophage-colony	stimulating	
factor	receptor.	
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Firstly,	 the	presence	of	Flt3	protein	within	 the	HSC	compartment	was	 investigated	 (Figure	
3.28A).	 Low	 levels	 of	 surface	 Flt3	 expression	were	 consistently	 detected	 on	 LT-HSCs	 (n=6	
mice)	 (4.6%	 ±	 1).	 There	 was	 a	 slight	 increase	 in	 Flt3	 expression	 within	 the	 ST-HSC	
compartment	 (n=6	mice)	 (7.7%	 ±	 1.2)	when	 compared	 to	 LT-HSCs,	 although	 this	was	 not	
significant	[p=0.1797].	For	each	experiment,	the	gating	was	set	according	to	the	Flt3	isotype	
control	 samples.	When	 setting	 the	 gates,	 the	 Flt3+	 values	 for	 LT-HSCs	 and	 ST-HSCs	 in	 the	
isotype	control	samples	(n=2)	only	accounted	for	0.59%	±	0.37	and	0.45%	±	0.07,	respectively,	
indicating	that	levels	of	Flt3	observed	in	the	HSC	compartment	were	due	to	staining	of	Flt3	
protein.	 The	number	of	 cells	 expressing	 Flt3	within	 the	HSC	 compartments	was	 similar	 to	
previously	published	findings.	The	Jacobsen	group	has	reported	that	Flt3	 is	present	on	the	
surface	 of	 approximately	 6%	 of	 LSK	 CD150+	 CD48−	 cells	 [323].	 Similarly,	 Chu	 et	 al.	 have	
reported	that	Flt3	is	present	on	the	surface	of	<5%	of	LSK	CD150+	CD48−	cells	[329].	While	a	
value	was	not	included	in	the	article,	Oguro	et	al.	detected	a	small	number	of	HSC-1	and	HSC-
2	cells	 that	expressed	Flt3	when	describing	 the	use	of	SLAM	markers	 to	purify	early	HSPC	
populations	[34].	Furthermore,	when	HSCs	were	stained	for	IL-7Rα,	a	marker	that	is	known	to	
be	absent	on	the	surface	of	these	cells	[66],	there	were	no	IL-7Rα+	cells	detected	within	this	
compartment.	This	indicated	that	the	Flt3	signal	in	the	HSC	compartment	was	not	due	to	an	
artefact	of	the	protocol	(Figure	3.29).		
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Figure	 3.28.	 Cell	 surface	 expression	 of	 Flt3	 and	 M-CSFR	 by	 haematopoietic	 stem	 and	
progenitor	cells.	The	expression	of	Flt3	and	M-CSFR	on	the	surface	of	HSPCs	was	measured	
by	flow	cytometry.	Data	are	the	mean	±	standard	error	of	values	obtained	from	n	=	3-6	mice.	
Each	data	point	represent	an	individual	mouse.	p	values	were	obtained	by	performing	two-
tailed	non-parametric	student’s	t-test	where;	*,	p	<	0.05.	LT-HSC,	long-term	haematopoietic	
stem	cell;	 ST-HSC	 long-term	haematopoietic	 stem	cell;	MPP,	multipotent	progenitor;	HPC,	
haematopoietic	 progenitor	 cell;	 LMPP,	 lymphoid-primed	 multipotent	 progenitor;	 CLP,	
common	 lymphoid	 progenitor;	 CMP,	 common	 myeloid	 progenitor;	 GMP,	 granulocyte-
macrophage	 progenitor;	MEP,	megakaryocyte-erythroid	 progenitor;	 LSK,	 Lineage−	 Sca1+	 c-
Kit+;	Flt3,	fms-like	tyrosine	kinase	3;	M-CSFR,	macrophage-colony	stimulating	factor	receptor;	
n.s.,	not	significant.	
	
	
There	was	a	large	and	significant	increase	in	the	number	of	cells	expressing	Flt3	(63.65%	±	3)	
when	MPPs	were	compared	to	the	ST-HSC	population	(n=6	mice)	[p=0.0022]	(Figure	3.28A).	
LSK	CD150−	CD48−	MPPs	are	known	to	express	high	levels	of	Flt3,	so	this	was	not	surprising	
[34].	 As	 the	 LMPP	 (n=6	mice)	 population	 is	 distinguished	 as	 Flt3hi,	 all	 of	 the	 cells	 in	 this	
population	 were	 Flt3+	 (100%	 ±	 0).	 Conversely,	 the	 number	 of	 Flt3	 expressing	 cells	 was	
significantly	 lower	 in	 the	 CMP	 compartment	 (36.8%	 ±	 1.4)	 when	 compared	 to	 MPPs	
[p=0.0022].	Interestingly,	Karsunky	et	al.	have	observed	Flt3	expression	on	the	surface	of	50-
65%	CMPs,	and	these	values	differ	from	the	findings	reported	here	[311].	When	analysing	the	
remaining	populations,	Flt3	was	found	to	be	expressed	by	a	high	proportion	of	CLPs	(n=6)	
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(80.4%	 ±	 2.1),	 and	 this	 was	 significantly	 higher	 when	 compared	 to	 the	 MPP	 population	
[p=0.0022].	Within	the	Flt3−/lo	HPC-1	(n=6)	compartment,	58.6%	±	3	of	cells	were	Flt3+,	while	
a	 lower	 percentage	 of	 Flt3	was	 present	 on	 the	 surface	 of	GMPs	 (n=3)	 (15.7%	 ±	 0.9).	 The	
percentage	of	Flt3+	cells	within	the	CLP	and	GMP	populations	shown	here	are	different	from	
what	has	been	previously	published.	The	Jacobsen	group	has	detected	Flt3	on	the	surface	of	
13%	±	4	of	GMPs	[322],	and	it	has	been	reported	that	60-70%	of	CLPs	are	Flt3+	[311].	Finally,	
Flt3	was	only	detected	on	a	small	population	of	HPC-2	(n=6)	(9.3%	±	1.1)	and	virtually	all	MEPs	
were	Flt3−	(n=3)	(0.4%	±	0.1)	(Figure	3.28A).		
	
	
	
Figure	3.29.	Cell	surface	expression	of	IL-7Rα	by	BM	haematopoietic	stem	and	progenitor	
cells.	Representative	histogram	showing	the	absence	of	 IL-7Rα	on	the	surface	of	BM	HSCs	
(LSK	CD150+	CD48−)	compared	to	BM	Lin−	Flt3+	cells.	The	solid	black	lines	depict	staining	with	
the	 IL-7Rα	 antibody	 and	 the	 shaded	 histograms	 depict	 the	 isotype	 control.	 HSC,	
haematopoietic	 stem	cell;	 Lin,	 lineage	markers;	Flt3,	 fms-like	 tyrosine	 kinase	3;	 BM,	bone	
marrow;	IL-7Rα,	interleukin-7	receptor	α	subunit.	
	
Although	 Csf1r	 transcripts	 were	 only	 rarely	 expressed	 within	 the	 LT-HSC	 and	 ST-HSC	
compartments,	M-CSFR	protein	was	consistently	detected	on	the	surface	of	a	fraction	of	LT-
HSCs	(n=6	mice)	and	ST-HSCs	(n=6	mice)	(Figure	3.28B).	Within	the	HSC	compartment,	18.6%	
±	3.8	of	LT-HSCs	and	23.4%	±	3.6	of	ST-HSCs	were	M-CSFR+,	and	the	difference	between	these	
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two	values	was	not	significant	[p=0.3125].	Again,	the	percentage	of	LT-HSCs	and	ST-HSCs	that	
stained	positive	 in	 the	M-CSFR	 isotype	controls	 (n=2)	were	0.41%	±	0.41	and	0.3%	±	0.07,	
respectively.	There	were	significantly	less	MPPs	(n=6	mice)	(13.4%	±	2.46)	expressing	M-CSFR	
when	compared	to	the	ST-HSC	population	[p=0.0313].	The	number	of	M-CSFR+	Flt3−/lo	HPC-1	
(n=6	mice)	(13.8%	±	2.4)	and	LMPPs	(n=6)	(13.9%	±	1.8)	was	comparable	to	the	number	of	M-
CSFR+	MPPs.	Although,	not	a	significant	when	compared	to	the	MPP	population	[p=0.0625],	
there	was	a	decrease	 in	 the	number	of	cells	expressing	M-CSFR	as	cells	committed	 to	 the	
lymphoid	lineage,	as	only	4.12%	±	0.3	of	the	CLP	(n=6	mice)	population	were	M-CSFR+	(Figure	
3.28B).	 Conversely,	 there	 was	 an	 increase	 in	 the	 number	 of	 M-CSFR+	 cells	 as	 cells	
differentiated	 towards	 the	myelomonocytic-granulocytic	 lineages.	When	 compared	 to	 the	
MPP	population,	the	HPC-2	compartment	(n=6)	(27.1%	±	4.4)	contained	significantly	more	M-
CSFR+	cells	[p=0.0313].	Additionally,	there	was	an	increase	in	the	number	of	cell	express	M-
CSFR	 in	 the	CMP	population	 (n=3)	 (27%	±	0.8)	when	compared	 to	MPPs,	but	 this	was	not	
significant	[p=0.25].	Furthermore,	the	GMP	compartment	(n=3)	(50.2%	±	2.12)	contained	the	
highest	fraction	of	M-CSFR+	cells	when	compared	to	all	other	populations.	Virtually	all	MEPs	
(n=3)	 were	 M-CSFR−,	 which	 was	 to	 be	 expected	 given	 their	 lack	 of	 myelomonocytic-
granulocytic	potential	[67]	(Figure	3.28B).		
	
For	both	Flt3	and	M-CSFR,	there	were	slight	variations	when	comparing	transcript	and	protein	
expression.	There	were	more	than	double	the	number	LT-HSCs	and	ST-HSCs	expressing	FLT3	
when	compared	to	the	number	of	cells	that	expressed	Flt3	protein	on	their	surface.	Flt3	was	
detected	on	the	surface	of	4.6%	±	1	(n=6)	LT-HSCs,	while	FLT3	expression	was	detected	 in	
11.6%	 ±	 2.19	 (n=6)	 of	 these	 cells.	 Similarly,	 21%	 ±	 3.4	 (n=6)	 of	 ST-HSCs	 expressed	 Flt3	
transcripts,	and	7.7%	±	1.1	(n=6)	expressed	Flt3	on	their	surface.	This	suggests	that	a	number	
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of	HSCs	express	FLT3	but	do	not	transcribe	the	Flt3	protein,	which	is	supported	by	previous	
studies	[312,	323].	Conversely,	some	populations	contained	more	Flt3+	cells	than	Flt3+	cells.	
Flt3	transcripts	were	detected	in	24.9%	±	5.4	of	CMPs	(n=	3),	while	36.8%	±	1.93	of	CMPs	were	
Flt3+.	Additionally,	91.5%	±	1	of	CLPs	(n=	3)	were	Flt3+,	but	only	66.2%	±	3.8	(n=	3)	expressed	
detectable	 levels	 of	 FLT3	 when	 analysed.	 For	 the	 other	 populations,	 the	 number	 of	 cells	
expressing	Flt3	protein	or	Flt3	transcripts	were	similar.	For	example,	63.65%	±	3	(n=6)	of	MPPs	
expressed	 Flt3	on	 their	 surface,	 and	64%	±	2.2	 (n=6)	 expressed	detectable	 levels	 of	FLT3.	
Similarly,	 there	 isn’t	a	correlation	between	 the	expression	of	M-CSFR	and	 the	CSF1R	 gene	
when	comparing	gene	expression	between	HSPC	populations.	CSF1R	expression	was	rarely	
detected	in	the	HSC	compartment,	but	when	M-CSFR	expression	was	investigated,	18.6%	±	
3.8	of	LT-HSCs	and	23.4%	±	3.6	of	ST-HSCs	were	M-CSFR+.	Conversely,	almost	all	of	the	GMPs	
analysed	expressed	detectable	levels	of	CSF1R	(n=3)	(92%	±	3.2)	but	only	50.2%	±	2.12	(n=3)	
were	M-CSFR+.	These	results	indicated	that	expression	of	FLT3	and	CSF1R	by	single	HSPCs	do	
not	correlate	with	the	presence	of	Flt3	and	M-CSFR	on	the	cell	surface.	
	
3.6.2			Investigation	 of	 Flt3	 and	 M-CSFR	 co-expression	 by	
haematopoietic	stem	cells	and	multipotent	progenitors	
	
Both	 Flt3	 and	 M-CSFR	 were	 detected	 on	 the	 surface	 of	 LT-HSCs,	 ST-HSCs	 and	 MPPs.	 As	
previously	 described,	 it	 was	 important	 to	 determine	 whether	 Flt3	 and	 M-CSFR	 are	 co-
expressed	by	these	cells.	As	such,	the	presence	of	Flt3+	M-CSFR+	cells	within	the	HSC	and	MPP	
compartments	was	investigated.	The	gating	strategy	used	for	this	analysis	is	shown	in	Figure	
3.30.		
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Figure	3.30.	Gating	strategy	used	to	investigate	the	co-expression	of	Flt3	and	M-CSFR	on	the	
surface	of	HSCs.	(A)	Representative	flow	cytometry	plots	showing	the	co-expression	of	the	
Flt3	and	M-CSFR	on	 the	 surface	of	HSCs	 (LSK	CD150+	CD48−).	 (B)	Staining	profiles	of	HSCs	
stained	with	the	Flt3	(left)	or	M-CSFR	(right)	isotype	controls.	Values	displayed	represent	the	
percentage	of	HSCs	within	the	given	gate.	HSC,	haematopoietic	stem	cell;	LSK,	Lineage−	Sca1+	
c-Kit+;	 Flt3,	 fms-like	 tyrosine	 kinase	 3;	 M-CSFR,	 macrophage-colony	 stimulating	 factor	
receptor.	
	
Co-expression	 of	 both	 Flt3	 and	 M-CSFR	 was	 rarely	 observed	 when	 analysing	 the	 HSC	
compartment.	Only	1.12%	±	0.48	of	LT-HSCs	(n=6	mice)	expressed	both	genes,	and	there	was	
a	slight,	but	significant,	increase	in	the	number	of	ST-HSCs	(n=6	mice)	co-expressing	Flt3	and	
M-CSFR	(2.8%	±	0.7)	(Figure	3.31A)	 [p=0.0313].	Additionally,	there	was	an	increases	 in	the	
percentage	of	MPPs	(n=6)	(9.9%	±	1.9)	co-expressing	the	receptors	when	compared	to	the	ST-
HSC	compartment	(Figure	3.31A)	[p=0.0313].	As	Flt3	is	only	expressed	by	a	small	number	of	
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HSCs,	co-expression	was	also	calculated	as	a	percentage	of	Flt3+	cells	within	the	LT-HSC	and	
ST-HSC	compartments	(Figure	3.31B).	Of	the	Flt3+	LT-HSCs	and	Flt3+	ST-HSCs,	20.1%	±	6.87	
and	34.47%	±	5.35	of	them	co-expressed	M-CSFR.	The	difference	between	these	two	groups	
was	not	significant	[p=0.0938].		
	
	
Figure	3.31.	Co-expression	of	Flt3	and	M-CSFR	on	the	surface	of	HSCs	and	MPPs.	(A)	The	co-
expression	of	Flt3	and	M-CSFR	on	the	surface	of	LT-HSCs,	ST-HSCs	and	MPPs	was	investigated	
using	flow	cytometry.	The	percentage	of	cells	within	each	population	that	express	Flt3	or	M-
CSFR	on	their	surface	is	included	for	comparison.	(B)	As	Flt3+	cells	account	for	such	a	small	
proportion	of	HSCs,	the	percentage	of	Flt3+	LT-HSCs,	ST-HSCs	and	MPPs	that	also	express	M-
CSFR	on	their	surface	is	depicted.	(C)	The	percentage	of	M-CSFR+	LT-HSCs,	ST-HSCs	and	MPPs	
that	also	express	Flt3	on	 their	 surface	 is	depicted.	Data	are	 the	mean	±	 standard	error	of	
values	 obtained	 from	n	 =	 6	mice.	p	 values	were	 obtained	 by	 performing	 two-tailed	 non-
parametric	 student’s	 t-test	 where;	 *,	 p	 <	 0.05.	 Flt3,	 fms-like	 tyrosine	 kinase;	 M-CSFR,	
macrophage-colony	stimulating	factor;	LT-HSC,	long-term	haematopoietic	stem	cell;	ST-HSC	
long-term	haematopoietic	stem	cell;	MPP,	multipotent	progenitor;	n.s.,	not	significant.	
	
When	 compared	 to	 Flt3+	 ST-HSCs,	 there	 was	 a	 decrease	 in	 the	 number	 of	 Flt3+	 MPPs	
expressing	M-CFR	(14.46%	±	2.62)	[p=0.0313].	This	decrease	can	be	explained	by	the	large	
increase	 in	 the	number	of	MPPs	expressing	Flt3	when	compared	 to	ST-HSCs.	Additionally,	
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5.55%	±	1.61	of	M-CSFR+	LT-HSCs	co-expressed	both	Flt3	and	M-CSFR,	and	this	significantly	
increased	 to	 11.52%	 ±	 1.71	 when	 analysing	 the	 M-CSFR+	 ST-HSCs	 population	 [p=0.0313]	
(Figure	3.31C).	There	was	 large	 increase	 in	M-CSFR+	MPPs	expressing	Flt3	 (69.17%	±	3.29)	
when	 compared	 to	 the	 ST-HSC	 population	 [p=0.0313],	 indicating	 that	 as	 M-CSFR+	 cells	
transition	from	the	ST-HSC	stage,	a	large	number	of	them	acquire	Flt3	expression.	
	
To	statistically	analyse	how	often	exclusive	expression	of	a	single	receptor	or	co-expression	
of	both	receptors	occurred	within	the	HSC	and	MPP	compartments,	the	absolute	number	of	
cells	expressing	neither	receptor	(Flt3−	M-CSFR−),	exclusively	expressing	one	of	the	receptors	
(Flt3+	or	M-CSFR+),	or	co-expressing	both	receptors	(Flt3+	M-CSFR+)	was	determined	(Figure	
3.32).	 This	 revealed	 that	 the	 majority	 of	 cells	 within	 both	 the	 LT-HSC	 and	 ST-HSC	
compartments	were	Flt3−	M-CSFR−.	In	the	LT-HSC	compartment,	821	of	1,000	cells	were	Flt3−	
M-CSFR−,	and	this	was	significantly	higher	than	the	number	of	cells	that	were	either	Flt3+	or	
M-CSFR+	(170	of	1,000	LT-HSCs)	[p<0.0001]	(Figure	3.32A).	Similarly,	there	were	significantly	
more	Flt3−	M-CSFR−	cells	in	the	ST-HSC	compartment	(718	of	1,000	ST-HSCs)	than	cells	that	
expressed	either	Flt3	or	M-CSFR	(254	of	1,000	ST-HSCs)	[p<0.0001]	(Figure	3.32B).	Only	9	of	
1,000	LT-HSCs	and	27	of	ST-HSCs	were	Flt3+	M-CSFR+	cells,	and	these	cells	were	significantly	
less	 frequent	 than	cells	 that	expressed	either	Flt3+	or	M-CSFR+	[LT-HSC,	p<0.0001;	ST-HSC,	
p<0.0001]	(Figure	3.32A,	B).	Most	MPPs	exclusively	expressed	either	Flt3	or	M-CSFR.	Of	1,000	
MPPs,	577	expressed	one	of	these	receptors	exclusively	and	this	was	significantly	more	than	
the	number	of	Flt3−	M-CSFR−	cells	(321	of	1,000	MPPs)	in	this	compartment	[p<0.0001]	(Figure	
3.32C).	 As	 observed	 in	 the	 HSC	 compartments,	 cells	 co-expressing	 both	 Flt3+	 or	M-CSFR+	
accounted	for	the	smallest	proportion	of	MPPs	(102	of	1,000	MPPs),	and	this	was	significantly	
less	that	the	number	of	Flt3−	M-CSFR−	cells	[p<0.0001]	(Figure	3.32C).	
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Figure	 3.32.	 Expression	 of	 Flt3	 and	 M-CSFR	 within	 the	 LT-HSC,	 ST-HSC	 and	 MPP	
compartments.	The	(A)	LT-HSC,	(B)	ST-HSC	and	(C)	MPP	populations	were	divided	into	cells	
that	 lacked	 expression	 of	 Flt3	 and	 M-CSFR	 (Flt3−	 M-CSFR−,	 white	 columns),	 cells	 that	
exclusively	expressed	either	Flt3	or	M-CSFR	(Flt3+	or	M-CSFR+,	grey	columns),	and	cells	that	
co-expressed	both	receptors	 (Flt3+	M-CSFR+,	black	columns).	The	absolute	number	of	cells	
within	each	of	these	groups	was	calculated	per	1,000	(A)	LT-HSCs,	(B)	ST-HSCs	or	(C)	MPPs	
and	rounded	to	the	nearest	whole	number.	The	graphs	represents	data	from	6	mice,	and	2	
independent	experiments.	p	values	obtained	by	McNemar’s	 test	where;	****,	p	<	0.0001.	
Flt3,	fms-like	tyrosine	kinase;	M-CSFR,	macrophage-colony	stimulating	factor;	LT-HSC,	long-
term	 haematopoietic	 stem	 cell;	 ST-HSC,	 long-term	 haematopoietic	 stem	 cell;	 MPP,	
multipotent	progenitor.	
	
3.6.3			Correlation	between	the	presence	of	Flt3	and	the	levels	
of	 CD150	 expressed	 on	 the	 surface	 of	 haematopoietic	 stem	
cells	
	
HSCs	 are	 routinely	 subdivided	 into	 functionally	 distinct	 compartments	 based	 on	 the	
expression	of	particular	surface	and	cytoplasmic	markers.	Varying	levels	of	CD150	expression	
have	been	used	 to	divide	HSCs	 into	CD150	high	 (CD150hi)	myeloid-biased	cells	and	CD150	
intermediate	(CD150int)	cells,	which	possess	less	self-renewal	capacity	and	MegE	potential	in	
comparison	 [25,	 26].	 To	 investigate	 if	 Flt3	 or	 M-CSFR	 associated	 with	 either	 of	 these	
subpopulations,	CD150hi	and	CD150int	cells	were	gated	in	both	the	Flt3+	and	M-CSFR+	fractions	
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of	the	HSC	compartment	(Figure	3.33).	During	flow	cytometric	analysis,	very	few	Flt3+	and	M-
CSFR+	cells	were	present	within	the	LT-HSC	and	ST-HSC	populations	(approximately	20-100	
cells).	 This	was	 considered	 too	 few	 for	 accurate	 analysis,	 so	 the	 correlation	 between	 the	
presence	 of	 Flt3	 and/or	M-CSFR	 and	 the	 levels	 of	 CD150	 expression	was	 investigated	 by	
analysing	the	whole	HSC	compartment	(LSK	CD150+	CD48−).	Representative	plots	of	CD150high	
and	CD150int	expression	in	Flt3+,	Flt3−,	M-CSFR+	and	M-CSFR−	HSC	fractions	are	depicted	in	
Figure	3.33B.		
	
	
Figure	3.33.	Analysis	of	CD150	expression	levels	on	the	surface	of	HSCs.	CD150hi	and	CD150int	
cells	were	 gated	when	 analysing	 Flt3	 and	M-CSFR	 expression	 on	 the	 surface	 of	 HSCs.	 (A)	
Gating	of	CD150hi	and	CD150int	cells	within	the	LSK	CD48−	population.	(B)	Representative	plot	
showing	 levels	 of	 CD150	 expressed	 on	 the	 surface	 of	 Flt3−	 HSCs	 and	 Flt3+	 HSCs.	 (C)	
Representative	plot	showing	levels	of	CD150	expressed	on	the	surface	of	M-CSFR−	HSCs	and	
M-CSFR+	HSCs.	Values	displayed	represent	the	percentage	of	the	parent	population	within	
the	given	gate.	Data	for	(A)	are	the	mean	±	standard	error	of	values	obtained	from	n	=	6	mice.	
Flt3,	 fms-like	 tyrosine	 kinase;	 M-CSFR,	 macrophage-colony	 stimulating	 factor;	 HSC,	
haematopoietic	stem	cell;	MPP,	multipotent	progenitor;	LSK,	Lineage	markers−	Sca1+	c-Kit+.	
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Figure	3.34.	Levels	of	CD150	expressed	by	Flt3+	and	M-CSFR+	HSCs.	Flt3+	and	M-CSFR+	HSCs	
(LSK	 CD150+	 CD48−)	were	 analysed	 according	 to	 high	 (CD150hi)	 or	 intermediate	 (CD150int)	
levels	of	CD150	expressed	on	 their	 surface.	Data	are	 the	mean	±	 standard	error	of	values	
obtained	 from	 n	 =	 6	mice,	 from	 2	 independent	 experiments.	 p	 values	 were	 obtained	 by	
performing	 two-tailed	 non-parametric	 student’s	 t-test	 where;	 **,	 p	 <	 0.01.	 HSC,	
haematopoietic	stem	cell;	LT,	long-term;	ST,	short-term;	Flt3,	fms-like	tyrosine	kinase	3;	M-
CSFR,	macrophage-colony	 stimulating	 factor	 receptor;	 LSK;	 Lineage−	 Sca1+	 c-Kit+;	 n.s.,	 not	
significant.	
	
Within	the	LSK	CD150+CD48−	compartment	(n=6),	88.5%	±	2.18	of	the	Flt3+	cells	expressed	
intermediate	levels	of	CD150	on	their	surface,	while	59.05%	±	1.35	of	the	Flt3−	fraction	were	
CD150int	 in	 comparison	 (Figure	 3.34).	 This	 difference	 was	 highly	 significant	 [p=0.0022],	
indicating	an	association	between	the	presence	of	Flt3	on	the	cell	surface	and	intermediate	
levels	of	CD150.	On	the	other	hand,	there	was	no	significant	difference	in	CD150	distribution	
when	 M-CSFR+	 and	 M-CSFR−	 HSCs	 (n=6)	 [p=0.5174]	 were	 compared	 (Figure	 3.34).	
Intermediate	levels	of	CD150	expression	were	detected	the	surface	on	59.76%	±	2.4	of	M-
CSFR+	and	61.15%	±	1.08	of	M-CSFR−	cells.	Thus,	these	findings	suggest	that	Flt3,	but	not	M-
CSFR,	can	be	used	for	enrichment	of	a	functionally	distinct	subpopulation	of	LSK	CD150+CD48−	
cells.	
n.s.$**$
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3.7			Discussion	
	
3.7.1			Flt3,	EpoR	and	M-CSFR	mark	distinct	subpopulations	of	
haematopoietic	 stem	 cells	 and	multipotent	 progenitors	 and	
these	receptors	are	rarely	co-expressed	
	
Previous	 studies	 have	 provided	 evidence	 to	 suggest	 that	 HGF	 receptors	 are	 differentially	
expressed	 by	 cells	 within	 the	 HSC	 compartment.	 Epo	 and	M-CSF	 have	 been	 reported	 to	
influence	lineage	fate	in	some,	but	not	all,	HSCs	[267,	269]	indicating	that	a	subpopulation	of	
HSCs	possess	the	receptors	for	these	factors.	Similarly,	single	cell	analysis	has	shown	that	the	
EPOR	and	CSF3R	genes,	and	Flt3	protein,	are	selectively	expressed	by	single	HSCs	[34,	116,	
320,	329].	However,	 it	 is	 largely	unclear	as	 to	 the	extent	 the	expression	of	HGF	 receptors	
changes	as	single	HSCs	exit	a	quiescent	state	and	begin	to	differentiate.	To	address	this,	the	
experiments	 outlined	 in	 this	 chapter	 utilised	 single	 cell	 gene	expression	 analysis	 and	 flow	
cytometry	to	investigate	the	expression	of	the	above	receptors	by	single	HSPCs	during	early	
haematopoiesis.	The	findings	presented	here	show	novel	patterns	of	Flt3,	M-CSFR	and	EpoR	
expression	 within	 the	 LT-HSC,	 ST-HSC	 and	 MPP	 compartments,	 and	 reveal	 that	 these	
receptors	are	differentially	regulated	during	multipotent	cell	maturation.	
	
The	 percentage	 of	 cells	 expressing	 Flt3,	 Epor,	 Csf1r	 mRNA	 within	 each	 analysed	 HSPC	
population	is	illustrated	using	the	pairwise	model	in	Figure	3.35,	while	the	percentage	of	cells	
expressing	Flt3	and	M-CSFR	protein	within	each	population	 is	depicted	 in	Figure	3.36.	 It	 is	
difficult	to	map	the	HPC-1	and	HPC-2	compartments	to	the	pairwise	model	as	they	represent	
heterogeneous	populations	that	have	not	been	well	characterised	[34].	HPC-1	primarily	give	
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rise	 to	 GM	 and	 lymphoid	 cells,	 but	 have	 limited	 MegE	 potential.	 Similarly,	 HPC-2	
predominantly	produce	MegE	cells	in	vivo,	but	are	also	capable	of	generating	a	small	number	
of	GM	cells	and	B-lymphocytes.	For	simplicity,	the	HPC-1	and	HPC-2	populations	have	been	
mapped	to	the	pairwise	model	based	on	their	efficiency	 in	repopulating	the	GM-lymphoid	
and	MegE	lineages,	respectively.	
	
Both	 Flt3	 protein	 and	 Flt3	 transcripts	 were	 detected	 in	 the	 LT-HSC,	 ST-HSC	 and	 MPP	
compartments.	FLT3	was	expressed	by	11.6%	±	2.19	of	LT-HSCs,	21%	±	3.4	of	ST-HSCs	and	
64%	±	2.2	of	MPPs	(Figure	3.17A),	while	Flt3	protein	was	detected	on	the	surface	of	4.6%	±	1	
LT-HSCs,	7.7%	±	1.1	ST-HSCs	and	63.65%	±	5	MPPs	(Figure	3.27A).	These	data	were	consistent	
with	previously	published	work.	The	 Jacobson	group	created	a	FLT3-Cre	 transgenic	mouse	
that	contained	a	loxP-flanked	eYFP	gene	(FLT3-Cre:loxp-eYFP),	and	reported	that	23%	of	HSCs	
(LSK	CD150+	CD48−)	were	eYFP+	[323].	The	group	also	detected	Flt3	protein	on	the	surface	of	
approximately	 6%	 of	 HSCs.	 Other	 studies	 have	 also	 confirmed	 the	 expression	 of	 the	 Flt3	
receptor	on	the	surface	of	a	small	population	of	HSCs	[34,	329].	However,	as	these	studies	did	
not	distinguish	HSC	subsets	using	CD34,	they	did	not	investigate	the	expression	of	the	FLT3	
gene	and	Flt3	protein	by	LT-HSCs	and	ST-HSCs.	Analysis	of	the	data	presented	here	revealed	
a	 slight	 increase	 in	 FLT3	 and	 Flt3	 expression	 as	 LT-HSCs	 differentiate	 into	 ST-HSCs	 (FLT3,	
[p=0.3125];	Flt3,	[p=0.0022])	and	a	greater	increase	as	ST-HSCs	transition	to	the	MPP	stage	
(FLT3,	 [p=0.0313];	 Flt3,	 [p=0.0313]),	 supporting	 proposals	 that	 Flt3	 is	 upregulated	 at	 the	
expense	of	self-renewal	ability	[19,	20,	323].	Notably,	the	mean	levels	of	FLT3	expressed	by	
the	Flt3+	cells	within	these	compartments	were	not	different	(Figure	3.18A),	indicating	that	
the	 number	 of	 cells	 expressing	 Flt3,	 but	 not	 the	 levels	 at	which	 these	 cells	 express	FLT3,	
increases	as	LT-HSCs	mature	towards	MPPs.		
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EPOR	expression	was	also	detected	in	a	small	proportion	of	the	HSCs	analysed	(Figure	3.17B).	
EPOR	was	expressed	by	12.8%	±	1.46	of	LT-HSCs,	and	there	was	a	slight	increase	in	the	number	
of	Epor+	ST-HSCs	(19.3%	±	4.6),	[p=0.2188].	These	data	were	similar	to	the	findings	published	
by	Karlsson	and	co-workers.	Karlsson	et	al.	have	defined	HSCs	as	LSK	CD34−	Flt3−	CD9high	based	
on	 long-term	 reconstitution	 assays,	 and	 found	 that	 only	 a	 small	 number	 of	 these	 cells	
expressed	EPOR	(the	percentage	was	not	included	in	the	text)	[320].	As	ST-HSCs	differentiated	
into	MPPs,	there	was	a	2-fold,	although	non-significant,	decrease	in	the	expression	of	EPOR	
(8.2%	±	4.6)	[p=0.0628].	Additionally,	the	levels	at	which	EPOR	was	expressed	within	the	MPP	
compartment	 varied	 greatly	 when	 compared	 to	 the	 ST-HSC	 compartment,	 giving	 further	
indication	that	 regulation	of	 the	EPOR	gene	changes	during	 the	ST-HSC	to	MPP	transition.	
Previous	studies	have	also	shown	a	decrease	in	EPOR	expression	as	HSCs	mature	and	support	
the	findings	presented	here.	Lai	et	al.	have	reported	a	decrease	in	EPOR	expression	by	the	
MPP	population	 (LSK	Thy1.1−)	when	compared	to	 the	HSC	population	 (LSK	Thy1.1lo)	 [324],	
while	Månsson	et	al.	have	shown	that	EPOR	expression	is	decreased	when	comparing	ST-HSCs	
(LSK	CD34+	Flt3−)	to	LT-HSCs	(LSK	CD34−	Flt3−)	[330].		
		
M-CSFR	was	expressed	by	18.6%	±	3.8	of	LT-HSCs	and	23.4%	±	3.6	of	ST-HSCs,	and	the	number	
of	cells	expressing	M-CSFR	significantly	decreased	as	ST-HSCs	matured	into	MPPs	(13.4%	±	
2.46)	[p=0.0313]	(Figure	3.28B).	Interestingly,	CSF1R	expression	was	very	rarely	expressed	by	
cells	in	the	LT-HSC,	ST-HSC	and	MPP	compartments	despite	the	presence	of	M-CSFR	protein	
on	the	surface	of	these	cells	(Figure	3.17C).	It	is	possible	that	the	levels	of	CSF1R	expressed	
by	these	cells	were	below	the	detection	threshold	for	the	CSF1R	qRT-PCR	assay.	Alternatively,	
HSCs	and	MPPs	may	only	need	to	transcribe	the	CSF1R	gene	rarely	to	maintain	M-CSFR	on	the	
surface	 of	 these	 cells.	 Surprisingly,	 when	 comparing	 the	 HSC	 compartment	 to	 the	 LMPP	
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compartment,	which	contained	fewer	M-CSFR+	cells	(13.9%	±	1.8),	CSF1R	was	more	regularly	
detected	in	LMPPs.	As	LMPPs	are	more	proliferative	than	HSCs	[73],	it	is	possible	that	these	
cells	need	to	continuously	transcribe	the	CSF1R	gene	to	maintain	M-CSFR	on	their	surface	as	
they	divide.	
	
	
Figure	 3.35.	Mapping	 of	 FLT3,	CSF1R	 and	EPOR	gene	 expression	 to	 the	 pairwise	model.	
Values	shown	correspond	to	the	percentage	of	cells	within	the	given	HSPC	population	that	
were	found	to	express	FLT3,	CSF1R	and	EPOR.	The	legend	is	shown	in	the	top	right	corner.	For	
these	 experiments,	 HPC-1	 was	 isolated	 as	 LSK	 CD48+	 CD150−	 Flt3−/lo.	 LT-HSC,	 long-term	
haematopoietic	 stem	cell;	 ST-HSC	 short-term	haematopoietic	 stem	cell;	MPP,	multipotent	
progenitor;	HSPC,	haematopoietic	stem	and	progenitor	cell;	HPC,	haematopoietic	progenitor	
cell;	 LMPP,	 lymphoid-primed	multipotent	 progenitor;	 CLP,	 common	 lymphoid	 progenitor;	
CMP,	 common	 myeloid	 progenitor;	 GMP,	 granulocyte-macrophage	 progenitor;	 MEP,	
megakaryocyte-erythroid	progenitor;	EPOR,	erythropoietin	receptor;	FLT3,	fms-like	tyrosine	
kinase	3;	CSF1R,	macrophage	colony-stimulating	factor	receptor.	
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These	data	revealed	that	Flt3,	M-CSFR	and	EPOR	were	only	expressed	by	a	small	number	of	
HSCs	 and	 that	 these	 receptors	 are	 differentially	 regulated	 following	 transition	 of	 HSCs	 to	
MPPs.	 To	 determine	 if	 the	 HSC	 and	 MPP	 subpopulations	 expressing	 these	 receptors	
overlapped,	the	co-expression	of	Flt3,	M-CSFR	and	EpoR	by	HSCs	and	MPPs	was	investigated.	
First,	qRT-PCR	analysis	revealed	that	of	136	single	LT-HSCs,	139	single	ST-HSCs	and	148	single	
MPPs	assayed,	co-expression	of	FLT3	and	EPOR	was	only	detected	in	2	ST-HSC	samples.	As	
discussed	in	section	3.5.2,	it	was	difficult	to	discern	whether	these	events	were	real	or	due	to	
contamination	 of	 a	 doublet	 during	 sorting.	 However,	 the	 results	 clearly	 indicate	 that	 co-
expression	of	FLT3	and	EPOR	rarely	occurs	during	the	early	stages	of	haematopoiesis.	
	
The	co-expression	of	Flt3	and	M-CSFR	protein	on	the	surface	of	single	LT-HSCs,	ST-HSCs	and	
MPPs	 was	 then	 investigated	 using	 flow	 cytometry.	 Flt3	 and	 M-CSFR	 co-expression	 was	
detected	on	the	surface	of	a	very	small	number	of	LT-HSCs	(1.12%	±	0.48)	and	ST-HSCs	(2.8%	
±	0.7)	(Figure	3.31A).	Even	when	represented	as	a	percentage	of	Flt3+	or	M-CSFR+	cells,	these	
receptors	were	mostly	found	to	be	exclusively	expressed	by	HSCs	(Figure	3.31B,	C).	Indeed,	
analysis	 of	 absolute	 numbers	 showed	 that	 Flt3+	 M-CSFR+	 cells	 represented	 the	 smallest	
fraction	of	LT-HSCs,	ST-HSCs	when	compared	to	Flt3−	M-CSFR−	cells	and	cells	that	exclusively	
expressed	one	of	the	receptors	(Flt3+	or	M-CSFR+)	(Figure	3.32A,	B).	When	analysing	the	MPP	
population,	it	was	clear	that	there	was	a	large	increase	in	the	co-expression	of	Flt3	and	M-
CSFR	(9.5%	±	1.9)	when	compared	to	ST-HSCs	[p=0.0313].	Although	Flt3+	M-CSFR+	were	the	
rarest	 cells	within	 this	 population	 (Figure	 3.32C),	 a	 high	 proportion	 of	M-CSFR+	MPPs	 co-
expressed	Flt3	(69.17%	±	3.29)	indicating	that	M-CSFR	expression	was	commonly	associated	
with	 the	 presence	 of	 Flt3	 at	 this	 stage.	 From	 these	 results,	 it	 was	 evident	 that	 a	 rare	
population	of	Flt3+	M-CSFR+	cells	exist	in	the	HSC	compartment,	and	that	there	is	a	gradual	
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increase	 in	 the	 co-expression	 of	 these	 receptors	 as	HSCs	mature	 towards	 the	MPP	 stage.	
However,	with	the	exception	of	M-CSFR	in	the	MPP	compartment,	these	receptors	are	more	
commonly	expressed	exclusively	rather	than	together	during	early	haematopoiesis.	
	
CSF1R	was	only	rarely	expressed	by	HSCs,	and	an	antibody	for	EpoR	could	not	be	sourced,	so	
it	was	not	possible	 to	determine	the	relationship	between	EpoR/EPOR	and	M-CSFR/CSF1R	
expression.	However,	given	that	FLT3-EPOR	and	Flt3-M-CSFR	co-expression	rarely	occurred	
within	the	HSC	compartment,	the	findings	do	not	support	the	presence	of	single	HSCs/MPPs	
that	 express	 all	 three	 receptors.	 Instead,	 the	 data	 indicates	 that	 the	 HSC	 and	 MPP	
compartments	contain	distinct	subpopulations	that	selectively	express	HGF	receptors.	This	
process	of	selective	expression	would	sensitise	HSCs	to	particular	environmental	cues	and,	
therefore,	prime	them	to	generate	specific	lineages	when	activated	by	particular	HGFs.		
	
Conventionally,	HSCs	are	thought	to	gradually	commit	to	mature	cells	fates	by	transitioning	
through	various	intermediate	progenitor	states.	However,	previous	studies	have	shown	that	
lineage	commitment	occurs	within	 the	early	HSPC	compartments.	 For	example,	 long-term	
repopulating	cells	that	are	committed	to	mature	cell	fates	have	been	identified	within	the	LSK	
CD34–	population	of	 the	mouse	BM.	As	described	 in	Section	1.3.3,	 Yamamoto	et	al.	 have	
enriched	 for	MkRPs,	 CMRPs	 and	MERPs	within	 this	 compartment	 using	 CD150	 and	 CD41	
staining	[23].	Similarly,	Notta	and	colleagues	have	reported	that	restricted	MkPs	are	primarily	
found	within	the	CD34+	CD38–	Thy1–	CD45RA–	CD49f+	HSC	compartment	of	the	human	BM,	
and	that	these	cells	are	rarely	generated	by	CMPs	and	MEPs	[24].	By	dividing	the	MPP,	CMP	
and	 MEP	 compartments	 using	 CD71	 and	 Mpl,	 the	 authors	 also	 reported	 that	 HSPC	
compartments	 are	 largely	 comprised	 of	 unilineage	 progenitors,	 rather	 than	 multilineage	
progenitors,	 during	 adult	 haematopoiesis.	 Additionally,	 the	 existence	 of	 lineage-biased	
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populations,	such	as	MyHSCs	and	LyHSCs,	further	support	a	model	whereby	HSCs	begin	to	
commit	towards	lineage	fates	during	the	early	stages	of	differentiation	[9,	29-31,	309,	331].	
The	selective	expression	of	particular	HGF	receptors,	as	seen	in	Section	3.5.2	and	3.6.2,	may	
represent	an	early	stage	in	this	process.		
	
Recent	studies	that	have	characterised	progenitor	populations	using	single	cell	analysis	also	
provide	evidence	for	the	early	lineage	commitment	of	HSPCs.	Using	lentiviral	barcodes	to	tag	
individual	CMPs,	Perié	et	al.	monitored	the	cellular	output	of	CMPs	following	transplantation	
into	irradiated	hosts	and	reported	that	few	cells	possessed	oligopotent	properties	[332].	The	
CMP	compartment	was	divided	into	multiple	subpopulations	that	were	already	committed	to	
the	 DC,	 megakaryocyte,	 erythroid	 and	 GM	 lineages.	 Paul	 and	 co-workers	 have	 reported	
similar	 findings	by	analysing	RNA	sequencing	data	 from	2,730	single	 index	 sorted	myeloid	
progenitors	 (LS−K	 cells)	 [304].	 The	 group	 identified	 19	 transcriptionally	 homogeneous	 cell	
populations	in	the	LS−K	compartment	that	could	not	be	defined	using	conventional	CD34	and	
CD16/32	staining.	Within	the	CMP	gating	strategy	(LS−K	CD34lo	CD16/32lo),	progenitors	with	
distinct	erythrocyte,	megakaryocyte,	basophil,	monocyte	and	DC	transcriptional	profiles	were	
identified,	suggesting	that	commitment	towards	these	lineages	occurs	upstream	of	the	CMP	
compartment.	
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Figure	3.36.	Mapping	of	Flt3	and	M-CSFR	protein	expression	to	the	pairwise	model.	Values	
shown	correspond	 to	 the	percentage	of	 cells	within	 the	given	HSPC	population	 that	were	
found	to	express	Flt3	and	M-CSFR	protein.	The	legend	is	shown	in	the	top	right	corner.	For	
these	 experiments,	 HPC-1	 was	 isolated	 as	 LSK	 CD48+	 CD150−	 Flt3−/lo.	 LT-HSC,	 long-term	
haematopoietic	 stem	cell;	 ST-HSC	 short-term	haematopoietic	 stem	cell;	MPP,	multipotent	
progenitor;	HSPC,	haematopoietic	stem	and	progenitor	cell;	HPC,	haematopoietic	progenitor	
cell;	 LMPP,	 lymphoid-primed	multipotent	 progenitor;	 CLP,	 common	 lymphoid	 progenitor;	
CMP,	 common	 myeloid	 progenitor;	 GMP,	 granulocyte-macrophage	 progenitor;	 MEP,	
megakaryocyte-erythroid	progenitor;	Flt3,	 fms-like	tyrosine	kinase	3;	M-CSFR,	macrophage	
colony-stimulating	factor	receptor.	
	
	
These	reports	provide	evidence	to	suggest	that	HSCs	are	primed	towards	myeloid-lineages	at	
an	early	 stage	of	 their	maturation.	 Indeed,	MyHSCs	are	upstream	of	 LyHSCs	 [25,	26],	 and	
studies	 that	 have	 investigated	 transcriptional	 lineage	 priming	 in	 HSCs	 have	 shown	 that	
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myeloid-related	 genes	 are	 enriched	 in	 the	 most	 primitive	 haematopoietic	 compartments	
prior	to	onset	of	lymphoid-associated	gene	expression.	In	2007,	Månsson	et	al.	used	multiplex	
single	 cell	 gene	 expression	 analysis	 to	 investigate	 lineage	 priming	 in	 single	 LT-HSCs	 (LSK	
CD34+Flt3−)	and	ST-HSCs	(LSK	CD34+Flt3−).	They	reported	that	of	the	single	LT-HSCs	analysed,	
37%	were	MegE	primed,	33%	were	GM	primed	and	virtually	none	were	 lymphoid	primed.	
When	analysing	single	ST-HSCs,	23%	were	MegE	primed,	81%	were	GM	primed	and,	again,	
lymphoid	priming	was	rarely	observed.	Similarly,	Akashi	et	al.	have	shown	that	most	single	
HSCs,	isolated	as	LSK	Thy1.1lo	cells	that	retain	low	levels	of	rhodamine	123	(Rh),	express	a	high	
level	of	MegE-	or	GM-associated	genes	but	 few	 lymphoid-associated	genes	 [333].	As	HSCs	
progressed	to	the	LSK	Thy1.1lo	Rhhigh	MPP	stage,	fewer	cells	were	MegE	or	GM	primed,	and	
lymphoid	priming	was	detected	in	approximately	30%	of	cells.	These	studies	might	explain	
the	differential	regulation	of	Flt3,	M-CSFR	and	EPOR	as	HSCs	make	the	transition	to	MPPs.	
Flt3	was	 upregulated	during	 this	 transition,	while	EPOR	 and	M-CSFR	were	downregulated	
(Figure	3.17).	EpoR	and	M-CSFR	may	be	preferentially	expressed	in	more	primitive	cells	during	
MegE	and	GM	priming	to	sensitise	the	cells	to	Epo	and	M-CSF,	respectively	[267,	269],	while	
Flt3	may	be	upregulated	as	the	cells	transition	through	a	more	mature	GM-lymphoid	primed	
state,	allowing	Flt3L	 to	drive	myelomonocytic,	granulocytic	and	 lymphoid	production	 from	
this	compartment	[288].	
	
In	support	of	this,	flow	cytometric	analysis	revealed	that	expression	of	the	Flt3	receptor	was	
strongly	 correlated	 with	 a	 functional	 subpopulation	 of	 HSCs	 (Figure	 3.34).	 High	 levels	 of	
CD150	expression	on	the	surface	of	HSCs	are	associated	with	increased	self-renewal	capacity	
and	 a	 bias	 towards	 the	myeloid	 lineage	 [25,	 26].	 These	 cells	 are	 capable	 of	 giving	 rise	 to	
CD150int	cells	that	possess	decreased	MegE	potential	and	self-renewal	capacity.	When	Flt3+	
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HSCs	were	divided	into	CD150hi	and	CD150int	fractions,	significantly	more	Flt3+	cells	expressed	
intermediate	levels	of	CD150	on	their	surface	when	compared	to	Flt3−	cells	[p=0.0022].	This	
finding	 suggests	 that	 Flt3	 is	 upregulate	 upon	 transition	 of	 HSCs	 towards	 a	 GM-lymphoid	
primed	state	(See	section	3.7.2	for	further	discussion).	
	
Altogether,	 this	study	has	 identified	a	number	of	subpopulations	within	 the	HSC	and	MPP	
compartments	based	on	expression	of	Flt3,	M-CSFR	and	EPOR.	These	receptors	are	rarely	co-
expressed,	 and	 are	 differentially	 regulated	 as	 HSCs	 begin	 to	 mature,	 suggesting	 that	
expression	 of	 these	 receptors	 mark	 different	 stages	 of	 lineage	 priming	 during	 early	
haematopoiesis.	Isolation	and	characterisation	of	Flt3+,	M-CSFR+	and	Epor+	HSCs	will	help	to	
determine	 if	 there	 is	 a	 hierarchical	 relationship	 between	 these	 populations	 and	 provide	
further	 insight	 into	how	HGFs	 regulate	early	haematopoiesis.	Furthermore,	 identifying	 the	
factors	that	regulate	the	expression	of	these	receptors	in	HSCs	will	likely	help	to	discern	how	
lineage	commitment	first	occurs	during	haematopoiesis.	
	
3.7.2			Expression	of	Flt3	within	the	haematopoietic	stem	cell	
compartment	 is	 associated	 with	 decreased	 self-renewal	
capacity	
	
As	 mentioned	 in	 the	 previous	 section,	 Flt3	 expression	 within	 the	 HSC	 compartment	 was	
associated	with	a	functional	subpopulation	of	HSCs	that	express	intermediate	levels	of	CD150	
on	their	surface	[p=0.0022].	In	comparison	to	the	more	mature	CD150hi	HSCs,	CD150int	cells	
are	not	as	efficient	at	producing	MegE	cells,	and	are	less	able	to	self-renew	[25,	26].	In	line	
with	 previous	 findings	 [19-21],	 this	 result	 indicates	 that	 Flt3	 upregulation	within	 the	 HSC	
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compartment	is	associated	with	a	decrease	in	MegE	potential	and	self-renewal	capacity.	As	
such,	it	is	possible	that	the	LSK	CD150+	CD48−	cells	expressing	the	Flt3	receptor	represent	a	
population	of	short-term/transiently	repopulating	GM-lymphoid-biased	progenitors,	rather	
than	true	HSCs.	
	
The	Jacobsen	group	has	performed	a	number	of	studies	to	investigate	if	self-renewing	cells	
within	the	HSC	compartment	express	Flt3.	In	2001,	Adolfsson	et	al.	transplanted	LSK	Flt3+	and	
LSK	 Flt3−	 cells	 into	 irradiated	hosts	 and	 compared	 the	multilineage	 reconstitution	of	 each	
population	[19].	The	authors	reported	that	LSK	Flt3+	failed	to	support	long-term	myelopoiesis,	
and	proposed	that	Flt3	was	upregulated	as	cells	 lost	self-renewal	ability	and	differentiated	
towards	 the	 lymphoid	 lineage.	 In	 a	 following	 study,	 Yang	et	al.	 added	CD34	 to	 the	 above	
staining	strategy	and	performed	a	similar	investigation	[21].	LSK	cells	were	divided	into	CD34−	
Flt3−,	CD34+	Flt3−	and	CD34+	Flt3+	fractions	and	assessed	for	their	ability	to	reconstitute	the	
haematopoietic	system	in	vivo.	In	agreement	with	the	previous	study,	the	LSK	CD34+	Flt3+	cells	
were	inefficient	at	reconstituting	myeloid	cells	when	compare	to	the	LSK	CD34−	Flt3−	and	LSK	
CD34+Flt3−	compartments,	and	the	authors	identified	these	cells	as	MPPs	with	limited	self-
renewal	 potential.	More	 recently,	 Buza-Vidas	et	 al.	 have	used	FLT3-Cre:loxp-eYFP	mice	 to	
investigate	 if	 FLT3	 gene	 expression	 is	 initiated	 in	 self-renewing	 cells	 present	 in	 the	 HSC	
compartment	[323].	Again,	the	group	preformed	BM	transplantation	assays	and	monitored	
the	 output	 of	 LSK	 eYFP+	 and	 LSK	 EFYP−	 in	 vivo.	 eYFP−	 cells	 but	 not	 EFYP+	 cells	 robustly	
reconstituted	the	myeloid	lineage	in	secondary	recipients	after	6	months,	and	the	Jacobsen	
group	concluded	that	FLT3	expression	did	not	mark	self-renewing	HSCs	[323].	
	
The	studies	performed	by	the	Jacobsen	group	provide	evidence	to	suggest	that	FLT3	and	its	
encoded	protein	are	not	expressed	by	self-renewing	LSK	CD150+	CD48−	cells.	However,	the	
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experimental	approaches	used	in	these	studies	may	not	have	been	sensitive	enough	to	detect	
a	 rare	population	of	 self-renewing	Flt3+/Flt3+	cells	 [323].	Firstly,	 the	above	studies	did	not	
assess	the	ability	of	LSK	CD34−	Flt3+	cells	to	reconstitute	irradiated	hosts.	Additionally,	as	Buza-
Vidas	 et	 al.	 used	 the	 same	 number	 of	 LSK	 eYFP+	 and	 LSK	 EFYP−	 in	 their	 transplantation	
experiments,	 then	 unequal	 numbers	 of	 Flt3+/Flt3+	 and	 Flt3−/Flt3−	 HSCs	 would	 have	 been	
compared	during	the	experiments,	as	Flt3+/Flt3+	cells	represent	such	a	small	fraction	of	the	
HSC	compartment.	Secondly,	self-renewal	capacity	was	evaluated	based	on	the	ability	of	cells	
to	reconstitute	the	myeloid	lineage	in	all	three	studies,	so	the	analysis	did	not	consider	that	
Flt3+	and	Flt3−	HSCs	may	have	different	lineage	potentials.	To	address	these	shortcomings,	it	
will	be	 important	 in	future	studies	to	perform	single-cell	 reconstitution	assays	using	single	
Flt3+	and	Flt3−	LSK	CD150+	CD48−	CD34−	cells	in	order	to	comprehensively	investigate	if	Flt3	is	
present	on	the	surface	of	a	rare	subpopulation	of	self-renewing	LSK	CD150+	CD48−	CD34−	cells.	
	
3.7.3			Heterogenic	 patterns	 of	 Flt3,	 EpoR	 and	 M-CSFR	
expression	 identify	distinct	subpopulations	within	maturing	
progenitor	compartments.	
	
The	expression	of	Flt3,	EpoR	and	M-CSFR	by	haematopoietic	progenitors	was	also	investigated	
to	 determine	 if	 these	 receptors	 were	 differentially	 expressed	 at	 later	 stages	 during	
haematopoiesis.	As	can	be	seen	from	Figure	3.35	and	Figure	3.36,	HGF	receptor	gene	and	
protein	expression	within	the	HSPC	compartments	changes	as	cells	mature	towards	particular	
cell	fates.	For	example,	as	cells	mature	towards	the	erythroid	lineage	via	the	MPP,	CMP,	HPC-
2	 and	MEP	 compartments,	 the	 number	 of	 cells	 expressing	 EPOR	 within	 each	 subsequent	
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population	steadily	increases.	Conversely,	populations	that	are	primed	towards	non-erythroid	
fates	 contain	 little	 to	 no	 cells	 that	 express	 EPOR.	 A	 similar	 pattern	 can	 be	 seen	 when	
considering	CSF1R	and	M-CSFR	expression.	 Interestingly,	expression	of	Flt3	protein	and	 its	
gene	followed	a	biphasic	pattern.	Only	a	small	number	of	cells	within	the	HSC	compartments	
expressed	 FLT3,	 but	 by	 the	 LMPP	 stage,	 almost	 all	 cells	were	 FLT3+.	 The	 number	 of	 cells	
expressing	FLT3	then	decreased	upon	transition	from	the	LMPP	stage	to	the	CLP	and	GMP	
compartments.	The	pattern	of	Flt3	protein	expression	is	similar,	though	the	decrease	in	Flt3+	
cells	upon	transition	from	the	LMPP	to	CLP	compartment	is	marginal.	As	M-CSFR	and	EpoR	
are	associated	with	the	GM	and	erythroid	 lineages,	the	expression	patterns	seen	in	Figure	
3.35	 and	 Figure	 3.36	 are	 unremarkable.	 However,	 it	 is	 interesting	 that	 Flt3	 is	 primarily	
expressed	by	progenitors,	such	as	the	LMPP.	Flt3	is	strongly	associated	with	the	DC	lineage,	
so	it	is	likely	that	Flt3	marks	progenitors	with	DC	potential	(further	discussed	below).	These	
findings	 indicate	 that	 Flt3	 primarily	 acts	 to	 regulate	 progenitor	 populations	 rather	 than	
mature	cell	populations.	
	
Notably,	the	single-cell	analysis	of	HGF	receptor	gene	and	protein	expression	revealed	distinct	
subpopulations	 within	 all	 progenitor	 compartments.	 Most	 populations	 could	 be	 clearly	
divided	based	on	the	expression	of	a	particular	HGF	receptor	(Figure	3.17	and	Figure	3.27B),	
and	some	populations	expressed	highly	variable	levels	of	each	gene	(Figure	3.18).	The	CMP	
population	is	a	prime	example	of	this.	Flt3	and	M-CSFR	proteins	were	expressed	by	29%	±	3.6	
and	27%	±	0.8	of	CMPs,	respectively,	while	43%	±	2.8	of	CMPs	expressed	EPOR.	Even	when	
comparing	CSF1R	expression	levels	between	individual	cells	there	were	disparities,	as	some	
Csf1r+	 CMPs	 expressed	 levels	 that	were	 40-fold	 higher	 than	 other	Csf1r+	 CMPs.	 The	 data	
presented	 here	 identify	 a	 large	 number	 of	 lineage-associated	 sub-fractions	 within	
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haematopoietic	 progenitor	 compartments	 based	 on	 the	 expression	 of	 HGF	 receptors,	
underscoring	the	heterogeneous	nature	of	these	populations.		
	
As	outlined	in	Section	3.7.1,	a	number	of	recent	studies	have	indicated	that	currently	defined	
oligopotent	 HPC	 compartments	 contain	 a	 heterogeneous	 mixture	 of	 lineage	 committed	
progenitors,	 rather	 than	 a	 uniform	 population	 of	 oligopotent	 progenitors	 [24,	 304,	 332].	
Current	 evidence	 also	 suggests	 that	 a	 number	 of	 oligopotent	 haematopoietic	 progenitor	
compartments	 can	 be	 subdivided	 into	 lineage	 committed	 subpopulations	 based	 on	 the	
expression	of	HGF	receptors.	Within	the	CMP	compartment,	DC	committed	progenitors	can	
be	isolated	based	on	their	expression	of	M-CSR	and	Flt3	[304].	Similarly,	the	DC	potential	of	
the	CLP	compartment	is	restricted	to	the	Flt3+	compartment	[311].	Chi	et	al.	have	also	used	
Flt3	to	isolate	unipotent	T-lymphocyte	progenitors	from	the	preGM	population	[77].	Finally,	
the	limited	megakaryocyte	potential	of	the	LSK	Flt3hi	compartment	is	restricted	to	the	Mpl+	
fraction	of	this	population	[334].	
	
These	studies	indicate	that	the	HGF	receptor	expression	patterns	identified	in	this	study	likely	
distinguish	functionally	distinct	subpopulations	within	the	Flt3−/lo	HPC-1,	HPC-2,	LMPP,	CLP,	
CMP	and	GMP	compartments.	For	example,	isolation	of	LMPPs	based	on	the	expression	of	
the	M-CSFR	may	allow	for	enrichment	of	the	GM	potential	within	this	compartment,	while	it	
is	 possible	 that	 EPOR	 expression	 within	 the	 CMP	 compartment	 marks	 EPs.	 If	 these	
subpopulations	identify	restricted	progenitors,	then	this	would	provide	further	evidence	to	
suggest	 that	 lineage	commitment	occurs	 in	early	HSPC	compartments,	 such	as	 the	HSC	or	
MPP	compartment	(see	Section	3.7.1	for	further	discussion).	Isolation	and	characterisation	
of	 the	 HPC	 subpopulations	 identified	 in	 this	 study	 will	 be	 required	 to	 confirm	 this.	
Furthermore,	 lineage	 fate	mapping	 analysis	 of	 these	 populations	would	 help	 to	 elucidate	
	
	
181	
when	lineage	commitment	occurs	during	haematopoiesis,	and	how	Flt3,	M-CSFR	and	EpoR	
play	a	role	in	this	process.	
	
3.7.4			The	 HemaExplorer	 and	 BloodSpot	 databases	 provide	
accurate	information	regarding	the	expression	of	FLT3,	EPOR	
and	CSF1R	during	haematopoiesis.	
	
The	 data	 extracted	 from	 the	 HemaExplorer	 and	 BloodSpot	 databases	 revealed	 that	 the	
expression	of	FLT3,	EPOR,	CSF1R	and	CSF3R	was	largely	restricted	to	cells	that	possessed	GM-
lymphoid,	erythroid,	GM	and	granulocytic	potential,	respectively,	and	this	was	comparable	to	
the	data	generated	from	the	single	cell	gene	expression	analysis	(Figure	3.1).	According	to	the	
HemaExplorer	 and	 BloodSpot	 databases,	 FLT3	 expression	was	 the	 highest	 in	 the	 CLP	 and	
LMPP	populations.	It	was	also	expressed	by	LT-HSCs,	ST-HSCs,	LMPPs,	preGMs,	CLPs,	Pro-B-
lymphocytes	and	ETPs,	and	to	a	lesser	extent,	the	GMP	population	(Figure	3.1).	The	erythroid	
and	 megakaryocyte	 progenitors	 expressed	 levels	 of	 FLT3	 that	 suggested	 amplification	 of	
contaminating	gDNA,	indicating	that	these	cells	do	not	express	Flt3	mRNA.	A	similar	pattern	
was	seen	when	HSPCs	were	analysed	using	single	cell	qRT-PCR	analysis.	Both	the	LMPP	and	
CLP	 population	 contained	 a	 high	 number	 of	 Flt3+	 cells,	 reflecting	 the	 high	 levels	 of	 FLT3	
expression	observed	when	analysing	the	databases.	Flt3	was	also	regularly	detected	in	the	
LT-HSC,	 ST-HSC,	 CMP	 and	GMP	 compartments,	 but	was	 absent	 from	 the	MEP	 population	
(Figure	3.17A).		
	
Similarly,	the	patterns	of	EPOR	expression	observed	from	single	cell	gene	expression	analysis	
was	analogous	to	the	HemaExplorer	and	BloodSpot	databases.	As	can	be	seen	from	the	data	
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extracted	 from	 the	 databases	 (Figure	 3.1),	 EPOR	 was	 highly	 expressed	 in	 the	 CFU-E,	 EP,	
preCFU-E	 and	 MEP	 populations.	 Epor	 was	 also	 detected	 in	 the	 LT-HSC	 and	 ST-HSC	
compartments.	On	the	other	hand,	the	GMP,	CLP	and	LMPP	compartments	expressed	levels	
of	EPOR	that	suggested	amplification	of	gDNA,	indicating	that	these	cells	did	not	express	Epor	
mRNA.	Although	the	single	cell	gene	expression	analysis	used	in	this	study	was	not	performed	
on	CFU-E,	EP	and	preCFU-E	populations,	almost	all	MEPs	expressed	EPOR	(Figure	3.17B),	and	
these	cells	expressed	the	highest	mean	 levels	of	EPOR	when	compared	to	the	other	HSPC	
populations	that	were	analysed	(Figure	3.18B).	On	the	other	hand,	EPOR	expression	was	not	
detected	in	the	LMPP	or	CLP	compartments,	and	was	only	detected	in	1	of	96	GMPs.	When	
analysing	the	LT-HSC	and	ST-HSC	compartments,	EPOR	expression	was	detected	 in	a	small	
number	 of	 cells,	 further	 supporting	 the	 accuracy	 of	 the	 databases	 in	 regard	 to	 EPOR	
expression	patterns.	
	
The	CSF1R	gene	expression	data	acquired	from	the	HemaExplorer	and	BloodSpot	databases	
also	accurately	reflected	the	findings	from	the	single	cell	gene	expression	analysis.	According	
to	the	HemaExplorer	and	BloodSpot	databases,	GMPs	expressed	high	levels	of	CSF1R,	while	
lower	levels	were	expressed	by	CLPs	and	LMPPs.	Again,	the	levels	at	which	CSF1R	expression	
was	detected	within	the	MegE	progenitor	populations	suggested	contamination	of	gDNA	and	
therefore,	that	these	cells	do	not	express	Csf1r	mRNA.	The	LT-HSC	and	ST-HSC	compartments	
expressed	slightly	higher	levels	of	CSF1R	than	the	MEP,	so	it	was	unclear	whether	this	was	
due	to	contaminating	gDNA	or	low	levels	of	Csf1r	mRNA	expression.	When	analysing	single	
cells,	a	high	proportion	of	GMPs	were	Csf1r+	(Figure	3.17C),	and	this	population	expressed	the	
highest	mean	levels	of	CSF1R	when	compared	to	the	other	HSPC	populations	(Figure	3.18C).	
A	 small	 number	 of	 CLPs	 and	 LMPPs	 were	 found	 to	 express	 CSF1R,	 so	 this	 would	 have	
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accounted	for	the	low	levels	of	CSF1R	expression	observed	when	analysing	the	HemaExplorer	
and	BloodSpot	databases.	CSF1R	was	not	expressed	by	single	MEPs,	confirming	the	findings	
generated	from	the	database.	Lastly,	expression	of	CSF1R	was	only	detected	in	very	few	single	
HSCs,	so	this	was	in	agreement	with	the	slightly	increased	levels	of	CSF1R	expression	in	LT-
HSCs	and	ST-HSCs	when	compared	to	the	MEP	population	in	the	database	values.		
	
Overall,	 the	data	presented	here	 indicate	 that,	although	the	HemaExplorer	and	BloodSpot	
databases	do	not	provide	information	regarding	single	cell	gene	expression,	they	provide	an	
accurate	source	for	data	regarding	the	expression	of	FLT3,	EPOR	and	CSF1R	within	whole	HSPC	
populations.		 	
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CHAPTER	4:			 INVESTIGATION	 OF	 FUNCTIONAL	
FLT3	 RECEPTOR	 EXPRESSION	 WITHIN	 THE	
HAEMATOPOIETIC	STEM	CELL	COMPARTMENT	
	
4.1			Introduction	
	
The	 studies	 undertaken	 in	Chapter	 3	 investigated	 the	 expression	 of	 the	 Flt3	 and	M-CSFR	
proteins,	and	the	FLT3,	EPOR	and	CSF1R	genes	by	HSPCs	to	determine	the	extent	to	which	
these	 receptors	 are	 heterogeneously	 expressed	within	HSPC	 compartments,	 and	whether	
early	HSPCs	co-express	these	receptors.	Expression	of	the	FLT3	and	EPOR	genes,	and	Flt3	and	
M-CSFR	 proteins,	 were	 detected	 in	 subpopulations	 within	 the	 LT-HSC,	 ST-HSC	 and	 MPP	
compartments.	Early	HSPCs	have	been	shown	to	respond	to	M-CSF	and	Epo	by	upregulating	
lineage-associated	 genes	 and	 acquiring	 a	 GM	 and	 erythroid	 fate,	 respectively	 [267,	 269].	
However,	while	past	studies	have	reported	the	expression	of	FLT3	and	its	encoded	protein	
within	the	LSK	CD150+	CD48−	compartment	[34,	323,	329],	the	influence	of	Flt3L	on	these	cells	
is	unclear.	
	
Tsapogas	et	al.	recently	reported	that	a	substantial	increase	in	the	level	of	Flt3L	in	vivo	causes	
a	 dramatic	 expansion	 of	 myelomonocytic,	 granulocytic	 and	 lymphoid	 progenitors,	 and	 a	
decrease	in	the	number	of	MEPs	and	EPs	in	the	BM	[288].	Intraperitoneal	injection	of	Flt3L	
into	mice	resulted	in	a	rapid	reduction	of	EPs	and	MEPs,	and	the	kinetics	of	this	response	led	
the	 authors	 to	 hypothesise	 that	 Flt3L	 instructs	 LSK	 CD150−	 CD48+	 cells	 towards	 a	 GM-
lymphoid	fate	at	the	expense	of	a	MegE	fate	[288].	As	Flt3	expression	is	present	within	the	
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LSK	CD150+	CD48−	and	LSK	CD150−	CD48−	compartments	(Figure	3.27),	Flt3L	may	drive	lineage	
fate	in	the	most	primitive	compartments	of	the	BM.	In	this	regard,	it	is	important	to	determine	
if	these	compartments	are	able	to	respond	to	Flt3L.	
	
4.1.1			Role	of	Flt3	during	early	haematopoiesis	
	
hHSCs	have	been	shown	to	reside	within	the	Lin−	CD34+	CD38−	compartment	of	BM	and	cord	
blood	[47,	50],	and	over	90%	of	Lin−	CD34+	CD38−	hHSCs	express	Flt3	[335,	336].	Additionally,	
culture	of	Lin−	CD34+	CD38−	hHSCs	with	Flt3L	increases	their	survival	in	vitro	[336].	Although	
the	Lin−	CD34+	CD38−	BM	and	cord	blood	compartment	in	humans	is	heterogeneous,	these	
studies	suggest	that	Flt3L	is	important	for	the	function	of	hHSCs.	On	the	other	hand,	the	role	
of	Flt3	during	the	early	stages	of	murine	haematopoiesis	is	not	as	clear.	In	1994,	Zeigler	et	al.	
were	the	first	to	propose	that	Flt3	was	absent	from	the	most	primitive	mouse	haematopoietic	
compartment	of	the	BM	[337].	They	isolated	Flt3+	Lin−/low	Sca1+	and	Flt3−	Lin−/low	Sca1+	BM	
cells	and	performed	reconstitution	assays	using	these	populations.	The	Flt3−	Lin−/low	Sca1+	cells	
more	efficiently	reconstituted	irradiated	recipients	when	compared	to	the	Flt3+	Lin−/low	Sca1+	
population,	 and	 the	 authors	 concluded	 that	 Flt3	was	 upregulated	 as	 stem	 cells	 began	 to	
mature.	In	later	studies,	both	the	Jacobsen	and	Weissman	groups	used	BM	transplantation	
assays	to	characterise	the	mouse	Flt3+	LSK	and	Flt3−	LSK	BM	populations,	and	reported	that	
Flt3	 expression	 within	 the	 LSK	 compartment	 marked	 a	 population	 of	 stem	 cells	 with	
decreased	self-renewal	capacity	when	compared	to	the	Flt3−	population	[19,	20].	
	
In	2005,	the	Jacobsen	group	provided	further	evidence	that	Flt3	is	absent	from	mouse	HSCs,	
and	also	reported	that	Flt3	is	upregulated	at	the	expense	of	MegE	potential	[21,	73].	In	the	
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first	study,	Yang	et	al.	characterised	the	LSK	compartment	based	on	Flt3	and	CD34	expression,	
and	proposed	a	haematopoietic	hierarchy	in	which	LT-HSCs	and	ST-HSCs	are	Flt3−,	and	Flt3	is	
upregulated	as	ST-HSCs	make	the	transition	to	a	transiently	reconstituting	MPP	state	[21].	
Subsequently,	 Adolfsson	 et	 al.	 assessed	 the	 ability	 of	 LSK	 subpopulations	 to	 give	 rise	 to	
erythrocytes	and	platelets,	and	reported	that	the	Flt3+	LSK	compartment	failed	to	generate	
MegE	progenitors	in	vitro	and	in	vivo	[73].		
	
Initial	studies	of	Flt3−/−	and	Flt3L−/−	mice	also	support	an	association	between	Flt3	expression,	
decreased	 self-renewal,	 and	 a	 loss	 of	 MegE	 potential.	 In	 1995,	 Mackarehtschian	 et	 al.	
generated	a	transgenic	mouse	model	which	 lacks	Flt3	expression,	and	reported	that	these	
mice	show	decreased	levels	of	B-lymphocyte	progenitors,	when	compared	to	WT	mice	[338].	
When	transplanted	into	irradiate	hosts,	Flt3−/−	cells	showed	a	deficiency	in	T-lymphocyte,	B-
lymphocyte,	monocyte	and	granulocyte	production	over	39	weeks.	Similarly,	McKenna	and	
co-workers	have	 shown	 that	 Flt3L−/−	mice	have	 less	B-lymphocytes,	DCs,	NK	 lymphocytes,	
granulocytes	and	monocytes	when	compared	to	WT	mice	[339].	The	Jacobsen	group	has	also	
generated	Flt3−/−	and	Flt3L−/−	mice,	and	has	characterised	them	in	parallel	[321,	340].	In	two	
separate	studies,	the	group	reported	that	Flt3	and	its	ligand	are	not	required	for	expansion	of	
myeloid	 progenitors	 during	 steady-state	 haematopoiesis	 or	 following	 transplantation	 of	
whole	BM.	Notably,	HSCs	(LSK	CD34−	[321]/LSK	CD150+	[340])	were	not	significantly	altered	in	
these	mice,	or	when	used	to	reconstitute	primary	or	secondary	hosts,	when	compared	to	WT	
mice.	While	these	studies	provided	contradicting	evidence	regarding	the	role	of	Flt3	in	the	
generation	of	myelomonocytic	and	granulocytic	cells,	none	of	these	studies	suggest	a	role	for	
Flt3	or	its	ligand	in	the	maintenance	of	HSCs,	or	the	generation	of	erythrocytes	and	platelets.		
	
Other	studies	have	challenged	the	association	between	Flt3	and	the	loss	of	MegE	potential,	
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suggesting	 that	multipotent	 cells	express	Flt3.	 In	2006,	Forsberg	et	al.	observed	 that	Flt3+	
progenitors	 gave	 rise	 to	 very	 small	number	of	platelets	when	 transplanted	 into	 irradiated	
hosts,	albeit	with	lower	efficiency	than	Flt3−	cells	[341].	Shortly	after,	Lai	et	al.	divided	LSK	
Thy-1.1−	 Flt3+	 cells	 into	 Flt3hi	 and	 Flt3low	 fractions,	 and	 reported	 that	 Flt3low	 cells	 could	
generate	 MEPs	 in	 vivo	 [324].	 These	 findings	 prompted	 the	 Jacobsen	 group	 to	 further	
investigate	the	ability	of	LMPPs	to	contribute	to	the	MegE	 lineage	[334].	They	 identified	a	
small	number	(1-2%)	of	BM	LMPPs	cells	that	expressed	Mpl,	and	reported	that	these	cells	are	
capable	of	producing	megakaryocytes	and	platelets	when	transplanted	into	irradiated	hosts.	
	
Recent	 lineage	 fate	 mapping	 experiments	 also	 indicate	 that	 all	 lineages,	 including	 the	
erythroid	and	megakaryocyte	lineages,	can	be	derived	from	a	FLT3+	multipotent	progenitor.	
Buza-Vidas	et	al.	generated	a	FLT3-Cre:loxp-eYFP	transgenic	mouse	model	and	showed	that	
over	70%	of	 lymphoid,	GM	and	MegE	progenitors	were	eYFP+	 [323].	Similarly,	Boyer	et	al.	
created	a	FLT3-Cre	“FlkSwitch”	mouse	model	in	which	all	FLT3−	cells	that	are	not	derived	from	
a	FLT3+	progenitor	express	the	red	fluorophore,	Tomato	[342].	Upon	upregulation	of	FLT3,	
Tomato	is	irreversibly	excised	and	GFP	expression	is	induced,	allowing	for	GFP	labelling	of	all	
progeny.	With	this	mouse	model,	the	authors	reported	that	up	to	98%	of	erythroid	cells	and	
platelets	were	GFP+,	indicating	a	FLT3+	ancestor	of	these	cells.	Finally,	the	Forsberg	group	has	
recently	reported	contradictory	findings	to	other	Flt3	knockout	studies.	The	group	showed	
that	Flt3−/−	mice	have	impaired	development	of	lymphoid,	GM	and	MegE	progenitors	[343],	
further	supporting	the	findings	reported	by	FLT3	lineage	fate	mapping.		
	
From	these	studies,	there	is	strong	evidence	to	suggest	that	MegE	potential	is	not	exclusive	
to	cells	that	lack	Flt3	expression.	However,	the	relationship	between	the	upregulation	of	Flt3	
and	loss	of	self-renewal	ability	may	still	hold	true.	Indeed,	as	was	shown	in	Figure	3.34,	Flt3	
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expression	 within	 the	 LSK	 CD150+	 CD48−	 compartment	 of	 the	 BM	 correlates	 with	 a	
subpopulation	of	cells	that	express	intermediate	levels	of	CD150	on	their	surface	and	have	
decreased	self-renewal	ability	when	compared	to	CD150hi	cells.	Thus,	it	is	possible	that	Flt3+	
cells	in	the	LSK	CD150−	CD48−	and	LSK	CD150+	CD48−	compartments	represent	multipotent	
cells	that	lack	self-renewal	capacity.	This	would	fit	with	the	model	proposed	by	Tsapogas	et	
al.	whereby	Flt3L	instructs	MPPs,	and	not	HSCs	[288].		
	
4.1.2			Flt3	signalling	 in	haematopoietic	stem	and	progenitor	
cells	
	
Although	Flt3L	acts	on	Flt3+	HSPCs	to	drive	GM-lymphoid	production	[288],	the	cell-intrinsic	
mechanisms	that	drive	this	process	are	unknown.	Flt3,	like	M-CSFR	and	c-Kit,	belongs	to	the	
class	 III	 subfamily	 of	 receptor	 tyrosine	 kinases	 and	 plays	 a	 role	 in	 the	 regulation	 of	
haematopoietic	cell	survival,	proliferation	and	differentiation	[344-346].	The	receptor	has	an	
extracellular	 domain	 consisting	 of	 five	 immunoglobulin-like	 motifs,	 a	 single-pass	
transmembrane	domain,	 a	 juxtamembrane	domain,	 and	 two	 intracellular	 kinase	domains.	
When	inactive,	it	is	present	on	the	cell	membrane	as	a	monomeric	unphosphorylated	protein.	
Binding	 of	 Flt3L	 promotes	 dimerisation	 of	 the	 receptor	 and,	 subsequently,	
autophosphorylation	 of	 tyrosine	 residues	 in	 the	 juxtamembrane	 domain	 [347,	 348].	 This	
results	in	the	recruitment	and	activation	of	a	number	of	adapter	proteins,	such	as	SHC,	GRB2	
and	CBL	[349-351].	Stimulation	of	Flt3	leads	to	activation	of	phosphoinositide	3	kinase	(PI3K)	
and	Ras	pathways	[352,	353].	Downstream	PI3K	signalling	is	mediated	via	Akt	and	mammalian	
target	of	rapamycin	(mTOR),	while	Ras	stimulates	the	activation	of	mitogen-activated	protein	
kinase	(MAPK)	and	ERKs.	Both	pathways	mediate	protein	translation	via	the	activation	of	the	
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ribosomal	protein	S6,	which	is	part	of	the	40S	ribosomal	subunit	[353].	S6	is	phosphorylated	
by	ribosomal	protein	S6	kinases	which	are	activated	by	mTOR,	and	to	a	lesser	extent,	MAPK	
[353,	354].	Transcription	is	also	initiated	by	both	the	PI3K	and	Ras	pathways	and	is	promoted	
by	 the	 activation	 of	 STAT	 proteins,	 cyclic	 adenosine	 monophosphate	 response	 element-
binding	protein	and	Elk1	[353].		
	
Given	their	clinical	 relevance,	many	studies	have	 investigated	how	Flt3	containing	 internal	
tandem	 duplications	 (Flt3-ITD),	 which	 are	 commonly	 found	 in	 acute	myeloid	 leukaemias,	
control	transcriptional	regulation	[353,	355-357].	On	the	other	hand,	transcriptional	targets	
of	canonical	Flt3	signalling	have	not	been	as	well	characterised.	Furthermore,	studies	carried	
out	with	transfected	cell	lines	indicate	that	the	transcriptional	targets	of	canonical	Flt3	and	
Flt3-ITD	signalling	do	not	entirely	overlap	[358].	In	one	particular	study,	Mizuki	et	al.	analysed	
the	gene	expression	of	32Dcl3	cells	(a	myeloid	cell	line)	transfected	with	WT	Flt3	or	Flt3-ITD	
following	 Flt3L	 stimulation	 [358].	 The	 authors	 found	 that	 Flt3-ITD	 signalling	 suppressed	
expression	of	SPI1	and	CEBPA,	while	WT	Flt3	signalling	stimulated	expression	of	these	genes.	
Similarly,	 sorted	 Lin−	 IL-7Rα−	 Thy1.1−	 c-Kit+	 Flt3−	 mouse	 BM	 cells	 which	 include	 MEPs,	
upregulate	 SPI1	 and	 CEBPA,	 and	 their	 dendritic	 cell	 potential	 greatly	 increases,	 when	
transfected	 with	 human	 Flt3	 [276].	 SPI1	 and	 CEBPA	 encode	 TFs	 that	 are	 associated	 with	
lineage	priming	 and	differentiation	of	HSPCs	 [125,	 359-361].	 If	 these	 genes	 are	 targets	 of	
canonical	Flt3	signalling,	they	may	mediate	the	instructional	effects	of	Flt3L.	
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4.1.3			Aims	of	chapter	
	
The	Rolink	group	has	proposed	from	studies	of	Flt3-Tg	mice	that	Flt3L	acts	on	LSK	CD150−	
CD48+	cells	to	the	drive	production	of	GM-lymphoid	cells	at	the	expense	of	erythrocytes	and	
platelets.	However,	as	can	be	seen	in	Chapter	3,	Flt3	protein	is	present	within	compartments	
upstream	 of	 the	 LSK	 CD150−	 CD48+	 population.	 The	majority	 of	 LSK	 CD150−	 CD48−	MPPs	
express	high	levels	of	Flt3	(See	Figure	3.27	and	[34]),	so	it	is	possible	that	Flt3L	acts	on	this	
population	to	regulate	the	generation	of	GM-lymphoid	cells.	Furthermore,	Flt3	protein	was	
detected	 within	 the	 LSK	 CD150+	 CD48−	 compartment,	 so	 Flt3L	 might	 also	 regulate	 the	
differentiation	of	a	small	proportion	of	HSCs	within	the	BM.		
	
In	the	mouse,	Flt3L	has	been	long	thought	to	act	on	maturing	progenitors	rather	than	HSCs.	
This	is	in	contrast	to	human	haematopoiesis,	in	which	Flt3L	has	been	shown	to	regulate	hHSCs	
survival	[336].	However,	the	findings	from	Chapter	3,	and	previous	reports	from	Chu	et	al.,	
indicate	that	a	small	number	of	cells	within	the	murine	HSC	compartment	express	Flt3	[329].	
If	a	small	population	of	murine	HSCs	express	functional	Flt3	on	their	surface,	then	it	is	possible	
that	Flt3	plays	similar	roles	in	both	human	and	mouse	haematopoiesis	during	the	early	stages	
of	HSPC	development.	This	is	important	to	consider	when	interpreting	results	from	studies	
that	have	used	FLT3-ITD	mice	as	a	model	of	human	acute	myeloid	leukaemia.	Furthermore,	if	
Flt3	 expression	 does	 mark	 a	 small	 subpopulation	 of	 HSCs	 within	 the	 LSK	 CD150+	 CD48−	
compartment	of	the	mouse	BM,	then	isolation	and	characterisation	of	this	population	will	be	
crucial	in	improving	our	understanding	of	how	Flt3	regulates	early	haematopoiesis.	Thus,	the	
purpose	 of	 this	 chapter	 was	 to	 determine	 at	 what	 stage	 during	 haematopoiesis	 do	 cells	
express	functional	Flt3.	To	investigate	this,	the	response	of	the	early	HSPC	compartments	to	
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Flt3L	was	characterised	using	a	number	of	in	vitro	techniques.		
	
Firstly,	the	Flt3	signalling	pathway	in	HSCs	and	MPPs	were	analysed	following	a	short	period	
of	 stimulation	 with	 Flt3L.	 This	 was	 carried	 out	 using	 flow	 cytometry	 to	 monitor	
phosphorylation	events	within	the	Flt3	signalling	pathway	in	single	cells	stimulated	with	Flt3L.	
Secondly,	 the	potential	 role	of	 Flt3	 in	HSPC	 transcriptional	 regulation	was	 investigated	by	
analysing	 the	expression	of	SPI1	 in	 single	 cells	 cultured	with	and	without	 Flt3L.	 Finally,	 to	
investigate	if	Flt3	was	involved	in	HSC	differentiation	and	survival,	colony	forming	assays	using	
methylcellulose	medium	containing	Flt3L	were	utilised	to	monitor	progenitor	output.	
	
4.2			Phospho-protein	 analysis	 of	 downstream	
signalling	proteins	within	the	haematopoietic	stem	cell	
compartment	following	stimulation	with	Flt3L	
	
One	of	the	most	direct	methods	of	investigating	the	presence	of	functional	receptors	on	the	
cell	surface	is	to	monitor	activation	and	phosphorylation	of	downstream	signalling	proteins	
following	receptor-ligand	 interactions.	Western	blotting	 is	a	commonly	used	technique	for	
identifying	phosphorylated	proteins.	However,	this	technique	requires	a	large	number	of	cells	
for	 experiments	 and	 measures	 the	 average	 expression	 of	 a	 target	 within	 a	 population.	
Therefore,	 signalling	 events	 within	 sub-fractions	 of	 a	 population	 may	 not	 be	 detected.	
Analysis	of	phosphorylated	proteins	using	flow	cytometry,	or	phosphoflow	analysis,	allows	
for	interrogation	of	signalling	events	at	the	single	cell	level.	Thus,	phosphoflow	was	used	to	
monitor	the	Flt3	signalling	cascade	in	LSK	CD150+	CD48−	cells	after	culture	with	Flt3L.		
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In	 order	 to	 stain	 for	 intracellular	 phosphorylated	 targets,	 cells	 need	 to	 be	 fixed	 and	
permeabilised.	 Recent	 studies	 have	 used	 methanol	 and	 acetone	 to	 permeabilise	
haematopoietic	cells	for	phosphoflow	analysis	[362-364].	A	study	by	Krutzik	and	Nolan	in	2003	
suggests	that	permeabilisation	with	methanol	provides	better	staining	of	some	phosphoflow	
targets	when	compared	to	acetone,	such	as	pSTAT1,	pERK	and	pJNK	[363].	However,	analysis	
of	 HSPC-associated	 cell	 surface	 markers	 after	 methanol	 permeabilisation	 indicates	 that	
methanol	destroys	particular	antigens	that	are	crucial	for	HSPC	analysis,	including	Sca1	and	
CD150	[364,	365].	On	the	other	hand,	acetone	has	been	reported	to	only	affect	CD150	antigen	
integrity	[364].	To	examine	if	either	organic	solvent	would	allow	for	accurate	analysis	of	LSK	
CD150+	CD48−	and	LSK	CD150−	CD48−	cells,	the	integrity	of	the	cell	surface	markers	used	to	
identify	HSPCs	 in	 this	 study	was	determined	 following	 treatment	with	 either	methanol	 or	
acetone.		
	
Whole	BM	was	stained	for	the	lineage	markers	CD3ε,	CD11b,	B220,	Gr-1,	TER-119,	and	the	
HSPC	markers,	CD48,	c-Kit,	Sca1,	CD150,	and	CD34.	Once	the	cells	were	stained,	they	were	
fixed	 using	 1.6%	 PFA	 (prepared	 in	 the	 lab)	 for	 15	 minutes	 at	 room	 temperature	 and,	
subsequently,	 permeabilised	 for	 15	 minutes	 at	 -20°C	 using	 either	 ice-cold	 methanol	 or	
acetone.	Samples	were	analysed	using	flow	cytometry,	and	the	staining	profiles	of	treated	
samples	were	compared	to	untreated	samples	to	determine	if	methanol	or	acetone	affected	
the	antigen	integrity	of	any	of	the	cell	surface	markers.		
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Figure	4.1.	Verification	of	cell	surface	marker	antigenicity	following	fixation	and	permeabilisation	of	cells.	Bone	marrow	cells	were	stained	
with	antibodies	specific	for	CD3ε,	CD11b,	B220,	Gr-1,	TER-119,	CD48,	c-Kit,	Sca1,	CD150,	and	CD34,	and	then	fixed	for	15	minutes	with	1.6%	PFA	
at	room	temperature.	Cells	were	then	either	permeabilised	with	ice-cold	acetone	(solid	black	lines)	or	ice-cold	methanol	(dotted	black	lines)	for	
15	minutes	at	-20˚C	before	being	analysed.	Untreated	cells	are	included	for	comparison	(shaded	histograms).	PFA,	paraformaldehyde.
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Compared	to	untreated	samples,	methanol	treatment	resulted	in	a	loss	of	c-Kit	staining	and	
a	decrease	in	the	levels	of	Sca1	and	CD150	staining	(Figure	4.1).	However,	CD3ε,	CD11b,	B220,	
Gr-1,	 TER-119,	 CD48,	 and	 CD34	 staining	 was	 unaffected.	 Acetone	 treatment	 preserved	
staining	 for	 all	 markers	 except	 CD150	 (Figure	 4.1).	 Interestingly,	 acetone	 treatment	 also	
affected	 the	 fluorescence	 of	 the	 anti-CD48	 APC-Cy7	 antibody.	 When	 analysing	 the	
fluorescence	of	the	APC-Cy7	antibody,	a	large	signal	was	observed	in	the	APC	channel	and	this	
could	not	be	resolved	through	compensation	(Figure	4.2).	The	level	of	fluorescence	detected	
in	the	APC	channel	suggested	that	the	permeabilisation	treatment	had	caused	the	APC-Cy7	
complex	 to	 unconjugate,	 which	 prevented	 the	 use	 of	 the	 anti-CD48	 ACP-Cy7	 antibody	
together	with	the	anti-CD34	APC	antibody	when	performing	phosphoflow.	To	overcome	this,	
CD48	 expression	was	measured	 using	 a	 FITC	 conjugated	 antibody,	 and	 this	 antibody	was	
included	 with	 the	 lineage	 cocktail	 on	 the	 FITC	 channel,	 for	 all	 future	 phosphoflow	
experiments.	
	
Although	the	staining	of	CD150	following	acetone	treatment	was	greatly	reduced	in	samples	
of	whole	BM	(Figure	4.1),	it	was	not	clear	whether	the	remaining	fluorescence	was	significant	
enough	 to	 distinguish	 between	 CD150+	 HSCs	 and	 CD150−	 MPPs	 within	 the	 LSK	 CD48−	
compartment.	To	investigate	this,	the	phosphoflow	protocol	was	repeated	using	whole	BM	
cells	stained	for	all	HSPC	surface	antigens.	Samples	were	fixed	and	permeabilised,	and	then	
analysed	to	determine	the	level	of	CD150	staining	within	the	LSK	compartment	alongside	an	
untreated	control	that	was	prepared	from	the	same	BM.	
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Figure	4.2.	Degredation	of	APC-Cy7	following	fixation	and	permeabilisation	of	cells.	Whole	
bone	marrow	cells	were	stained	for	CD48	with	an	APC-Cy7	antibody.	The	cells	were	then	fixed	
with	1.6%	paraformaldehyde	and	permeabilised	with	ice-cold	acetone.	Analysis	of	the	APC-
Cy7+	 cells	 revealed	 that	 there	was	an	 increased	amount	of	 signal	within	 the	APC	channel.	
Compensation	did	not	resolve	the	issue,	indicating	that	the	APC-Cy7	antibody	was	not	suitable	
for	use	when	using	acetone	as	a	permeabilisation	agent.	APC,	allophycocyanin	
	
	
As	 before,	when	 the	 two	 samples	were	 compared,	 the	 CD150	 staining	 of	whole	 BM	was	
decreased	 in	 the	 fixed	 and	 permeabilised	 sample	 (Figure	 4.3C).	 Despite	 this,	 the	 CD150	
staining	was	bright	enough	to	distinguish	LT-HSC,	ST-HSC	and	MPP	populations	within	the	LSK	
compartment	in	the	treated	sample	(Figure	4.3B).	Furthermore,	all	populations	gated	in	the	
fixed	 and	 permeabilised	 sample	 represented	 comparable	 fractions	 of	 BM	 singlets	 when	
compared	to	the	untreated	sample.	In	the	untreated	sample,	0.0044%,	0.0094%	and	0.023%	
of	all	BM	singlets	were	LT-HSCs,	ST-HSCs	and	MPPs,	respectively.	Similarly,	in	the	fixed	and	
permeabilised	sample,	0.0051%,	0.0111%	and	0.026%	of	all	BM	stained	positive	for	the	LT-
A
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HSC,	ST-HSC	and	MPP	immunophenotypes,	respectively.	The	results	indicated	that,	following	
fixation	 and	 permeabilisation,	 CD150	 antigen	 integrity	 is	 maintained	 within	 the	 LSK	
compartment.	The	reason	for	this	 is	unclear,	but	may	be	explained	by	differences	in	splice	
variants	or	glycosylation	patterns	of	CD150	[366].	Nonetheless,	these	results	confirmed	that	
LT-HSCs,	ST-HSCs	and	MPPs	could	be	successfully	distinguished	when	using	the	phosphoflow	
protocol.	
	
Once	 the	 fixation	 and	 permeabilisation	 treatments	 for	 the	 protocol	 were	 chosen,	
downstream	 signalling	 proteins	 of	 the	 Flt3	 receptor	 were	 considered	 as	 a	 target	 for	
monitoring	 Flt3	 stimulation.	 Both	 the	 Ras	 and	 PI3K	 pathways	 converge	 by	 promoting	
phosphorylation	 of	 the	 ribosomal	 protein	 S6	 via	 activation	 of	 p90	 and	 p70	 S6	 kinases,	
respectively	[353].	By	monitoring	a	protein	within	both	main	Flt3	signalling	pathways,	analysis	
may	benefit	from	an	increased	number	of	targets	due	to	signal	amplification,	and	an	increased	
level	of	fluorescence.	
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Figure	 4.3.	 Verification	 of	 HSPC	 staining	 protocol	 following	 fixation	 with	 PFA	 and	
permeabilisation	with	acetone.	Bone	marrow	cells	were	stained	with	an	antibody	panel	for	
the	analysis	of	LT-HSCs,	ST-HSCs	and	MPPs.	Half	of	the	sample	was	fixed	for	15	minutes	with	
1.6%	PFA	at	room	temperature	and	then	permeabilised	with	ice-cold	acetone	for	15	minutes	
at	 -20˚C,	 while	 the	 other	 half	 was	 left	 untreated.	 Both	 the	 (A)	 untreated	 and	 (B)	
fixed/permeabilised	cells	were	then	analysed	to	compare	staining	of	LT-HSCs,	ST-HSCs	and	
MPPs.	All	three	populations	represented	comparable	fractions	of	BM	singlets	in	both	samples.	
Despite	the	similar	levels	of	CD150	staining	within	the	LSK	compartment	between	(A,	B)	both	
samples,	 CD150	 staining	was	 decreased	when	 comparing	 the	 expression	 of	 CD150	 by	 (C)	
whole	 bone	 marrow	 cells	 in	 the	 fixed/permeabilised	 sample	 (dotted	 black	 line)	 when	
compared	to	the	untreated	sample	(solid	black	line).	LT-HSC,	long-term	haematopoietic	stem	
cell;	 ST-HSC,	 short-term	 haematopoietic	 stem	 cell;	 MPP,	 multipotent	 progenitor;	 PFA,	
paraformaldehyde.	
	
Kalaitzidis	and	Neel	measured	levels	of	phospho-proteins	in	Lin−	cells	following	stimulation	
with	a	number	of	HGFs	[364].	Of	the	HGFs	analysed,	they	observed	a	large	increase	in	the	
levels	 of	 pS6	 following	 Flt3	 stimulation.	 As	 such,	 an	 antibody	 specific	 for	 the	 S235/236	
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phosphorylation	sites	of	S6	was	used	 to	determine	 if	 the	phosphoflow	protocol	described	
here	was	able	to	accurately	detect	pS6	expression	in	whole	BM	after	culture	with	Flt3L.	To	
ensure	that	any	changes	to	pS6	levels	were	due	to	Flt3	activation,	and	not	events	that	are	
related	to	the	isolation	and	processing	of	the	samples,	the	cells	were	starved	for	3	hours	in	
serum-free	 IMDM	 immediately	 prior	 to	 Flt3L	 treatment.	 Cells	 were	 then	 stimulated	 with	
150ng/mL	Flt3L	before	being	fixed	with	1.6%	PFA	for	15	minutes	at	room	temperature	and	
permeabilised	using	ice-cold	acetone	for	15	minutes	at	-20°C.	Subsequently,	the	sample	was	
stained	 for	pS6.	A	 second,	unstimulated,	 cell	 suspension	was	prepared	as	a	 control	 in	 the	
same	manner.	In	agreement	with	the	findings	of	Kalaitzidis	and	Neel	[364],	analysis	revealed	
a	 clear	 shift	 in	 the	 levels	 of	 pS6	 in	 Flt3L	 treated	 whole	 BM	 cells	 when	 compared	 to	 the	
untreated	control	(Figure	4.4).	
	
	
Figure	4.4.	Staining	of	pS6	in	BM	cells	using	flow	cytometry.	Unstained	BM	cells	were	starved	
in	serum-free	medium	for	3	hours	and	then	stimulated	with	150ng/mL	Flt3L	for	7.5	minutes	
before	being	 fixed	and	permeabilised	using	1.6%	paraformaldehyde	and	 ice-cold	acetone.	
Cells	were	then	stained	for	expression	of	pS6	(S235/236).	Histograms	show	the	level	of	pS6	
expressed	by	Flt3L	stimulated	cells	 (solid	black	 line)	compared	to	unstimulated	cells	 (black	
dotted	 line).	 pS6,	 phosphorylated	 ribosomal	 protein	 S6;	 Flt3L,	 fms-like	 tyrosine	 kinase	 3	
ligand;	BM,	bone	marrow.	
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Having	successfully	identified	a	downstream	signalling	protein	of	the	Flt3L	cascade	that	could	
be	measured	using	the	phosphoflow	protocol,	the	next	step	was	to	upscale	the	number	of	
cells	used	in	the	experiment	so	that	HSCs	and	MPPs	could	be	analysed.	BM	cells	were	isolated	
and	 stained	 using	 the	 HSPC	 antibody	 staining	 panel,	 and	 the	 phosphoflow	 protocol	 was	
repeated	as	before.	As	a	large	number	of	MPPs	express	Flt3,	the	level	of	pS6	was	monitored	
in	this	cell	population	as	a	positive	control.	Unfortunately,	when	analysing	the	samples,	there	
was	no	clear	shift	in	the	levels	of	pS6	in	MPPs	treated	with	Flt3L,	indicating	that	the	protocol	
was	unsuccessful	(Figure	4.5).	
	
	
Figure	4.5.	Staining	of	pS6	in	MPPs	using	flow	cytometry.	As	the	pS6	staining	of	whole	BM	
was	successful,	a	second	experiment	was	carried	out	to	determine	if	a	shift	in	pS6	could	be	
seen	in	Flt3L	simulated	MPPs.	BM	cells	were	isolated	and	stained	using	an	antibody	panel	to	
identify	MPPs.	The	cells	were	then	starved	in	serum-free	medium	for	3	hours.	Following	the	
starvation	period,	 the	 sample	was	 stimulated	with	150ng/mL	Flt3L	 for	7.5	minutes	before	
being	 fixed	 and	 permeabilised	 using	 1.6%	 paraformaldehyde	 and	 ice-cold	 acetone.	
Histograms	 show	 the	 level	 of	 pS6	 expressed	 by	 Flt3L	 stimulated	 MPPs	 (solid	 black	 line)	
compared	 to	 unstimulated	MPPs	 (black	 dotted	 line).	 There	 was	 no	 significant	 difference	
between	 the	 levels	 of	 pS6	 expressed	 by	 Flt3L	 stimulated	 MPPs	 and	 untreated	 controls,	
indicating	that	the	phosphoflow	protocol	was	working	intermittently	and,	thus,	not	reliable.	
pS6,	 phosphorylated	 ribosomal	 protein	 S6;	 Flt3L,	 fms-like	 tyrosine	 kinase	 3	 ligand;	 MPP,	
multipotent	progenitor;	BM,	bone	marrow.	
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The	protocol	was	previously	successful	when	using	whole	BM,	and	 it	was	unclear	why	the	
experiment	 had	 failed	 when	 analysing	MPPs.	 Regardless,	 this	 suggested	 that	 the	 current	
phosphoflow	 protocol	 was	 not	 reliable	 and	 could	 not	 be	 used	 to	 produce	 consistently	
reproducible	 data.	 As	 such,	 the	 protocol	 needed	 to	 be	 optimised	 further.	 For	 the	 initial	
phosphoflow	 experiments,	 cells	 were	 fixed	 using	 PFA	 that	 had	 been	 prepared	 in	 the	
laboratory.	To	determine	if	the	quality	of	the	PFA	prepared	in	the	laboratory	was	an	issue,	the	
experiment	 was	 repeated	 using	 commercial	 EM-grade	 PFA.	 Using	 the	 same	 protocol	 as	
before,	BM	cells	were	stained	using	the	HSPC	antibody	staining	panel,	stimulated	with	Flt3L,	
and	then	 fixed	with	either	 laboratory	prepared	PFA	or	EM-grade	PFA	to	compare	 the	 two	
solutions.	Finally,	the	samples	were	permeabilised,	stained	for	pS6	and	then	analysed	on	a	
flow	cytometer.	
	
As	observed	in	the	previous	experiment,	a	clear	shift	was	not	seen	for	Flt3L	treated	MPPs	that	
had	 been	 fixed	 using	 laboratory	 prepared	 PFA	 when	 compared	 to	 untreated	 controls.	
However,	 there	 was	 a	 large	 shift	 in	 the	 level	 of	 pS6	 in	 Flt3L	 stimulated	MPPs	 fixed	with	
commercial	EM-grade	PFA	(Figure	4.6).	This	indicated	that	the	quality	of	the	PFA	used	to	fix	
the	cells	during	the	phosphoflow	protocol	was	 important	 for	optimal	staining	of	phospho-
proteins,	 and	 so	 commercial	 EM-grade	 PFA	 was	 used	 for	 all	 future	 experiments.	 The	
experiments	also	revealed	that	the	LSK	CD150−	CD48−	compartment	contains	a	large	number	
of	Flt3L	responsive	cells.	
	
Once	the	phosphoflow	method	had	been	optimised	for	the	analysis	pS6	expression	by	LSK	
cells,	the	method	was	used	to	investigate	whether	incubation	of	LT-HSCs	and	ST-HSCs	with	
Flt3L	resulted	in	an	increase	in	the	levels	of	intracellular	pS6.	To	ensure	changes	in	pS6	levels	
were	analysed	in	a	consistent	manner,	treated	and	untreated	cells	from	the	same	mouse	were	
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compared.	Samples	of	BM	cells	were	stained	using	the	HSPC	antibody	panel,	and	starved	in	
serum-free	IMDM	for	3	hours.	After	the	starvation	period,	each	cell	suspension	was	divided	
into	a	treated	sample	(150ng/ml	Flt3L	for	7.5	minutes),	an	untreated	sample	(maintained	in	
starvation	medium	(-Flt3L)	for	the	period	of	stimulation)	and	an	isotype	control	sample.	All	
three	 samples	 were	 subsequently	 fixed	 (using	 EM-grade	 PFA),	 permeabilised,	 and	 then	
stained	for	pS6.	The	samples	were	then	analysed	and	the	levels	of	pS6	in	gated	LT-HSCs,	ST-
HSCs	and	MPPs	were	determined	(Figure	4.7A).		
	
	
	
Figure	4.6.	Comparison	of	lab	prepared	PFA	to	commercial	EM-grade	PFA	for	the	use	in	the	
phosphoflow	pS6	staining	protocol	for	LSK	cells.	As	the	pS6	staining	method	was	not	reliably	
reproducible,	 pS6	 levels	 in	 MPPs	 were	 measured	 following	 fixation	 with;	 (A)	 laboratory	
prepared	PFA,	or	(B)	commercially	available	EM-grade	PFA.	Whole	bone	marrow	cells	were	
stained	 using	 the	 HSPC	 antibody	 staining	 panel,	 starved	 in	 serum-free	 medium	 for	
approximately	3	hours	and	then	stimulated	with	150ng/mL	Flt3L	for	7.5	minutes.	One	of	the	
samples	(A)	was	fixed	with	1.6%	PFA	that	was	prepared	in	the	laboratory,	while	the	other	(B)	
was	fixed	using	1.6%	commercial	EM-grade	PFA.	Both	samples	were	permeabilised	using	ice-
cold	 acetone	 and	 were	 subsequently	 stained	 for	 pS6	 before	 being	 analysed	 using	 flow	
cytometry.	 The	 sample	 that	was	 fixed	with	 (B)	 EM-grade	PFA	 showed	a	 clear	 shift	 in	 pS6	
staining	within	the	MPP	compartment	when	compared	to	the	unstimulated	control.	However,	
the	sample	that	was	fixed	with	(A)	laboratory	prepared	PFA	did	not	show	an	increase	in	pS6	
staining	when	compared	to	the	untreated	control.	pS6,	phosphorylated	ribosomal	protein	S6;	
Flt3L,	fms-like	tyrosine	kinase	3	ligand;	MPP,	multipotent	progenitor;	PFA,	paraformaldehyde;	
EM,	electron-microscopy.	
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Figure	4.7.	Response	of	HSCs	and	MPPs	to	Flt3L.	Bone	marrow	cells	were	starved	in	serum-free	medium	for	approximately	3	hours	prior	to	
stimulation	with	150	ng/ml	Flt3L	for	7.5	minutes.	For	analysis,	LT-HSCs,	ST-HSCs	and	MPPs	were	identified	using	the	gating	strategy	depicted	in	
(A).	The	histograms	presented	in	(B)	show	representative	flow	cytometric	analysis	of	pS6	staining	in	LT-HSCs,	ST-HSCs	and	MPPs	for	treated	(solid	
black	line)	and	untreated	cells	(dotted	black	line).	Shaded	histograms	depict	the	isotype	control	staining.	(C)	Shows	the	fold	change	in	the	MFI	
of	pS6	staining	in	LT-HSCs,	ST-HSCs	and	MPPs	treated	with	150ng/mL	Flt3L	for	7.5	minutes	compared	to	untreated	cells.	Data	in	(C)	are	the	mean	
and	standard	error	of	the	values	obtained	from	n=5	mice	from	5	separate	experiments.	LT-HSC,	long-term	haematopoietic	stem	cell;	ST-HSC	
short-term	haematopoietic	stem	cell;	MPP,	multipotent	progenitor;	pS6,	phosphorylated	ribosomal	S6	protein;	Flt3L,	fms-like	tyrosine	kinase	3	
ligand;	MFI,	mean	fluorescence	intensity.	
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When	comparing	the	pS6	staining	to	the	isotype	control	staining,	it	was	clear	that	there	was	
a	basal	 level	of	S6	phosphorylation	in	untreated	LT-HSCs,	ST-HSCs	and	MPPs	(Figure	4.7B).	
Therefore,	to	accurately	measure	the	Flt3L	response,	samples	were	compared	by	calculating	
the	fold	change	in	pS6	mean	fluorescence	intensity	(Δ	MFI)	between	treated	and	untreated	
LT-HSCs,	ST-HSCs	and	MPPs	(Figure	4.7C).	When	compared	to	untreated	MPPs,	the	MFI	of	
pS6	 staining	 in	 treated	 MPPs	 was	 increased	 by	 3.42	 ±	 0.46-fold	 (n=5	 mice),	 once	 again	
confirming	that	a	large	number	of	cells	within	this	population	respond	to	Flt3L.	On	the	other	
hand,	MFI	of	pS6	staining	in	treated	LT-HSCs	and	ST-HSCs	was	only	increased	1.06	±	0.16-	(n=5	
mice)	and	1.08	±	0.08-fold	(n=5	mice),	respectively,	when	compared	to	untreated	samples.	
These	findings	indicated	that	MPPs,	but	not	LT-HSCs	and	ST-HSCs,	phosphorylated	detectable	
levels	 of	 S6	 following	 stimulation	with	 150ng/mL	 of	 Flt3L.	 Accordingly,	 these	 data	 do	 not	
support	the	presence	of	functional	Flt3	on	the	surface	of	LSK	CD150+	CD48−	cells.	
	
4.3			Expression	of	SPI1	within	the	haematopoietic	stem	
cell	compartment	following	stimulation	with	Flt3L	
	
Culturing	 of	 HSCs	 in	 the	 presence	 of	 Flt3L	 did	 not	 result	 in	 an	 increase	 in	 the	 levels	 of	
intracellular	 pS6,	 indicating	 that	 cells	 within	 the	 LSK	 CD150+	 CD48−	 compartment	 do	 not	
express	 functional	 Flt3	 receptor.	 However,	 as	 only	 a	 small	 percentage	 of	 the	 HSC	
compartment	express	detectable	levels	of	Flt3	on	their	surface	[34,	329],	and	Figure	3.28,	any	
response	of	these	cells	to	Flt3L	may	have	been	overshadowed	by	the	large	proportion	of	Flt3−	
HSCs.	Additionally,	Flt3+	LSK	CD150+	CD48−	cells	express	very	low	levels	of	Flt3,	so	it	is	possible	
that	any	phosphorylation	of	S6	following	Flt3	stimulation	could	have	been	below	the	limit	of	
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detection	of	flow	cytometry	[367].	As	an	alternative	method	of	investigating	the	presence	of	
Flt3	in	the	HSC	compartment,	single	cell	gene	expression	analysis	of	cells	following	culture	
with	Flt3L	may	provide	a	more	accurate	measurement	of	a	response	to	Flt3L.	Thus,	a	single	
cell	qRT-PCR	assay	for	a	potential	Flt3	target	gene	was	designed	and	optimised	for	analysis	of	
LSK	CD150+	CD48−	cells	following	culture	with	Flt3L.		
	
	
Table	12:	Details	of	the	SPI1	qRT-PCR	assay	
	
SPI1	qRT-PCR	assay	
Forward	primer	 5’-	GCCATAGCGATCACTACTGGGATT-3’	
Reverse	primer	 5’-CACACTCTGCAGCTCTGTGA-3’	
Hydrolysis	probe	 5’-CCGCACACCATGTCCACAACAAC-3’	
Interrogated	exon-exon	junction	 Exon	2	–	exon	3	
Intron	size	 13,728	nt	
nt,	nucleotides.	
	
	
As	described	 in	Section	4.1,	studies	using	cells	 transfected	with	Flt3	suggest	that	SPI1	and	
CEBPA	 are	both	downstream	 targets	of	 Flt3	 signalling	 [276,	358].	As	 the	Rolink	group	has	
proposed	that	Flt3L	instructs	lineage	fate	[288],	this	process	may	be	mediated	by	PU.1	and	C-
EBPα	TFs,	given	their	role	in	HSPC	specification/differentiation	[125,	359-361].	PU.1,	which	is	
encoded	by	the	SPI1	gene,	is	a	key	player	in	lineage	commitment	of	HSCs	and	drives	a	myeloid-
bias	in	M-CSF	stimulated	HSCs	[267].	If	LT-HSCs	and	ST-HSCs	express	functional	Flt3,	and	Flt3L	
provides	lineage	instruction,	it	is	possible	that	PU.1	mediates	this	process.	Furthermore,	PU.1	
controls	Flt3	expression	in	DCs,	so	Flt3	expression	may	control	its	own	expression	through	a	
positive	 feedback	mechanism	 [368].	 As	 such,	 to	 determine	 if	 SPI1	 is	 upregulated	 in	 cells	
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expressing	 Flt3	 and	 particularly	 in	 a	 subpopulation	 of	 LSK	 CD150+	 CD48−	 cells	 following	
treatment	with	Flt3L,	a	single-cell	qRT-PCR	assay	to	detect	SPI1	transcripts	was	designed.	
	
The	SPI1	assay	was	designed	and	optimised	in	the	same	manner	as	described	in	Section	3.4.	
The	details	and	the	alignment	of	the	assay	are	shown	in	Figure	4.9	and	Table	12.	The	assay	
was	designed	to	span	the	exon	junction	between	exon	2	and	exon	3,	and	no	pseudogenes	
were	 detected	when	 the	 sequence	was	 analysed	 using	 the	BLAST	 genomic	 database.	 The	
assay	was	first	tested	using	reactions	with	and	without	the	RT	to	determine	if	the	assay	was	
specific	 for	 Spi1	mRNA.	 Surprisingly,	 the	 assay	 amplified	 targets	 in	 both	 the	 +RT	 and	 –RT	
samples,	 indicating	that	the	assay	detected	gDNA.	This	suggested	that	the	mouse	genome	
contains	a	SPI1	processed	pseudogene	that	lacks	the	intron	between	exon	2	and	exon	3,	and	
that	the	detected	pseudogene	is	not	present	in	the	BLAST	genomic	database	(Figure	4.9A).	
However,	the	detection	of	gDNA	was	not	considered	to	be	an	issue.	The	SPI1	qRT-PCR	assay	
was	designed	to	quantify	the	difference	in	expression	of	SPI1	between	cells	treated	with	and	
without	Flt3L,	so	-RT	controls	could	be	used	during	analysis	to	help	discriminate	amplification	
of	gDNA	from	RNA.		
	
	
Figure	4.8.	Sequence	alignment	of	SPI1	qRT-PCR	assay	within	the	SPI1	gene.	A	region	within	
the	 SPI1	 gene	 is	 depicted	 to	 show	 the	 alignment	 of	 the	 SPI1	qRT-PCR	 assay	 primers	 and	
hydrolysis	 probe.	 The	 forward	 primer,	 reverse	 primer	 and	 probe	 sequences	 are	 shown	
highlighted	in	green,	blue,	and	pink,	respectively.	The	red	box	highlights	the	junction	between	
exon	2	and	exon	3.	
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Figure	 4.9.	 Optimisation	 of	 the	 SPI1	 qRT-PCR	 assay	 for	 detection	 of	 single	 cell	 gene	
expression.	 (A)	 When	 the	 SPI1	 assay	 was	 tested	 with	 (+RT)	 and	 without	 (-RT)	 reverse	
transcriptase	the	assay	amplified	targets	in	both	samples,	indicating	that	the	assay	detected	
gDNA.	(B,	C)	To	determine	the	optimum	limiting	primer	concentrations	for	the	SPI1	qRT-PCR	
assay,	amplification	of	target	sequences	in	whole	bone	marrow	lysate	was	carried	out	using	
multiple	 combinations	 of	 different	 primer	 concentrations	 (B)	 The	 Ct	 for	 all	 primer	
combinations	was	determined,	and	any	sample	with	a	Ct	value	of	>0.5	cycles	greater	than	the	
Ct	 value	 of	 the	 reference	 reaction	 (300nM	 forward	 primer/300nM	 reverse	 primer)	 was	
considered	to	have	low	efficiency	(below	the	transparent	grey	pane).	(C)	Of	the	remaining	
efficient	 reactions,	 the	 primer	 combination	 with	 the	 lowest	 peak	 fluorescence	 value	 was	
selected	as	the	limiting	reaction.	(D)	Similarly,	multiple	hydrolysis	probe	concentrations	were	
tested	to	determine	the	optimum	probe	conditions.	Of	the	reactions	with	a	Ct	value	that	was	
not	>0.5	cycles	greater	than	the	Ct	value	of	the	reference	reaction	(250nM	hydrolysis	probe;	
below	 the	 dotted	 line),	 the	 lowest	 probe	 concentration	 was	 selected	 as	 the	 optimum.	
Optimum	forward	primer,	reverse	primer	and	hydrolysis	probe	concentrations	were	found	to	
be	300nM,	40nM	and	175nM,	respectively.	gDNA,	genomic	DNA;	RT,	reverse	transcriptase;	
Ct,	threshold	cycle;	AU,	arbitrary	units.	
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Next,	the	primer	and	probe	concentrations	of	the	assay	were	optimised.	The	optimal	limiting	
primer	 concentrations	 for	 the	 forward	and	 reverse	primers	were	 found	 to	be	300nM	and	
40nM,	 respectively	 (Figure	 4.9B,	 C).	 The	 optimum	 probe	 concentration	 was	 found	 to	 be	
175nM	(Figure	4.9D).	To	test	the	single	cell	sensitivity	of	the	SPI1	qRT-PCR	assay,	single	GMPs	
were	used,	as	these	cells	are	known	to	express	Spi1	transcripts	[369].	The	assay	successfully	
detected	 expression	 of	 SPI1	 by	 single	 GMPs	 and,	 on	 average,	 an	 increase	 of	 1	 cycle	was	
observed	for	each	cell	number	doubling,	indicated	that	the	assay	was	efficiently	amplifying	
target	sequences	in	single	cells	(Figure	4.10).	
	
Mossadegh-Keller	et	al.	designed	an	in	vitro	experiment	to	analyse	gene	expression	of	HSCs	
after	16	hours	of	culture	with	M-CSF,	and	found	SPI1	to	be	upregulated	in	a	number	of	cells	
[267].	The	response	of	HSCs	to	Flt3L	was	examined	by	adapting	the	protocol	described	in	the	
above	 paper,	 and	 the	 expression	 of	 SPI1	 by	 HSCs	 following	 incubation	 with	 Flt3L	 was	
investigated.	As	studies	to	date	have	only	shown	that	SPI1	is	a	direct	target	of	Flt3	signalling	
in	cells	that	ectopically	express	Flt3,	it	was	difficult	to	identify	an	endogenous	haematopoietic	
cell	 population	 that	 could	 be	 used	 as	 a	 positive	 control.	 Stimulation	 of	 CMPs	 with	 Flt3L	
promotes	 the	 development	 of	 DCs,	 and	 SPI1	 plays	 an	 integral	 role	 in	 DC	 differentiation,	
suggesting	an	endogenous	relationship	between	the	two	[311,	368].	Thus,	single	CMPs	were	
used	as	a	control	to	determine	if	SPI1	 is	a	direct	target	of	endogenous	Flt3	signalling.	As	a	
negative	control,	single	MEPs	were	chosen	as	these	cells	do	not	express	the	Flt3	receptor	and	
should	not	respond	to	Flt3L	(Figure	3.27).	
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Figure	 4.10.	 Detection	 of	 single	 cell	 gene	 expression	 using	 the	 SPI1	 qRT-PCR	 assay.	The	
optimised	primer	and	probe	concentrations	for	the	SPI1	qRT-PCR	assay	were	used	to	amplify	
SPI1	expression	by	single	GMPs.	The	assay	clearly	amplified	expression	of	SPI1	by	single	GMPs	
and	there	was	an	average	increase	of	1	cycle	per	cell	number	doubling	(dotted	line	represents	
an	 increase	 of	 1	 cycle	 per	 cell	 number	 doubling	 for	 comparison).	 GMP,	 granulocyte-
macrophage	progenitor;	Ct,	threshold	cycle.	
	
To	determine	if	Flt3	stimulation	results	in	upregulation	of	SPI1	 in	HSPCs,	LT-HSCs,	ST-HSCs,	
CMPs	and	MEPs	were	bulk	sorted	 from	whole	mouse	BM	 into	 IMDM	containing	10%	FCS,	
1,000 U/mL	penicillin	and	1,000 μg/mL	streptomycin,	50 ng/mL	Tpo	and	20 ng/mL	Scf,	with	
and	 without	 Flt3L.	 As	 150ng/mL	 of	 Flt3L	 produced	 a	 strong	 response	 in	 MPPs	 when	
monitoring	 pS6	 levels;	 the	 same	 concentration	 of	 Flt3L	 was	 used	 to	 investigate	 if	 Flt3	
signalling	 upregulates	 SPI1	 expression.	 These	 cells	 were	 then	 cultured	 in	 medium	
supplemented	with	the	above	factors	±	Flt3L	overnight	for	18	hours.	Following	the	overnight	
incubation,	single	LT-HSCs,	ST-HSCs,	CMPs	and	MEPs	were	sorted	from	the	cultures	into	wells	
of	a	384-well	PCR	plate	and	analysis	of	SPI1	expression	by	single	cells	was	performed.	To	avoid	
sorting	noise/debris	events,	the	same	FSC/SSC	gating	strategy	that	was	used	to	sort	the	bulk	
populations	for	the	overnight	culture	was	applied	when	sorting	the	cells	into	the	PCR	plates	
(Figure	4.11).	
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Figure	 4.11.	 Sorting	 of	 single	 cells	 to	 determine	 the	 effects	 Flt3L	 stimulation	 on	 SPI1	
expression.	Representative	plots	show	the	FSC	and	SSC	profile	for	(A)	whole	bone	marrow	
and	(B)	purified	cells	following	Flt3L	stimulation	in	culture	for	18	hours.	The	FSC/SSC	gating	
strategy	used	during	(B)	was	identical	to	(A).	FSC,	forward	scatter;	SSC,	side	scatter;	Flt3L,	fms-
like	tyrosine	kinase	3	ligand.	
	
	
As	the	SPI1	qRT-PCR	assay	detected	gDNA,	samples	that	were	negative	for	SPI1	amplification	
were	likely	due	to	empty	wells.	Thus,	only	samples	that	were	positive	for	SPI1	amplification	
were	included	during	analysis.	However,	when	analysing	the	expression	of	SPI1	 in	LT-HSCs,	
ST-HSCs,	 CMPs	 and	 MEPs,	 it	 was	 difficult	 to	 discern	 between	 positive	 and	 negative	
amplification	curves	(Figure	4.12C).	This	was	likely	to	be	due	to	amplification	of	SPI1	gDNA	
and	the	amplification	was	not	of	major	importance	as	-RT	control	samples	could	be	used	to	
distinguish	RNA	amplification.		
	
Of	the	cells	cultured	with	150ng/mL	of	Flt3L,	successful	amplification	of	SPI1	was	detected	in	
25	LT-HSC,	183	ST-HSC,	31	CMP	and	18	MEP	samples.	Additionally,	SPI1	was	detected	in	58	
LT-HSC,	122	ST-HSC,	80	CMP	and	50	MEP	samples	that	were	cultured	without	Flt3L.	Analysis	
revealed	that	virtually	all	MEPs,	and	all	of	the	-RT	samples	had	Ct	values	of	>35,	indicating	
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that	a	Ct	value	of	35	cycles	or	lower	was	due	to	amplification	of	Spi1	mRNA	transcripts	(Figure	
4.12A).	The	majority	of	reactions	containing	SPI1+	CMPs	had	Ct	values	of	<35	cycles	but	there	
was	no	difference	in	levels	of	mean	expression	when	comparing	cells	that	had	been	cultured	
with	and	without	Flt3L	[p=0.7541].	Furthermore,	the	expression	of	SPI1	by	the	LT-HSCs	and	
ST-HSCs	suggested	that	a	large	percentage	of	cells	within	these	populations	were	also	positive	
for	Spi1	mRNA	transcripts	(<35	Ct)	(Figure	4.12A).	However,	as	seen	for	the	CMPs,	there	was	
no	 change	 seen	 in	 the	 expression	 levels	 of	 SPI1	when	 LT-HSCs	 [p=0.2512]	 and	 ST-HSCs	
[p=0.6638]	were	cultured	with	Flt3L.		
	
As	SPI1	was	detected	after	35	cycles	in	almost	all	of	the	MEP	and	RT	samples,	any	amplification	
of	 SPI1	 detected	 before	 35	 cycles	 was	 likely	 due	 to	 mRNA	 amplification	 and	 not	 gDNA	
amplification.	To	determine	if	Flt3L	stimulation	initiated	the	expression	of	Spi1	mRNA	in	cells,	
the	 percentage	 of	 LT-HSCs,	 ST-HSCs	 and	MPPs	 expressing	 SPI1	 at	 levels	 above	 the	 gDNA	
threshold	(<35	cycles)	within	the	-Flt3L	and	+Flt3L	groups	were	determined.	When	analysed,	
there	was	a	slight	decrease	in	the	number	of	Flt3L	stimulated	LT-HSCs	expressing	Spi1	mRNA	
(<35	cycles)	(44%)	when	compared	to	the	LT-HSCs	that	were	cultured	without	Flt3L	(53%).	
However,	 this	 change	 was	 not	 significant	 [p=0.4794].	 Similarly,	 there	 was	 no	 significant	
difference	 between	 the	 number	 of	 Flt3L	 treated	 ST-HSCs	 that	 expressed	 Spi1	mRNA	 (<35	
cycles,	65%)	and	when	compared	to	the	number	of	Spi1+	ST-HSCs	that	were	not	treated	with	
Flt3L	 (68%)	 [p=0.6224].	 Furthermore,	 there	was	no	 change	 in	Spi1	mRNA	expression	 (<35	
cycles)	 when	 comparing	 the	 CMPs	 that	 were	 cultured	with	 (85%)	 or	 without	 (78%)	 Flt3L	
[p=0.6067].	
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Figure	4.12.	Expression	of	SPI1	by	HSCs	after	culture	with	or	without	Flt3L.	(A)	Expression	of	
SPI1	by	LT-HSCs,	ST-HSCs,	CMPs	and	MEPs	after	culture	 in	10%	FCS,	1,000 U/mL	penicillin,	
1,000 μg/mL	streptomycin,	50 ng/mL	Tpo	and	20 ng/mL	Scf,	with	and	without	150ng/mL	Flt3L	
for	18	hours,	including	-RT	control	reactions.	The	mean	values	of	expression	are	depicted	by	
the	grey	lines.	(B)	The	percentage	of	LT-HSCs,	ST-HSCs	and	MPPs	that	expressed	SPI1	mRNA	
(Expression	of	SPI1	at	levels	above	the	gDNA	threshold	[<35	cycles])	were	compared	between	
the	treated	(+Flt3L)	and	untreated	(-Flt3L)	groups	(C)	Amplification	of	SPI1	in	single	HSCs.	Red	
curves	 represent	 amplification	 and	 green	 curves	 represent	 background	 fluorescence.	
Fluorescence	is	plotted	on	a	log	scale.	p	values	were	obtained	by	performing	(A)	two-tailed	
non-parametric	 student’s	 t-tests	 or	 (B)	 Fisher’s	 exact	 tests	 where;	 n.s.,	 p	 >	 0.05.	 HSC,	
haematopoietic	stem	cell;	LT,	long-term;	ST,	short-term;	CMP,	common	myeloid	progenitor;	
MEP,	 megakaryocyte-erythroid	 progenitor;	 -RT,	 reactions	 without	 reverse	 transcriptase;	
Flt3L,	Fms-like	tyrosine	kinase	3	ligand;	n.s.,	not	significant.	
	
	
When	analysing	the	response	of	cells	to	Flt3L	using	the	phosphoflow	technique,	cells	were	
starved	 in	 serum-free	medium	 prior	 to	 stimulation	 with	 Flt3L	 to	minimise	 the	 activity	 of	
biological	 pathways.	 As	 this	 strategy	 worked	 well	 for	 the	 phosphoflow	 analysis,	 the	 SPI1	
expression	analysis	was	 repeated	 to	examine	whether	 the	 inclusion	of	a	 starvation	period	
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prior	to	stimulating	the	cells	with	Flt3L	would	reveal	a	response.	The	experiment	was	repeated	
by	 first	 sorting	 cells	 into	 serum-free	 IMDM	 and	 starving	 them	 for	 3	 hours	 before	
supplementing	 the	 medium	 with	 10%	 FCS,	 1,000 U/mL	 penicillin	 and	 1,000 μg/mL	
streptomycin,	50 ng/mL	Tpo	and	20 ng/mL	Scf,	with	and	without	150ng/mL	Flt3L.	The	cells	
were	 cultured	 overnight	 for	 18	 hours	 as	 before.	 To	 ensure	 that	 the	 cells	were	 accurately	
analysed	the	next	day,	the	FSC/SSC	gating	strategy	that	was	used	to	initially	sort	the	cells	into	
starvation	medium	was	used	again	to	sort	the	cells	 into	PCR	plates	after	culture	with	Flt3L	
(Figure	4.13).		
	
	
Figure	4.13.	Sorting	of	single	cells	to	determine	the	effects	Flt3L	stimulation	after	a	serum-
free	starvation	period	on	SPI1	expression.	Representative	plots	show	the	FSC	and	SSC	profile	
for	(A)	whole	bone	marrow	and	(B)	purified	cells	that	were	starved	for	3	hours	in	serum-free	
medium	and	then	stimulated	with	Flt3L	stimulation	in	culture	for	18	hours.	When	sorting	the	
cells	after	the	18	hour	 incubation	period,	 it	was	clear	that	the	cells	were	 in	the	process	of	
dying	or	had	died	during	the	overnight	culture,	as	they	had	a	very	low	FSC	profile.	This	made	
it	difficult	to	discriminate	between	background	noise	and	cells.	The	FSC/SSC	gating	strategy	
used	during	 (B)	was	 identical	 to	 (A).	FSC,	 forward	scatter;	SSC,	side	scatter;	Flt3L,	 fms-like	
tyrosine	kinase	3	ligand.	
	
	
Once	the	cells	had	been	starved	for	3	hours,	and	subsequently	stimulated	with	Flt3L	overnight	
for	18	hours,	the	cells	were	sorted	by	FACS.	When	comparing	the	FSC/SSC	profile	of	the	cells	
that	were	cultured	with	Flt3L	(Figure	4.13B)	to	the	FSC/SSC	profiles	that	were	obtained	when	
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sorting	the	cells	from	whole	BM	(Figure	4.13A),	there	was	a	clear	change	in	the	FSC	profile	of	
the	cells.	All	of	the	events	appeared	to	have	very	low	levels	of	FSC,	and	there	were	very	few	
live	cells.	From	the	FSC/SSC	profile,	it	was	clear	that	the	cells	were	in	the	process	of	dying	or	
had	died	during	the	overnight	culture.	Therefore,	cells	were	not	sorted	into	PCR	plates	for	
analysis.		
	
As	there	was	no	change	detected	in	the	expression	of	SPI1	by	CMPs	when	they	were	cultured	
with	Flt3L	in	the	first	experiment	(Figure	4.12),	this	set	of	experiments	provides	inconclusive	
data	in	regard	to	the	expression	of	Flt3	by	HSCs.	However,	it	may	provide	some	insight	into	
the	relationship	between	Flt3	and	SPI1,	as	discussed	in	Section	4.5.1.	
	
4.4			Effects	 of	 Flt3L	 on	 haematopoietic	 stem	 cells	
during	colony	formation	in	vitro	
	
Analysis	of	the	Flt3	response	within	the	signalling	pathway	and	at	the	transcriptional	level	do	
not	support	the	presence	of	functional	Flt3	receptor	within	the	HSC	compartment.	However,	
these	 experiments	 measured	 the	 response	 to	 Flt3L	 over	 short	 periods	 of	 exposure.	 By	
measuring	 downstream	 effects	 of	 Flt3	 signalling	 such	 as	 differentiation	 and	 survival	 after	
longer	 periods	 of	 treatment,	 the	 analysis	may	 benefit	 from	 an	 amplified	 response	 that	 is	
easier	 to	detect.	 There	 is	 evidence	 to	 suggest	 that	 Flt3L	 stimulates	HSPCs	 to	differentiate	
towards	non-MegE	fates	[288].	In	addition,	Flt3	signalling	promotes	cell	survival	[352].	Thus,	
culturing	HSCs	in	methylcellulose	medium	and	monitoring	the	formation	of	colonies	after	11	
days	of	culture	with	Flt3L	may	provide	 insight	 into	whether	Flt3	promotes	survival	and/or	
differentiation	of	these	cells	towards	a	certain	lineage.	To	investigate	this,	a	colony	forming	
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assay	was	performed	using	HSCs	(LSK	CD150+	CD48−),	with	and	without	Flt3L.		
	
Figure	4.14.	Brightfield	images	of	colonies	formed	after	seeding	HSCs	into	methylcellulose	
medium.	HSCs	(LSK	CD150+	CD48−)	were	sorted	from	murine	bone	marrow	and	seeded	into	
M3434	supplemented	with	25ng/mL	thrombopoietin,	1,000 U/mL	penicillin	and	1,000 μg/mL	
streptomycin.	M3434	cultures	were	incubated	at	37°C,	5%	CO2	for	11	days	and	colonies	were	
identified.	Representative	images	of	each	colony	type	scored	are	shown.	The	magnification	
used	to	take	the	image	is	shown	in	the	bottom	right	of	each	picture.	HSC,	haematopoietic	
stem	 cell;	 CFU,	 colony	 forming	 unit;	 M,	 macrophage;	 G,	 granulocyte;	 GM,	 granulocyte-
macrophage;	 GEMM,	 granulocyte-erythroid-macrophage-megakaryocyte;	 Meg,	
megakaryocyte.	
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HSCs	were	sorted	from	the	BM	of	3	mice	into	IMDM	supplemented	with	10%	FCS,	1,000 U/mL	
penicillin	and	1,000 μg/mL	streptomycin.	These	HSC	samples	were	then	mixed	into	Methocult	
M3434	 (supplemented	 with	 25ng/mL	 Tpo	 to	 allow	 for	 measurement	 of	 megakaryocyte	
output)	with	and	without	Flt3L.	Flt3L	was	used	at	a	similar	concentration	(25ng/mL)	to	the	
other	HGFs	in	the	M3434	medium	(50ng/mL	SCF,	10ng/mL	IL-3,	10ng/mL	IL-6,	3	units/mL	Epo,	
25ng/mL	Tpo).	The	samples	were	then	plated	in	duplicate	and	incubated	at	37°C	5%	CO2	for	
11	days.	Colonies	were	scored	on	day	11,	and	CFU-M,	CFU-G,	CFU-GM,	CFU-GEMM,	CFU-Meg	
and	CFU-MegMix	were	observed	(Figure	4.14).	Colony	types	were	confirmed	by	centrifuging	
representative	colonies	onto	slides	and	staining	them	using	a	Differential	Quik	Staining	kit	
(Figure	 4.15).	 The	 criteria	 used	 to	 score	 the	 types	 of	 colonies	 and	 analyse	 the	 cytospin	
preparations	are	described	in	Section	2.13.3.	Once	all	of	the	colonies	had	been	scored	and	
their	nature	confirmed	using	the	cytospin	preparations,	the	data	obtained	for	HSCs	plated	
into	M3434	with	and	without	Flt3L	were	compared.	There	were	no	differences	in	the	number	
of	total	colonies	[p=0.75]	(Figure	4.16B),	or	the	number	of	CFU-M	[p>0.999],	CFU-G	[p=0.75],	
CFU-GM	 [p>0.999],	 CFU-GEMM	 [p>0.999],	 CFU-Meg	 [p>0.999]	 or	 CFU-MegMix	 [p>0.999]	
(Figure	4.16A)	 (n=3	mice)	between	plates	with	and	without	Flt3L.	Similarly,	 there	were	no	
differences	in	colony	size	between	the	two	cultures.	These	findings	indicated	that	addition	of	
25ng/mL	of	 Flt3L	 to	M3434	did	 not	 confer	 a	 survival	 advantage	or	maturation	bias	when	
seeding	HSCs	onto	methylcellulose.	All	of	the	duplicate	plating	values	are	shown	in	Table	13.		
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Figure	 4.15.	 Cytospin	 preparations	 of	 colonies	 formed	 after	 seeding	 HSCs	 into	
methylcellulose	medium.	Representative	colonies	were	picked	from	methylcellulose	cultures	
that	were	seeded	with	HSCs	(LSK	CD150+	CD48−).	Cultures	were	incubated	at	37°C,	5%	CO2	for	
11	days,	and	then	representative	colonies	of	each	colony	type	were	centrifuged	onto	glass	
slides	 for	 staining	 with	 a	 Differential	 Quik	 stain	 kit.	 Macrophage/monocytes	 (M)	 were	
recognised	as	 cells	with	 abundant	dull	 blue/grey	 cytoplasms	and	usually	dark	blue	 kidney	
shaped	nuclei	[300].	Promyelocytes	(Pm)	and	granulocytes	(G)	were	identified	as	cells	with	
dark	to	pale	pink	cytoplasms	[300,	301].	Megakaryocytes	(Mk)	and	promegakaryocytes	(MkP)	
were	distinguished	by	their	size.	Promegakaryocytes	had	dark	pink	granular	cytoplasms,	while	
megakaryocytes	were	highly	polyploidy	cells	with	intense	blue	(basophilic)	cytoplasms	[300,	
302,	303].	Erythroblasts	(E)	were	identified	as	cells	with	high	a	nucleus	to	cytoplasm	ratio,	
that	had	intensely	basophilic-purple	cytoplasms	[301,	302].	The	insert	at	the	top	right	of	the	
CFU-GM	picture	shows	a	macrophage/monocytes	 from	the	same	cytospin	preparation.	All	
images	were	taken	at	the	same	magnification	(x200).	HSC,	haematopoietic	stem	cell;	CFU,	
colony	forming	unit;	M,	macrophage;	G,	granulocyte;	GM,	granulocyte-macrophage;	GEMM,	
granulocyte-erythroid-macrophage-megakaryocyte;	Meg,	megakaryocyte.	
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Figure	4.16.	Effects	of	Flt3L	on	colony	formation	after	seeding	HSCs	into	methylcellulose	medium.	HSCs	(LSK	CD150+	CD48−)	were	sorted	from	
murine	bone	marrow	and	seeded	into	M3434	(supplemented	with	10%	FCS,	25ng/mL	thrombopoietin	and	1,000U/mL	penicillin/streptomycin)	
with	 and	without	 25ng/ml	 Flt3L.	 (A)	 colony	 type	 and	 (B)	 total	 colony	 numbers	 (per	 100	 HSCs)	 were	 counted	 on	 day	 11,	 n	 =	 3	mice.	 For	
confirmation,	representative	colonies	were	centrifuged	onto	microscope	slides,	air-dried	and	stained	using	a	Differential	Quik	Staining	kit.	p	
values	obtained	by	two-tailed	non-parametric	student’s	t-test	where;	n.s.,	p	>	0.05.	HSC,	haematopoietic	stem	cell;	Flt3L,	fms-like	tyrosine	kinase	
3	ligand;	CFU,	colony	forming	unit;	M,	macrophage;	G,	granulocyte;	GM,	granulocyte-macrophage;	GEMM,	granulocyte-erythroid-macrophage-
megakaryocyte;	Meg,	megakaryocyte;	n.s.,	not	significant.	
A B n.s.$
n.s.$
n.s.$
n.s.$
n.s.$
n.s.$ n.s.$
	
	
218	
Table	13:	Types	and	number	of	colonies	identified	when	scoring	the	growth	and	development	of	HSCs	in	M3434	with	and	without	Flt3L	
	 -Flt3L	 +25ng/mL	Flt3L	
	 Mouse	#1	 Mouse	#2	 Mouse	#3	 Mouse	#1	 Mouse	#2	 Mouse	#3	
Number	of	HSCs	
seeded/plate	 278	 335	 433	 278	 335	 433	
	 Plate	1	 Plate	2	 Plate	1	 Plate	2	 Plate	1	 Plate	2	 Plate	1	 Plate	2	 Plate	1	 Plate	2	 Plate	1	 Plate	2	
CFU-GEMM	 40	 40	 49	 60	 54	 49	 18	 26	 65	 47	 85	 104	
CFU-GM	 9	 13	 19	 12	 72	 53	 21	 18	 11	 28	 26	 18	
CFU-M	 8	 4	 8	 10	 19	 22	 8	 8	 8	 7	 23	 10	
CFU-G	 0	 2	 3	 2	 2	 6	 2	 4	 1	 4	 6	 2	
CFU-Meg	 5	 5	 13	 6	 16	 15	 8	 4	 10	 9	 9	 14	
CFU-Meg-Mix	 5	 3	 2	 2	 12	 6	 5	 3	 5	 1	 6	 6	
Total	 67	 67	 94	 92	 175	 151	 62	 63	 100	 96	 155	 154	
M3434	medium	allows	 for	 the	 formation	of	CFU-GEMM,	CFU-GM,	CFU-M,	CFU-G,	CFU-Meg,	CFU-Meg-Mix.	HSCs	were	 sorted	 from	
murine	bone	marrow	and	seeded	onto	M3434	and	incubated	at	37°C	5%	CO2	for	11	days.	On	day	11,	the	colony	type	was	determined	
based	 on	 their	 morphology.	 For	 this	 experiment,	 M3434	 was	 supplemented	 with	 10%	 fetal	 calf	 serum,	 25ng/mL	 thrmbopoietin,	
1,000 U/mL	penicillin	and	1,000 μg/mL	streptomycin.	For	confirmation,	representative	colonies	were	centrifuged	onto	glass	slides	and	
stained	using	a	Differential	Stain	kit.	Groupings	of	50	or	more	cells	were	considered	a	colony.	Flt3L,	fms-like	tyrosine	kinase	3	ligand;	
CFU,	colony	forming	unit;	M,	macrophage;	G,	granulocyte;	GM,	granulocyte-macrophage;	GEMM,	granulocyte-erythroid-macrophage-
megakaryocyte;	Meg,	megakaryocyte,	CFU-Meg-Mix,	sparse	colonies	that	contained	megakaryocytes	and	macrophages/granulocytes.	
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4.5			Discussion	
	
4.5.1			Multipotent	 progenitors	 but	 not	 haematopoietic	 stem	
cells	respond	to	Flt3L	stimulation	in	vitro	
	
The	Rolink	group	has	proposed	that	Flt3L	drives	LSK	CD150−	CD48+	cells	towards	GM-lymphoid	
cell	 fates	 [288].	However,	 the	data	generated	 in	Chapter	3	 revealed	 the	presence	of	FLT3	
transcripts	and	Flt3	protein	within	the	LSK	CD150+	CD48−	HSC	and	LSK	CD150−	CD48−	MPP	
compartments,	 suggesting	 that	 Flt3L	may	also	act	on	 these	 cells.	Hence,	 the	 focus	of	 this	
chapter	 was	 to	 investigate	 the	 presence	 of	 functional	 Flt3	 expression	 within	 early	 HSPC	
compartments	by	monitoring	for	the	downstream	effects	of	Flt3	activation.	While	it	is	clear	
that	LSK	CD150+	CD48−	MPPs	responded	to	Flt3L,	the	data	presented	here	does	not	provide	
evidence	to	support	the	viewpoint	that	Flt3L	can	stimulate	cells	within	the	LSK	CD150+	CD48−	
HSC	compartment.		
	
By	monitoring	the	phosphorylation	of	ribosomal	protein	S6	(a	target	of	both	the	PI3k	and	Ras	
pathways	during	Flt3	signalling	[353,	354])	using	flow	cytometry,	activation	of	 intracellular	
signalling	in	MPPs	was	clearly	identified	following	in	vitro	stimulation	with	150	ng/mL	Flt3L.	
Given	that	such	a	high	proportion	of	MPPs	are	Flt3+	(63.65%	±	3),	it	was	not	surprising	to	find	
that	there	was	a	3.42	±	0.46-fold	(n=5	mice)	increase	in	pS6	MFI	when	comparing	Flt3L	treated	
MPPs	to	untreated	MPPs.	On	the	other	hand,	there	was	no	clear	shift	in	pS6	levels	observed	
in	 either	 the	 LT-HSC	or	 ST-HSC	 compartments	 following	 culture	with	 Flt3L,	 and	 the	mean	
expression	 level	of	pS6	did	not	 change	 in	either	population	when	compared	 to	untreated	
controls	(1.06	±	0.16-	(n=5	mice)	and	1.08	±	0.08-fold	(n=5	mice),	respectively).	These	findings	
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show	that	Flt3L	elicits	a	large	response	within	the	MPP	(LSK	CD150+	CD48−),	but	not	the	HSC,	
population,	 supporting	 a	 model	 whereby	 Flt3L	 drives	 lineage	 decisions	 in	 the	 non-self-
renewing	multipotent	compartment	of	the	BM	[288].	On	a	technical	note,	the	phosphoflow	
protocol	described	here	allows	for	the	novel	analysis	of	phosphorylation	events	within	HSCs	
(LSK	CD150+	CD48−)	and	MPPs	(LSK	CD150−	CD48−).	Previous	studies	have	reported	difficulty	
in	distinguishing	between	these	two	groups	when	preforming	phosphoflow	due	to	the	loss	of	
HSPC	surface	antigen	integrity	following	permeabilisation	[364].	However,	while	the	integrity	
of	 the	 CD150	 antigen	 is	 compromised	 when	 analysing	 whole	 BM	 cells	 after	 acetone	
treatment,	 CD150	 can	 still	 be	 used	 to	 successfully	 distinguish	 HSCs	 from	MPPs	 using	 the	
phosphoflow	protocol	described	here	(Figure	4.3).		
	
When	 monitoring	 the	 Flt3	 signalling	 cascade,	 cells	 within	 the	 HSC	 compartment	 did	 not	
respond	to	Flt3L.	Therefore,	the	expression	of	a	potential	transcriptional	target	of	the	Flt3	
signalling	pathway	was	investigated.	However,	a	lack	of	information	regarding	canonical	Flt3	
gene	targets	made	it	difficult	to	select	an	adequate	experimental	controls.	If	Flt3L	acts	on	cells	
to	drive	lineage	bias	[288],	it	likely	controls	the	regulation	of	TFs	important	in	GM-lymphoid	
differentiation,	such	as	SPI1,	CEBPA	or	 IKZF1	 [125,	359,	360,	370].	 Indeed,	upregulation	of	
SPI1	 occurs	 in	 FLT3	 transfected	 cells	 following	 receptor	 stimulation	 [276,	 358],	 so	 the	
expression	of	SPI1	by	HSCs,	following	culture	with	Flt3L,	was	measured	to	determine	if	these	
cells	expressed	functional	Flt3.	As	the	results	from	these	studies	have	not	been	confirmed	by	
means	of	endogenous	Flt3	signalling,	cells	that	are	known	to	express	the	Flt3	receptor	were	
cultured	with	Flt3L	alongside	HSCs	as	an	endogenous	control.	A	large	proportion	of	CMPs	are	
Flt3+	(36.8%	±	1.4),	and	CMPs	are	efficient	at	producing	DCs	[371].	As	SPI1	is	integral	for	the	
development	of	DCs,	Flt3+	CMPs	provided	a	good	control	to	determine	if	SPI1	was	upregulated	
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following	activation	of	Flt3	[311,	368].	Interestingly,	no	response	was	seen	in	either	cell	type	
following	culture	with	Flt3L.	As	such,	nothing	could	be	inferred	regarding	the	expression	of	
Flt3	by	LSK	CD150+	CD48−	cells.		
	
It	 is	unclear	why	CMPs	did	not	upregulate	SPI1	following	Flt3	stimulation.	The	lack	of	Flt3L	
response	may	be	explained	by	the	death	of	the	cells	during	the	overnight	culture.	However,	
this	 is	 unlikely,	 as	 dead	 cells	 can	 be	 identified	 by	 their	 FSC/SSC	 profile	 (Figure	 4.13).	
Furthermore,	while	the	culture	conditions	used	are	adequate	for	HSC	culture	[267],	they	may	
not	have	been	adequate	for	the	culture	of	CMPs.	For	example,	IL-3	was	not	included	in	the	
medium,	 and	 IL-3	 is	 known	 to	 promote	 the	 survival	 of	 myeloid	 progenitors	 [372].	
Alternatively,	the	experiment	may	have	failed	due	to	a	technical	 issue,	such	as	the	culture	
conditions.	This	is	also	unlikely,	considering	the	same	medium	and	Flt3L	stock	was	used	for	
the	phosphoflow	experiments,	and	a	response	was	seen	in	MPPs	(Figure	4.7),	leaving	the	final	
possibilities;	either	SPI1	is	not	a	target	of	endogenous	Flt3	signalling	in	HSPCs	or,	if	SPI1	is	a	
target	of	Flt3	signalling,	an	increase	in	transcription	may	not	be	detected	at	18	hours	after	
Flt3L	stimulation.	
	
Measurement	of	SPI1	expression	at	other	time	points	may	provide	a	more	comprehensive	
analysis	 when	 investigating	 the	 transcriptional	 response	 of	 haematopoietic	 cells	 to	 Flt3L.	
Furthermore,	real-time	tracking	of	PU.1-GFP	HSPCs	cultures	containing	Flt3L	would	be	useful	
in	determining	if	SPI1	is	a	transcriptional	target	of	Flt3	signalling.	Alternatively,	other	potential	
targets	could	be	used	to	monitor	HSPC	response	to	Flt3L,	such	as	CEBPA	[276,	358,	373].	Given	
the	 limited	 information	 currently	 available	 in	 the	 literature	 regarding	 transcriptional	
regulation	of	canonical	Flt3	signalling,	monitoring	changes	in	gene	expression	using	a	single	
gene	has	its	pitfalls.	Gene	expression	analysis	of	Flt3L	stimulated	haematopoietic	cells	at	a	
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single	cell	level	using	an	Affymetrix	gene	chip	would	be	useful	in	identifying	a	downstream	
target	 of	 Flt3	 signalling.	 The	use	of	 such	 techniques	 in	 future	 experiments	would	 provide	
greater	clarity	on	the	transcriptional	regulation	of	Flt3	signalling	in	cells	that	are	known	to	
express	Flt3	and,	thus,	could	be	used	to	determine	if	single	HSCs	respond	to	Flt3L.		
	
In	 addition	 to	monitoring	 the	molecular	 changes	of	HSCs	 following	 culture	with	Flt3L,	 the	
cellular	response	of	HSCs	to	Flt3L	was	also	investigated.	If	a	fraction	of	LSK	CD150+	CD48−	cells	
expressed	 functional	 Flt3,	 stimulation	 of	 the	 receptor	 may	 improve	 their	 survival	 [352].	
Additionally,	 if	 Flt3L	 is	 indeed	 instructive,	 any	 Flt3+	 HSCs	 would	 be	 driven	 away	 from	
megakaryocyte/erythroid	 fates	 and	 towards	 myelomonocytic/lymphoid	 fates	 [288].	 Thus,	
HSCs	were	seeded	into	M3434	with	and	without	Flt3L	to	monitor	these	responses.	When	the	
colony	formation	of	HSCs	was	analysed,	the	number	of	colonies,	and	the	types	of	colonies	
observed	were	similar	to	the	results	obtained	by	Oguro	et	al.	when	they	monitored	the	colony	
forming	 potential	 of	 HSC-1	 (LSK	 CD150+	 CD48−	 CD229−/low)	 and	 HSC-2	 (LSK	 CD150+	 CD48−	
CD229+)	[34].	Comparison	of	the	colony	forming	potential	of	HSCs	in	M3434	with	and	without	
25ng/mL	Flt3	revealed	no	change	 in	the	numbers	of	CFU-M,	CFU-G,	CFU-GM,	CFU-GEMM,	
CFU-Meg	or	CFU-MegMix.	Additionally,	 the	 total	number	of	 colonies	 in	both	 samples	was	
similar.	 Together,	 these	 indicate	 that	 the	 presence	 of	 25ng/mL	 Flt3L	 did	 not	 alter	 the	
contribution	 of	 HSCs	 to	 particular	 lineages	 or	 confer	 a	 survival	 advantage	 to	HSCs	 during	
colony	formation.		
	
While	 the	 data	 presented	 in	 this	 chapter	 do	 not	 suggest	 that	 Flt3L	 acts	 on	 HSCs,	 the	
experiments	and	analysis	carried	out	may	have	lacked	the	sensitivity	required	to	accurately	
measure	the	response	of	such	a	small	number	of	Flt3+	cells	within	the	HSC	compartment	(4.6%	
±	1	of	LT-HSCs	[n=6],	7.7%	±	1.1	of	ST-HSCs	[n=6]).	By	using	the	fold	change	 in	MFI	during	
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analysis	 of	 the	 phosphoflow	 experiments,	 an	 average	 response	 within	 the	 whole	 HSC	
population	was	calculated.	This	analysis	may	have	neglected	any	changes	that	occurred	at	the	
single	cell	level.	Ideally,	the	response	of	cells	to	Flt3L	would	be	presented	as	a	percentage	of	
the	 total	 population	 so	 that	 the	 exact	 number	 of	 cells	 that	 upregulated	 pS6	 following	
stimulation	could	be	obtained.	However,	as	cells	express	a	basal	level	of	pS6	at	rest,	gating	on	
pS6	expression	was	not	feasible.	Additionally,	as	mentioned	previously,	the	limit	of	detection	
for	flow	cytometry	has	been	estimated	to	be	2,000	molecules	[367],	so	cells	with	a	limited	
number	 of	 receptors	 on	 their	 surface	may	not	 express	 levels	 of	 pS6	 above	 this	 threshold	
following	Flt3	stimulation	and	would	not	be	detected.	 Indeed,	 it	has	been	estimated	early	
HSPCs	may	express	less	than	100	copies	of	certain	HGF	receptors	on	their	surface,	such	as	G-
CSF	and	M-CSF	[374].	
	
The	 concentration	 of	 Flt3L	 used	 for	 the	 colony	 forming	 assays	 was	 lower	 than	 the	
concentration	used	in	the	phosphoflow	assays,	so	the	results	from	the	colony	forming	assay	
do	not	preclude	the	possibility	that	higher	amounts	of	Flt3L	are	required	to	elicit	a	response	
from	 LSK	 CD150+	 CD48−	 cells.	 In	 fact,	 in	 the	model	 proposed	 by	 the	 Rolink	 group,	 a	 high	
threshold	of	Flt3L	is	required	to	drive	multipotent	cells	towards	myelomonocytic,	granulocytic	
and	lymphoid	fates.	Also,	Flt3L	plays	an	integral	role	in	DC	and	lymphoid	development	[288,	
311,	343,	375],	but	the	production	of	DCs	and	lymphoid	cells	from	HSCs	stimulated	with	Flt3L	
was	not	monitored	in	the	colony	forming	experiments.	
	
Lastly,	 if	 Flt3	 is	 present	 in	 the	HSC	 compartment	 it	may	only	 have	 a	minor	 role,	 or	 share	
function	with	another	receptor	on	the	surface	of	HSCs,	making	it	difficult	to	detect.	Indeed,	
Flt3	shares	overlapping	signalling	pathways	with	c-Kit	[234,	376,	377],	and	there	is	evidence	
to	suggest	that	c-Kit	and	Flt3	may	heterodimerise	[378].	Early	studies	investigating	the	effects	
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of	Flt3L	on	primitive	HSPC	colony	formation	also	suggest	that	Flt3L	provides	weak	proliferative	
signals	in	isolation,	but	primarily	acts	synergistically	with	other	HGFs,	such	as	the	CSFs	[196,	
379,	380].	Moreover,	Flt3	is	known	to	be	expressed	on	fetal	HSCs,	but	Flt3L−/−	mice	show	no	
deficiency	of	the	LSK	CD150+	compartment	in	E14.5	liver,	suggesting	that	Flt3	expression	may	
be	 redundant	 in	 HSCs	 [340].	 A	 combination	 of	 the	 factors	 highlighted	 above	 may	 have	
hindered	the	detection	of	any	HSC	response	during	the	experiments	carried	in	this	chapter.	
Altogether,	 it	 is	 clear	 from	 the	 findings	 presented	 here	 that	 the	 LSK	 CD150−	 CD48−	MPP	
compartment	 responds	 to	 Flt3L,	 but	 the	 presence	 of	 functional	 Flt3	 within	 the	 HSC	
compartment	remains	uncertain.	
	
4.5.2			A	 role	 for	 Flt3L	 in	 the	 regulation	 of	 multipotent	
progenitors	during	steady-state	haematopoiesis	
	
Tsapogas	 et	 al.	 observed	 the	 expansion	 of	 BM	 DCs	 and	 a	 rapid	 decrease	 in	 BM	 MegE	
progenitors	following	administration	of	Flt3L	to	WT	mice,	and	suggested	that	Flt3L	may	drive	
an	upstream	progenitor	 towards	a	GM-lymphoid	 fate	at	 the	expense	of	MegE	production	
[288].	As	there	was	a	significant	expansion	of	LSK	CD150−	CD48+	cells	in	Flt3-Tg	mice	when	
compared	to	wild	type	controls,	the	Rolink	group	largely	attributed	the	Flt3L	response	to	this	
population.	 However,	 the	 LSK	 CD150−	CD48+	 compartment	 contains	GM-lymphoid	 primed	
progenitors	 that	 possess	 limited	MegE	 potential	 during	 steady	 state	 haematopoiesis	 [34,	
381],	indicating	that	stimulation	of	this	population	with	Flt3L	would	not	cause	a	significant	
decrease	in	MegE	progenitor	production.	Thus,	another	multipotent	population	upstream	of	
LSK	CD150−	CD48+	is	likely	responsible	for	driving	GM-lymphoid	production	at	the	expense	of	
the	 MegE	 lineage	 in	 this	 model.	 Flt3	 expression	 was	 detected	 on	 the	 surface	 of	 LSK	
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CD150+CD48−	HSCs	and	LSK	CD150+	CD48−	MPPs	(Figure	3.27),	which	are	both	upstream	of	
LSK	 CD150−	 CD48+	 progenitors	 [34],	 so	 the	 response	 of	 these	 populations	 to	 Flt3L	 was	
investigated.	 The	 findings	 presented	 in	 this	 chapter	 indicate	 that	 any	 Flt3L-mediated	
instruction	away	from	the	MegE	lineage	would	be	predominantly	driven	from	the	LSK	CD150−	
CD48−	MPP	compartment,	and	not	from	the	HSC	compartment.		
	
Recent	studies	have	reported	that	non-self-renewing	multipotent	cells,	rather	than	HSCs,	are	
the	main	drivers	of	blood	production	during	steady-state	haematopoiesis.	This	highlights	the	
importance	of	Flt3L	as	a	regulator	of	GM-lymphoid	development	at	the	MPP	stage.	Busch	et	
al.	have	used	a	mouse	model,	whereby	tamoxifen	administration	induces	the	expression	of	
the	yellow	fluorescent	protein	(YFP)	in	Tie2+	HSCs	(LSK	CD150+	CD48−),	to	describe	the	kinetics	
of	HSPC	differentiation	 in	situ	 [382].	By	monitoring	the	development	of	YFP+	cells	 through	
various	haematopoietic	progenitor	stages,	the	authors	observed	that	only	a	small	percentage	
(approximately	30%)	of	HSCs	were	active,	and,	on	an	average,	1	in	110	HSCs	gave	rise	to	a	LSK	
CD150−	CD48−	cell	per	day.	On	the	other	hand,	populations	of	upstream	progenitors	were	
maintained	through	proliferation	and	had	a	much	higher	rate	of	differentiation.	For	example,	
a	single	LSK	CD150−	CD48+	cell	gave	rise	to	4	CMPs	per	day,	and	the	net	proliferation	rate	of	
this	compartment	was	over	30-fold	higher	than	that	of	the	HSC	compartment.	Similarly,	Sun	
et	al.	monitored	the	contribution	of	individual	HSPCs	to	the	haematopoietic	system	by	using	
a	 temporarily	 inducible	 hyperactive	 ‘Sleeping	 Beauty’	 transposase	 mouse	 model	 [383].	
Doxycycline	 induction	 of	 the	 hyperactive	 Sleeping	 Beauty	 transposase	 results	 in	 the	
mobilisation	 of	 a	 specific	 transposon	 within	 the	 genome.	 Due	 to	 the	 variable	 nature	 of	
transposon	 insertion,	 individual	 cells	 and	 its	progeny	 could	be	 identified	based	on	unique	
patterns	 of	 genomic	 transposition.	 By	 sequencing	 the	 genome	 of	 single	 mature	
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haematopoietic	 cells	 at	 a	 number	 of	 time	 points	 after	 hyperactive	 Sleeping	 Beauty	
transposase	 induction,	 the	 authors	 revealed	 that	 production	 of	 mature	 cells	 was	 mostly	
driven	by	large	pools	of	progenitors,	and	not	HSCs.		
	
While	these	studies	implicate	an	important	role	for	MPPs,	and	therefore	Flt3L,	during	steady-
state	haematopoiesis,	further	investigation	is	required	to	determine	how	Flt3L	might	regulate	
MPP	development	towards	non-MegE	fates.	As	discussed	in	Section	3.7.3,	previous	findings	
indicate	that	currently	defined	HSPC	compartments	are	not	homogeneous	populations	with	
mixed	state	progenitors,	but	contain	a	number	of	distinct	lineage-biased	or	lineage-restricted	
progenitors	 [24,	 304,	 332].	 LSK	 CD150−	 CD48−	 MPPs	 robustly	 reconstitute	 platelets	 and	
erythroid	cells	in	vivo	[22,	34].	However,	this	compartment	can	be	divided	into	Flt3−	and	Flt3+	
fractions,	 and	 studies	 have	 yet	 to	 characterise	 these	 two	 populations	 to	 determine	 their	
lineage	 potential.	 For	 Flt3L	 responses	 to	 cause	 a	 significant	 decrease	 in	MegE	 progenitor	
development,	then	the	Flt3+	MPP	population	would	need	to	possess	substantial	potential	for	
this	lineage.	While	the	Flt3hi	fraction	of	the	LSK	compartment	minimally	contributes	to	the	
megakaryocyte	lineage	[334],	the	Kondo	group	has	shown	that	Flt3lo	LSK	cells	can	give	rise	to	
CMPs	and	MEPs	 indicating	significant	MegE	potential	 [324].	Hence,	Flt3L	might	act	on	the	
Flt3lo	fraction	of	the	LSK	CD150−	CD48−	MPP	compartment	to	instruct	 lineage	fate.	Further	
study	of	the	Flt3+	and	Flt3−	LSK	CD150−	CD48−	compartments	will	be	required	to	confirm	this.	
	
Ultimately,	this	chapter	clearly	shows	Flt3L	stimulates	a	large	response	in	LSK	CD150−	CD48−	
MPPs,	and	not	in	LSK	CD150+	CD48−	HSCs,	suggesting	that	the	Flt3L	response	seen	in	Flt3L-Tg	
mice	 might	 be	 related	 to	 the	 LSK	 CD150−	 CD48−	 compartment.	 As	 Flt3	 is	 differentially	
expressed	by	cells	within	this	population,	further	studies	will	be	required	to	confirm	whether	
Flt3L	acts	to	instruct	the	development	of	multipotent	cells	away	from	a	MegE	fate,	or	if	Flt3L	
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acts	on	a	subpopulation	of	lineage-restricted/biased	progenitors	with	limited	MegE	potential.	
Lastly,	while	FLT3	and	its	encoded	protein	are	present	within	the	HSC	compartment	[34,	323,	
329],	Figure	3.17	and	Figure	3.27,	the	role	and/or	function	of	Flt3+	LSK	CD150+	CD48−	is	still	
not	entirely	clear.	Isolation	and	characterisation	of	Flt3+	LSK	CD150+	CD48−	cells	might	provide	
further	insight	into	the	relationship	between	Flt3	and	self-renewal.	 	
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CHAPTER	5:			 CONCLUSIONS	
	
5.1			Final	Discussion	
Various	studies,	carried	out	since	the	1980s,	have	provided	contradictory	evidence	regarding	
the	role	of	HGFs	 in	 the	 lineage	commitment	of	HSPCs.	Some	studies	support	a	permissive	
action	of	HGFs,	whereby	these	factors	provide	proliferative	and	survival	cues	to	permit	the	
stochastic	 lineage-specification	 of	 HSPCs.	 Other	 studies	 support	 a	 deterministic	 model	 in	
which	HGFs	act	on	HSPCs	to	influence	their	commitment	towards	a	particular	lineage	fate.	
Early	evidence	for	these	two	very	different	models	was	obtained	from	the	analysis	of	ectopic	
expression	of	growth	factor	receptors,	transgenic	ligand/receptor	knock-out	mouse	models	
and	 studies	 that	 investigated	 the	 effects	 of	 growth	 factors	 on	 the	 commitment	 of	 paired	
progenitor	daughter	cells.	Given	the	conflicting	data	from	such	early	studies,	the	effects	of	
growth	factors	on	HSPCs	lineage	commitment	was	largely	unclear	at	the	time.	
	
The	recent	use	of	single	cell	analysis	and	real-time	bioimaging	techniques	has	provided	strong	
support	for	a	deterministic	role	of	HGFs.	In	2009,	Rieger	et	al.	demonstrated,	for	the	first	time	
using	unmanipulated	progenitor	cells,	that	G-CSF	and	M-CSF	can	instruct	bipotent	GMPs	to	
become	 granulocytes	 and	 macrophages,	 respectively	 [268].	 As	 both	 cell	 death	 and	
differentiation	 were	monitored	 at	 the	 single	 cell	 level,	 the	 data	 firmly	 argue	 against	 the	
permissive	 action	 of	 G-CSF	 and	M-CSF.	M-CSF	 has	 also	 been	 shown	 to	 drive	 single	 HSCs	
towards	a	GM	fate	via	upregulation	of	PU.1	[267].	Similarly,	Pietras	et	al.	have	reported	that	
IL-1	acts	on	HSCs	to	stimulate	PU.1	expression	and	drive	their	maturation	towards	the	GM	
lineage	[175].	In	2014,	Grover	and	colleagues	demonstrated	that	Epo	induces	the	expression	
of	 erythroid-associated	 genes	 in	 single	 LSK	 CD150+	 Flt3−	 progenitors,	 and	 promotes	
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differentiation	towards	an	erythroid	fate	[269].	Finally,	work	by	the	Rolink	group	suggests	that	
Flt3L	 drives	multipotent	 progenitors	 towards	 a	 lympho-GM	 fate	 at	 the	 expense	 of	MegE	
development	[288].	As	a	result	of	these	studies,	the	deterministic	model	of	haematopoiesis	
has	become	more	popular	in	recent	years.	
	
In	a	deterministic	model	of	haematopoiesis	in	which	HSPC	lineage	specification	is	regulated	
by	cell-extrinsic	factors,	one	would	expect	receptors	for	such	factors	to	be	co-expressed	on	
the	surface	of	HSPCs.	This	would	allow	for	the	lineage	output	of	HSPCs	to	be	modulated	based	
on	the	availability	of	each	instructive	factor.	However,	there	is	evidence	to	suggest	that	HGF	
receptors	are	expressed	by	subpopulations	of	multipotent	HSPCs	and	not	to	any	appreciable	
extent	co-expressed	[115,	116,	304].	For	example,	Miyamoto	et	al.	have	reported	that	CSF3R	
and	EPOR	are	variably	expressed	by	the	LSK	CD34−	Thy1.1lo	HSC	compartment,	and	that	CSF3R	
and	EPOR	are	rarely	co-expressed	in	these	cells	[116].	Similarly,	Hu	et	al.	have	demonstrated	
that	the	genes	encoding	the	CSF	receptors	are	rarely	co-expressed	with	EPOR	 in	FDCP-mix	
and	mouse	CD34+	Lin−	BM	cells	[115].	Analysis	of	individual	cells	following	treatment	with	M-
CSF,	Epo	and	IL-1	have	also	demonstrated	that	these	factors	act	on	some,	but	not	all,	cells	
within	early	HSPC	compartments	[175,	268,	269].	
	
While	these	reports	have	provided	some	insight	into	the	selective	expression	of	growth	factor	
receptor	genes	during	haematopoiesis,	it	is	unclear	to	what	extent	co-expression	of	growth	
factor	receptor	genes	and	proteins	occurs	 in	currently	defined	multipotent	compartments.	
Furthermore,	single	cell	analysis	has	not	been	used	to	investigate	how	expression	of	these	
receptors	changes	as	multipotent	cells	make	a	transition	from	a	quiescent	to	a	proliferative	
state	and	begin	to	commit	towards	a	particular	lineage(s).	Hence,	the	purpose	of	this	study	
was	 to	 generate	 a	 comprehensive	 map	 of	 growth	 factor	 receptor	 expression	 during	
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haematopoiesis,	and	determine	whether	co-expression	of	HGF	receptors	regularly	occurs	in	
the	LT-HSC,	ST-HSC	and	MPP	compartments.	
	
Using	single-cell	analysis	techniques,	Flt3,	EpoR	and	M-CSFR	were	shown	to	be	expressed	to	
a	 varying	 degree	 in	 almost	 all	 HSPC	 compartments	 (Figure	 3.17	 and	 Figure	 3.27).	 The	
expression	 patterns	 of	 these	 receptors	 identified	 a	 number	 of	 novel	 and	 distinct	 HSPC	
subpopulations,	including	subpopulations	within	the	LT-HSC,	ST-HSC	and	MPP	compartments.	
As	quiescent	LT-HSCs	transitioned	into	a	more	proliferative	MPP	phenotype,	the	expression	
of	Flt3,	EpoR	and	M-CSFR	primarily	occur	at	different	stages	of	development,	indicating	that	
the	ligands	for	these	receptors	regulate	haematopoiesis	at	different	stages	of	multipotent	cell	
maturity.	 Notably,	 multiplex	 analysis	 revealed	 that	 co-expression	 of	 these	 receptors	 is	
uncommon	within	the	multipotent	compartments,	though	co-expression	of	M-CSFR	and	Flt3	
increases	 as	 HSCs	 differentiated	 into	MPPs.	 Finally,	 as	 Flt3	 was	 detected	 within	 the	 HSC	
compartment,	it	was	investigated	whether	LSK	CD150+	CD48−	cells	could	respond	to	Flt3L,	or	
if	this	ligand	predominantly	acts	on	LSK	CD150−	CD48−	MPPs.	No	signalling,	transcriptional	or	
cellular	responses	were	detected	when	HSCs	were	cultured	with	Flt3L.	A	large	response	was	
observed	 within	 the	 LSK	 CD150−	 CD48−	 MPP	 compartment	 following	 stimulation	 of	 Flt3,	
suggesting	that	Flt3L	predominantly	acts	further	upstream	than	M-CSF	and	Epo	(Figure	4.7).	
However,	 this	 study	 may	 underestimate	 the	 number	 of	 Flt3+	 cells	 within	 the	 HSC	
compartment.	 The	 techniques	 used	 in	 this	 study	may	 not	 have	 been	 sensitive	 enough	 to	
identify	HSCs	that	express	very	few	Flt3	proteins	on	their	surface	(further	discussed	below).	
	
The	 data	 generated	 in	 this	 study	 indicate	 that	 Epo,	 M-CSF	 and	 Flt3L	 primarily	 regulate	
haematopoiesis	by	acting	on	distinct	subpopulations	of	early	HSPCs	that	selectively	express	
particular	growth	factor	receptors.	Therefore,	these	findings	support	a	permissive	rather	than	
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deterministic	role	of	Epo,	M-CSF	and	Flt3L	within	the	multipotent	compartment	of	the	BM.	
This	is	surprising	considering	the	findings	of	Rieger	and	colleagues	[268].	M-CSF	and	G-CSF	
were	 shown	 to	 stimulate	 bipotent	 GMPs	 to	 differentiate	 towards	 macrophage	 and	
granulocyte	fates,	respectively.	By	tracking	cell	death	using	real-time	imaging,	Rieger	et	al.	
demonstrated	that	this	response	was	not	due	to	the	selective	expansion	of	distinct	unilineage	
subpopulations,	 indicating	 that	 M-CSFR	 and	 G-CSFR	 are	 co-expressed	 by	 committed	
progenitors	[268].	Additionally,	Hu	et	al.	have	shown	that	the	genes	encoding	M-CSFR,	GM-
CSFR	and	G-CSFR	are	commonly	co-expressed	by	individual	mouse	Lin−	CD34+	BM	cells	[115].	
On	the	other	hand,	past	studies	that	have	investigated	multilineage	gene	expression	in	early	
HSPCs	have	rarely	observed	the	co-expression	of	EPOR	and	genes	encoding	GM-associated	
growth	 factor	 receptors	 (CSF1R,	 CSF2R	 or	 CSF3R)	 [115,	 116].	 The	 extent	 to	 which	 HGF	
receptors	are	co-expressed	by	HSPCs	is	still	a	matter	of	debate.	However,	evidence	suggests	
that	some	HSPCs	might	co-express	receptors	that	are	associated	with	lineages	that	are	closely	
related,	such	as	the	granulocyte	and	macrophage	lineages.	The	expression	of	G-CSFR	by	early	
HSPCs	was	not	investigated	in	Chapter	3,	and	therefore,	it	is	uncertain	whether	M-CSFR	and	
G-CSFR	are	co-expressed	by	multipotent	cells.	
	
As	to	co-expression	of	receptors,	the	results	from	this	study	showed	that	Flt3	and	M-CSFR	
(Figure	3.31)	are	more	commonly	co-expressed	by	early	HSPCs	than	FTL3	and	EPOR	(Figure	
3.24).	When	analysing	Flt3	and	M-CSFR	expression,	1.12%	±	0.48,	2.8%	±	0.7	and	9.9%	±	1.9	
of	LT-HSCs,	ST-HSCs	and	MPPs	were	found	to	co-express	both	receptors.	When	the	LT-HSC	
and	MPP	compartments	were	analysed	 for	FLT3	and	EPOR	expression,	a	 total	of	284	cells	
were	interrogated	and	co-expression	of	FLT3	and	EPOR	was	not	detected.	Of	the	139	ST-HSCs	
analysed,	only	2	cells	were	found	to	co-express	FLT3	and	EPOR.	Flt3	and	M-CSFR	are	both	
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important	 for	 the	 development	 of	 myelomonocytic	 cells,	 while	 Flt3	 and	 EpoR	 signalling	
regulate	 distinct	 lineages	 [384,	 385].	 Therefore,	 in	 light	 of	 the	 findings	 of	 this	 study,	 it	 is	
possible	that	 if	co-expression	of	HGF	receptors	does	occur,	certain	combinations	are	more	
likely	than	others.		
	
As	discussed	in	detail	in	Section	3.7,	the	selective	expression	of	particular	HGF	receptors	may	
mark	distinct	lineage-biased	or	lineage-restricted	subpopulations	with	HSPCs	compartments.	
Functionally	 distinct	 subpopulations	within	 currently	 defined	 HPC	 compartments,	 such	 as	
CMP,	LMPP	and	CLP,	have	been	isolated	based	on	the	expression	of	growth	factor	receptors	
[77,	304,	311].	This	suggests	the	selective	expression	of	such	receptors	within	more	primative	
HSPC	compartments	might	identify	novel	 lineage-biased	or	lineage-restricted	cells.	 Indeed,	
certain	 HGFs	 have	 been	 shown	 to	 differentially	 regulate	 distinct	 lineage-biased	 HSC	
subpopulations	 and	 their	 progeny.	 Platelet-biased	 vWF+	 HSCs	 but	 not	 vWF−	 HSCs	 are	
dependent	on	Tpo	[29].	TGF-β1	positively	regulates	MyHSCs	but	inhibits	the	proliferation	of	
LyHSCs	[25].	The	lymphoid	progeny	of	MyHSCs	are	unresponsive	to	IL-7	and	express	lower	
levels	of	IL7R	when	compared	to	LyHSC-derived	lymphoid	progenitors.	Furthermore,	evidence	
suggest	that	lineage-specification	occurs	within	early	HSPC	populations.	A	number	of	studies	
have	identified	lineage-restricted	progenitors	within	the	HSC	compartment,	including	long-
term	 repopulating	 CMRPs,	 MkRPs	 and	 MERPs	 [23,	 24].	 Other	 studies	 have	 shown	 that	
currently	defined	HPCs	are	heterogeneous	populations	containing	a	mixture	of	unilineage	and	
bipotent	 progenitors,	 indicating	 that	 lineage	 commitment	 occurs	 upstream	 of	 the	 HPC	
compartments.	 [24,	 304,	 332].	 For	 example,	 Paul	et	 al.	 have	 demonstrated	 that	 the	CMP	
compartment	 of	 the	 mouse	 BM	 contains	 at	 least	 19	 transcriptionally	 distinct	 progenitor	
populations,	 including	 those	 restricted	 to	 the	 megakaryocyte,	 erythrocyte,	 monocyte,	
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basophil	and	DC	fates	[304].	The	findings	shown	in	Figure	3.17	and	Figure	3.27	further	support	
this	viewpoint,	as	a	number	of	late	HPC	populations,	such	as	CMP	and	LMPP,	were	observed	
to	be	heterogeneous	as	to	their	expression	of	at	least	one	HGF	receptor.		
	
If	selective	upregulation	of	particular	receptors	indicates	an	early	stage	in	the	maturation	of	
a	 cell	 toward	 a	particular	 lineage,	 then	 the	 findings	 from	 this	 study	will	 be	useful	 for	 the	
isolation	and	characterisation	of	the	lineage-biased	and/or	lineage	committed	cells	within	the	
early	HSPC	compartments.	For	example,	8.2%	±	4.6	of	MPPs	expressed	EPOR,	while	Flt3	and	
M-CSFR	were	expressed	on	the	surface	of	63.65%	±	3	and	13.4%	±	2.5	of	MPPs,	respectively.	
A	 large	proportion	of	M-CSFR+	MPPs	also	expressed	Flt3	 (69.17%	±	3.29	of	M-CSFR+	MPPs	
were	Flt3+).	On	the	other	hand,	no	Epor+	cells	were	found	to	co-express	FLT3.	This	suggests	
the	existence	of	at	least	5	distinct	subpopulations	within	the	MPP	compartment	based	on	the	
expression	of	these	three	receptors;	Flt3+	M-CSFR−	MPPs,	Flt3−	M-CSFR+	MPPs,	Flt3+	M-CSFR+	
MPPs,	EpoR+	MPPs	and	MPPs	that	do	not	express	any	of	these	receptors	on	their	surface.	
	
Given	 that	 Flt3	 is	 associated	with	DC,	 granulocyte,	monocyte	 and	 lymphoid	 development	
[288],	the	Flt3+	M-CSFR−	MPP	fraction	may	represent	a	population	of	GM-lymphoid	biased	
cells.	M-CSFR	is	important	in	the	development	of	GM	cells.	Thus,	Flt3−	M-CSFR+	MPPs	might	
be	biased	towards	a	GM	fate.	The	Flt3+	M-CSFR+	population	may	display	a	lineage-potential	
somewhere	between	these	two,	while	EpoR+	MPPs	might	be	biased	towards	the	erythroid	
lineage.	The	isolation	and	characterisation	of	such	MPP	subpopulations	will	be	required	to	
confirm	whether	they	display	such	distinct	lineage	potentials	(Figure	5.1).	
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Figure	 5.1.	 Selective	 expression	 of	 haematopoietic	 growth	 factors	 within	 the	 MPP	
compartment.	Recent	evidence	suggests	that	currently	defined	HSPC	populations	contain	a	
number	of	distinct	subpopulations	that	express	different	lineage-potentials.	During	this	study,	
Flt3+	M-CSFR−,	Flt3+	M-CSFR−,	Flt3+	M-CSFR+	and	EpoR+	subpopulations	were	identified	within	
the	LSK	CD150−	CD48−	MPP	compartment	of	the	BM,	suggesting	that	these	phenotypes	mark	
distinct	 lineage-restricted	 and/or	 lineage-biased	 subpopulations.	 The	 isolation	 and	
characterisation	of	the	lineage	potentials	of	these	cell	fractions	will	be	required	to	confirm	
this.	 MPP,	 multipotent	 progenitor;	 EpoR,	 erythropoietin	 receptor;	 M-CSFR,	 macrophage-
colony	stimulating	factor;	Flt3,	fms-like	tyrosine	kinase	3.	
	
	
Although	the	data	described	in	this	thesis	indicates	that	Flt3,	EpoR	and	M-CSFR	are	primarily	
selectively	expressed	during	the	early	stages	of	haematopoiesis,	there	is	still	a	large	amount	
of	data	that	supports	a	deterministic	model	of	haematopoiesis.	It	is	possible	that	some	early	
HSPCs	express	a	very	small	number	of	HGF	receptor	molecules	on	their	surface,	resulting	in	
an	 underestimate	 of	 the	 number	 of	 Flt3+	 and	 M-CSFR+	 cells	 within	 the	 HSC	 and	 MPP	
compartments.	 McKinstry	 et	 al.	 have	 estimated	 that	 less	 than	 100	 molecules	 of	 HGF	
receptors,	such	as	G-CSF	and	M-CSF,	are	expressed	on	the	surface	of	early	HSPCs	[374],	which	
is	well	below	the	limit	of	detection	of	conventional	flow	cytometry	[367].	Additionally,	gene	
expression	does	not	always	correlate	to	protein	expression,	so	the	expression	of	EPOR	might	
not	accurately	represent	the	number	of	early	HSPCs	that	express	functional	EpoR	protein.	It	
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is	 also	 possible	 that	 co-expression	 of	 other	 HGF	 receptors	 is	 commonplace	 during	
haematopoiesis.	As	highlighted	above,	 there	 is	evidence	 to	 suggest	 that	HSPCs	co-express	
certain	 receptors,	 such	as	M-CSFR	and	G-CSFR.	Co-expression	of	 such	 receptors	may	help	
HSPCs	to	choose	between	closely	related	fates.	
	
Even	if	HGF	receptors	are	selectively	expressed	by	multipotent	cells,	their	activation	may	still	
provide	instructional	cues	to	cells	that	might	otherwise	still	have	the	capacity	to	generate	all	
cell	types	in	a	balanced	fashion.	This	is	supported	by	the	findings	of	Mossadegh-Keller	and	co-
workers	[267].	The	group	cultured	LSK	CD150+	CD34−	Flt3−	cells	in	the	presence	of	M-CSF,	and	
reported	 that	 M-CSF	 is	 capable	 of	 upregulating	 PU.1	 in	 a	 large	 number	 of	 these	 cells.	
Transplantation	of	M-CSF-stimulated	PU.1+	HSCs	into	irradiated	hosts	revealed	that,	although	
these	 cells	 were	 multipotent,	 their	 development	 was	 skewed	 towards	 the	 GM	 lineage.	
However,	after	6	weeks,	this	bias	had	disappeared	and	the	contribution	of	these	cells	to	other	
lineages	had	become	comparable	to	the	lineage-output	of	unstimulated	HSCs.	These	findings	
indicate	 that	M-CSF-responsive	cells	are	not	permanently	biased	 towards	 the	GM	 lineage.	
Rather,	M-CSF	had	temporarily	skewed	the	development	of	these	cells.	
	
There	are	a	number	of	caveats	to	the	conclusion	that	HGFs	do	not	play	a	deterministic	role,	
as	a	number	of	additional	factors	need	to	be	taken	into	consideration.	Studies	have	shown	
that	a	high	concentration	of	a	particular	HGF	is	required	to	elicit	the	lineage	commitment	of	
HSPCs	 [267,	269,	288].	This	 suggests	 that	 signalling	below	a	certain	 threshold,	due	 to	 low	
growth	 factor	 availability	 or	 a	 low	 level	 of	 receptor	 expression,	 does	not	mediate	 lineage	
instruction.	There	 is	also	evidence	 to	suggest	 that	HGFs	 regulate	 lineage-specification	 in	a	
dose-dependent	manner.	Metcalf	has	reported	that	low	concentrations	of	GM-CSF	promote	
the	 differentiation	 of	 GM-CFU	 daughter	 cells	 towards	 a	 myeloid	 fate,	 while	 high	
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concentrations	promote	a	granulocyte	fate	[257].	Similarly,	Kulessa	et	al.	have	reported	that	
there	 is	 a	 relationship	 between	 the	 levels	 of	 Gata-1	 expressed	 by	 a	 cell	 and	 its	 lineage	
potential	[386].	For	example,	the	group	ectopically	expressed	GATA-1	in	a	macrophage	cell	
line	and	demonstrated	that	these	cells	were	transformed	into	three	distinct	cell	types.	Low	
levels	 of	 GATA-1	 expression	 were	 shown	 to	 transform	 these	 cells	 into	 myeloblasts,	
intermediate	 levels	 induced	 an	 eosinophilic	 fate	 and	 high	 expression	 levels	 of	 GATA-1	
promoted	 their	 transformation	 into	 erythroblasts.	 As	 Epo	 has	 been	 shown	 to	 induce	
expression	 of	 GATA-1	 [269],	 these	 findings	 suggests	 that	 Epo	 may	 regulate	 lineage	
commitment	in	a	dose-dependent	fashion.		
	
The	Sieweke	group	has	proposed	that	the	ability	of	HGFs	to	regulate	lineage	commitment	is	
reliant	on	the	intrinsic	state	of	the	target	cell	[387].	Sarrazin	et	al.	have	demonstrated	that	
MafB	expression	regulates	HSC	sensitivity	to	M-CSF-mediated	lineage	instruction	[388].	The	
authors	 reported	 that	 MafB−/−	 LSK	 cells	 proliferate	 at	 a	 much	 higher	 rate	 and	 produce	
significantly	more	GM	cells	in	response	to	M-CSFR	stimulation	when	compared	to	WT	HSCs.	
Ectopic	expression	of	MafB	in	an	M-CSFR-transduced	T-lymphocyte	cell	line	prevented	these	
cells	 from	 proliferating	 in	 the	 presence	 of	 M-CSF.	 However,	 their	 response	 to	 IL-7	 was	
unaffected.	Furthermore,	using	a	PU.1:GFP	reporter	model,	it	was	shown	that	an	increased	
number	of	MafB−/−	LSK	Flt3−	cells	upregulated	PU.1	in	the	presence	of	M-CSF	when	compared	
to	WT	cells.	Oburoglu	et	al.	have	also	 shown	that	Epo-mediated	erythroid	 specification	 in	
CD34+CD38−	hHSCs	is	sensitive	to	the	availability	of	cell	metabolites	[289].	The	group	reported	
that	 blocking	 glutaminolysis	 in	 Epo-stimulated	 hHSCs	 abrogated	 erythroid	 output	 and	
promoted	differentiation	towards	a	GM	fate.	Conversely,	inhibiting	glycolysis	enhanced	Epo-
mediated	erythropoiesis.	These	studies	highlight	the	importance	of	cell-intrinsic	mechanisms	
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in	regulating	the	sensitivity	of	cells	to	instructive	cues.		
	
The	findings	of	Sarrazin	et	al.	[388]	and	Oburoglu	et	al.	[289]	may	explain	the	contradictory	
evidence	that	has	been	generated	from	studies	that	have	reported	on	the	ectopic	expression	
of	HGF	 receptors.	 For	example,	ectopic	expression	of	GM-CSFR	by	pro-T-lymphocytes	and	
CLPs	restores	GM	potential	in	these	cells	[275,	389].	However,	enforced	expression	of	GM-
CSFR	in	pro-B-lymphocytes	or	MEPs	does	not	restore	GM	potential	[389].	Future	studies	of	
HGFs	will	need	to	consider	receptor	signalling	thresholds	and	the	intrinsic	state	of	target	cells	
when	investigating	their	role	in	lineage	commitment.	Specifically,	characterisation	of	relevant	
intrinsic	factors	will	help	to	determine	the	mechanisms	that	regulate	the	sensitivity	of	certain	
cells	to	HGF	signalling.	
	
To	 further	 explore	 how	 HGFs	 regulate	 lineage	 commitment	 during	 haematopoiesis,	 the	
factors	that	control	the	expression	of	their	receptors	will	need	to	be	determined.	There	 is	
evidence	 to	 suggest	 that	 some	HGF	 receptors	 are	upregulated	 following	 the	 activation	of	
other	 growth	 factor	 receptor	 signalling	 cascades.	 IL-1	 has	 been	 shown	 to	 stimulate	 the	
upregulation	 of	 the	 genes	 encoding	 GM-CSFR	 and	M-CSFR	 in	 HSCs	 [175].	M-CSF	 induces	
expression	of	PU.1	in	HSCs	[267],	and	FLT3	is	a	target	of	PU.1	[368],	suggesting	that	M-CSFR	
signalling	upregulates	Flt3	expression.	It	has	also	been	reported	that	expression	of	particular	
growth	factor	receptors	can	be	induced	during	periods	of	stress,	allowing	HSPCs	to	adapt	to	
the	 requirements	of	 the	host.	Chen	et	al.	have	 reported	 that	 type	 I	 interferon,	a	cytokine	
produced	during	infection	[390],	stimulates	the	upregulation	of	Flt3	on	the	surface	CLPs	[373].	
A	number	of	studies	have	also	demonstrated	that	EpoR	expression	 is	regulated	by	oxygen	
tension	 [391-393].	 In	 mice	 embryos	 lacking	 the	 hypoxia-sensitive	 α	 subunit	 of	 hypoxia-
inducible	factor-1,	EPOR	expression	is	decreased,	and	erythropoiesis	is	significantly	impaired	
	
	
238	
[394].	
	
A	further	consideration	is	that	the	selective	expression	of	HGFs	may	occur	as	a	result	of	gene	
expression	noise.	While	popularity	for	a	stochastic	model	of	haematopoiesis	has	faded	over	
recent	years,	gene	expression	noise	is	an	intrinsic	property	of	many	biological	systems.	Chang	
et	 al.	 have	 demonstrated	 that	 transcriptional	 noise	 can	 mediate	 the	 transition	 of	 HSPC	
populations	 through	 lineage-biased	metastable	 states	 [118].	 These	 transitions	 can	 lead	 to	
changes	in	the	expression	of	cell	surface	proteins	and	lineage-associated	TFs,	such	as	PU.1	
and	GATA-1.	In	turn,	PU.1	and	GATA-1	have	been	shown	to	upregulate	the	expression	of	M-
CSFR	[395]	and	EpoR	[396],	respectively,	so	this	suggests	that	expression	of	HGF	receptors	
might	be	affected	by	stochastic	fluctuations	 in	gene	transcription.	However,	the	viewpoint	
that	PU.1	and	GATA-1	are	co-expressed	in	multipotent	HSPCs	has	been	recently	challenged	
[138],	 so	 it	 remains	 to	 be	 seen	 if	 the	 findings	 of	 Chang	et	 al.	 are	 relevant	 to	 the	 lineage	
commitment	processes	that	occur	in	vivo	[118].	Even	so,	though	it	is	evident	that	a	number	
of	different	factors	regulate	the	expression	of	HGFs,	it	is	unclear	how	they	contribute	towards	
the	selective	expression	of	such	receptors	by	distinct	HSPCs	subpopulations.	
	
Ultimately,	while	there	is	strong	evidence	to	suggest	that	cell-extrinsic	factors	play	a	role	in	
regulating	lineage	commitment	during	haematopoiesis,	the	results	obtained	from	this	study	
indicate	that	aspects	of	a	selective	model	still	hold	true.	In	a	selective	model	whereby	HSPCs	
can	differentiate	towards	certain	lineage	fates	based	on	selective	growth	factor	expression,	
it	is	unlikely	that	this	lineage-specification	arises	in	a	stochastic	manner.	Progressive	lineage	
commitment	of	HSPCs	does	not	occur	randomly.	Only	particular	cell-fate	combinations	are	
possible.	For	example,	progenitors	with	granulocyte	and	macrophage	potential	exist,	but	a	
bipotent	progenitor	with	megakaryocyte	and	T-lymphocyte	potential	has	not	been	described.		
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There	 is	still	more	work	to	be	done	to	truly	 identify	the	mechanisms	that	regulate	 lineage	
commitment	during	haematopoiesis.	However,	 this	 study	has	provided	an	 insight	 into	 the	
expression	 patterns	 of	 HGF	 receptors	 by	 HSPCs	 and	 has	 revealed	 several	 novel	 findings.	
Firstly,	 the	observation	that	early	HSPCs	rarely	co-express	Flt3,	M-CSFR	and/or	EPOR	adds	
further	complexity	to	the	debate	regarding	the	role	of	HGFs	 in	the	 lineage-specification	of	
HSPCs.	 It	appears	 that	 simply	defining	 lineage	specification	using	either	a	deterministic	or	
selective	model	of	haematopoiesis	is	impractical;	the	findings	from	this	study,	taken	together	
with	previous	 studies,	 suggest	 that	HGFs	 regulate	haematopoiesis	 in	 both	 a	 selective	 and	
deterministic	manner.	Secondly,	Flt3,	EpoR,	M-CSFR	are	predominantly	expressed	by	distinct	
subpopulations	within	the	multipotent	compartment	of	the	BM,	and	can	be	used	to	identify	
small	subfractions	of	cells	within	progenitor	populations.	As	discussed	before,	it	is	possible	
that	these	receptors	can	be	used	to	isolate	lineage-biased	and	restricted	progenitors	within	
currently	defined	HSPC	compartments.	Thirdly,	Flt3	is	expressed	within	the	HSC	compartment	
of	 the	adult	mouse	BM.	However,	 it	 is	 currently	unclear	what	 relevance	 this	has,	and	 the	
studies	carried	out	here	indicate	that	Flt3L	primarily	acts	on	upstream	MPPs.		
	
These	findings	are	important,	as	their	translation	to	human	haematopoiesis	will	be	useful	for	
the	 advancement	 of	 clinical	 therapies.	 Firstly,	 understanding	 how	 HGFs	 regulate	 HSPC	
differentiation	will	help	to	improve	a	number	of	haematological	therapies.	For	example,	 in	
vitro	manipulation	of	HSPCs	for	the	purpose	of	cell	manufacturing,	such	as	erythrocytes	and	
platelets	for	transfusions,	will	benefit	from	a	greater	understanding	of	lineage	specification	
during	haematopoiesis.	Similarly,	if	HGF	receptor	expression	marks	lineage-biased/restricted	
HSPCs	in	humans,	then	these	receptors	could	be	used	for	the	isolation	of	cells	that	are	highly	
efficient	at	producing	particular	cell	types.	It	is	also	important	to	consider	the	effects	of	HGF	
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on	HSPCs	in	currently	used	therapies,	such	as	the	use	of	G-CSF	to	harvest	hHSC	for	stem	cell	
transplants.	If	G-CSF	induces	a	granulocyte	bias	(as	M-CSF	induces	a	temporary	GM	bias	[267])	
in	HSPCs,	does	this	result	in	an	increased	production	of	granulocytes	in	the	recipient	during	
the	early	stages	of	recovery?	Alternatively,	if	G-CSF	selects	for	a	subpopulation	of	HSCs,	then	
do	 recipients	 receive	 a	 long-term	 granulocyte-biased	 transplant?	 As	 infection	 is	 a	 severe	
complication	of	BM	transplantation	[397],	an	increased	production	in	granulocytes	following	
the	procedure	would	be	favoured	as	to	avoid	post-transplantation	infections.	However,	this	
is	 an	 important	 consideration	 so	 that	 we	 understand	 the	 physiological	 mechanisms	 that	
underlie	this	therapy.	Finally,	as	mentioned	previously,	if	Flt3	is	expressed	on	the	surface	of	
mouse	HSCs,	then	this	would	make	Flt3-ITD	mouse	models	even	more	relevant	to	the	study	
of	acute	myeloid	leukaemia	than	currently	thought.		
	
Further	work	is	required	to	fully	elucidate	how	selective	growth	factor	receptor	expression	is	
regulated	 and,	 as	 highlighted	 above,	 how	 the	 intrinsic	 state	of	 target	 cells	 affects	 lineage	
instruction.	Specifically,	 the	 isolation	and	characterisation	of	distinct	HSPC	subpopulations	
based	on	the	expression	of	HGF	receptors	will	be	important	to	investigate	the	mechanism(s)	
that	underlies	 fate	determination	during	haematopoiesis.	 The	work	carried	out	here	 is	an	
important	step	towards	understanding	such	processes.	
	
5.2			Future	Directions	
Whilst	the	findings	from	this	study	provide	an	insight	into	the	selective	expression	and	co-
expression	 of	 HGF	 receptors	 by	 HSPCs,	 a	 lot	 more	 work	 is	 required	 to	 understand	 the	
significance	 of	 these	 patterns	 of	 HGF	 receptor	 expression	 and	 how	 they	 emerge.	 To	
determine	the	significance	of	selective	HGF	receptor	expression	within	HSPC	compartments,	
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Flt3+,	 M-CSFR+	 and	 EPOR+	 cells	 within	 each	 BM	 compartment	 should	 be	 isolated	 and	
characterised.	 It	 will	 be	 of	 interest	 to	 perform	 in	 vitro	 colony	 forming	 assays	 and	 in	 vivo	
reconstitution	assays	to	determine	the	lineage	potential	and	self-renewal	capacity	of	these	
cells.	Additional	analysis,	such	as	the	use	of	single	cell	gene	expression	assays,	will	help	to	
identify	 the	 functional	and	 transcriptional	properties	of	 these	cells.	These	approaches	will	
confirm	 whether	 or	 not	 selective	 expression	 of	 HGF	 receptors	 marks	 lineage-
biased/restricted	progenitors,	especially	within	 the	early	HSPC	compartments.	Specifically,	
the	characterisation	of	Flt3+	cells	within	the	LSK	CD150+	CD48-	compartment	is	of	particular	
interest,	as	it	is	important	to	determine	whether	a	small	population	of	HSCs	express	functional	
Flt3,	or	if	this	receptor	marks	non-self-renewing	progenitors	within	the	compartment.	
	
It	is	also	important	to	determine	if	the	findings	reported	here	accurately	reflect	the	expression	
patterns	of	other	HGF	receptors.	Initially,	it	would	be	advantageous	to	analyse	the	expression	
of	a	 large	number	of	other	HGF	receptors,	such	as	G-CSF,	GM-CSF,	TPO	and	 IL-1R,	using	a	
single	cell	gene	chip.	The	findings	from	this	could	then	be	later	confirmed	using	more	sensitive	
multiplex	qRT-PCR	analysis	 and	protein	expression	analysis.	Any	 subpopulations	 identified	
from	this	approach	would	then	be	isolated	and	characterised	as	described	above.	
	
Lastly,	most	studies	of	HGF	function	in	HSPC	lineage	specification	have	focused	on	the	effects	
of	a	single	growth	factor	or	a	high	concentration	of	growth	factor	on	HSPCs	differentiation.	
However,	it	is	likely	that	this	does	not	truly	represent	the	physiological	environment	within	
the	HSPC	niches.	It	will	be	important	for	future	studies	to	investigate	the	effects	of	stimulating	
multiple	HGF	signalling	pathways	in	HSPCs.	For	example,	it	would	be	interesting	to	assess	how	
early	Flt3+	M-CSFR+	HSPCs	respond	to	stimulation	with	Flt3L	and	M-CSF	in	combination	when	
compared	to	stimulation	with	only	one	of	these	growth	factors,	as	this	would	more	accurately	
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represent	what	occurs	in	the	BM	microenvironment.	
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APPENDIX	A:	MATERIALS	
All	materials	used	during	this	project	are	listed	in	Table	14.	
Table	14:	Materials	used	during	study	
Agar	Scientific	 Square	covergalsses	(15x15mm)	
BD	Biosciences	 See	Table	15	for	antibodies	purchased	from	BD	Biosciences.	
Biolegend	
	
See	Table	15	for	antibodies	purchased	from	Biolegend.	
Recombinant	mouse	Flt3	ligand	(carrier-free)	
Biosearch	
Technologies	
All	 primers	 and	 probes	 (as	 listed	 in	 Table	 3)	 were	 purchased	 from	
Biosearch	Technologies	
eBiosciences	 See	Table	15	for	antibodies	purchased	from	eBiosciences	
Greiner	 Sterile	96-well	plates,	V-bottomed	
Innova	
Biosciences	
Lightning-Link	Allophycocyanin	Kit	
Peprotech	
	
Recombinant	murine	thrombopoietin	
Recombinant	murine	stem	cell	factor	
Qiagen	 QuantiTect	Multiplex	RT-PCR	Kit	
Roche	
	
LightCycler	480	multiwell	plate	384,	white	
RealTime	ready	RNA	Virus	Master	
LightCycler	Multiplex	RNA	Virus	Master	
Sigma	Aldrich	
	
Dulbecco's	Phosphate-Buffered	Saline	without	Ca2+	Mg2+	
Fetal	Calf	Serum	(Heat	inactivated)	
EDTA	
Acetone	
Methanol	
StemCell	
Technologies	
MethoCult	GF	M3434	
60mm	Gridded	Scoring	Dish	
Sysmex	 Partec	CellTrics	Sterile	Filters	
Thermo	Fisher	
Scientific	
ACK	Lysis	buffer	
Iscove's	Modified	Dulbecco's	Medium	(With	phenol	red)	
Penicillin/Streptomycin	
Twin	frosted	microscope	slides	
VWR	
International	
Cytology	funnel	
8-tube	strips	PCR	tubes,	individually	attached	domed	caps	
PCR,	polymerase	chain	reaction;	Flt3,	fms-like	tyrosine	kinase.	 	
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APPENDIX	B:	ANTIBODIES	
All	antibodies	used	during	this	project	are	listed	in	Table	15.	
Table	15:	Monoclonal	antibodies	used	for	flow	cytometric	analysis	
Specificity	 Isotype	 Clone	 Source	 Conjugate	 Dilution	
Lin	Cocktail	 -	 -	 eBiosciences	 FITC	 1/10	
CD3	 Rat	IgG2b,	κ	 17A2	 BioLegend	 AF488	 1/100	
CD11b	 Rat	IgG2b,	κ	 M1/70	 BioLegend	 AF488	 1/200	
B220/CD45R	 Rat	IgG2a,	κ	 RA3-6B2	 BioLegend	 AF488	 1/100	
TER-119	 Rat	IgG2b,	κ	 TER-119	 BioLegend	 AF488	 1/400	
Gr-1	 Rat	IgG2b,	κ	 RB6-8C5	 BioLegend	 AF488	 1/200	
CD11b	 Rat	IgG2b,	κ	 M1/70	 BioLegend	 AF488	 1/200	
CD48	 Ar	Ham	IgG1	 HM48-1	 BioLegend	 AF488	 1/200	
CD71	 Rat	IgG2a,	λ	 R17217	 eBiosciences	 PE	 1/200	
CD16/32	 Rat	IgG2a,	λ	 93	 BioLegend	 PE	 1/200	
CD150	 Rat	IgG2a,	λ	 TC15-12F12.2	 BD	Biosciences	 PE	 1/50	
IL-7Rα	(CD127)	 Rat	IgG2a,	κ	 A7R34	 eBiosciences	 PE	 1/50	
Flt3	(CD135)	 Rat	IgG2a,	κ	 A2F10	 eBiosciences	 PE	 1/100	
pS6	 Rb	IgG	 D57.2.2E	 Cell	Signalling	 PE	 1/50	
Flt3	(CD135)	 Rat	IgG2a,	κ	 A2F10.1	 BD	Biosciences	 PE-CF594	 1/200	
c-Kit	(CD117)	 Rat	IgG2b,	κ	 2B8	 BD	Biosciences	 PE-CF594	 1/400	
Sca1	(Ly-6a)	 Rat	IgG2a,	κ	 D7	 eBiosciences	 PE-Cy5	 1/100	
IL-7Rα	(CD127)	 Rat	IgG2a,	κ	 A7R34	 BioLegend	 PE-Cy5	 1/200	
CD150	 Rat	IgG2a,	λ	 TC15-12F12.2	 BioLegend	 PE-Cy5	 1/100	
Sca1	(Ly-6a)	 Rat	IgG2a,	κ	 D7	 eBiosciences	 PCP-Cy5.5	 1/100	
CD48	 Ar	Ham	IgG	 HM48-1	 BD	Biosciences	 PE-Cy7	 1/200	
Sca1	(Ly-6a)	 Rat	IgG2a,	κ	 D7	 eBiosciences	 PE-Cy7	 1/100	
IL-7Rα	(CD127)	 Rat	IgG2a,	κ	 A7R34	 eBiosciences	 PE-Cy7	 1/50	
CD115	 Rat	IgG2a,	κ	 AFS98	 BD	Biosciences	 BV421	 1/200	
CD16/32	 Rat	IgG2a,	λ	 93	 BioLegend	 BV421	 1/200	
CD150	 Rat	IgG2a,	λ	 TC15-12F12.2	 BioLegend	 PB	 1/50	
IL-3R	(CD123)	 Rat	IgG2a,	κ	 5B11	 eBiosciences	 APC	 1/50	
Sca1	(Ly-6a)	 Rat	IgG2a,	κ	 D7	 eBiosciences	 APC	 1/100	
CD34	 Rat	IgG2a,	λ	 RAM34	 eBiosciences	 eFluor	
660	
1/50	
CD48	 Ar	Ham	IgG1	 HM48-1	 BioLegend	 APC-Cy7	 1/200	
CD114	 Rat	IgG2A	 723806	 R&D	Systems	 Purified	 -	
Lin,	lineage;	Ar	Ham,	Armenian	hamster;	AF488,	alexa	fluor	488;	pS6,	phospho-S6	ribosomal	
protein;	PB,	pacific	blue;	IL-7R,	interleukin-7	receptor	α	subunit;	IL-3R,	interleukin-3	
receptor;	Flt3,	fms-like	tyrosine	kinease	3;	APC,	allophycocyanin.	
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